

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/29964> holds various files of this Leiden University dissertation.

Author: Verbiest, Marjolein Elisabeth Anna

Title: The implementation of smoking cessation care in general practice

Issue Date: 2014-12-02

**THE IMPLEMENTATION OF
SMOKING CESSATION CARE
IN GENERAL PRACTICE**

Marjolein E.A. Verbiest

The implementation of smoking cessation care in general practice

Leiden University Medical Centre
Department of Public Health and Primary Care
© Marjolein E.A. Verbiest, 2014

Lay-out Optima BV Rotterdam
Cover 'Portraits of Peuken' by Peter Janssen, www.portraits-of.nl
Print Optima BV Rotterdam
ISBN 978-90-9028611-2

This book is printed on recycled paper

All rights reserved. No part of this book may be reproduced in any form by print, photo print, microfilm, or any other means without written permission from the author

**THE IMPLEMENTATION OF
SMOKING CESSATION CARE
IN GENERAL PRACTICE**

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
te verdedigen op dinsdag 2 december 2014
klokke 13:45 uur

door

Marjolein Elisabeth Anna Verbiest
geboren te Bergen op Zoom
in 1986

PROMOTIECOMMISSIE

Promotores Prof. dr. W.J.J. Assendelft
 Prof. dr. A.A. Kaptein

Co-promotores Dr. M.R. Crone
 Dr. N.H. Chavannes

Overige leden Prof. dr. A.M. van Dulmen, Radboud Universiteit Nijmegen
 Prof. dr. M.E. Numans
 Prof. dr. M.C. Willemsen, Maastricht University

CONTENTS

Chapter 1	General introduction	7
Chapter 2	Training health professionals in smoking cessation care	23
Chapter 3	One-hour training for general practitioners in reducing the implementation gap of smoking cessation care: A cluster-randomized controlled trial	83
Chapter 4	Use of action planning to increase provision of smoking cessation care by general practitioners: Role of plan specificity and enactment	103
Chapter 5	Sequence-analysis of video-recorded practitioner-patient communication about smoking in general practice: Do smokers express negative statements about quitting?	127
Chapter 6	An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: Population based study	151
Chapter 7	General discussion	169
Chapter 8	Summary	185
	Nederlandse samenvatting	199
	Curriculum vitae	203
	Dankwoord	207

1

General introduction

1 *Customes lothsome to the eye, hatefull to the nose, harmefull to the braine, dangerous to*
2 *the lungs, and in the blacke stinking fume thereof, neerest resembling the horrible Stigian*
3 *smoke of the pit that is bottomelesse.*

4

5

King James I of England

6

1566 - 1625

7

8 The history of smoking starts in the Americas and dates back to as early as
9 5,000 BC.¹ Native Americans not only used tobacco for religious and recreational
10 purposes, it was also often part of rituals such as healing practices. Experienced
11 medicine men used tobacco as a painkiller for ear- and toothache. In addition, a
12 mix of tobacco and local vegetation was thought to be a particularly good reme-
13 dely for tuberculosis and asthma. With the arrival of Europeans in the sixteenth
14 century, the consumption, cultivation, and trading of tobacco quickly spread.
15 Tobacco smoking was then adopted for pleasure or as a socializing tool. With the
16 modernization of cigarette consumption, adverse health effects became increas-
17 ingly noticeable.

18 The first formal statistical evidence on the association between tobacco and
19 lung cancer was identified in Germany in the late 1920s.² Thereafter, scientific
20 studies on the health effects of smoking continued, and British epidemiologists
21 published the clear relationship between smoking and cancer in the British
22 Medical Journal in 1954.³ After years of intensive research this resulted in a wide
23 recognition of the negative influence of tobacco smoking on overall health. Po-
24 litical action against the usage of tobacco was prompted and resulted in multiple
25 governmental policies which were all aimed at the discouragement of tobacco
26 usage. Nowadays, it is widely recognized that tobacco smoking is one of the
27 largest contributors to non-communicable disease, primarily including cancers,
28 cardiovascular and chronic lung diseases, which account for 63% of all deaths
29 worldwide.⁴ For this reason, the World Health Organization (WHO) indicates the
30 tobacco epidemic as one of the biggest public health threats the world has ever
31 faced.⁵

32 Proven (cost-)effectiveness of many tobacco control measures has led to sub-
33 stantial political involvement in all parts of the world. In 2003, the Framework
34 Convention on Tobacco Control of the WHO summarized these measures into a
35 policy package called 'MPOWER' which has currently been ratified by 177 coun-
36 tries. The six evidence-based measures include: 1) Monitoring tobacco use and
37 prevention policies, 2) Protecting people from the hazardous effects of tobacco
38 smoke, 3) Offering help to smokers who want to quit, 4) Warning people for the
39 dangers of tobacco, 5) Enforcing bans on tobacco advertising, and 6) Raising

1 taxes on tobacco. Despite substantial progress in many countries – a third of the
2 world’s population is now covered by at least one of these measures – tobacco
3 use continues to be the leading global cause of preventable death.⁴

4 The global prevalence of daily tobacco smoking was approximately 18.6% in
5 2012; 31.3% for men and 6.2% for women aged 15 years and older.⁶ Prevalence
6 rates are substantially higher in developing countries than in developed coun-
7 tries. At the beginning of the 21st century, 80% of the approximately one billion
8 smokers worldwide live in low- and middle-income countries, such as Armenia,
9 Indonesia, and Russia, where daily smoking among men rises up to 54.0%, 55.8%,
10 and 48.8%, respectively.⁶ In Northern and Western Europe, North America and
11 the Western Pacific region, tobacco use is on a decline. However, a still relatively
12 high prevalence of tobacco smoking is measured in the Netherlands when com-
13 pared to other developed countries; 22.4% of Dutch adults aged 15 years or older
14 smoked in 2012, compared to only 18.4% in New Zealand, 17.2% in the United
15 States, 15.9% in Iceland, and 12.3% in Sweden.⁶

16

17

18 **SMOKING CESSATION**

19

20 The UN High-Level Meeting on Non-Communicable Diseases in New York identi-
21 fied tobacco control as the “most urgent and immediate priority” intervention to
22 reduce the prevalence of non-communicable diseases.⁷ However, smokers report
23 substantial difficulties when attempting to give up smoking; smoking is more
24 than an ingrained habit. The substance nicotine, which is present in all types of
25 cigarettes, has a highly addictive character and is known to elicit reinforcing ef-
26 fects, such as relaxation, reduced stress, enhanced vigilance, improved cognitive
27 function, mood modulation, and lower body weight. In addition, smokers report
28 negative reinforcing effects of nicotine which refer to withdrawal symptoms in
29 the context of physical dependence, such as nervousness, restlessness, irrita-
30 bility, anxiety, impaired concentration, impaired cognitive function, increased
31 appetite, and weight gain.^{8;9}

32 Yet the positive health effects of giving up smoking are instantly noticeable:
33 blood pressure and pulse rate stabilize within 20 minutes, carbon monoxide
34 levels in blood drops within eight hours, and the ability to smell and taste is
35 enhanced within 48 hours. Excessive risks of coronary heart diseases and lung
36 cancer death rates are decreased by 50% within one and five years after cessa-
37 tion, respectively.^{10;11} In general, the advantages of smoking cessation outweigh
38 the disadvantages.

39

1 Therefore, it may come as no surprise that, overall, 80% of the smokers report
2 their willingness to quit in the nearby future.^{12;13} The percentage of smokers
3 reporting a quit attempt in a given year is estimated to range from 28-46%.¹²⁻¹⁴
4 Without any support most relapses occur within eight days after the quit at-
5 tempt due to nicotine craving and insufficient plans regarding how to cope with
6 these moments of craving or temptation.¹⁵ Evidence-based behavioural support
7 delivered by healthcare professionals, nicotine replacement therapy (NRT), and
8 stop-smoking medication can assist smokers and facilitate smoking abstinence.¹⁶
9 In recent years, a series of randomized controlled trials, reviews, and reviews of
10 reviews have been performed on the effectiveness of various types of smoking
11 cessation interventions. The following interventions were found to significantly
12 benefit long-term quit rates compared to no intervention or a placebo: tailored
13 (written) quit smoking advice¹⁷⁻¹⁹, individual (telephone) counseling¹⁸⁻²², group
14 behavioural interventions^{18;19}, tailored self-help interventions^{18;20}, pharmaco-
15 therapy, including bupropion^{18;19;23;24}, varenline²⁴, nortriptyline^{19;23-25}, multiple
16 types of NRT^{18;19;24;26;27}, as well as a combination of behavioural interventions and
17 pharmacotherapy.^{28;29} Additionally, meta-analyses show the cost-effectiveness
18 of different forms of cessation support, such as NRT^{26;30}, stop-smoking medica-
19 tion^{31;32}, telephone counseling^{26;33-35}, and face-to-face (motivational interviewing)
20 cessation interventions³⁶, when compared to unsupported cessation.

21 22 23 **GENERAL PRACTICE** 24

25 In the Netherlands, every citizen has to be registered with a general practitioner
26 (GP). When encountering a health problem patients first visit their GP, who is
27 freely accessible and acts as a gatekeeper for specialized medical care.³⁷ Nearly
28 80% of the total population visits their GP on a yearly basis with an average of
29 four visits each year.³⁷⁻³⁹ The standard general practice in the Netherlands con-
30 sists of 2,350 patients and an average consultation has a length of ten minutes⁴⁰,
31 which results in considerable time pressure and workload for GPs. To reduce the
32 workload of GPs and improve the quality of care for chronically ill patients, with
33 a special focus on lifestyle counseling, practice nurses (PNs) were introduced in
34 Dutch general practice in 1999.⁴¹ PNs work under the supervision of GPs, manage
35 their consultations independently, and base their clinical practice on guidelines
36 developed by the Dutch College of General Practitioners (NHG) and on other
37 multidisciplinary guidelines. The collaboration between GPs and PNs provides
38 a good basis for identifying smokers, motivating them to quit, and delivering
39 effective quit smoking support.

1 **Guideline on smoking cessation care**

2 The first Dutch multidisciplinary guideline for the treatment of tobacco depen-
3 dence in health care was published in 2004.⁴² Subsequently, the NHG developed
4 the first guideline for the treatment of tobacco dependence in general practice in
5 2007.⁴³ This guideline is based on the widely accepted 5A-Model.⁴⁴⁻⁴⁸ The model
6 recommends GPs to actively Ask patients about their smoking behaviour. If a
7 patient smokes, GPs are urged to provide a patient-tailored Advise to quit, which
8 emphasizes the relevance of quitting and provides a direct link with the current
9 health status of the patient. Evidence shows that this intervention is time-
10 efficient and can increase cessation rates with 2-3% compared to unassisted quit
11 rates.^{49,50} Although this effect may seem small from a clinician's point of view, it
12 has the potential to result in substantial positive effects on public health level if
13 systematically provided.

14 Regardless of the smoker's motivation to quit, GPs are recommended to provide
15 the patient with information on the possibilities of quit smoking support in gen-
16 eral practice and offer them a follow-up appointment. The GP can also provide
17 the patient with educational leaflets. GPs are further recommended to Assess the
18 patient's willingness to quit and register the smoking status and degree of the
19 patient's quit intention systematically in the electronic patient record. Patients
20 who indicate their unwillingness to quit are asked their permission to discuss
21 smoking cessation during a future consultation.


22 If patients do indicate their willingness to quit, the guideline urges GPs to
23 directly Assist them with intensive quit smoking support, which anticipates both
24 psychological and physiological withdrawal symptoms. Previous unsuccessful
25 quit attempts are evaluated and potential difficult moments are summarized
26 in a quit plan which describes how the patient will cope with these moments
27 in advance. The GP should assess the patient's degree of nicotine dependence
28 in order to evaluate suitable pharmacological support such as NRT, bupropion,
29 nortriptyline, or varenicline. According to the guideline, patients who contem-
30 plate smoking cessation are assisted with a behavioural intervention aimed
31 at increasing their level of motivation. During this intervention, the guideline
32 recommends GPs to discuss the experienced advantages and disadvantages of
33 smoking, alongside the advantages of quitting. An essential component of this
34 intervention is the exploration of the barriers to cessation, such as fear of failure,
35 craving, and weight gain. The guideline informs GPs how to deal with these often
36 mentioned barriers. Finally, GPs are recommended to Arrange a follow-up ap-
37 pointment or a referral to the PN or external quit smoking support if they are
38 short on time and resources to provide the quit smoking support themselves.

1 Studies have shown that a successful implementation of the 5A-Model for
 2 smoking cessation care in general practice reduces smoking rates in patients
 3 compared to no intervention.⁴⁶⁻⁴⁸ Nevertheless, the introduction of innovations
 4 in healthcare, such as the 5A-Model for the treatment of tobacco dependence in
 5 Dutch general practice, is widely known to be a complex process.⁵¹

8 IMPLEMENTATION GAP

10 A study published in 2010 found that, over the years, lifestyle counseling has
 11 been given more priority in Dutch general practice.⁵³ Nevertheless, smoking is
 12 currently discussed in only a minority of all consultations (8.3%).⁵³ In addition,
 13 around 80% of all smokers and 40% of smokers who discuss smoking with their
 14 GP do not receive a quit smoking advice.⁵⁴ With regard to more intensive quit
 15 smoking support, GPs do not routinely refer their patients to PNs or external
 16 quit support.^{53;55} Also, these professionals apply motivational interviewing tech-
 17 niques only to a minor extent.^{53;55} Apparently, a substantial gap exists between
 18 the evidence-based knowledge on the treatment of tobacco dependence and
 19 real-world practices of primary care professionals.

20 GPs report numerous factors that influence their uptake of clinical guidelines
 21 for smoking cessation care. Figure 1 depicts a five-level social-ecological model
 22 in order to better understand these factors. This model looks beyond the indi-
 23 vidual GP and considers the complex interplay between all factors that influence
 24 the implementation of smoking cessation care in general practice. These factors
 25 are related to the GP, patient, organization, community, and public policy.



38 **Figure 1.** Social-ecological model: a theoretical framework depicting levels that influence the imple-
 39 mentation of smoking cessation guidelines in general practice

1 GP level

2 The first level of the model identifies GP-related determinants of implementa-
3 tion, including GPs' attitudes and beliefs, such as doubts regarding the (cost-)
4 effectiveness of routinely intervening on their patients' smoking behaviour⁵⁶⁻⁵⁸, a
5 lack of sufficient skills to deliver quit smoking support^{56;57;59} or low confidence in
6 these skills⁵⁷, and a lack of health education or training.⁵⁸⁻⁶¹

8 Patient level

9 The second level comprises patient-related determinants of implementation,
10 including the absence of smoke-related complaints^{59;62}, reluctance of the pa-
11 tient to discuss smoking cessation⁶³⁻⁶⁵, a high nicotine dependence, and a lack
12 of motivation to quit.^{56;58-60} This level also includes the interaction between GPs
13 and patients which may influence the likelihood of a successful implementa-
14 tion of smoking cessation care. These factors include GPs' fear for resistance of
15 patients^{56;66}, unpleasant personal experiences⁵⁷, and concerns about the doctor-
16 patient relationship.⁵⁸

18 Organization level

19 The third level addresses determinants of implementation within the general
20 practice, including a lack of time^{56-58;60}, the presence of a PN, and availability of
21 quit smoking interventions within the own organization.⁵⁶

23 Community level

24 The fourth level of the social-ecological model includes determinants of imple-
25 mentation within the community. These include a lack of overview of health
26 promoting programmes in the community, a lack of accessible and affordable
27 quit smoking programmes, and a lack of collaboration between general practices
28 and hospitals.⁵⁶

30 Public policy level

31 The fifth level looks at broader societal determinants that help to create a climate
32 in which the delivery of smoking cessation care in general practice is facilitated.
33 The most important factors include a lack of or unclearness regarding the reim-
34 bursement for quit smoking support^{56;67} and a lack of financial compensation for
35 the delivery of quit smoking care.^{56;58;60}

36
37
38
39

1 **FACILITATION OF GUIDELINE IMPLEMENTATION**

2
3 A number of theoretical frameworks have been developed in order to assess
4 implementation processes, explain implementation problems, and inform im-
5 plementation interventions.⁶⁸⁻⁷⁴ Several of these frameworks integrate behaviour
6 change theories that can be used to design implementation interventions.^{74,75} The
7 field of psychology includes an extensive body of evidence regarding such theo-
8 ries to predict and change human behaviour. In the past decade, researchers in
9 this field have acknowledged that clinical behaviour of healthcare professionals
10 can be regarded as a form of human behaviour.⁷⁵⁻⁷⁹ Therefore, a growing number
11 of interventions that aim to facilitate guideline implementation in healthcare
12 integrate such behaviour change theories. These theory-driven interventions
13 aim to improve guideline-recommended clinical behaviours of healthcare pro-
14 fessionals, thereby increasing the number of patients who receive care according
15 to these guidelines.

16 17 18 **AIM OF DISSERTATION**

19
20 The overall aim of this dissertation is to examine the implementation of guide-
21 line-recommended smoking cessation care in general practice. The five-level
22 socio-ecological model is the conceptual framework that guides this disserta-
23 tion. All empirical studies adress one or more factors related to the GP, patient,
24 organization, community, or public policy level, which determine the implemen-
25 tation of smoking cessation care in general practice. *Chapter two* discusses the
26 results of a meta-analysis on the effectiveness of training health professionals in
27 smoking cessation care. *Chapter three* addresses the effectiveness of a pragmatic,
28 practice-tailored training programme for GPs in which several determinants of
29 implementation were targeted. *Chapter four* examines whether action planning
30 among GPs is an effective strategy to increase the provision of guideline-recom-
31 mended smoking cessation care. *Chapter five* discusses the extent to which smok-
32 ers express negative statements about quitting when primary care professionals
33 provide guideline-recommended smoking cessation care. Additionally, this chap-
34 ter examines the degree to which smokers' negative statements about quitting
35 impede or facilitate the use of guideline-recommended smoking cessation care
36 by GPs and PNs. Finally, *chapter six* discusses the results of a population-based
37 study on the effects of two national tobacco control interventions (the introduc-
38 tion of the GP guideline for smoking cessation care in 2007 and the introduction
39 of full health insurance coverage for stop-smoking programmes in 2011) on GP

1 prescriptions of stop-smoking medication and on smoking prevalence in the
2 Netherlands.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

1 REFERENCES

- 2 1. Nies JE. Native American History. A Chronology of the Vast Achievements of a Culture
3 and Their Links to World Events. The Random House Publishing Group; 1996.
- 4 2. Roffo AH. The carcinogenic effects of tobacco. *Monatsschrift für Krebsbekämpfung*
5 1940; 8(5).
- 6 3. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary
7 report. *Brit Med J* 1954; 1(4877):1451-1455.
- 8 4. World Health Organization. WHO Report on the Global Tobacco Epidemic 2013:
9 Enforcing bans on tobacco advertising, promotion and sponsorship. 2013. Geneva,
10 Switzerland, World Health Organization. [http://apps.who.int/iris/bitstream/](http://apps.who.int/iris/bitstream/10665/85380/1/9789241505871_eng.pdf?ua=1)
11 [am/10665/85380/1/9789241505871_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/85380/1/9789241505871_eng.pdf?ua=1)
- 12 5. World Health Organization. Tobacco factsheet. 2012. Geneva, Switzerland, World
13 Health Organization. <http://www.who.int/mediacentre/factsheets/fs339/en/>
- 14 6. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B et al.
15 Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. *JAMA-J*
16 *Am Med Assoc* 2014; 311(2):183-192.
- 17 7. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P et al. Priority actions
18 for the non-communicable disease crisis. *Lancet* 2011; 377(9775):1438-1447.
- 19 8. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. *Annu Rev Pharmacol*
20 1996; 36:597-613.
- 21 9. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. *Arch Gen*
22 *Psychiat* 1986; 43(3):289-294.
- 23 10. U.S Department of Health and Human Services. What happens after you quit smoking?
24 The benefits of quitting smoking timeline. 2013. [http://www.healthline.com/](http://www.healthline.com/health-slideshow/quit-smoking-timeline)
25 [health-slideshow/quit-smoking-timeline](http://www.healthline.com/health-slideshow/quit-smoking-timeline)
- 26 11. Knol K, Hilvering C, Wagener DJTH, Willemsen M. Tabaksgebruik. Gevolgen en
27 Bestrijding. [Tabacco Use. Consequences and Control]. Utrecht: Uitgeverij LEMMA BV;
28 2005.
- 29 12. Borland R, Partos TR, Yong HH, Cummings KM, Hyland A. How much unsuccessful
30 quitting activity is going on among adult smokers? Data from the International
31 Tobacco Control Four Country cohort survey. *Addiction* 2012; 107(3):673-682.
- 32 13. STIVORO. Core figures of smoking in the Netherlands: An overview of recent Dutch
33 data regarding smoking behaviour. [Kerncijfers roken in Nederlands: Een overzicht
34 van recente Nederlandse basisgegevens over rookgedrag]. 2013. The Hague, the
35 Netherlands, STIVORO - For a smokefree future. [http://stivoro.nl/wp-content/up-](http://stivoro.nl/wp-content/uploads/factsheets/20130419%20Kerncijfers%20roken%20in%20Nederland_%202012.pdf)
36 [loads/factsheets/20130419%20Kerncijfers%20roken%20in%20Nederland_%202012.](http://stivoro.nl/wp-content/uploads/factsheets/20130419%20Kerncijfers%20roken%20in%20Nederland_%202012.pdf)
37 [pdf](http://stivoro.nl/wp-content/uploads/factsheets/20130419%20Kerncijfers%20roken%20in%20Nederland_%202012.pdf)
- 38 14. West R. Feasibility of a national longitudinal study ('The Smoking Toolkit Study')
39 to monitor smoking cessation and attempts at harm reduction in the UK. 2006.
London, United Kingdom, Cancer Research UK Health Behaviour Unit, University
College London. <file:///C:/Users/meaverbiest/Downloads/stp001.pdf>
15. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence
among untreated smokers. *Addiction* 2004; 99(1):29-38.
16. Modesto-Lowe V, Chmielewska A. Coping with urges to smoke: what is a clinician to
do? *Conn Med* 2013; 77(5):289-294.

- 1 17. Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation inter-
2 ventions: a systematic review and meta-analysis to compare advice to quit and offer
3 of assistance. *Addiction* 2011; 107(6):1066-1073.
- 4 18. Lemmers V, Oenema A, Klepp Knut I, Brug J. Effectiveness of smoking cessation
5 intervention among adults: a systematic review of reviews. *Eur J of Canc Prev* 2007;
6 17(5):535-544.
- 7 19. Willemsen MC, Wagena EJ, van Schayck CP. The efficacy of smoking cessation meth-
8 ods available in the Netherlands: a systematic review based on Cochrane data. *Neth
9 J Med* 2003; 147(19):922-927.
- 10 20. Lancaster T, Stead LF. Individual behavioural counseling for smoking cessation.
11 *Cochrane Database of Systematic Reviews* 2008; (4).
- 12 21. Stead LF, Perera R, Lancaster T. Telephone counseling for smoking cessation. *Co-
13 chrane Database of Systematic Reviews* 2006; (3).
- 14 22. Stead LF, Perera R, Lancaster T. A systematic review of interventions for smokers
15 who contact quitlines. *Tob Control* 2007; 16:3-8.
- 16 23. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane
17 Database of Systematic Reviews* 2007; (1)
- 18 24. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking
19 cessation: an overview and network meta-analysis. *Cochrane Database of Systemat-
20 ic Reviews* 2013; (5)
- 21 25. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review.
22 *Nicotine & Tobacco Research* 2005; 7(4):491-499.
- 23 26. Saul JE, Lien R, Schillo B, Kavanaugh A, Wendling A, Luxenberg M et al. Outcomes
24 and cost-effectiveness of two nicotine replacement treatment delivery models for
25 a tobacco quitline. *Internal Journal of Environmental Research and Public Health* 2011;
26 8(5):1547-1559.
- 27 27. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for
28 smoking cessation. *Cochrane Database of Systematic Reviews* 2008; (1)
- 29 28. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions
30 for smoking cessation. *Cochrane Database of Systematic Reviews* 2012; (10)
- 31 29. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for
32 smoking cessation. *Cochrane Database of Systematic Reviews* 2012; (12)
- 33 30. Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the
34 nicotine transdermal patch for smoking cessation. *Prev Med* 1997; 26(2):264-270.
- 35 31. Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T. Cost effective-
36 ness of varenicline versus bupropion and unaided cessation for smoking cessation
37 in a cohort of Finnish adult smokers. *Curr Med Res Opi* 2010; 26(3):549-560.
- 38 32. Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, Salto E et al. Cost-effectiveness
39 of pharmacotherapies for nicotine dependence in primary care settings: a multina-
tional comparison. *Tob Control* 2007; 15(3):152-159.
33. Fellows JL, Bush T, McAfee T, Dickerson J. Cost effectiveness of the Oregon quitline
"free patch initiative". *Tob Control* 2007; 16(1):47-52.
34. Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, Riedlinger K. The effective-
ness and cost effectiveness of telephone counseling and the nicotine patch in a
state tobacco quitline. *Tob Control* 2007; 16(1):53-59.

- 1 35. Parker DR, Windsor RA, Roberts MB, Hecht J, Hardy NV, Strolla LO et al. Feasibility, cost, and cost-effectiveness of a telephone-based motivational intervention for underserved pregnant smokers. *Nicotine & Tobacco Research* 2007; 9(10):1043-1051.
- 2
- 3 36. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling
- 4 study. *Value in Health* 2005; 8(3):178-190.
- 5
- 6 37. Schellevis FG, Westert GP, de Bakker DH. [The actual role of general practice in the
- 7 dutch health-care system. Results of the second dutch national survey of general
- 8 practice]. *Med Klin* 2005; 100(10):656-661.
- 9
- 10 38. Drenthen T. Challenges to prevention in Dutch general practice. *Am J Clin Nutr* 1997;
- 11 65:194-1945.
- 12
- 13 39. Verheij R.A., Schellevis FC, Hingstman L, de Bakker DH. Wat is huisartsenzorg? [Gen-
- 14 eral practice: How large is the usage and what does it consist of?] Nationaal Kompas
- 15 Volksgezondheid 2012. Bilthoven, the Netherlands.
- 16
- 17 40. Deveugele M, Derese A, Brink-Muinen A, Bensing J, De MJ. Consultation length in
- 18 general practice: cross sectional study in six European countries. *Brit Med J* 2002;
- 19 325(7362):472.
- 20
- 21 41. Heiligers PJM, Noordman J, Korevaar J, Dorsman S, Hingstman L, van Dulmen AM
- 22 et al. Praktijkondersteuners in de huisartspraktijk (POH's), klaar voor de toekomst?
- 23 [Practice nurses in general practice (PNs), ready for the future?]. 2012. Utrecht, the
- 24 Netherlands, NIVEL.
- 25
- 26 42. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Behandeling van Tabaks-
- 27 verslaving [Guideline Treatment of Tobacco Dependence]. Alphen aan den Rijn, the
- 28 Netherlands: Van Zuiden Communications B.V.; 2009.
- 29
- 30 43. Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al.
- 31 NHG-Standaard Stoppen met roken [Dutch College of General Practitioners Guide-
- 32 line for Smoking Cessation]. *Huisarts Wet* 2007; 50(7):306-314.
- 33
- 34 44. Fiore MC, Wetter DW, Bailey WC, Blennett G, Cohen SJ, Dorfman SF et al. The Agency
- 35 for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline.
- 36 *JAMA-J Am Med Assoc* 1996; 275(16):1270-1280.
- 37
- 38 45. Fiore MC, Jaén CR, Baker TB, Bailey WC, Bennett G, Benowitz NL et al. A clinical
- 39 practice guideline for treating tobacco use and dependence: 2008 update. A U.S.
- Public Health Service report. *Am J Prev Med* 2008; 35(2):158-176.
46. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal
- contact smoking cessation program for Dutch general practitioners: a randomized
- controlled trial. *Prev Med* 2001; 32(2):182-190.
47. Puschel K, Thompson B, Coronado G, Huang Y, Gonzalez L, Rivera S. Effectiveness of
- a brief intervention based on the '5A' model for smoking cessation at the primary
- care level in Santiago, Chile. *Health Promot Int* 2008; 23(3):240-250.
48. Takahashi K, Saso H, Saka H, Saso H, Iwata M, Hashimoto I et al. A pilot study on
- inducement of smoking cessation by a simple 5A (asking, advice, assess, assist, and
- arrange) approach at outpatient clinics. *Asian Pac J Canc Prev* 2006; 7(1):131-135.
49. Ashenden R, Silagy C, Weller D. A systematic review of the effectiveness of promot-
- ing lifestyle change in general practice. *Fam Pract* 1997; 14(2):169-176.
50. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane*
- Database Systematic Reviews 2008; (4).

- 1 51. Fleuren M, Wiefferink K, Paulussen T. Determinants of innovation within health care
2 organizations: literature review and Delphi study. *Int J Qual Health C* 2004; 16(2):107-
3 123.
- 4 52. Francke AL, Smit MC, de Veer AJ, Mistiaen P. Factors influencing the implementation
5 of clinical guidelines for health care professionals: a systematic meta-review. *Med*
6 *Inform Decis Mak* 2008; 8:38.
- 7 53. Noordman J, Verhaak P, van Dulmen S. Discussing patient's lifestyle choices in the
8 consulting room: analysis of GP-patient consultations between 1975 and 2008. *Fam*
9 *Pract* 2010; 11(87).
- 10 54. de Korte D, Nagelhout GE, Willemsen MC. Themapublicatie Stoppen-met-rokenadvi-
11 sering door huisartsen in Nederlands 2001-2009 [Smoking cessation advisement in
12 Dutch general practice 2001-2009] 2010. The Hague, the Netherlands, STIVORO - for
13 a smoke-free future.
- 14 55. Noordman J, Koopmans B, Korevaar JC, van der Weijden T, van Dulmen S. Exploring
15 lifestyle counseling in routine primary care consultations: the professionals' role.
16 *Fam Pract* 2012; 30(3):332-340.
- 17 56. Geense WW, van de Glind IM, Visscher TL, van Achterberg T. Barriers, facilitators and
18 attitudes influencing health promotion activities in general practice: an explorative
19 pilot study. *Fam Pract* 2013; 14(20).
- 20 57. Vogt F, Hall S, Marteau TM. General practitioners' and family physicians' negative
21 beliefs and attitudes towards discussing smoking cessation with patients: a system-
22 atic review. *Addiction* 2005; 100(10):1423-1431.
- 23 58. Young JM, Ward JE. Implementing guidelines for smoking cessation advice in Austra-
24 lian general practice: opinions, current practices, readiness to change and perceived
25 barriers. *Fam Pract* 2001; 18(1):14-20.
- 26 59. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs'
27 engagement in smoking cessation: a multi-country literature review. *Brit J Gen Pract*
28 2009; 59(566):682-690.
- 29 60. Pipe A, Sorensen M, Reid R. Physician smoking status, attitudes toward smoking, and
30 cessation advice to patients: an international survey. *Patient Educ Counseling* 2009;
31 74(1):118-123.
- 32 61. Twardella D, Brenner H. Lack of training as a central barrier to the promotion of
33 smoking cessation: a survey among general practitioners in Germany. *Eur J Public*
34 *Health* 2005; 15(2):140-145.
- 35 62. Hutchison BG, Abelson J, Woodward CA, Norman G. Preventive care and barriers
36 to effective prevention. How do family physicians see it? *Can Fam Physician* 1996;
37 42:1693-1700.
- 38 63. Coleman T, Murphy E, Cheater F. Factors influencing discussion of smoking between
39 general practitioners and patients who smoke: a qualitative study. *Brit J Gen Pract*
2000; 50(452):207-210.
64. Coleman T, Cheater F, Murphy E. Qualitative study investigating the process of giving
anti-smoking advice in general practice. *Pat Educ Counseling* 2004; 52:159-163.
65. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs'
engagement in smoking cessation: a multi-country literature review. *Brit J Gen Pract*
2009; 59(566):682-690.

- 1 66. Francis N, Rollnick S, McCambridge J, Butler C, Lane C, Hood K. When smokers are
2 resistant to change: experimental analysis of the effect of patient resistance on
3 practitioner behaviour. *Addiction* 2005; 100(8):1175-1182.
- 4 67. Krist AH, Woolf SH, Johnson RE, Rothemich SF, Cunningham TD, Jones RM et al.
5 Patient costs as a barrier to intensive health behaviour counseling. *Am J Prev Med*
6 2010; 38(3):344-348.
- 7 68. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA et al. Why don't
8 physicians follow clinical practice guidelines? A framework for improvement. *JAMA-*
9 *J Am Med Assoc* 1999; 282(15):1458-1465.
- 10 69. Ferlie EB, Shortell SM. Improving the quality of health care in the United Kingdom
11 and the United States: a framework for change. *Milbank Q* 2001; 79(2):281-315.
- 12 70. Fleuren M, Wiefferink K, Paulussen T. Determinants of innovation within health care
13 organizations: literature review and Delphi study. *Int J Qual Health C* 2004; 16(2):107-
14 123.
- 15 71. Grol RP, Bosch MC, Hulscher ME, Eccles MP, Wensing M. Planning and studying
16 improvement in patient care: the use of theoretical perspectives. *Milbank Q* 2007;
17 85(1):93-138.
- 18 72. Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of
19 health innovations: a systematic review of structural, organizational, provider,
20 patient, and innovation level measures. *Implement Sci* 2013; 8:22.
- 21 73. Flottorp SA, Oxman AD, Krause J, Musila NR, Wensing M, Godycki-Cwirko M et al. A
22 checklist for identifying determinants of practice: a systematic review and synthesis
23 of frameworks and taxonomies of factors that prevent or enable improvements in
24 healthcare professional practice. *Implement Sci* 2013; 8:35.
- 25 74. Huijg JM, Gebhardt WA, Crone MR, Dusseldorp E, Pesseau J. Discriminant content
26 validity of a theoretical domains framework questionnaire for use in implementa-
27 tion research. *Implementation Sci* 2014; 9:11.
- 28 75. Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A. Making psychologi-
29 cal theory useful for implementing evidence based practice: a consensus approach.
30 *Qual Safet Health C* 2005; 14(1):26-33.
- 31 76. Eccles MP, Grimshaw J, Walker A, Johnston M, Pitts N. Changing the behaviour of
32 healthcare professionals: the use of theory in promoting the uptake of research
33 findings. *J Clin Epidemiol* 2005; 58(2):107-112.
- 34 77. Eccles MP, Hrisos S, Francis J, Kaner EF, Dickinson HO, Beyer F et al. Do self- reported
35 intentions predict clinicians' behaviour: a systematic review. *Implementation Sci* 2006;
36 1(21).
- 37 78. Godin G, Belanger-Gravel A, Eccles M, Grimshaw J. Healthcare professionals' inten-
38 tions and behaviours: a systematic review of studies based on social cognitive
39 theories. *Implementation Sci* 2008; 3(36).
79. Perkins MB, Jensen PS, Jaccard J, Gollwitzer P, Oettingen G, Pappadopulos E et al.
Applying theory-driven approaches to understanding and modifying clinicians'
behaviour: what do we know? *Psychiatr Serv* 2007; 58(3):342-348.



2

Training health professionals in smoking cessation care

Kirsten V. Carson¹, Marjolein E.A. Verbiest²,
Mathilde R. Crone², Malcolm P. Brinn¹, Adrian J. Esterman³,
Willem J.J. Assendelft² & Brian J. Smith⁴ (2012)

¹Clinical Practice Unit, the Queen Elizabeth Hospital, Adelaide, Australia

²Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands

³University of South Australia, Adelaide, Australia

⁴Department of Medicine, University of Adelaide, the Queen Elizabeth Hospital, Adelaide, Australia

Cochrane Database of Systematic Reviews, issue 5

1 **ABSTRACT**

3 **Background**

4 Cigarette smoking is one of the leading causes of preventable death worldwide.
5 There is good evidence that brief interventions from health professionals can in-
6 crease smoking cessation attempts. A number of trials have examined whether
7 skills training for health professionals can lead them to have greater success in
8 helping their patients who smoke.

10 **Objectives**

11 To determine the effectiveness of training health care professionals in the de-
12 livery of smoking cessation interventions to their patients, and to assess the ad-
13 ditional effects of training characteristics such as intervention content, delivery
14 method and intensity.

16 **Search methods**

17 The Cochrane Tobacco Addiction Group's Specialised Register, electronic data-
18 bases and the bibliographies of identified studies were searched and raw data
19 was requested from study authors where needed. Searches were updated in
20 March 2012.

22 **Selection criteria**

23 Randomized trials in which the intervention was training of health care profes-
24 sionals in smoking cessation. Trials were considered if they reported outcomes
25 for patient smoking at least six months after the intervention. Process outcomes
26 needed to be reported, however trials that reported effects only on process out-
27 comes and not smoking behaviour were excluded.

29 **Data collection and analysis**

30 Information relating to the characteristics of each included study for interven-
31 tions, participants, outcomes and methods were extracted by two independent
32 reviewers. Studies were combined in a meta-analysis where possible and re-
33 ported in narrative synthesis in text and table.

35 **Main results**

36 Of seventeen included studies, thirteen found no evidence of an effect for
37 continuous smoking abstinence following the intervention. Meta-analysis of 14
38 studies for point prevalence of smoking produced a statistically and clinically
39 significant effect in favour of the intervention (OR 1.36, 95% CI 1.20 to 1.55, p=

1 0.004). Meta-analysis of eight studies that reported continuous abstinence was
2 also statistically significant (OR 1.60, 95% CI 1.26 to 2.03, $p=0.03$). Healthcare
3 professionals who had received training were more likely to perform tasks of
4 smoking cessation than untrained controls, including: asking patients to set a
5 quit date ($p<0.0001$), make follow-up appointments ($p<0.00001$), counseling of
6 smokers ($p<0.00001$), provision of self-help material ($p<0.0001$) and prescription
7 of a quit date ($p<0.00001$). No evidence of an effect was observed for the provi-
8 sion of nicotine gum/replacement therapy.

9 10 **Conclusions**

11 Training health professionals to provide smoking cessation interventions had a
12 measurable effect on the point prevalence of smoking, continuous abstinence
13 and professional performance. The one exception was the provision of nicotine
14 gum or replacement therapy, which did not differ between groups.

15 16 17 **INTRODUCTION**

18
19 Every year approximately 5.4 million people die from tobacco-related diseases,
20 translating to 1 in every 10 deaths among adults worldwide.¹ Approximately 80%
21 of those deaths are from people living in less developed countries and by 2030
22 this figure will increase to more than 8 million per year if no action is taken.¹
23 If current trends continue on this trajectory, an estimated 500 million people
24 alive today will be killed by tobacco. In the 27 countries that form the European
25 Union, over 25% of cancer deaths and 15% of all deaths can be attributed to
26 smoking. Smoked tobacco is known to cause up to 90% of all lung cancers and
27 is a significant risk factor for strokes and fatal heart attacks. In addition, tobacco
28 use is linked to the development and treatment of many oral diseases^{2,3} includ-
29 ing oral cancer, delayed wound healing and periodontitis contributing to loss of
30 teeth and edentulism.^{4,5}

31 32 **Description of the intervention**

33 Health professionals are at the forefront of tobacco epidemics as they consult
34 millions of people and can encourage them to quit smoking.⁶ In developed coun-
35 tries, more than 80% of the population will see a primary care physician at least
36 once a year, with doctors perceived to be influential sources of information on
37 smoking cessation.⁶⁻⁸ It has been reported that most dentists and dental hygien-
38 ists believe the lack of skills and training is a significant barrier to effectively
39 providing tobacco cessation interventions into routine care.^{4,9-11}

1 Providing training in smoking cessation care is one possible method for
2 increasing the number and quality of delivered interventions by primary care
3 health professionals, and a variety of training methods are available.¹²⁻¹⁴ To date,
4 individual studies have shown an effect of training on physician's activities, but
5 there have been doubts about the extent to which this translates into changes
6 in patient behaviour and actual smoking abstinence.¹⁵⁻¹⁷ Training health pro-
7 fessionals to deliver smoking cessation messages has been known to increase
8 the frequency with which interventions are offered to patients in the clinical
9 context.¹⁸

10 11 **How the intervention might work**

12 Provision of advice and support to smokers by healthcare professionals in
13 primary care settings has been shown to be the most cost-effective preventive
14 service and has a small but significant effect on cessation rates.¹⁹⁻²¹ Even though
15 these rates appear low from the perspective of many clinicians, they could
16 translate into a substantial public health benefit if consistently provided, as ap-
17 proximately 70-80% of adults have contact with a health care practitioner, usu-
18 ally in primary care, at least once each year.^{6-8;22} It is therefore disappointing that
19 despite ongoing developments in this field worldwide, the number of patients
20 who report receiving advice on smoking cessation from health professionals is
21 still low.²³

22 23 **Why it is important to do this review**

24 On a worldwide scale, tobacco use currently costs hundreds of billions of dollars
25 each year.²⁴ Data on the global impact of tobacco is incomplete, however it is
26 known to be high, with annual tobacco related health care costs being US\$81
27 billion for the USA, US\$7 billion for Germany and US\$1 billion for Australia.²⁵

28 The first systematic review on this topic was published over a decade ago
29 and showed that training health professionals to provide smoking cessation
30 interventions had a positive effect on professional performance. However, there
31 was no strong evidence that it changed smoking behaviour of patients.²⁶ Since
32 then, a number of new trials have examined whether specific skills training for
33 health professionals leads them to overcome frequently mentioned barriers and
34 to have greater success in helping their patients to quit smoking.

35 We therefore systematically identified and reviewed the evidence from new
36 published randomized controlled trials that have studied the effects of training
37 and supporting health care professionals in providing smoking cessation advice.
38 Furthermore, we assessed the effects of training characteristics, such as the
39 content, setting, and intensity.

1 Objectives

2 The aim of this review was to assess the effectiveness of training health care
3 professionals to deliver smoking cessation interventions to their patients, and to
4 assess the effects of training characteristics (such as contents, setting, delivery
5 and intensity).

8 METHODS

10 Criteria for considering studies for this review

12 Types of studies

13 We considered only randomized controlled trials.

15 Types of participants

16 We considered trials in which the unit of randomization was a healthcare prac-
17 titioner or practice, and that reported the effects on patients who were smokers.

19 Types of interventions

20 We considered interventions in which healthcare professionals were trained in
21 methods to promote smoking cessation among their patients. To be included
22 in the review studies had to have allocated healthcare professionals to at least
23 two groups (including one which received some form of training) by a formal
24 randomization process. Studies that used historical controls were excluded. We
25 included studies that compared a trained group to an untrained control group,
26 and studies that examined the effectiveness of adding prompts and reminders
27 to training.

29 Types of outcome measures

30 The primary outcome measure was abstinence from smoking six months or
31 more after the start of the intervention, assessed as:

- 33 • point prevalence (defined as not smoking at a set period (e.g., seven days)
34 prior to the follow-up), and
- 35 • continuous abstinence (defined as not smoking for an extended/prolonged
36 period at follow-up)

38 The strictest available criteria to define abstinence were used. In studies where
39 biochemical validation of cessation was available, only those participants who

1 met the criteria for biochemically confirmed abstinence were regarded as being
2 abstinent. Those lost to follow-up were regarded as being continuing smokers.
3 Secondary 'patient level' outcome measures included process variables such as
4 the number of smokers who were:

- 5
- 6 • asked to set a date for stopping (quit date)
 - 7 • given a follow-up appointment
 - 8 • counselled
 - 9 • given self-help materials
 - 10 • offered nicotine gum/replacement therapy
 - 11 • prescribed a quit date, and
 - 12 • cost effectiveness for interventions.
- 13

14 Secondary 'physician level' outcome measures include the number of referrals
15 made (to local smoking cessation services). To be included in the review, studies
16 had to assess changes in the long term smoking behaviour of patients. Stud-
17 ies which only assessed the effect of training on the consultation process were
18 excluded.

19

20 **Search methods for identification of studies**

21 We identified potentially relevant study reports from the Cochrane Tobacco Ad-
22 diction Group Specialised Register. This Register includes reports of trials and
23 other evaluations of interventions for smoking cessation and prevention, based
24 on regular highly sensitive searches of multiple electronic databases including
25 MEDLINE, EMBASE, PsycINFO and CENTRAL, and hand searches of conference
26 abstracts. For details of search strategies and dates see the Cochrane Tobacco
27 Addiction Group Module in the Cochrane Library. The most recent search of the
28 Register was in March 2012. Records were identified from the Register as poten-
29 tially relevant if they included the free text terms 'training' or 'trained' or the
30 MeSH keywords 'Education, Premedical' or 'Education, Professional' or 'Inservice
31 Training' or 'Physician's Practice Patterns' or 'Dentist's Practice Patterns' or
32 'Delivery of Health Care' or 'Comprehensive Health Care' or 'Critical Pathways'
33 or 'Disease Management' or the EMBASE indexing terms 'clinical education' or
34 'continuing education provider' or 'continuing education' or 'medical education'
35 as indexing terms. We conducted an additional search of MEDLINE (via OVID, to
36 2012 Feb week 5) exploding the same MeSH keywords in combination with the
37 terms for smoking cessation and controlled trials used in the regular search of
38 MEDLINE for the Specialised Register. Records included definite and probable
39 reports of randomized trials, and reviews.

1 Data collection and analysis

2

3 Selection of studies

4 Two reviewers (KC, MV) pre-screened all study reports identified from the Spe-
 5 cialised Register (limited to papers published after 1999 for this update). Articles
 6 were rejected if the title and/or abstract did not meet the inclusion/exclusion
 7 criteria. In instances where the study could not be categorically rejected, the
 8 full text was obtained and screened. Reference lists of screened articles were
 9 scanned for other potentially relevant articles. Two reviewers then independent-
 10 ly assessed the relevant studies for inclusion (KC and MV), with discrepancies
 11 resolved by consensus.

12

13 Data extraction and management

14 A combination of two reviewers independently extracted data from published
 15 reports (KC, MV, and MB). Disagreements were resolved by referral to a third
 16 party. No attempt was made to blind any of these reviewers to either the results
 17 of the primary studies or the intervention the subjects received. The data extrac-
 18 tion process identified information on the following design characteristics:

19

- 20 • Country and setting of study
- 21 • Description of training delivery method, duration, content
- 22 • Number of therapists (intervention, control, post randomization dropouts)
- 23 • Number of patient participants (intervention, control, losses to follow-up in
 24 each condition), method of identification/enrolment
- 25 • Number of patients per therapist (range and/or average)
- 26 • Description of intervention and control conditions
- 27 • Definition of abstinence for smoking cessation outcome(s), duration of
 28 follow-up, method of biochemical validation if used
- 29 • Secondary outcomes reported

30

31 Data was extracted and entered into Review Manager for the following outcome
 32 variables, where reported:

33

- 34 • Point prevalence abstinence at longest follow-up (preferred outcome for
 35 meta-analysis is continuous or sustained abstinence)
- 36 • Continuous or sustained smoking abstinence at longest follow-up
- 37 • Cost effectiveness analysis for intervention

38

39

1 We also extracted data on process outcomes where reported. These included
2 patient reported or documented delivery of interventions, such as: setting a quit
3 date, making a follow-up appointment, number of smokers counselled, provi-
4 sion of self-help materials, prescription of nicotine replacement therapy and/or
5 prescription of a quit date.

6 7 **Assessment of risk of bias in included studies**

8 Two reviewers independently assessed the full text versions of all included papers
9 for risk of bias using the Cochrane Handbook guidelines, using a domain-based
10 evaluation.²⁷ In addition, extra criteria developed by the Cochrane EPOC Group
11 (2009) were used to address potential sources of bias related to clustering effects.
12 These domains included sequence generation, allocation concealment, blind-
13 ing for participants, blinding for outcome assessors, incomplete outcome data,
14 selective reporting, imbalance of outcome measures at baseline, comparability
15 of intervention and control group characteristics at baseline, protection against
16 contamination, selective recruitment of participants and any other sources of
17 potential biases. The risk of bias was assessed for each domain as 'high risk', 'low
18 risk', and 'unclear risk' (using the guidelines from Table 8.5.c of the Cochrane
19 Handbook²⁷). Two of three reviewers (KC, MV or MB) independently assessed
20 the included studies for risk of bias. Conflicts were resolved by consensus or by
21 referring to a third party if disagreement persisted.

22 23 **Unit of analysis issues**

24 The trials included in the review used cluster randomization. Outcomes relate to
25 individual patients whilst allocation to the intervention is by provider or practice,
26 and ignoring this may introduce unit of analysis errors. Using statistical methods
27 which assume for example that all patients' chances of quitting are independent
28 ignores the possible similarity between outcomes for patients seen by the same
29 provider. This may underestimate standard errors and give misleadingly narrow
30 confidence intervals, leading to the possibility of a type 1 error. All trials were ex-
31 pected to be cluster randomized studies, with analysis performed at the level of
32 individuals whilst accounting for the clustering in the data. This was performed
33 by using a random effects model for pooled meta-analysis as recommended in
34 the Cochrane Handbook (Chapter 16.3.3)²⁷ and checked by a statistician (AE).
35 For those studies which did not adjust for clustering the actual sample size was
36 replaced with the effective sample size (ESS), calculated using a $\rho = 0.02$.²⁸
37 Trials may use a variety of statistical methods to investigate or compensate
38 for clustering; we have recorded whether studies used these and whether the
39 significance of any effect was altered. In instances where the studies appeared

1 homogenous via a combination of the statistical I^2 test in addition to homogene-
2 ity expressed in the visual inspection of a Funnel plot we meta-analysed using
3 a fixed effect model. However in the presence of significant heterogeneity (as
4 defined below under 'Data Synthesis') the random effects model was used. In the
5 case of multi-arm trials each pair-wise comparison was included separately, but
6 with shared intervention groups divided out approximately evenly among the
7 comparators. However, if the intervention groups were deemed similar enough
8 to be pooled, the groups were combined using appropriate formulas in the Co-
9 chrane Handbook.²⁷

10 11 **Dealing with missing data**

12 Missing participant data were evaluated on an available case analysis basis
13 as described in Chapter 16.2.2 of the Cochrane Handbook.²⁷ Missing standard
14 deviations were addressed by imputing data from the studies within the same
15 meta-analysis or from a different meta-analysis as long as these use the same
16 measurement scale, have the same degree of measurement error and the same
17 time periods (between baseline and final value measurement, as per Chapter
18 16.1.3.2 of the Cochrane Handbook)²⁷. Where statistics essential for analysis
19 were missing (e.g. group means and standard deviations for both groups are
20 not reported) and could not be calculated from other data, we attempted to
21 contact the authors to obtain data. Loss of participants that occurred prior to
22 performance of baseline measurements was assumed to have no effect on the
23 eventual outcome data of the study. Losses after the baseline measurement were
24 taken were assessed and discussed. Studies that had more than 30% attrition
25 (i.e., deaths and withdrawals) were reported in text only and excluded from the
26 meta-analysis. We made an attempt to contact all authors for verification of
27 methodological quality, classification of the intervention(s) and outcomes data.
28 We attempted to contact the second author if we were unsuccessful in contact-
29 ing the first author.

30 31 **Assessment of heterogeneity**

32 The review was expected to have some heterogeneity due to factors such as
33 differing characteristics of clinics, practices and medical surgeries, differences
34 in intervention characteristics and varying measurement tools used to assess
35 outcomes. The Chi^2 and I^2 statistic²⁷ were used to quantify inconsistency across
36 studies. The presence of significant heterogeneity was further explored through
37 subgroup analyses. These were conducted for:

38
39

- 1 • 'treatment type' (e.g., counseling alone, counseling plus nicotine replacement
- 2 therapy, counseling plus request for additional appointments, etc.)
- 3 • 'treatment intensity' (number of sessions)
- 4 • 'treatment intensity' (total exposure)
- 5 • 'mode of delivery' (e.g., face-to-face, group sessions or both)
- 6 • 'behavioural change techniques' (e.g., prompting, providing feedback, use of
- 7 behavioural change theories)
- 8 • 'type of professional being trained' (e.g., dentist, doctor, health care worker
- 9 etc.)
- 10 • 'length of follow-up' (i.e., >6 to <9 months, >9 to <12 months, >12 to <24
- 11 months), and
- 12 • 'risk of bias' (i.e., high risk of bias for: < 2 domains, 3 – 5 domains, 6 - 8
- 13 domains or > 9 domains).

14

15 The likelihood of false positive results among subgroup analyses increase with
16 the number of potential effect modifiers being investigated.²⁷ As such we have
17 adjusted these analyses using a Holm-Bonferroni method using $\alpha = 0.05$.

18

19 **Assessment of reporting biases**

20 With the inclusion of more than ten included studies, potential reporting biases
21 were assessed using a funnel plot. Asymmetry in the plot could be attributed to
22 publication bias, but may well be due to true heterogeneity, poor methodologi-
23 cal design or artefact. Contour lines corresponding to perceived milestones of
24 statistical significance ($p = 0.01, 0.05, 0.1$ etc.) were applied to funnel plots, which
25 may help to differentiate between asymmetry due to publication bias from that
26 due to other factors.²⁷

27

28 **Data synthesis**

29 For dichotomous outcomes the fixed effect model with an odds ratio (OR) was
30 calculated with 95% confidence interval (CI), which was synthesised using in-
31 verse variance. However for outcomes with greater than 10 included studies a
32 test for heterogeneity was conducted using a combination of two methods. If
33 heterogeneity was found (defined as the I^2 test >60% and visual inspection of
34 the funnel plot indicating no clustering of large or small studies) the random
35 effects model was used in place of the fixed effect model, as suggested by the
36 Cochrane Handbook (Section 9.5.2 and 9.5.3).²⁷ Reasons for heterogeneity are
37 further explored in the discussion. When studies appeared homogenous, the
38 meta-analysis was redone using the fixed effect model.

39

1 For continuous outcomes, a fixed effect model with a weighted mean dif-
2 ference (WMD) or standardised mean difference (SMD) with 95% confidence
3 intervals were calculated as appropriate. However, in the presence of significant
4 heterogeneity (as defined above) the random effects model was used in place of
5 the fixed effect model.

6 7 **Sensitivity analysis**

8 Sensitivity analysis was conducted on studies with an unclear or high risk of bias
9 for sequence generation and/or allocation concealment.

10 11 12 **RESULTS**

13 14 **Description of studies**

15 Table 1 (p. 58) shows the characteristics of included studies.

16 17 **Results of the search**

18 Of 381 articles screened, 17 studies met all of the inclusion criteria (see Figure 1).


19 20 **Included studies**

21 22 **Design**

23 All 17 included studies used a randomized controlled trial design with clustering
24 and eleven studies also adopted nesting of participants within practices/hospitals.
25 ^{4,15,17,29-35} One study incorporated a 2x2 factorial design with randomization
26 to: training plus incentive, training plus medication, training plus incentive and
27 medication or usual care.¹²

28 29 **Sample sizes**

30 In total 28,531 patients were assessed at baseline (following randomization)
31 with 21,031 remaining in the studies at final follow-up. Authors report a total of
32 1,434 individual health professionals recruited at baseline (across a known 260
33 practices) with follow-up available for 1,204. Sample sizes for individual studies
34 were medium to large, with the smallest number of patients (randomized at
35 baseline) found in the Wang 1994 study (n= 93) and the largest in the Kottke 1989
36 study. The smallest sample at follow-up remained with the Wang 1994 study (n=
37 82), and the largest remained with the Kottke 1989 study (n= 5266). At the health
38 professional level, the Hymowitz 2007 study had the largest number of residents
39 randomized at baseline (n= 275) and follow-up (n= 235) and likewise, Wang 1994



27 **Figure 1.** Study flow diagram

28
29 had the smallest number of residents at baseline and follow-up ($n=27$ for both).
30 Seven studies also reported baseline cluster sizes at the practice level: Lennox
31 1998 ($n=16$); Sinclair 1998 ($n=62$); Swartz 2002 ($n=50$); Joseph 2004 ($n=20$);
32 Hymowitz 2007 ($n=16$); Twardella 2007 ($n=82$); and Gordon 2010 ($n=14$).

34 Setting

35 Eleven of the 17 studies were conducted in the USA, one in Canada³⁴, one in Tai-
36 wan³⁶, one in Scotland³⁷, one in the United Kingdom³⁵, one in Switzerland³⁸ and
37 one in Germany.¹² Two studies were performed in a dentistry setting^{4;30}, whilst
38 the remaining 15 were conducted within primary care clinics, HMO (Health
39

1 Maintenance Organisation) medical centres^{15;39}, VAMC's (Veterans Affairs Medi-
 2 cal Centres)⁴⁰ and one in a pharmacy setting.³⁷

3

4 **Participants**

5 At the health professional level, two studies were performed with dentists^{4;30}, six
 6 studies included only primary care physicians^{12;15;17;29;33;34}, two studies were con-
 7 ducted with residents^{31;38}, three studies incorporated a combination of primary
 8 care physicians and internists^{15;32;36}, one study used pharmacists³⁷, whilst the
 9 remaining three studies used a combination of health professionals including
 10 physicians, nurse practitioners, physician assistants, psychologists, pharmacists
 11 and other health visitors.^{35;39;40}

12 The individual patients in 16 of the 17 included studies were those visiting
 13 their health professional during the recruitment phase of each study. They were
 14 recruited during standard GP, dentist or outpatient visits, emergency depart-
 15 ment visits or from waiting rooms. The Hymowitz 2007 study was the only one
 16 to perform the training in a paediatric setting, targeting the parents/guardians
 17 of children visiting 16 primary care clinics.³¹

18

19 **Interventions**

20

21 *Treatment type*

22 Six studies provided patients with a counseling plus nicotine replacement ther-
 23 apy intervention arm.^{12;29;30;34;37;40} The two Cohen et al studies had a second inter-
 24 vention arm of counseling plus a reminder for physicians to ask about smoking
 25 (chart prompt), and a third intervention arm combining the counseling, nicotine
 26 replacement therapy and chart prompt.^{29;30} Another study¹² also had three in-
 27 tervention arms: counseling plus nicotine replacement therapy; counseling plus
 28 a monetary incentive to the physician following study completion per success-
 29 ful smoke-free participant (€130); and a counseling plus nicotine replacement
 30 therapy plus incentive arm. The Wilson 1988 study had two intervention arms
 31 in addition to usual care: counseling and nicotine gum (as mentioned above)
 32 and a second arm of nicotine gum plus usual care (i.e., physicians were not
 33 trained in counseling).³⁴ Three studies included multiple intervention methods
 34 to curtail smoking including counseling, nicotine replacement therapy, request
 35 for additional follow-up appointments and provision of self-help materials^{4;15;16},
 36 whilst one study combined three of those four (counseling, nicotine replacement
 37 therapy, and self-help materials).³⁸ Five studies used counseling alone^{32;33;35;36;39}
 38 and two studies used counseling with the addition of self-help materials.^{17;31}

39

1 *Treatment intensity*

2 The level of training intensity for health professionals ranged from one 40-min-
 3 ute session in the Unrod 2007 study, to four or five day long sessions in the Joseph
 4 2004 study. Nine studies had a training session for one day or less: Wilson 1988
 5 (four hours), Cohen (Dent) 1989 (one hour), Cohen (Doc) 1989 (one hour), Kottke
 6 1989 (6 hours), Lennox 1998 (one day), Sinclair 1998 (two hours), Twardella 2007
 7 (two hours), Unrod 2007 (40 minutes) and Gordon 2010 (three hours). Four studies
 8 had two separate sessions: Strecher 1991 (two, one hour sessions scheduled two
 9 weeks apart), Wang 1994 (two sessions of unknown duration), Cornuz 2002 (two,
 10 four hour training sessions scheduled two weeks apart) and Swartz 2002 (two, 20
 11 minute training sessions and another session of unknown duration, where resi-
 12 dents were able to practice counseling techniques with standardised patients).
 13 Four studies had three or more sessions: Cummings (Priv) 1989 and Cummings
 14 1989 both had three, one hour sessions over a four to five week period, Hymowitz
 15 2007 had four, one hour sessions, four times a year and Joseph 2004 had four to
 16 five, day long sessions within six months.

17

18 *Mode of intervention delivery*

19 Three different modes of intervention delivery were used being groups ses-
 20 sions, one-on-one or a combination of the two. Two studies only used one-on-
 21 one sessions^{33;40}, eleven studies delivered the intervention in a group setting
 22 only^{4;12;15;17;31;32;34-37;39} with an eighth study using group delivery as the primary
 23 mode, however doctors who were unable to attend received a private session in
 24 their office.¹⁵ Finally three studies used both modes of intervention delivery^{29;30;38},
 25 with health professionals in the two Cohen et al studies provided the option of a
 26 group or individual session.^{29;30}

27

28 *Theoretical model - behavioural change technique*

29 Nine studies used behavioural change theories to underpin the intervention
 30 techniques. These included the 'stages of change' (also known as the trans-
 31 theoretical) model^{12;17;32;35-38} and the '5A' (Ask, Assess, Advise, Assist and Arrange)
 32 approach.^{4;33} Three studies incorporated prompting or reminders to ask about
 33 tobacco use²⁹⁻³¹ and four provided feedback to the health providers, for example
 34 number of patients counselled.^{33;38-40}

35

36 *Type of professional being trained*

37 Two studies only focused on dentists^{29;30}, one focused on pharmacists³⁷, and the
 38 remaining fourteen studies all involved doctors. Five of these fourteen studies
 39 included doctors still undergoing training, either residents^{31;32;36;38} or a combina-

tion of physicians and internists.¹⁵ Three other studies included training to other health care workers as well as doctors: Lennox 1998 also involved nurses and other health visitors; Swartz 2002 also trained nurse practitioners, physicians assistants and other health professionals; and, in addition to doctors, Joseph 2004 included nurses, psychologists and pharmacists.

Length of follow-up

Eight studies reported follow-up periods between six and nine months post intervention^{4;29;30;32;33;35-37}, eleven studies presented 12 month follow-up data^{4;12;15;17;29;30;34;36;38-40} and two studies assessed extended follow-up periods of 14 months³⁵ and four years.³¹ However, only two-year post intervention data was available for Hymowitz 2007 at the time of writing.

Outcomes

Smoking abstinence was assessed in all included studies through self-report of either continuous abstinence (no smoking for an extended period of time) or point prevalence (for example, no smoking for seven days prior to the time of outcome collection). Of the eight studies that reported continuous abstinence, six also reported a point prevalence measure of abstinence.^{4;15;16;34;35;37} Ten of the included studies used biochemical validation through either exhaled carbon monoxide^{29;30;32;38}, serum cotinine^{12;17}, saliva cotinine^{33;34} or a combination of exhaled carbon monoxide and serum cotinine.^{15;16} A number of secondary outcomes measures were reported by some studies including: patients asked to set a quit date; patients asked to make a follow-up appointment; number of smokers counselled; number of smokers receiving self-help material; number of smokers receiving nicotine gum/replacement therapy; and number of smokers prescribed a quit date. Two studies reported n-values as a total across both intervention and control arms^{29;30} and six studies reported n-values as percentages, which had to be transformed into whole numbers.^{31;33;34;38-40} As such there is likely to be some small variance between actual n-values and those reported in these analyses, but this is not significant. Seven studies had multiple intervention arms, which were considered similar enough to be pooled together, two in the Wilson 1988, Kottke 1989 and Wang 1994 studies and three intervention arms in the Cohen (Dent) 1989, Cohen (Doc) 1989, Strecher 1991 and Twardella 2007 studies. One study did not report the n-value for subjects at randomization, and hence this was calculated based on the number eligible for study and the number at follow-up.³² The Kottke 1989 study reported all outcome data as continuous variables, as such it was unable to be pooled in the meta-analyses. Smoking related outcomes

1 in the Hymowitz 2007 study were unable to be pooled as only change scores from
2 baseline were presented.

3

4 **Excluded studies**

5 Sixty-five studies (71 articles) were excluded for the following reasons: 21 in-
6 cluded consultation process only, 18 did not include a control group, 13 failed to
7 measure smoking related outcome data, 12 were considered to be inadequately
8 randomized and one only reported on smokeless tobacco use.

9

10 **Risk of bias in included studies**

11 Key methodological features are summarised in Figure 2.

12

13 **Random sequence generation (selection bias)**

14 Five studies reported adequate methods of sequence generation^{12;15;31;33;38}, two
15 had inadequate methods^{17;32} whilst the remaining ten did not provide enough in-
16 formation to assess risk of bias for sequence generation and were hence judged
17 to be at unclear risk in this category. Adequate methods included the use of a
18 random number generator or coin toss, whilst unclear methods were described
19 as being 'random' in design, however methods were not described. The Kottke
20 1989 study required some physicians to be re-assigned due to inappropriate al-
21 location methods during assignment. For the Strecher 1991 study appropriate
22 randomization did not occur as residents were randomly assigned by clinic half-
23 day session to one of four groups, which risks introducing bias. All 17 trials used
24 cluster randomization, with five studies inadequately accounting for potential
25 clustering effects in the data, requiring manual clustering adjustments.^{15-17;34;36}
26 Only two studies^{17;31} reported outcome data at the level of randomization. No
27 authors reported that differences in the method of analysis affected the results.

28

29 **Allocation concealment (selection bias)**

30 Allocation concealment was unclear in all 17 included studies as authors did
31 not describe methods of allocation concealment. Authors of the Lennox 1998
32 study report that physicians were randomly and blindly allocated to control or
33 intervention groups, however the methods were not described. Another study
34 mentioned that an independent research assistant concealed the result of
35 randomization until two weeks before the intervention, when residents were
36 provided with details about training sessions, however, methods of concealment
37 were again not reported.³⁸

38

39

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39




Figure 2. Risk of bias graph: review authors' judgement about each risk of bias presented as percentages across all included studies

1 Blinding of participants (performance bias and detection bias)

2 Only one study reported adequately blinding participants to the intervention³⁸,
3 as residents were not informed about the aim of the trial and were advised only
4 that a survey on cardiovascular risk factors and prevention would be conducted.
5 Authors announced that a training programme in clinical prevention that in-
6 cluded sessions on smoking cessation and management of dyslipidemia was
7 being conducted. Authors also report that patients were blinded to the aim of the
8 study and group allocation of their physician. Due to the nature of the interven-
9 tion, blinding of participants was not possible for the remaining 16 studies. An
10 attempt was made to blind physicians in the Unrod 2007 study, with physicians
11 learning their group assignment only after signing the informed consent, how-
12 ever they were not blinded during the study intervention period and follow-up.

13

14 Blinding of outcome assessors (performance bias and detection bias)

15 Three studies reported methods blinding of outcome assessors that we judged at
16 low risk of bias. Authors of Cummings (Priv) 1989 stated that 'outcome assessors
17 were blinded', authors of the Joseph 2004 study report interviewers collecting
18 patient outcomes were blinded to subject treatment status and authors in the
19 Strecher 1991 study report that telephone interviewers, who were blinded to
20 residents' and patients' group assignments, obtained the patient reports. The
21 remaining 14 studies did not report any attempts to blind outcome assessors
22 and as such are unclear for this category.

23

24 Incomplete outcome data (attrition bias)

25 Incomplete outcome data was adequately addressed in three studies^{4;15;16} and
26 unclear in the remaining 14 studies. The Cummings (Priv) 1989 and Cummings
27 1989 studies reported that missing data was accounted for in analyses, whilst
28 the Gordon 2010 study reported the use of multiple imputation procedures to
29 account for missing data with participants lost to attrition discussed in the text.
30 All unclear studies failed to mention if there was any missing outcome data and
31 if so, how this was addressed when reporting results.

32

33 Selective reporting (reporting bias)

34 Selective reporting was evident in three studies^{4;31;33}, unclear in three studies^{17;32;36}
35 and not detected in the remaining eleven studies. Although all pre-specified out-
36 comes were addressed in the four year follow-up for the Hymowitz 2007 study,
37 the authors mention that outcome data for year one was omitted in order to pro-
38 vide a 'cleaner look' at the progress of the data. In the Unrod 2007 study, smoking
39 abstinence from baseline to follow-up (an outcome that would be expected to

1 have been assessed in this study) was not reported. The Gordon 2010 authors
 2 report that secondary participant outcomes were examined with no significant
 3 differences on any variables, and that therefore they were not presented in the
 4 publication. Also, receipt of intervention was reported in text as percentages,
 5 however no information regarding this outcome was reported for the control.

6 7 **Imbalance of outcome measures at baseline**

8 One study did not report data for baseline smoking and made no mention of
 9 statistical analyses to potentially adjust for any imbalances³⁶, as such the risk
 10 of bias category was assessed as unclear. All remaining studies adequately ad-
 11 dressed imbalances of outcome measures at baseline. Thirteen studies accounted
 12 for baseline imbalances through analysis of covariance, regression analyses or
 13 other analysis techniques, whilst three studies reported outcomes at baseline to
 14 be similar across groups and as such did not require adjustment.^{16;35;37}

15 16 **Comparability of intervention and control group characteristics at baseline**

17 Five studies had unclear comparability between intervention and control groups
 18 at baseline^{12;15;29;30;34} and the remaining twelve studies adequately addressed any
 19 differences found between groups via appropriate analysis methods.

20 21 **Protection against contamination**

22 Two studies reported contamination.^{4;32} In Gordon 2010, authors reported
 23 contamination due to a tax increase on cigarettes in New York, which resulted
 24 in a drop in smoking prevalence from 18.4% in 2006 to 15.8% in 2008. Authors
 25 believed that this tax increase contributed to the unusually high rate of smoking
 26 cessation in the usual care patients, thereby affecting the relative impact of the
 27 intervention. Authors of the second study, Strecher 1991, mention that “all four
 28 groups worked closely with one another at each site”, leading to the possibility
 29 of contamination, however they also state that “...the effects appeared to be
 30 slight.” Nine studies had unclear risk of bias for contamination with insufficient
 31 information to permit a judgement of yes or no, whilst the remaining six studies
 32 reported no potential contamination during the study period.^{15-17;34;35;38}

33 34 **Selective recruitment of participants**

35 Although no studies were identified as having selectively recruited participants,
 36 this could not be completely ruled out for eleven studies, which were deter-
 37 mined to have an unclear risk of bias for this outcome.^{4;12;15;17;29;30;32;34;36;37;39} The
 38 sampling frames in these studies were unclear and as such, generalisability is of

1 a potential concern. The remaining six studies adequately reported recruitment
2 methods and were determined as having a low risk of bias.

3

4 **Other bias**

5 No other biases were identified for the 17 included studies.

6

7 **Effects of interventions**

8 Intervention effectiveness was assessed in all seventeen included studies
9 through smoking prevalence, as well as through multiple secondary outcomes.

10 All data were analysed as per the pre-defined methodology outlined in the
11 Methods section. For a summary of intervention effectiveness for each of these
12 outcomes see Table 2.

13

14 **Overall summary of smoking behaviour**

15 Four out of 13 studies detected significant intervention effectiveness in training
16 health professionals to influence point prevalence of smoking in their patients
17 at primary follow-up.^{4,12,29,38} Out of the eight studies reporting continuous absti-
18 nence at primary follow-up, only one reported a statistically significant effect
19 in favour of the intervention.⁴ Fifteen of the 17 included studies (the exceptions
20 being Kottke 1989 and Hymowitz 2007) could be included in a meta-analysis for
21 the primary outcome of smoking (see Appendix 1: Analysis 1.1a and 1.1b). Using
22 a fixed effect model there was a statistically and clinically significant effect in
23 favour of the intervention for point prevalence abstinence (OR 1.36, 95% CI 1.20
24 to 1.55, 14 trials, $I^2 = 57\%$) and continuous abstinence (OR 1.60, 95% CI 1.26 to
25 2.03, 8 trials, $I^2 = 59\%$). Using only the stricter outcome of continuous abstinence
26 for studies reporting both types of cessation, a pooled estimate for all 15 trials
27 gave a similar estimate (OR 1.60, 95% CI 1.35 to 1.89, $I^2 = 55\%$, data not dis-
28 played). Since the heterogeneity in this analysis approached the level at which
29 we proposed a random-effects model we did a sensitivity analysis; the point
30 estimates were similar and the wider confidence intervals continued to exclude
31 no effect. The trial contributing most evidently to the heterogeneity, particularly
32 for the continuous outcome, was Lennox 1998 in which the point estimates for
33 both abstinence outcomes favoured the control group. Two studies could not be
34 included in the meta-analyses. In the Kottke 1989 study at one year follow-up
35 almost half of the participants in each group who were smoking at baseline
36 reported quit attempts for at least 24 hours during the previous year, with a
37 mean duration of cessation of two months. No differences between the three
38 groups were identified. For the Hymowitz 2007 study there was an increase in the
39 special training condition of reported quitting during the past year of 3.8% (an

Table 2. Summary of findings for the main comparisons

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)**
	Assumed risk	Corresponding risk			
	Control	Training health professionals			
Point prevalence of smoking cessation self-report and some biologically validated Follow-up: 6 to 14 months	78 per 1000	107 per 1000 (88 to 131)	OR 1.41 (1.13 to 1.77)	13459 (14 studies)	⊕⊕⊕⊖ moderate ^{1,2}
Continuous smoking abstinence self-report and some biologically validated Follow-up: 6 to 14 months	27 per 1000	42 per 1000 (28 to 62)	OR 1.59 (1.05 to 2.42)	9443 (8 studies)	⊕⊕⊕⊖ moderate ^{1,2}
Number of smokers counselled self-report Follow-up: 6 to 48 months	465 per 1000	664 per 1000 (578 to 739)	OR 2.28 (1.58 to 3.27)	8531 (14 studies)	⊕⊕⊕⊖ low ^{1,3}
Patients asked to make a follow-up appointment self-report Follow-up: 6 to 12 months	166 per 1000	400 per 1000 (233 to 593)	OR 3.34 (1.52 to 7.30)	3114 (7 studies)	⊕⊕⊕⊖ very low ^{1,2,3}
Number of smokers receiving self-help material self-report Follow-up: 6 to 48 months	134 per 1000	351 per 1000 (227 to 500)	OR 3.51 (1.90 to 6.47)	4925 (9 studies)	⊕⊕⊕⊖ very low ^{1,2,3}
Number of smokers receiving nicotine gum/replacement therapy self-report Follow-up: 12 to 48 months	312 per 1000	416 per 1000 (283 to 563)	OR 1.57 (0.87 to 2.84)	5073 (9 studies)	⊕⊕⊕⊖ low ^{1,3}

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio

**High quality: Further research is very unlikely to change our confidence in the estimate of effect

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very low quality: We are very uncertain about the estimate


¹ Unclear methods of sequence generation and allocation concealment in the majority of studies and all studies had inadequate blinding of participants

² Wide confidence intervals around the estimate of effect

³ Significantly large amounts of heterogeneity were observed (I-squared >90%)

1 8.5% increase over baseline levels), however the change from baseline failed to
 2 achieve statistical significance. Among parents associated with standard train-
 3 ing, the change was only 0.8%.

4 As per pre-specified methodology, a funnel plot examined the primary outcome
 5 of smoking cessation using contour lines to assess the presence of reporting
 6 biases. No publication biases were identified (Figure 3).



24 **Figure 3.** Funnel plot of comparison: the effect of training health professionals on patient smoking
 25 cessation (outcome: point prevalence of smoking cessation)

27 Overall summary of secondary outcomes

29 Asked to set a quit date for stopping (quit date)

30 Nine studies reported the effect of training health professionals on the number
 31 of patients being asked to set a quit date, eight of which could be included in the
 32 meta-analysis producing a significant result (random effects OR 4.98, 95% CI 2.29
 33 to 10.86; see Appendix 1: Analysis 1.2). Only three of the seven studies crossed
 34 the line of no effect^{32;38;39} but there was a very high level of heterogeneity ($I^2 =$
 35 90%) suggesting that not all interventions had the same impact on this outcome.
 36 Subgroup analyses suggest that some of the heterogeneity might be due to
 37 whether or not the patient intervention included an offer of NRT. The two stud-
 38 ies that reported this outcome and did not include NRT showed no difference
 39 between groups.^{32;39} The other studies showed more consistent evidence that

1 intervention increased numbers although the size of effect remained variable.
2 Contrary to what might have been expected, the studies where training took
3 only a single session^{29;30;34} had higher effect sizes compared to the five studies us-
4 ing multiple sessions. Duration of training was similar for the three sub-groups
5 being examined as was intervention delivery via one-on-one compared to group
6 sessions. There was a large amount of variability between the use of prompting
7 and provision of feedback, however this difference was not significant. Interven-
8 tion delivery by a doctor (six studies) or dentist (one study) produced a larger ef-
9 fect size compared to delivery by a healthcare worker³⁹, which may also explain
10 some of the heterogeneity. When comparing follow-up periods, studies reporting
11 between six and nine months^{29;30;32} and between nine and 12 months (seven
12 studies) produced similar effect sizes and large amounts of variability. Studies
13 judged to be at lower risk of bias were more likely to show evidence of an effect
14 (seven studies) compared to studies with between three and five categories rated
15 at high risk of bias³², however the between group analysis did not suggest that
16 this was a source of heterogeneity.

17 18 **Given a follow-up appointment**

19 There was a significant increase in the intervention arm for patients being
20 asked to make a follow-up appointment, as reported in seven studies available
21 for meta-analysis (random effects OR 3.34, 95% CI 1.51 to 7.37; see Appendix 1:
22 Analysis 1.3), although significant heterogeneity was observed ($I^2 = 92\%$). When
23 comparing interventions using NRT with those that used counseling alone, an
24 I^2 of 96% was observed, meaning any results from a pooled analysis would be
25 too unreliable. As such only a visual analysis of odds ratios and confidence
26 intervals are presented, showing similar variability between sub-groups. Sub-
27 group analyses for treatment intensity suggest that some of the heterogeneity
28 might be due to whether or not the training sessions were single or multiple.
29 Two studies that employed single sessions^{33;34} were more likely to show an ef-
30 fect (although variability was observed), compared to five studies using multiple
31 sessions, which produced a smaller effect estimate with less variability. When
32 comparing the duration of the training, significant heterogeneity was once again
33 observed between groups, with studies presenting large amounts of variability,
34 resulting in a pooled estimate being unreliable for comparison. There was little
35 difference between delivery by one-on-one compared to group sessions, and due
36 to significant heterogeneity ($I^2=96\%$) the pooled comparison of prompting and
37 provision of feedback was not possible, although a visual display shows vari-
38 ability is mostly due to the Unrod 2007 study. Similar to other outcomes, delivery
39 of the intervention by a doctor (assessed in seven studies) meant that more

1 patients were likely to have a follow-up appointment compared to intervention
2 delivery by a healthcare worker (one study), however the Swartz 2002 study was
3 present in both sub-groups as the intervention included delivery by both a doc-
4 tor and healthcare worker, as such a statistical between group comparison was
5 not performed. Reporting of results at different follow-up periods were similar
6 between sub-groups, although the five studies with follow-up between nine and
7 12 months had similar distributions with the exception of the Wilson 1988 study,
8 which significantly favoured the intervention and had wide confidence intervals.
9 No between group differences were observed for quality of the studies.

10 11 **Counselled**

12 Fourteen of the fifteen studies reporting on the number of smokers counselled
13 were meta-analysed. Overall, a statistically and clinically significant effect in
14 favour of the intervention was observed (OR 2.28, 95% CI 1.58 to 3.27, $p < 0.00001$;
15 see Appendix 1: Analysis 1.4), assessed using the random effects model due to sig-
16 nificant heterogeneity ($I^2 = 93\%$). An investigation into the causes of heterogeneity
17 found no differences between counseling with and without nicotine replacement
18 therapy, however implementation via multiple sessions or single sessions did
19 produce between group differences, with a larger effect size for single session
20 delivery. Duration of intervention delivery also produced significant differences
21 with total exposure of between 40 minutes and two hours producing a larger
22 effect size compared to durations of between two and four hours and greater
23 than four hours. Mode of intervention delivery (one-on-one compared to group
24 sessions) produced very similar effect sizes, as did the provision of feedback and
25 prompting to aid intervention delivery by the health professional. The type of
26 health professional being trained may contribute to the heterogeneity with the
27 one study evaluating dentists³⁰ producing a larger effect size compared to those
28 with doctors and other health professionals which showed a more conservative
29 effect with narrow confidence intervals. When examining follow-up periods,
30 there was a slightly larger effect and more variability in the studies reporting
31 results between six and nine months compared to results between nine and
32 twelve months and 12 and 24 months. No sub-group differences were observed
33 when analysing studies based on risks of bias.

34 35 **Given self-help materials**

36 The number of smokers receiving self-help material increased significantly in
37 favour of the intervention for the nine studies able to be included in the meta-
38 analysis (OR 3.52, 95% CI 1.90 to 6.52, $p < 0.0001$; see Appendix 1: Analysis 1.5).
39 Provision of cessation materials in the Hymowitz 2007 study, which could not

1 be included in the meta-analysis, did increase significantly across both groups
2 over the four year study period when compared to baseline values (intervention
3 28.8%, control 17.6%) however, this interaction was not statistically different
4 between groups. The other study unable to be meta-analysed¹⁷ also produced a
5 statistically significant effect ($p < 0.001$). Significant heterogeneity was observed
6 in the meta-analysis ($I^2 = 91\%$) which was explored through subgroup analyses.
7 The type of treatment did not show a significant difference between groups, al-
8 though the counseling plus nicotine replacement therapy group did have a larger
9 effect size compared to counseling alone. Likewise, no differences were observed
10 for single compared to multiple session delivery or duration of delivery, although
11 the Cornuz 2002 study with a total exposure over four hours did produce a very
12 large effect with wide confidence intervals. No differences were observed for the
13 mode of intervention delivery or provision of prompting or feedback to aid health
14 professionals in the provision of self-help materials. The one study³⁹ which in-
15 cluded healthcare workers for intervention delivery produced less of an effect
16 compared to the pooled result of studies using doctors. No difference between
17 sub-groups was observed for length of follow-up although studies identified as
18 having less risk of bias did have a larger effect size compared to those with larger
19 amounts of bias.

20 21 **Offered nicotine gum/replacement therapy**

22 Nine studies were pooled to assess the number of smokers receiving nicotine
23 gum/replacement therapy. The meta-analysis did not produce evidence of an
24 effect (OR 1.57, 95% CI 0.87 to 2.84, $p = \text{NS}$; see Appendix 1: Analysis 1.6), but
25 significant heterogeneity was detected ($I^2 = 91\%$). The Hymowitz 2007 study also
26 assessed this outcome with few patients in either condition reporting that resi-
27 dents prescribed nicotine replacement therapy (intervention 7.6%, control 5.9%).
28 An exploration into the possible sources of heterogeneity found no difference
29 between interventions containing counseling with or without nicotine replace-
30 ment therapy, however surprising results were observed with much larger effect
31 sizes for single session intervention delivery compared to multiple session, which
32 could account for some of the heterogeneity. No differences were observed be-
33 tween sub-groups for treatment intensity, mode of intervention delivery, use of
34 feedback or prompting, type of professional being trained or length of follow-up.
35 However studies with less risk of bias did produce larger effect sizes compared to
36 studies with three to five sources of bias identified, which could also contribute
37 to some of the observed heterogeneity.

38
39

1 Prescribed a quit date

2 Only three studies reported on smokers being prescribed a quit date.^{16;32;34} Pooling
3 these together produced a statistically and clinically significant effect in favour
4 of the intervention (OR 14.18, 95% CI 6.57 to 30.61, $p < 0.00001$; see Appendix 1:
5 Analysis 1.7) with minimal observed heterogeneity. As such, sub-group analyses
6 were not necessary for this outcome.

8 Cost effectiveness of interventions

9 Cost effectiveness data was presented in one study³⁸, with the incremental cost of
10 the intervention reported to amount to (U.S.) \$2.58 per consultation by a smoker.
11 When considering 'cost per life-year saved', this translated to (U.S.) \$25.40 for
12 men and \$35.20 for women, with one-way sensitivity analyses yielding a range
13 of \$4.00 to \$107.10 in men and \$9.70 to \$148.60 in women. The Joseph 2004 study
14 reported that the dollar spent per 1000 primary care patients did increase in the
15 intervention sites and decrease in control sites, however this was not significant.
16 Number of referrals made. No studies reported on the number of referrals made
17 to local smoking cessation services.

19 Statistical analyses and cluster adjustments

20 All 17 studies used a cluster randomized design for practical reasons, with the
21 unit of randomization being the health care practitioner or practice. However, in
22 15 of the 17 studies patients were the unit of analysis. Hymowitz 2007 and Kottke
23 1989 were the exceptions, reporting outcomes at the level of randomization (the
24 doctor/resident). The majority of studies that reported outcomes at the level of
25 patient accounted for potential clustering effects within their reported results,
26 with four studies (three in the late 1980's^{15;16;34} and one in the mid-1990's³⁶) being
27 the exceptions. The two Cummings et al studies did perform clustering analyses,
28 however they were not included in the published results as they were seen to
29 have had no effect on the final outcome. As such, the data for these studies
30 were manually adjusted for potential clustering effects as per the pre-specified
31 methodology outlined in the unit of analysis issues section of this review.

33 Sub-group analyses

34 Multiple sub-group analyses have been considered as per the predefined meth-
35 odology to further explore heterogeneity. When considering these outcomes
36 the level of statistical significance should be considered at $p < 0.01$, to account
37 for potential false positive results (as per the Bonferroni adjustment described
38 Assessment of heterogeneity), which increase with the number of potential
39 effect modifiers being investigated. Total study confidence intervals were as-

1 sessed at the 99% level for all sub-group analyses. Significant heterogeneity was
2 determined through a combination of the I^2 statistic ($I^2 > 60\%$), Chi^2 statistic and
3 visual inspection of the Forest plots, and was present for all outcomes with the
4 exception of 'Smoking cessation at longest follow-up' and 'Number of smokers
5 prescribed a quit date' where significant heterogeneity was not identified. In the
6 presence of heterogeneity based on the I^2 statistic of $> 96\%$, the pooled estimate
7 has been removed, as the outcomes are considered too different to be combined
8 in meta-analysis. Likewise, when a comparison contained the same study in dif-
9 ferent sub-groups, the pooled estimate was not used.

11 **DISCUSSION**

14 **Summary of main results**

15 Seventeen completed studies (total 28,531 subjects) assessed the benefits of
16 interventions to train health professionals to provide smoking cessation initia-
17 tives to their patients. Whilst some methodological variations occurred between
18 studies in relation to intervention, delivery mode, type of health professional
19 and duration, they were all aimed at training health professionals to help their
20 patients stop smoking. The primary outcome of smoking cessation was presented
21 in pooled meta-analyses as point prevalence (14 studies) and continuous absti-
22 nence (eight studies). A statistically and clinically significant effect in favour
23 of the intervention was observed for both of these outcomes at final follow-up
24 (see Table 2 for a summary of findings for the main comparison). All secondary
25 outcomes (with one exception) produced a statistically and clinically significant
26 effect in favour of the intervention at final follow-up. These outcomes include
27 asking patients to set a quit date, asking patients to make follow-up appoint-
28 ments, counseling of smokers, provision of self-help material and prescription of
29 a quit date. No evidence of an effect was observed for the secondary outcome of
30 providing patients with nicotine gum/replacement therapy. No studies were able
31 to be meta-analysed to assess the cost effectiveness of interventions.

33 **Overall completeness and applicability of evidence**

34 In the context of current practice, this review should be used to provide readers
35 with an outline of what interventions have a proven effect, and where resources
36 need to be directed for future investigations. Studies which incorporated multi-
37 ple intervention components such as provision of nicotine replacement therapy,
38 requests for follow-up appointments and provision of self-help material were
39 more likely to be successful than those with interventions of counseling alone.

1 Surprisingly, health professionals who were trained using only a single session
2 and in a group setting were just as likely if not more likely to have patients quit
3 smoking as those being trained with multiple delivery sessions and one-on-one
4 training (i.e., face to face with the trainer). Similarly, the duration of training
5 for the health professional of between 40 minutes to two hours was just as ef-
6 fective, and in some cases more so, than a duration of greater than two hours.
7 Studies with multiple follow-up periods and closer monitoring of outcomes by
8 investigators (including the provision of feedback) were more successful than
9 those of lesser intensity. Smoking cessation interventions delivered by a doc-
10 tor or dentist were more likely to produce successful quit attempts than those
11 delivered by other health care workers. To ensure methodological rigour, future
12 studies should aim to incorporate the following into the study design:

- 13
- 14 • Report patient level outcomes (e.g., smoking cessation) as well as health pro-
15 fessional outcomes (e.g., physician report of number of smokers counselled)
16 rather than providing details only relating to the consultation process
 - 17 • Adequate methods of randomization and allocation concealment
 - 18 • Report smoking related outcome data both pre and post intervention
 - 19 • Incorporate a control group which adequately matches the demographic
20 characteristics of the intervention population.

21 **Quality of the evidence**

22 Study quality was a potential issue in this review with many of the studies being
23 of unclear methodological design. It is extremely difficult to blind participants
24 in relation to what intervention they will be receiving, as there are two levels to
25 consider: the health professional and the patient. All 17 included studies had
26 unclear allocation concealment whilst only five studies adequately reported
27 methods of random sequence generation, two had a high risk of bias with the
28 remaining ten studies being unclear. Overall, the body of evidence identified per-
29 mits a moderately robust conclusion regarding the objectives of this review, with
30 17 included studies (28,531 participants). Evidence presented in the summary of
31 findings table (Table 2) was downgraded to take into account:

- 32
- 33
 - 34 • limitations in design: methods of randomization, allocation concealment
35 and/or blinding were not described or inadequate for the majority of studies
36 assessing the particular outcome (-1)
 - 37 • Inconsistencies: significant heterogeneity (-1)
 - 38 • Imprecision: only few participants in few studies available to assess the out-
39 come (-1)

1 **Potential biases in the review process**

2 A potential bias in the review process is exclusion of studies examining interven-
3 tions that train health professionals in smoking cessation that are of question-
4 able methodological design. This review does sacrifice inclusion of some relevant
5 information, however the trade-off is a meta-analysis of higher quality evidence
6 on which future investigations can be based. Some of the pertinent information
7 from these studies is discussed below under agreements and disagreements
8 with other studies or reviews though results should be interpreted with caution.
9 Another limitation to the review is the under-reporting of the intervention for
10 included studies. This means that some studies may have indeed included ad-
11 ditional intervention components that, had we known they existed, would have
12 led us to classify the study differently within the sub-groups. One key strength of
13 the review process to address potential biases is the use of two experienced and
14 independent review authors who assessed the studies for risk of bias, although
15 this can do little to account for biases which occur in the methodological designs
16 of the included studies.

17 18 **Agreements and disagreements with other studies or reviews**

19 A compilation of systematic reviews and surveys of key informants were pub-
20 lished as a special edition in the journal 'Drug and Alcohol Review' in 2009, relat-
21 ing to the education and training of health professionals and students in tobacco,
22 alcohol and other drugs.⁴¹ The first published survey of 21 key informants from
23 eight countries found a high level of consistency in the content of the smoking
24 cessation interventions, with 72% of programmes using the 5 A's (Ask, Assess,
25 Advise, Assist, Arrange) model, 64% using the stages of change (trans-theoretical)
26 model, 84% including pharmacotherapies, with 84% having some reference to
27 clinical practice guidelines.⁶ Only five of the seventeen included studies in our
28 review had reference to any particular behavioural change technique, however
29 it is quite likely that the majority of studies are based around some kind of
30 theoretical behavioural change context, which is not reported in the publication.
31 These results are similar to those reported elsewhere.⁴¹ The authors identified a
32 lack of interest (with other continuing education topics considered to be a higher
33 priority) and lack of funding for interventions to be the major barriers for the up-
34 take and sustainability of training programmes.⁶ Some possible solutions were
35 provided to address these barriers including raising awareness of the importance
36 of smoking cessation for the health of patients and incorporating education on
37 smoking cessation into vocational courses for specialties. Another systematic
38 review of postgraduate smoking cessation training for physicians in 28 European
39 countries found nine studies which met all of the inclusion criteria containing a

1 total of 170 postgraduate training programmes.⁴² The key implications reported
2 by the authors were that postgraduate training in smoking cessation may not be
3 reaching physicians and was not rigorously evaluated. To combat this problem
4 multiple authors suggest that future research needs to incorporate methods of
5 disseminating effective educational activities with the intention of increasing
6 participation.^{42,43} It is also imperative that health professional organisations ad-
7 vocate for the systematic implementation of comprehensive tobacco cessation
8 training programmes to increase the number of patients receiving tobacco cessa-
9 tion interventions.⁴⁴ Another study using direct observation of physician-patient
10 encounters found similar results and concluded that strategies are needed to
11 assist physicians to incorporate systematic approaches that will standardise
12 smoking cessation care.⁴⁵ In this investigation, discussions around tobacco were
13 more common in practices that utilised standard forms for recording smok-
14 ing status and during new patient visits. Interestingly, the authors also found
15 that discussions around tobacco use occurred less often among physicians in
16 practice for more than 10 years and with older patients⁴⁵, which is similar to an
17 observational study by Bertakis et al. investigating the factors associated with
18 physician discussion of tobacco use with patients.⁴⁶ Considerable resistance was
19 also observed in a cohort of physicians receiving academic detailing to promote
20 tobacco-use cessation counseling in dental offices. Dental staff members (in-
21 cluding receptionists, office managers, dental assistants and dental hygienists)
22 were reluctant to participate in the interventions due to increased paperwork,
23 having to deal with uncooperative patients, and the perception that only a few
24 patients use tobacco anyway and that counseling does not work.^{38,47} However,
25 the resistance observed did decrease as follow-up visits progressed and staff
26 became more comfortable with the intervention and the procedures involved.
27 This evidence suggests that through the provision of first-hand experience
28 prior to guiding patients through the same process, physicians may feel more
29 comfortable in implementing smoking cessation interventions into standard
30 practice, which has the potential to be highly cost-effective. One of the included
31 studies by Cornuz et al. reported that training residents in smoking cessation
32 counseling is very cost-effective and may be more efficient than the majority of
33 currently accepted tobacco control interventions.³⁸ This has also been supported
34 by more recent systematic reviews and investigations.¹⁹⁻²¹ As such, the provision
35 of counseling, advice and/or offers of assistance to the patient has the potential
36 to significantly increase the number of quit attempts, which subsequently has
37 the potential to reduce health related costs as well as morbidity and mortal-
38 ity associated with ongoing chronic tobacco use. The previous version of this
39 Cochrane review included eight studies with six finding no effect of intervention.

1 The authors also stated that effects of training on process outcomes increased
2 if prompts and reminders were used, however they concluded that there was no
3 strong evidence that training health professionals to provide smoking cessation
4 interventions changed smoking behaviour. With the addition of nine studies
5 (more than half the initial number of inclusions), the findings of this review have
6 now changed to support the training health professionals in smoking cessation
7 interventions.

8 9 10 **CONCLUSIONS**

11 **Implications for practice**

12 Overall, a moderately large amount of methodologically rigorous evidence has
13 been presented to support the effectiveness of training health professionals in
14 smoking cessation. The following programme characteristics could be consid-
15 ered for individuals involved in future clinical practice initiatives:
16

- 17
18 • Combination of multiple intervention components including the provision
19 of counseling, offer of follow-up appointments, setting or being prescribed a
20 quit date and provision of self-help material
- 21 • A one-off group training session for health professionals of between one to
22 two hours duration, providing there is adequate follow-up and monitoring of
23 progress. This will need to include provision of follow-up feedback to health
24 professionals and resources such as patient self-help materials, with consid-
25 eration given to other intervention components as mentioned above.
- 26 • Consider organisational factors to ensure that smoking cessation messages
27 are reliably delivered. Training can be expensive, and simply providing pro-
28 grammes for health care professionals, without addressing the constraints
29 imposed by the conditions in which they practise, is unlikely to be a wise use
30 of health care resources.

31 **Implications for research**

32 Multi-component investigations incorporating new pharmacological interven-
33 tions for smoking cessation (such as varenicline tartrate and bupropion) or other
34 cessation aids (such as electronic cigarettes) alongside physician training should
35 be considered to determine if any additional benefit in long-term abstinence
36 can be obtained. Future research needs to ensure that adequate methodological
37 rigour is met with considerations relating to:
38
39

- 1 • Sequence generation and allocation concealment
- 2 • Demographics and comparability of the control comparison
- 3 • Reporting of smoking related outcome data
- 4 • Collection of data both pre and post intervention implementation.

5

6 So as to enable interventions to be replicated in clinical practice, it is also impor-
7 tant that authors of future trial reports describe the content of the training in
8 sufficient detail, for example detailing the educational methods, strategies and
9 theories used to train the professionals.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

1 REFERENCES

- 2 1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from
3 2002 to 2030. *PLoS Med* 2006; 3(11):e442.
- 4 2. Bergstrom J, Eliasson S, Dock J. A 10-year prospective study of tobacco smoking and
5 periodontal health. *J Periodontol* 2000; 71(8):1338-1347.
- 6 3. Balaji SM. Tobacco smoking and surgical healing of oral tissues: a review. *Indian J*
7 *Dent Res* 2008; 19(4):344-348.
- 8 4. Gordon JS, Andrews JA, Albert DA, Crews KM, Payne TJ, Severson HH. Tobacco cessa-
9 tion via public dental clinics: results of a randomized trial. *Am J Public Health* 2010;
10 100(7):1307-1312.
- 11 5. Tomar SL, Asma S. Smoking-attributable periodontitis in the United States: findings
12 from NHANES III. National Health and Nutrition Examination Survey. *J Periodontol*
13 2000; 71(5):743-751.
- 14 6. Zwar NA, Richmond RL, Davidson D, Hasan I. Postgraduate education for doctors in
15 smoking cessation. *Drug Alcohol Rev* 2009; 28(5):466-473.
- 16 7. Richmond R, Mendelsohn C, Kehoe L. Family physicians' utilization of a brief smok-
17 ing cessation program following reinforcement contact after training: a randomized
18 trial. *Prev Med* 1998; 27(1):77-83.
- 19 8. Mullins R, Livingston P, Borland R. A strategy for involving general practitioners in
20 smoking control. *Aust N Z J Public Health* 1999; 23(3):249-251.
- 21 9. Gelskey SC. Impact of a dental/dental hygiene tobacco-use cessation curriculum on
22 practice. *J Dent Educ* 2002; 66(9):1074-1078.
- 23 10. Warnakulasuriya S. Effectiveness of tobacco counseling in the dental office. *J Dent*
24 *Educ* 2002; 66(9):1079-1087.
- 25 11. Rosseel JP, Jacobs JE, Hilberink SR, Maassen IM, Allard RH, Plasschaert AJ et al. What
26 determines the provision of smoking cessation advice and counseling by dental care
27 teams? *Br Dent J* 2009; 206(7):E13-E17.
- 28 12. Twardella D, Brenner H. Effects of practitioner education, practitioner payment and
29 reimbursement of patients' drug costs on smoking cessation in primary care: a
30 cluster randomised trial. *Tob Control* 2007; 16(1):15-21.
- 31 13. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs'
32 engagement in smoking cessation: a multi-country literature review. *Brit J Gen Pract*
33 2009; 59(566):682-690.
- 34 14. Anderson P, Jane-Llopis E. How can we increase the involvement of primary health
35 care in the treatment of tobacco dependence? A meta-analysis. *Addiction* 2004;
36 99(3):299-312.
- 37 15. Cummings SR, Richard RJ, Duncan CL, Hansen B, Vander MR, Gerbert B et al. Training
38 physicians about smoking cessation: a controlled trial in private practice. *J Gen Intern*
39 *Med* 1989; 4(6):482-489.
16. Cummings SR, Coates TJ, Richard RJ, Hansen B, Zahnd EG, VanderMartin R et al.
Training physicians in counseling about smoking cessation. A randomized trial of
the "Quit for Life" program. *Ann Intern Med* 1989; 110(8):640-647.
- Kottke TE, Brekke ML, Solberg LI, Hughes JR. A randomized trial to increase smoking
intervention by physicians. Doctors Helping Smokers, Round I. *JAMA-J Am Med Assoc*
1989; 261(14):2101-2106.

- 1 18. Thorogood M, Ileson M, Summerbell C. Changing behaviour 2006; 8 (203). Available
2 from: [http:// //clinicalevidence.bmj.com/ceweb/conditions/cvd/0203/020318.jsp](http://clinicalevidence.bmj.com/ceweb/conditions/cvd/0203/020318.jsp)
- 3 19. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane*
4 *Database Systematic Reviews* 2008; (4).
- 5 20. Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ. Repeated
6 tobacco-use screening and intervention in clinical practice: health impact and cost
7 effectiveness. *Am J Prev Med* 2006; 31(1):62-71.
- 8 21. Maciosek MV, Coffield AB, Edwards NM, Flottesch TJ, Goodman MJ, Solberg LI.
9 Priorities among effective clinical preventive services: results of a systematic review
10 and analysis. *Am J Prev Med* 2006; 31(1):52-61.
- 11 22. Hung DY, Shelley DR. Multilevel analysis of the chronic care model and 5A services
12 for treating tobacco use in urban primary care clinics. *Health Serv Res* 2009; 44(1):103-
13 127.
- 14 23. Centers for Disease Control and Prevention (CDC). Smoking-cessation advice from
15 health-care providers Canada. *Morbidity & Mortality Weekly Report* 2005; 56(28):708-
16 712.
- 17 24. World Health Organization. Tobacco factsheet. 2012. Geneva, Switzerland, World
18 Health Organization. Available from [http://www.who.int/mediacentre/factsheets/
19 fs339/en/](http://www.who.int/mediacentre/factsheets/fs339/en/).
- 20 25. Guidon GE. The cost attributable to tobacco use: a critical review of the literature.
21 *Popul Dev Rev* 2008; 34(1):188-194.
- 22 26. Lancaster T, Silagy C, Fowler G. Training health professionals in smoking cessation.
23 *Cochrane Database Syst Rev* 2000; (3).
- 24 27. Higgins JPT, Green S. *Cochrane Handbook for systematic Reviews of Interventions*
25 *Version 5.1.0. The Cochrane Collaboration; 2011.*
- 26 28. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised
27 trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Ac-
28 tion). *J Health Serv Res Policy* 2000; 5(1):12-16.
- 29 29. Cohen SJ, Stookey GK, Katz BP, Drook CA, Smith DM. Encouraging primary care
30 physicians to help smokers quit. A randomized, controlled trial. *Ann Intern Med* 1989;
31 110(8):648-652.
- 32 30. Cohen SJ, Stookey GK, Katz BP, Drook CA, Christen AG. Helping smokers quit: a
33 randomized controlled trial with private practice dentists. *J Am Dent Assoc* 1989;
34 118(1):41-45.
- 35 31. Hymowitz N, Schwab JV, Haddock CK, Pyle SA, Schwab LM. The pediatric residency
36 training on tobacco project: four-year resident outcome findings. *Prev Med* 2007;
37 45(6):481-490.
- 38 32. Strecher VJ, O'Malley MS, Villagra VG, Campbell EE, Gonzalez JJ, Irons TG et al. Can
39 residents be trained to counsel patients about quitting smoking? Results from a
randomized trial. *J Gen Intern Med* 1991; 6(1):9-17.
33. Unrod M, Smith M, Spring B, DePue J, Redd W, Winkel G. Randomized controlled trial
of a computer-based, tailored intervention to increase smoking cessation counseling
by primary care physicians. *J Gen Intern Med* 2007; 22(4):478-484.
34. Wilson DM, Taylor DW, Gilbert JR, Best JA, Lindsay EA, Willms DG et al. A randomized
trial of a family physician intervention for smoking cessation. *JAMA-J Am Med Assoc*
1988; 260(11):1570-1574.

- 1 35. Lennox AS, Bain N, Taylor RJ, McKie L, Donnan PT, Groves J. Stages of Change training
2 for opportunistic smoking intervention by the primary health care team. *Health Educ*
3 *J* 1998; 57:140-149.
- 4 36. Wang WD. Feasibility and effectiveness of a stages-of-change model in cigarette
5 smoking cessation counseling. *J Formos Med Assoc* 1994; 93(9):752-757.
- 6 37. Sinclair HK, Bond CM, Lennox AS, Silcock J, Winfield AJ, Donnan PT. Training pharma-
7 cists and pharmacy assistants in the stage-of-change model of smoking cessation: a
8 randomised controlled trial in Scotland. *Tob Control* 1998; 7(3):253-261.
- 9 38. Cornuz J, Humair JP, Seematter L, Stoianov R, van MG, Stalder H et al. Efficacy of
10 resident training in smoking cessation: a randomized, controlled trial of a program
11 based on application of behavioural theory and practice with standardized patients.
12 *Ann Intern Med* 2002; 136(6):429-437.
- 13 39. Swartz SH, Cowan TM, DePue J, Goldstein MG. Academic profiling of tobacco-related
14 performance measures in primary care. *Nicotine Tob Res* 2002; 4 Suppl 1:S38-S44.
- 15 40. Joseph AM, Arikian NJ, An LC, Nugent SM, Sloan RJ, Pieper CF. Results of a random-
16 ized controlled trial of intervention to implement smoking guidelines in Veterans
17 Affairs medical centers: increased use of medications without cessation benefit. *Med*
18 *Care* 2004; 42(11):1100-1110.
- 19 41. Richmond R. Education and training for health professionals and students in to-
20 bacco, alcohol and other drugs. *Drug Alcohol Rev* 2009; 28(5):463-465.
- 21 42. Kralikova E, Bonevski B, Stepankova L, Pohlova L, Mladkova N. Postgraduate medi-
22 cal education on tobacco and smoking cessation in Europe. *Drug Alcohol Rev* 2009;
23 28(5):474-483.
- 24 43. Muramoto ML, Lando H. Faculty development in tobacco cessation: training health
25 professionals and promoting tobacco control in developing countries. *Drug Alcohol*
26 *Rev* 2009; 28(5):498-506.
- 27 44. Botelho R, Wassum K, Benzian H, Selby P, Chan S. Address the gaps in tobacco cessa-
28 tion training and services: developing professional organisational alliances to create
29 social movements. *Drug Alcohol Rev* 2009; 28(5):558-566.
- 30 45. Ellerbeck EF, Ahluwalia JS, Jolicoeur DG, Gladden J, Mosier MC. Direct observation of
31 smoking cessation activities in primary care practice. *J Fam Pract* 2001; 50(8):688-693.
- 32 46. Bertakis KD, Azari R. Determinants of physician discussion regarding tobacco and
33 alcohol abuse. *J Health Commun* 2007; 12(6):513-525.
- 34 47. Albert DA, Anluwalia KP, Ward A, Sadowsky D. The use of 'academic detailing' to
35 promote tobacco-use cessation counseling in dental offices. *J Am Dent Assoc* 2004;
36 135(12):1700-1706.
- 37
- 38
- 39

Table 1. Characteristics of included studies

Cohen (Dent) 1989

Methods	<p>Country: United States of America, Indianapolis area</p> <p>Design: Randomized controlled trial; Nested; Clustered</p> <p>Objective: To improve the effectiveness of dentists helping their patients quit smoking</p> <p>Methods of analysis: A generalized linear model was used to analyse the results of the quit-smoking rates and a scale-factor was used to reflect the expected extra variance in quit rates caused by between-dentist variability; Chi-squared statistic based on changes in the deviance function for a series of nested models was used to test for main effect and interactions; Two-way analyses of variance were calculated on the weighted data for the amount of time spent in counselling patients about their smoking</p> <p>Clustering adjustment made: Yes - Generalised linear model allowed a scale-factor to reflect the extra variance expected to be inflated due to variability between dentists</p> <p>Significance of cluster adjustment: Not reported</p>
Participants	<p>Therapist description: Dentists</p> <p>Eligible for study: n= 54</p> <p>Randomized: n= 50</p> <p>Completed: Gum n= 9, reminder n= 10, gum & reminder n= 12, control n= 13 (total n= 44)</p> <p>Age: Not reported</p> <p>Gender: Not reported</p> <p>Patient description: n= 1027 patients from American private dental practices</p> <p>Eligible for study: n= 1027</p> <p>Randomized: n= 1027</p> <p>Completed: n= 647</p> <p>Age: Mean = 37.1 (SD ± 10.4) (total population only)</p> <p>Gender: Males= 43.2% males (total population only)</p>
Interventions	<p>Setting: American private dental practices</p> <p>Training of those delivering the intervention to the health professional: Not reported</p> <p>Intervention description: Three intervention groups: Training & nicotine gum, training & reminder (chart prompt), combined training with prompt & nicotine gum</p> <p>Control description: Training alone (advice, quit date, follow up check); Dentists provided a booklet containing the four-step care protocol and were encouraged to counsel their patients who were smokers</p> <p>Duration of intervention: One hour</p> <p>Intervention delivered by: General dentist</p> <p>Intensity: One lecture</p>
Outcomes	<p>Pre-specified outcome data: Point prevalence of cessation at 12 months; Number advised to quit; Number asked about setting a quit date</p> <p>Follow-up period: Twelve months total: 6 months (defined as the smoking status determined at any visit that occurred at least 3 months after the initial appointment but not more than 9 months); 12 months (defined as the smoking status determined at any visit that occurred at least 9 months and 1 day and up to 15 months after the initial visit)</p>
Notes	<p>Process measures: Outcomes reported in Cohen 1987; Patients not having a visit during the 6 or 12 month periods were assumed to be smokers</p> <p>Validation: Expired carbon monoxide</p> <p>The three intervention groups were combined for meta-analyses to produce the single 'Intervention' sample</p>

Cohen (Doc) 1989

Methods Country: United States of America
 Design: Randomized controlled trial; Nested; Clustered
 Objective: Evaluation of a RCT of interventions designed to improve effectiveness of physicians and dentists in helping their patients quit smoking
 Methods of analysis: Analysis of variance performed on percentages; Stepwise multiple regression analyses performed using the weighted number of minutes as the criterion to determine the extent to which the amount of counselling time was a function of the health professionals' initial attitudes and habits; Chi-squared analysis used to test main effects and interactions; Generalised linear interactive modelling (GLIM) software used
 Clustering adjustment made: Yes - Generalised linear model allowed a scale-factor to reflect the extra variance expected to be inflated due to variability between physicians
 Significance of cluster adjustment: Not reported

Participants Therapist description: n= 112 primary care physicians (including n= 97 physicians in training)
 Eligible for study: Not reported
 Randomized: Total= 97 internal medicine residents and 15 faculty general internists
 Completed: Total= 97 internal medicine residents and 15 faculty general internists
 Age: Not reported
 Gender: Not reported
 Patient description: n= 1420 patients receiving primary care, not selected by motivation to quit
 Eligible for study: Participation refusal rate was 9.7% of all eligible patients contacted
 Randomized: n= 1420
 Completed: n= 1091 medical patients
 Age: 18 to 64 years; Mean = 46.2 + 11.6 years
 Gender: Male= 37%; Female= 63%

Interventions Setting: General medicine (primary care) clinic of a city-county teaching hospital in the USA
 Training of those delivering the intervention to the health professional: Registered internist
 Intervention description: Three intervention groups: Training & nicotine gum, training & reminder (chart prompt), combined training with prompt & nicotine gum
 Control description: Training alone (advice, quit date, follow up check); Physicians provided a booklet containing the four-step care protocol and were encouraged to counsel their patients who were smokers
 Duration of intervention: One-hour lecture or personalised instruction
 Intervention delivered by: David M Smith, registered internist
 Intensity: One, one hour lecture maximum

Outcomes Pre-specified outcome data: Point prevalence of abstinence at 12 months; Patients who did not have an appointment in the period regarded as smokers; Rates also reported giving returnees as denominator; Number advised to quit; Number asked about setting a quit date; Had their doctor talked to them about smoking
 Follow-up period: Six and 12 months (12 months defined as patients visited 9 and 15 months after the initial visit)

Notes Process measures: Outcomes reported in Cohen 1987; Patients not having a visit during the 6 or 12 month periods were assumed to be smokers
 Validation: Expired carbon monoxide
 The three intervention groups were combined for meta-analyses to produce the single 'Intervention' sample

Cornuz 2002

1 **Methods** *Country:* Geneva and Lausanne, Switzerland, Europe
2 *Design:* Randomized controlled trial; Clustered
3 *Objective:* To assess the efficacy of an educational program based on behavioural
4 *theory,* active learning methods, and practice with standardized patients in helping
5 *patients* abstain from smoking and changing physicians' counselling practices
6 *Methods of analysis:* To compare baseline characteristics of patients and physicians'
7 *practices* between groups, the authors used the chi-square or Fisher exact tests for
8 *categorical* data and the t-test or Wilcoxon rank-sum test for continuous data; To
9 *test* the effectiveness of the training on the outcomes, the authors performed a
10 *logistic* regression with generalized estimating equation to stratify by clinic and
11 *adjust* for clustering on residents; Intention-to-treat analysis was performed for
12 *abstinence* from smoking, in which smokers lost at follow-up were considered to be
13 *continuing* smokers; Because smoking abstinence was validated in a sub sample of
14 *the study* participants, the authors used simulation to perform sensitivity analysis
15 *of the likelihood* of smoking cessation
16 *Clustering adjustment made:* Yes - to test the effectiveness of the training on the
17 *outcomes,* the authors performed a logistic regression with generalized estimating
18 *equation* to stratify by clinic and adjust for clustering on residents
19 *Significance of cluster adjustment:* Not reported

14 **Participants** *Therapist description:* Resident physicians; All residents were at the end of
15 *postgraduate* training in general internal medicine or family medicine
16 *Eligible for study:* n= 35
17 *Randomized:* Intervention n= 17; Control n= 18
18 *Completed:* Intervention n= 17; Control n= 18
19 *Age:* Median 31 years
20 *Gender:* 18 females and 17 males
21 *Patient description:* Patients aged 16 to 75 years who consulted one of the outpatient
22 *clinics* for a follow-up or an emergency visit
23 *Eligible for study:* n= 1456
24 *Randomized:* Intervention n= 115; Control n= 136
25 *Completed:* Intervention n= 77; Control n= 100
26 *Age:* Range 16 to 75 years; Mean + SD: Intervention 35.1 + 14 years; Control 36.9 + 15
27 *years*
28 *Gender:* Intervention = 63% male; Control= 57% male

Interventions *Setting:* Two general internal medicine clinics of the university hospitals of Lausanne and Geneva, Switzerland; Both sites are public service clinics that provide adult ambulatory care to approximately 25,000 outpatient visits per year
Training of those delivering the intervention to the health professional: Teachers are two authors, who are experienced physicians active in both clinical practice and teaching; Both were previously trained in smoking cessation counselling through a Master of Public Health course and are considered as national experts in smoking cessation
Intervention description: The training program is based on 5 principles: 1) recent evidence-based content on tobacco use and cessation, 2) behavioural theory (stage-of-change model), 3) pharmacological therapy, 4) educational methods focusing on active skills training, and 5) tobacco control context; Session 1: Video-clips observations, interactive workshops and role plays; Sessions 2: practice with standardized patients; At the end of the first session, participants received a set of documents (reference manual, two algorithms of counselling strategies and pharmacological therapy, record sheet for consultations with smokers, brochures for patients and patient instructions for NRT)
Control description: Training in management of dyslipidaemia with equal contact time to the intervention; This course taught residents about through the Swiss guidelines on screening for and diagnosis/management of high blood levels of cholesterol; Residents that were trained in smoking cessation attended the lesson on dyslipidaemia 4 months later, and vice versa
Duration of intervention: Two, 4 hour sessions scheduled 2 weeks apart
Intervention delivered by: Not specified though face-to-face workshops took place
Intensity: Two, half-day sessions; Total contact time 8 hours

Outcomes *Pre-specified outcome data:* Self-reported abstinence from smoking, 1 week point prevalence of abstinence; score of overall quality of counselling based on use of 14 counselling strategies; patient willingness to quit; and daily cigarette consumption; socio-demographic data, cardiovascular risk factors, smoking history, nicotine dependence, smoking intervention
Follow-up period: Twelve months

Notes *Process measures:* None reported
Validation: Exhaled carbon monoxide testing at one clinic

Cummings (Priv) 1989

Methods *Country:* United States of America
Design: Randomized controlled trial; Nested; Clustered
Objective: To test if physicians who are trained to use the 'Quit for Life' (QFL) program are more effective in helping patients to quit smoking
Methods of analysis: Chi-squared test for proportions and t-tests for means; Multiple logistic regression (for proportions) and ordinary least-squares (for means) and calculated adjustment rates from the partial slopes associated with a dummy variable; Individual patients were the unit of analysis
Clustering adjustment made: No adjustment to presented data but separate analyses tested clustering effects
Significance of cluster adjustment: Clustering effects were tested in separate analyses; These adjustments had no discernible effect on significance levels and did not alter the conclusion

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

1	Participants	<i>Therapist description:</i> Primary care physicians in private practice
2		<i>Eligible for study:</i> n= 844
3		<i>Randomized:</i> Intervention n= 31; Control n= 28
4		<i>Completed:</i> Intervention n= 20; Control n= 18
5		<i>Age:</i> Not reported
6		<i>Gender:</i> Intervention females n= 4; Control females n= 2
7		<i>Patient description:</i> n= 916 smoking patients not selected by motivation to quit
8	Interventions	<i>Eligible for study:</i> Not reported
9		<i>Randomized:</i> Intervention n= 470; Control n= 446
10		<i>Completed:</i> Intervention n= 360; Control n= 364
11		<i>Age:</i> Intervention mean = 43 years; Control mean = 45 years
12		<i>Gender:</i> Intervention mean = 53%; Control mean = 61%
13		<i>Setting:</i> Private primary care internal medicine and family practice (primary care) in San Francisco, USA; Local hospitals at times that fit with the schedules of the participating physicians; Four who were unable to attend the second sessions received the training privately in their office
14		<i>Training of those delivering the intervention to the health professional:</i> Not described
15	Outcomes	<i>Intervention description:</i> Training (personalised advice, quit date, one follow up visit, self help materials and nicotine gum)
16		<i>Control description:</i> Normal care (no training)
17		<i>Duration of intervention:</i> Three, one hour seminars
18		<i>Intervention delivered by:</i> Internist or psychologist
19		<i>Intensity:</i> Three, one hour seminars; second seminar one or two weeks after the first; third seminar four to twelve weeks later
20		<i>Pre-specified outcome data:</i> Demographic characteristics; smoking history; how much do you want to quit smoking; how confident are you that you will not be smoking one year from now; pressure to quit from family and friends; was smoking discussed; did you receive a self-help booklet; did you receive a follow-up appointment about smoking
21		<i>Follow-up period:</i> Twelve months
22	Notes	<i>Process measures:</i> None reported
23		<i>Validation:</i> Expired carbon monoxide and serum cotinine
24		Manual adjustment for potential clustering effects performed in the meta-analyses for primary outcome data
25	Cummings 1989	
26	Methods	<i>Country:</i> San Francisco, California, United States of America
27		<i>Design:</i> Randomized controlled trial; Clustered
28		<i>Objective:</i> To test whether physicians who receive a continuing education program about how to counsel smokers to quit would counsel smokers more effectively and have higher rates of long-term smoking cessation among their patients that smoke
29		<i>Methods of analysis:</i> Chi-square for proportions and t-tests for means were used for significance measures; Binomial test for difference between paired proportions used to calculate confidence intervals for changes in attitudes and self-reported counselling practices of physicians in the experimental group before and after training; To analyse differences between the groups in patient reports about physicians counselling and rates of abstinence, large-sample difference-of-proportions and difference-of-means tests were used; To determine significance of intervention among those patients who had the greatest desire to quit, an interaction was tested between assignment to the experimental or control group and the smoker's rating of his or her desire to quit; Multiple logistic regression analysis used to determine significance for specific counselling strategies by experimental group physicians for abstinence levels
30		<i>Clustering adjustment made:</i> No - The individual patient was the unit of analysis for these results; However, patients were clustered by physician and physicians were clustered by work station; "...Therefore for simplicity, we present the results with the patient as the unit of analysis"
31		<i>Significance of cluster adjustment:</i> Not reported
32		
33		
34		
35		
36		
37		
38		
39		

1 2 3 4 5 6 7 8	Participants	<p><i>Therapist description:</i> Physicians <i>Eligible for study:</i> n= 189 internists <i>Randomized:</i> n= 81; Control n= 41; Intervention n= 40 <i>Completed:</i> n= 81; Control n= 41; Intervention n= 40 <i>Age:</i> Not reported <i>Gender:</i> Control: 27% female; Intervention 30% female <i>Patient description:</i> <i>Eligible for study:</i> n= 2056; Control n= 1032; Intervention n= 1024 <i>Randomized:</i> n= 2056; Control n= 1032; Intervention n= 1024 <i>Completed:</i> n= 2012; Control n= 1008; Intervention n= 1004 <i>Age:</i> Control 45 years; Intervention 46 years <i>Gender:</i> Control 53% female; Intervention 58% female</p>
9 10 11 12 13 14	Interventions	<p><i>Setting:</i> Four Health Maintenance Organisation (HMO) medical centres in northern California <i>Training:</i> Three, one hour group tutorials <i>Training of those delivering the intervention to the health professional:</i> Not stated but delivered by internist or psychologist <i>Intervention description:</i> Training (personalised advice, quit date, one follow up visit, self help materials and nicotine gum) <i>Control description:</i> Normal care (no training) <i>Duration of intervention:</i> Three sessions over a five to fourteen week period <i>Intervention delivered by:</i> Internist or psychologist <i>Intensity:</i> Three, one hour sessions</p>
15 16 17 18	Outcomes	<p><i>Pre-specified outcome data:</i> long-term abstinence from smoking (≥ 9 months); Number of smokers counselled; Asked to set a quit date; Asked to make a follow up appointment; Number receiving self help materials; Number receiving nicotine gum; Number of smokers prescribed a quit date <i>Follow-up period:</i> Point prevalence abstinence at 12 months</p>
19 20 21	Notes	<p><i>Process measures:</i> None reported <i>Validation:</i> Expired carbon monoxide and serum cotinine Manual adjustment for potential clustering effects performed in the meta-analyses for primary outcome data</p>
Gordon 2010		
22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Methods	<p><i>Country:</i> United States of America <i>Design:</i> Randomized controlled trial; Nested; Clustered <i>Objective:</i> With consideration to the oral health effects associated with chronic tobacco use, the dental visit provides a "teachable moment" during which the dental team can relate oral health and systemic problems to tobacco use and provide evidence-based brief interventions to patients who use tobacco in lower socio-economic areas <i>Methods of analysis:</i> Analysis of variance with clinics as a random, nested factor within condition and patients nested within clinic for both outcomes, for all participants, and within each racial/ethnic group; Logistic regression used for baseline measures of tobacco use with condition included as a covariate <i>Clustering adjustment made:</i> Yes: ICC and analysis of variance with nesting <i>Significance of cluster adjustment:</i> Not reported</p>

1	Participants	<i>Therapist description:</i> Federally funded public health dental clinics in lower socio-economic areas
2		<i>Eligible for study:</i> Not reported
3		<i>Randomized:</i> Intervention n= 7 practices; Control n= 7 practices
4		<i>Completed:</i> Intervention n= 7 practices; Control n= 7 practices
5		<i>Age:</i> Not reported
6		<i>Gender:</i> Not reported
7		<i>Patient description:</i> Dental patients aged 18 years and older who were seen for a non-emergency visit to the clinic and were self-identified current tobacco users (within the past 7 days)
8		<i>Eligible for study:</i> n= 2751 completed informed consent and baseline survey
9		<i>Randomized:</i> Intervention n= 1434; Control n= 1203
10		<i>Completed:</i> Six weeks Intervention n= 1214; Control n= 1026; 7.5 months Intervention n= 990; Control n= 885
11	Interventions	<i>Age:</i> Total sample only: Mean = 40.5 ± 12.6 years
12		<i>Gender:</i> Total sample only: Female= 45.8% n= 1508
13		<i>Setting:</i> Baseline survey completed in the clinic and were mailed follow-up surveys at 6 weeks and 7.5 months (lower socio-economic areas)
14		<i>Training of those delivering the intervention to the health professional:</i> Not reported
15		<i>Intervention description:</i> '5A approach' (Ask, Advise, Assess, Assist and Arrange): Ask - ask all patients about their tobacco use at every visit; Advise - relating the oral effects of tobacco use to the patients' oral health status and advising patients to quit tobacco; Assess - setting a quit date, discussing pharmacotherapy, providing free self-help materials and free nicotine replacement therapy; Arrange - arranging for follow-up by mail or phone for patients setting a quit date; Each intervention practice was provided with a supply of nicotine patches and lozenges, as well as printed patient self-help materials and information on the local tobacco quit line, which providers were asked to give to all tobacco-using patients
16		<i>Control description:</i> Usual care - delayed intervention control; Following the study period control clinics received the in-service workshop and received all the intervention materials
17		<i>Duration of intervention:</i> One workshop
18		<i>Intervention delivered by:</i> Dentists, dental hygienists and dental assistants
19		<i>Intensity:</i> One, 3 hour workshop
20		Outcomes
21	<i>Follow-up period:</i> Seven and a half months (6 months post-enrolment plus a 6 week grace period)	
22		
23	Notes	<i>Process measures:</i> Intervention subjects only - 66.5% reported receiving the reading materials and the majority of patients reported reading them (96.7%); 16.9% reported using nicotine replacement therapy and 10.9% reported receiving quit line counselling
24		<i>Validation:</i> No bio-chemical validation
25		n-values re-calculated for meta-analysis to permit intention-to-treat analysis for primary outcome data
26		
27		
28	Hymowitz 2007	
29	Methods	<i>Country:</i> United States of America
30		<i>Design:</i> Randomized controlled trial; Nested; Clustered
31		<i>Objective:</i> The primary aim of the study was to compare the effects of the two training conditions on resident tobacco intervention as measured by annual resident tobacco survey and OSCEs, baseline, and end-of-study patient and parent/guardian tobacco surveys, and a survey of program graduates who enter paediatric practice
32		<i>Methods of analysis:</i> Due to training site being the unit of randomization, analyses were based on aggregated data rather than on individuals; Likert scales were calculated as means; Two-stage mixed model relationship was used for waves of residents at baseline and 2 year follow-up
33		<i>Clustering adjustment made:</i> No – However data were analysed based on aggregated data to account for unit of analysis issues; authors state that this will provide "...an unbiased estimate of the intervention effect and standard error." (also known as a 'mean analysis')
34		<i>Significance of cluster adjustment:</i> Not reported
35		
36		
37		
38		
39		

1 2 3 4 5 6 7 8 9 10 11 12 13 14	<p>Participants</p> <p><i>Therapist description:</i> Paediatric residents undergoing training in the New York/New Jersey metropolitan area</p> <p><i>Eligible for study:</i> n= 16 Paediatric residencies; n= 2069 Residents</p> <p><i>Randomized:</i> n= 16 residency training programs; 3rd year residents n= 140 in intervention arm; n= 135 in control arm</p> <p><i>Completed:</i> n= 14 residency training programs; 3rd year residents n= 136 in intervention arm; n= 99 in control arm</p> <p><i>Age:</i> Approximately 33 years of age for overall population; Intervention mean = 32.3 ± 5.1 years; Control mean = 33.7 ± 5.7 years</p> <p><i>Gender:</i> Intervention female= 69.1%; Control female= 59.3%</p> <p><i>Patient description: Parent/Guardian:</i> Parents of the patients visiting the primary care clinics</p> <p><i>Eligible for study:</i> n= 1770</p> <p><i>Randomized:</i> Intervention n= 849; Control n= 776</p> <p><i>Completed:</i> Intervention n= 724; Control n= 617</p> <p><i>Age: Overall=</i> 29.88 ± 8.65 years</p> <p><i>Gender: Female=</i> 85.8%</p> <p><i>Patient description: Children:</i> Patients (children) visiting the primary care clinics</p> <p><i>Eligible for study:</i> n= 550</p> <p><i>Randomized:</i> Intervention n= 255; Control n= 300</p> <p><i>Completed:</i> Intervention n= 255; Control n= 300</p> <p><i>Age: Intervention</i> 14.89 ± 1.84 years; Control 15 ± 2.16 years</p> <p><i>Gender: Intervention female=</i> 55.3%; Control female= 60%</p>
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	<p>Interventions</p> <p><i>Setting:</i> New York/New Jersey metropolitan area; Continuity clinic (primary care clinic) served as the venue for resident tobacco-intervention activities</p> <p><i>Training of those delivering the intervention to the health professional:</i> Not specified</p> <p><i>Intervention description:</i> Special training – ‘Solutions for Smoking’ was the main teaching tool; Also provided with assistance with clinics (e.g., take-home educational and behavioural-change materials available in the waiting areas, anti-tobacco posters, marking charts of smokers etc); Packets of educational and behavioural materials designed for mothers of newborns, adolescent smokers, parents who smoke etc.; Seminar series provided opportunities to distribute program materials, highlight key concepts and aspects of the background material, and utilise role-playing to help residents acquire interviewing, counselling and tobacco-intervention skills; Power point presentations were used during these seminars on environmental tobacco smoke, smoking cessation and prevention of smoking onset and solutions for smoking audio/visual vignettes to demonstrate and model state-of-the-art counselling and intervention skills</p> <p><i>Control description:</i> Standard training – Background reading material that included the clinical practice guideline ‘Treating Tobacco Use and Dependence’ and ‘American Academy of Pediatrics Statement on Tobacco’; A manual entitled ‘Clinical Interventions to Prevent Tobacco Use by Children and Adolescents’; A journal article on approaches to tobacco prevention and control in clinic and office settings; Standard training sites did not receive assistance with clinic mobilisation or have access to companion intervention material; They did receive pamphlets and related material to facilitate intervention on tobacco; Seminar also conducted the same as the intervention group with the exception of vignettes to demonstrate counselling and intervention skills</p> <p><i>Duration of intervention:</i> One hour seminars, four times per year</p> <p><i>Intervention delivered by:</i> Unclear, though the manuscript mentions ‘training directors’; Seminars delivered by senior investigators from the New Jersey Medical School</p> <p><i>Intensity:</i> One hour seminars, four times per year</p>
31 32 33 34 35	<p>Outcomes</p> <p><i>Pre-specified outcome data:</i> Primary outcome measures included changes in resident tobacco intervention activities and skills in the area of environmental tobacco smoke, tobacco-use prevention and tobacco-use cessation; Demographic information, knowledge and attitudes about tobacco prevention and control, tobacco-intervention activities during the past year, use of specific tobacco-intervention skills and strategies, and beliefs about the efficacy of tobacco intervention in patients and parents</p> <p><i>Follow-up period:</i> Four years in total; Outcome data for participants only published for 2 year follow-up</p>
36 37 38 39	<p>Notes</p> <p><i>Process measures:</i> Sixty percent of residents in the special training condition reported review of ‘Solutions for Smoking’, although a higher proportion attended the seminar series (80%) and had access to companion intervention material in the clinic</p> <p><i>Validation:</i> No bio-chemical validation</p>

Joseph 2004

Methods

Country: United States of America
Design: Randomized controlled trial; Clustered
Objective: To test the effect of modest intensity, practical systems changes that might increase the delivery of smoking cessation treatment within VAMCs (Veterans Medical centres); Authors hypothesized that an intervention addressing common barriers to delivery of smoking cessation treatment at the organisation level (as opposed to provider or patient level) might be an effective strategy to improve compliance with guideline recommendations; The trial was designed to test the effectiveness of this intervention
Methods of analysis: McNemar odds on change to assess differences in the change between intervention groups; Pearson chi-squared statistic to compute the significant of the resulting odds ratio between the intervention and control group; Differences in smoking cessation rates were determined via the Pearson Goodness-of-Fit chi-squared statistic; Change scores were used for continuous variables and the relative difference in change was measured using the Wilcoxon rank sum test; Logistic regression was used for binary outcomes; SAS glimmix macro was used to incorporate the design effect and allow for the binary outcome
Clustering adjustment made: Yes - SAS glimmix macros used to incorporate the design effects
Significance of cluster adjustment: Not reported

Participants

Therapist description: Physicians, nurses, psychologists and pharmacists were present at the training meeting
Eligible for study: n= 164 VAMCs (Veteran Medical Centres) nationwide
Randomized: Intervention n= 10; Control n= 10
Completed: Intervention n= 10; Control n= 10
Age: Not reported
Gender: Not reported
Patient description: A random selection of patients who had seen their primary care provider (at VAMCs) within 6 weeks were phoned for baseline surveys; Current smokers were identified and underwent 1 year follow-up also via phone
Eligible for study: Cohort n= 5793; Eligible n= 5367
Randomized: Intervention n= 2112; Control n= 2142
Completed: Intervention n= 641; Control n= 783
Age: Baseline - Intervention 64.6 years; Control 63.1 years; Follow-up - Intervention 64.9 years; Control 63.8 years
Gender: Baseline (male) - Intervention 96.1%; Control 95.3%; Follow-up - Intervention 95.8%; Control 98.0%

Interventions

Setting: Veterans Affairs Medical Centers (VAMCs)
Training of those delivering the intervention to the health professional: Registered nurse who was trained in smoking cessation methods and had considerable administrative experience within Veteran Affairs
Intervention description: Intervention sites received 5 copies of the AHCPR Smoking Cessation Guideline for distribution; Plus a multi-component intervention designed to increase implementation of 3 specific Guideline recommendations: 1) documentation of tobacco use status in the medical record 2) delivery of intervention to all smokers and 3) liberal use of smoking cessation medications; The organisational support included a training meeting, site visits and a study interventionist at the co-ordinating site in Minneapolis; Removal of formulary restrictions were encouraged for smoking cessation aids as were the requirements for attendance at a cessation class to access pharmacotherapies; Bupropion SR was suggested as an addition to formulary; However approaches were individualised for each site
Control description: Control sites also received 5 copies of the AHCPR Smoking Cessation Guideline for distribution
Duration of intervention: Authors state intervention lasted through a 6 month period, however level of exposure for participants not specified
Intervention delivered by: Registered nurse face-to-face through 2 to 3 site visits within the first 6 months to communicate with directors of primary care, pharmacy service chiefs, smoking cessation co-ordinators and primary care nurses, as well as the 2 day training meeting
Intensity: One, 2 day training meeting held in Minneapolis for the site-based principal investigator; Two to 3 day visit to each site by the interventionist within the first 6 months

1	Outcomes	<i>Pre-specified outcome data:</i> General health, smoking history/status, nicotine dependence, services provided at the last primary care visit, mood, alcohol use and demographics, provision of counselling, referred to a smoking cessation clinic, provided advice or medications and cessation discussed (documented in medical records)
2		
3		<i>Follow-up period:</i> Twelve months
4	Notes	<i>Process measures:</i> None reported
5		<i>Validation:</i> No bio-chemical validation
6	Kottke 1989	
7	Methods	<i>Country:</i> United States of America
8		<i>Design:</i> Randomized controlled trial, cluster
9		<i>Objective:</i> "...the task of Doctors Helping Smokers was to be the development and testing of a program to help physicians incorporate currently identified smoking cessation intervention into their practice routine." Hypothesis: that physicians trained in a workshop would be more effective in helping their smoking patients quit than would similar volunteer physicians who received only patient education materials or a group of physicians that received no assistance
10		<i>Methods of analysis:</i> Data presented as proportions were analysed with the chi-squared analysis; Data reported as means and SDs were analysed with analysis of variance; Life-table analysis used to examine relapse patterns of the patients who attempted to quit smoking
11		<i>Clustering adjustment made:</i> Physicians unit of analysis; Multivariate regression used to adjust for confounding effects of differences among the groups of doctors and their patients
12		<i>Significance of cluster adjustment:</i> Not reported
13	Participants	<i>Therapist description:</i> n= 109 family practitioners
14		<i>Eligible for study; n-value:</i> 1110; n= 109 physicians returned postcards
15		<i>Randomized; n-value:</i> Workshop group n= 27; No-assistance group n= 17; Materials group n= 22
16		<i>Completed; n-value:</i> Workshop group n= 27; No-assistance group n= 17; Materials group n= 22
17		<i>Age:</i> Workshop group 37.9 ± 9.7; No-assistance group 39.5 ± 7.7; Materials group 44.3 ± 11.7
18		<i>Gender:</i> Workshop group F=22.2%; No-assistance group F=9.1%; Materials group f=11.8%
19		<i>Patient description:</i> n= 1653 primary care smoking patients not selected by motivation to quit
20		<i>Eligible for study; n-value:</i> Not reported
21		<i>Randomized; n-value:</i> 6053 total (89.4% of patients whose names were submitted by the physicians)
22		<i>Completed; n-value:</i> 87% of the n= 6053 were available for follow-up; 86.8%, 87.5% and 86.8% for the workshop, materials and no-assistance groups respectively
23		<i>Age:</i> 18 to 70 years; Mean =slightly over 40
24		<i>Gender:</i> Two thirds women

1	Interventions	<i>Setting:</i> Private family practice (primary care) in Minnesota, USA; workshop site not described though likely centralised
2		<i>Training of those delivering the intervention to the health professional:</i> Not described
3		<i>Intervention description:</i> Two intervention groups: Materials group - physicians given self-help manuals to distribute; Workshop group - self-help manuals plus 6 hour group workshop
4		<i>Control description:</i> Normal care
5		<i>Duration of intervention:</i> Workshop group: 6-hour workshop given on two occasions.
6		Workshop started in the morning with two presentations of 30-minutes about the effects of smoking, chronic disease and organisation for smoking cessation interventions; 1-hour presentation on doctor-patient intervention skills; 1-hour introduction to smoking cessation techniques; Two 1-hour small-group workshop sessions on counselling sessions and planning for smoking cessation interventions and 30-minutes for summary and discussion; Materials group: 100 copies of Quit-and-Win, a smoking cessation manual
7		<i>Intervention delivered by:</i> Not described
8		<i>Intensity:</i> Workshop: 6-hr workshop given on 2 occasions; Materials group: None; No assistance: None
9		
10		
11		
12		
13	Outcomes	<i>Pre-specified outcome data:</i> Physicians: Characteristics, knowledge, skills, confidence and beliefs about smoking cessation in relation to their performance during the trial
14		Patients: demographics, smoking habits, health status, details about visit with physician, prevalence of smoking in their social environment and support received from spouse or others who were emotionally important to them; Four questions about extent to which they felt in control of their life, the confidence they felt about handling personal problems, extent that "things were going [their] way," and the extent to which difficulties were piling up; serum cotinine levels
15		<i>Follow-up period:</i> 12-months
16	Notes	<i>Process measures:</i> None
17		<i>Validation:</i> Serum cotinine
18		Not able to be meta-analysed due to unit of analysis being the practitioners instead of the individuals
19		
20	Lennox 1998	
21	Methods	<i>Country:</i> United Kingdom
22		<i>Design:</i> Randomized controlled trial; Nested; Clustered
23		<i>Objective:</i> To assess the impact of the training intervention on both health professionals and smoking subjects
24		<i>Methods of analysis:</i> Comparison of binary outcomes were analysed using the chi-squared test; Logistic and multiple regression analyses were carried out where appropriate for these outcome measures; Comparisons of continuous outcomes were analysed using t-tests and multiple linear regression; Confounders were adjusted including age, sex and deprivation score for the regression analysis as well as for indicators for the intervention group
25		<i>Clustering adjustment made:</i> Yes - GLMM (Generalised linear mixed model) approach used for regression techniques which added the general practice as a random factor nested within the treatment groups to the other fixed-effect factors
26		<i>Significance of cluster adjustment:</i> Regression techniques used to explore clustering effects for variables significant in individual level analyses; No significant difference in point prevalence of abstinence after adjustment
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		

1 2 3 4 5 6 7 8 9 10 11	Participants	<p><i>Therapist description:</i> n= 16 general practices with training for doctors, nurses and health visitors <i>Eligible for study:</i> n= 26 practices <i>Randomized:</i> n= 16 practices <i>Completed:</i> n= 16 practices <i>Age:</i> Not reported <i>Gender:</i> Not reported <i>Patient description:</i> Smoking patients of the practices identified from questionnaires to random sample <i>Eligible for study:</i> Not reported <i>Randomized:</i> Number of patients surveyed: Intervention n= 6631; Control n= 6631; <i>Number of patients responding:</i> Intervention n= 5022; Control n= 5217; <i>Number of smokers identified:</i> Intervention n= 1381; Control n= 1207 <i>Completed:</i> Eight months - Intervention n= 941; Control n= 864; 14 months - Intervention n= 898; Control n= 795 <i>Age:</i> Not reported <i>Gender:</i> Not reported</p>
12 13 14 15 16 17 18 19	Interventions	<p><i>Setting:</i> Primary care medical practices in Aberdeen, UK <i>Training of those delivering the intervention to the health professional:</i> Two authors conducted the training, one a senior health promotion officer experienced in group work with primary health care teams and the other a GP <i>Intervention description:</i> One day training workshop based on stages of change model <i>Control description:</i> Usual care control group <i>Duration of intervention:</i> Six identical one day training workshops were held within a three week period based on stages of change model <i>Intervention delivered by:</i> Two authors, one a senior health promotion officer experienced in group work with primary health care teams and the other a GP <i>Intensity:</i> One day training workshop</p>
20 21 22	Outcomes	<p><i>Pre-specified outcome data:</i> Changes in attitudes, self-reported behaviour, change in readiness to change, cessation attempt made, point prevalence, continuous abstinence <i>Follow-up period:</i> Eight and 14 months post workshop for patient questionnaires</p>
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Notes	<p><i>Process measures:</i> Some subjects did not attend their practice during the study and therefore were not exposed to the effects of the training <i>Validation:</i> No bio-chemical validation <i>n-values re-calculated for meta-analysis to permit intention-to-treat analysis for primary outcome data</i></p>

Sinclair 1998

Methods *Country:* Scotland
Design: Randomized controlled trial
Objective: To evaluate a training workshop for community pharmacy personnel to improve their counselling in smoking cessation based on the stage-of-change model
Methods of analysis: To demonstrate the differences between intervention and control groups, parametric tests (t-tests for quantitative variables) and non-parametric tests (Mann-Whitney tests for quantitative variables) were used. Multiple logistic regression was carried out for the binary outcomes of point prevalence at one month, and continuous abstinence at four and nine months, and to assess the effect of potential confounders
Clustering adjustment made: Yes; authors mention that the effect of cluster randomization was assessed by firstly calculating the degree of intra-cluster correlation for each of the binary outcomes of abstinence. Secondly, regression techniques, adding the pharmacy as a random factor nested within the treatment groups to the other fixed effect factors, were considered leading to a generalised linear mixed model. The authors mention that intra-cluster correlations for the outcomes at each time point were calculated. The estimated values were less than 0.0001 and therefore negligible
Significance of cluster adjustment: No; authors mention that trends in outcome were not affected by potential confounders or adjustment for clustering
Setting: Residents and physicians in Family Medicine, Taiwan
Training: Two lessons
Randomization: Stratified by number of years in practice (method not stated)

Participants *Therapist description:*
Eligible for study; n-value: n= 76 pharmacies
Randomized; n-value: Intervention n= 32 pharmacies; Control n= 30 pharmacies
Completed; n-value: Intervention n= 32 pharmacies (specify: n= 94 (54 assistants, 40 pharmacists); Control n= 29 pharmacies
Age: Not described
Gender: Intervention: 54 female assistants; 25 female pharmacists; Control: not described
Patient description:
Eligible for study; n-value: n= 775 smokers
Randomized; n-value: Intervention n= 224; Control n= 268
Completed; n-value: Intervention n= 159; Control n= 188
Age: Intervention 41.7 (17-74); Control 41.5 (17-77)
Gender: Intervention 61.2% men; Control 62.7% men

Interventions *Setting:* Eight workshops were scheduled with a choice of dates, times and location (Aberdeen or Elgin - the major population centres which are located 70 miles apart at opposite ends of the study area)
Training of those delivering the intervention to the health professional: Not described
Intervention description: Training in stages of change approach to smoking cessation
Control description: Usual care
Duration of intervention: two-hour workshop
Intervention delivered by: Not described
Intensity: One workshop

Outcomes *Pre-specified outcome data:* self-reported point prevalence smoking cessation rates at one month; self-reported continuous abstinence from zero to four months and from zero to nine months; the pharmacy support process (registration, counselling and client record)
Follow-up period: 1, 4, 9 months; Point prevalence of abstinence at 12 months
No process outcomes

Notes *Validation:* none
n-values re-calculated for meta-analysis to permit intention-to-treat analysis for primary outcome data

Strecher 1991

1	Methods	<p>Country: United States of America</p> <p>Design: Randomized Controlled Trial; Factorial design; Nested; Cluster</p> <p>Objective: The study evaluated the effectiveness of training and prompting under realistic conditions, including: the use of simple and generalisable interventions; training conducted by existing faculty; and evaluation at several sites with residents from three primary care specialties</p> <p>Methods of analysis: Contingency tables with chi-squared tests, t-tests, and analysis of variance (ANCOVA) were used to investigate the pre-test equivalencies of the four groups and all outcomes for selected other variables; ANCOVA compared the effects of the two interventions, alone and in combination, whilst controlling for pre-test scores and physician speciality</p> <p>Clustering adjustment made: No</p> <p>Significance of cluster adjustment: N/A (Physician speciality adjusted for but not individual physician clustering effects)</p>
11	Participants	<p>Therapist description: 250 residents in internal medicine, family practice and paediatrics</p> <p>Eligible for study; n-value: 261</p> <p>Randomized; n-value: 250; Tut (Tutilage) and Pro (Prompt) n= 66; Tut only n= 66; Pro only n= 60; Control n= 58</p> <p>Completed; n-value: 234; Tut and Pro n= 62; Tut only n= 63; Pro only n= 55; Control n= 54</p> <p>Age: Not reported</p> <p>Gender: Not reported</p> <p>Patient description: 937 patients from American primary care medical practice</p> <p>Eligible for study; n-value: 937; Tut and Pro n= 250; Tut only n= 243; Pro only n= 228; Control n= 225</p> <p>Randomized; n-value: 843</p> <p>Completed; n-value: 659; Tut and Pro n= 184; Tut only n= 156; Pro only n= 162; Control n= 157</p> <p>Age: 17 to 75 years; Mean age = 45 years</p> <p>Gender: Female =63%</p>
23	Interventions	<p>Setting: American primary care residency programmes (physicians in training)</p> <p>Training of those delivering the intervention to the health professional: Not specified though one of the authors in each instance conducted the tutorial</p> <p>Intervention description: Three intervention groups: Tutilage only (minimal contact counselling); Prompt only (chart-reminder and advice sheet); Tutilage and Prompt</p> <p>Control description: Normal care</p> <p>Duration of intervention: Only held once, two sessions in total - the first included slide presentations the second group discussions</p> <p>Intervention delivered by: One of the authors, usually a clinic director or a faculty member conducted the tutorial</p> <p>Intensity: Tutorial: two sessions - initial one-hour long, second session two weeks later</p>
31	Outcomes	<p>Pre-specified outcome data: Self-administered questionnaires requesting self-reports on smoking-cessation counselling frequency, content, attitude and training; patients were asked about smoking habits and physicians advice to stop smoking</p> <p>Follow-up period: 6-months</p>
34	Notes	<p>Process measures: None</p> <p>Validation: Expired CO; Bio-chemical verification was obtained where possible</p> <p>The three intervention groups were combined for meta-analyses to produce the single 'Intervention' sample; n-values re-calculated for meta-analysis to permit intention-to-treat analysis for primary outcome data</p>

Swartz 2002

1	Swartz 2002	
2	Methods	<p>Country: United States of America</p> <p>Design: Randomized controlled trial; Clustered</p> <p>Objective: Primary goal of this study was to determine if in-person feedback intervention, compared to mailed feedback, would lead to a higher use of tobacco treatments by patients who smoke</p> <p>Method of Analysis: Odds ratios, 95% confidence intervals and p-values were calculated to evaluate intervention effects on patient and provider behaviour; Unadjusted models and models adjusted for age, insurance at baseline, practice speciality and region of the state were calculated using logistic regression; All analyses were completed with SAS statistical software</p> <p>Clustering adjustments made: Yes – survey logistic procedures</p> <p>Significance of clustering: Not reported</p>
10	Participants	<p>Therapist description: Primary care providers with practices of at least 75% internal medicine or family medicine clinicians providers combined with Medicaid and HMO panel size of at least 200 adults; n= 176 were physicians, n= 26 nurse practitioners, n= 20 physician assistants, n= 3 unknown classification</p> <p>Eligible for study: n= 150 practices; n= 230 providers within the 50 practices recruited were eligible</p> <p>Randomized: n= 50 practices; n= 225 providers</p> <p>Completed: n= 50 practices; n= 179 providers</p> <p>Age: Not reported</p> <p>Gender: Not reported</p> <p>Patient description: Patients were adults receiving primary care by a study practice aged 18 years and older who were seen within the prior year</p> <p>Eligible for study: n= 17318 identified as receiving primary care by a study practice; n= 11547 eligible</p> <p>Randomized: n= 7461 completed baseline survey; n= 1238 patients identified as smokers at baseline</p> <p>Completed: n= 807 reporting provider visit in the year proceeding follow-up; n= 516 smokers with baseline and follow-up surveys reporting one serious quit attempt</p> <p>Age: Intervention mean age= 41.9 years; Control mean age= 42.9 years</p> <p>Gender: Intervention male= 26.4%; Control male= 23.2%</p>
23	Interventions	<p>Setting: Maine Medicaid and Maine HMO, USA</p> <p>Training of those delivering the intervention to the health professional: Not reported</p> <p>Intervention description: Experimental study practices received two educational office sessions, with data feedback presented during the first visit; Second visit reinforced the guidelines and discussed office systems to improve tobacco treatment</p> <p>Control description: Control practices received information and feedback data by mail</p> <p>Duration of intervention: For the intervention: Two educational office sessions, the second occurred five months after the first</p> <p>Intervention delivered by: One nurse practitioner well-versed in motivational interviewing and tobacco guidelines</p> <p>Intensity: Twenty minute slide presentation followed by feedback and discussions for the first visit; Second visit discussions time not stated</p>
31	Outcomes	<p>Pre-specified outcome data: Reports of provider asking about tobacco, advice to quit, spending time talking about smoking or quitting, discussing tobacco treatment medications, and discussing counselling services or programs; Smokers were asked about serious attempts at quitting for 24 hours or longer, use of medication or counselling to aid quitting, and use of any tobacco in the previous week (7 day point prevalence)</p> <p>Follow-up Period: Fifteen to 18 months later which corresponded to 12 months following the practice intervention</p>
37	Notes	<p>Process measures: None reported</p> <p>Validation: No bio-chemical validation</p>

Twardella 2007

Methods*Country:* Germany*Design:* Randomized controlled trial; Nested; Clustered; Factorial design 2x2

Objective: The aim of this study was to examine whether and to what extent structural changes could enhance promotion of smoking cessation in general practice. In particular, we aimed to investigate the effect of the following strategies on smoking cessation rates: (1) specific training of general practitioners in methods of promoting smoking cessation and a financial incentive to general practitioners for each recruited patient who successfully quits; and (2) specific training of general practitioners in promotion of smoking cessation and the cost-free prescription of drugs proved effective in supporting smoking cessation

Methods of analysis: Primary end-point data were assessed on an intention-to-treat basis; smoking abstinence at 12 months was assessed using a mixed logistic regression model accounting for cluster randomization including a random effect for medical practice in the model; baseline imbalances between intervention arms were adjusted using multivariate analyses; the effect of drug use during follow-up, as recorded by general practitioners, was evaluated in a bivariate mixed logistic regression model

Clustering adjustment made: Yes - mixed logistic regression model, using PROC NL MIXED in "SAS V8.1" (including a random effect for medical practice)

Significance of cluster adjustment: Not reported

Participants

Therapist description: General practitioners in the Rhine-Neckar region located in southwest Germany

Eligible for study: n= 174 met the inclusion criteria

Randomized: Total= 94 general practitioners from n= 82 practices; Usual care: n= 21 therapists (20 practices); Training + incentive: n= 24 therapists (21 practices); Training + medication: n= 23 therapists (21 practices); Training, incentive + medication: n= 26 therapists (20 practices)

Completed: n= 59 practices; Usual care: n= 14 practices; Training + incentive: n= 16 practices; Training + medication: n= 11 practices; Training, incentive + medication: n= 18 practices

Age: Not reported

Gender: Not Reported

Patient description: Patients visiting the practices and who smoked at least 10 cigarettes per day and aged between 36 to 75 years, were recruited by participating general practitioners, irrespective of intention to quit smoking and conditional on written informed consent

Eligible for study: n= 587

Randomized: n= 587; Usual care: n= 76; Training + incentive: n= 146; Training + medication: n= 144; Training, incentive + medication: n= 221

Completed: n= 488; Usual care: n= 61; Training + incentive: n= 123; Training + medication: n= 121; Training, incentive + medication: n= 183

Age: Range 36 to 75 years; <45 years: Usual care n= 30; Training + incentive n= 55; Training + medication n= 59; Training, incentive + medication n= 95; 45 to 54 years: Usual care n= 24; Training + incentive n= 63; Training + medication n= 44; Training, incentive + medication n= 86; > 55 years: Usual care n= 22; Training + incentive n= 28; Training + medication n= 41; Training, incentive + medication n= 40

Gender: Female: Usual care n= 38; Training + incentive n= 74; Training + medication n= 71; Training, incentive + medication n= 121

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

1	Interventions	<p><i>Setting:</i> Not reported</p> <p><i>Training of those delivering the intervention to the health professional:</i> Not reported</p> <p><i>Intervention description:</i> Three intervention groups: Training + incentive – Two hour cost-free group tutorial for general practitioners in methods of promoting smoking cessation including stages of change model, approaches for counselling in general practice and potential of pharmacological support; Financial remuneration of €130 after study completion per smoke-free participant; Training + medication – Same group tutorial as above plus general practitioners could offer cost-free prescription of drugs proved effective in supporting smoking cessation; Training, incentive + medication – All of the above</p> <p><i>Control description:</i> Usual care</p> <p><i>Duration of intervention:</i> A single 2 hour tutorial available at two session times</p> <p><i>Intervention delivered by:</i> Not reported</p> <p><i>Intensity:</i> Two Hour workshop</p>
10	Outcomes	<p><i>Pre-specified outcome data:</i> Primary outcome measure - Self-reported point prevalence of smoking abstinence obtained at 12 months follow-up</p> <p>Second outcome measure - Continuous smoking abstinence for at least 6 months (183 days) at 12 months follow-up; Frequency of the use of methods to support smoking cessation among patients during the follow-up period as reported by general practitioners</p> <p><i>Follow-up period:</i> Twelve months</p>
15	Notes	<p><i>Process measures:</i> None reported</p> <p><i>Validation:</i> Serum cotinine</p> <p><i>Other:</i> Definition of abstinence - Participants were categorised as 'at least 6 months abstinent' if they were smoke free at 12 months follow-up, validated by serum cotinine, and, according to self-report, had stopped smoking at least 6 months before the date of follow-up</p> <p>The three intervention groups were combined for meta-analyses to produce the single 'Intervention' sample</p>
21	Unrod 2007	
22	Methods	<p><i>Country:</i> United States of America</p> <p><i>Design:</i> Randomized controlled trial; Nested; Clustered</p> <p><i>Objective:</i> To bolster the rate at which physicians delivered smoking cessation services and to increase patients' quit rates</p> <p><i>Methods of analysis:</i> Descriptive statistics for characterisation of sample at baseline; Pearson's chi-squared test and independent sample t-test to measure differences between groups; Hierarchic generalised linear model analysis of variance controlling for baseline variables used to measure physician performance; Abstinence analysed via generalised linear model</p> <p><i>Clustering adjustment made:</i> Yes - Mixed linear modelling with physician as clustering variable used for smoking related outcomes</p> <p><i>Significance of cluster adjustment:</i> Not reported</p>
30	Participants	<p><i>Therapist description:</i> Primary care physicians recruited from the four largest metropolitan boroughs, Bronx, Brooklyn, Manhattan and Queens</p> <p><i>Eligible for study:</i> n= 579</p> <p><i>Randomized:</i> Intervention n= 35; Control n= 35</p> <p><i>Completed:</i> Intervention n= 35; Control n= 35</p> <p><i>Age:</i> Mean = 51.1 ± 8.1 years (total population only)</p> <p><i>Gender:</i> Males= 74% (total population only)</p> <p><i>Patient description:</i> Patients in primary care physician waiting rooms who were identified as smokers</p> <p><i>Eligible for study:</i> n= 5826</p> <p><i>Randomized:</i> Intervention n= 270; Control n= 248</p> <p><i>Completed:</i> Intervention n= 237; Control n= 228</p> <p><i>Age:</i> Intervention mean= 43.5 ± 14.7 years; Control mean= 42.8 ± 14.2 years</p> <p><i>Gender:</i> Intervention 58% male; Control 64% male</p>

1 **Interventions** *Setting:* Training conducted during a 40 minute visit to the physicians' office
 2 *Training of those delivering the intervention to the health professional:* Not reported
 3 *Intervention description:* Physician training in brief smoking cessation counselling
 4 based on the 5As Clinical Practice Guideline algorithm; Patients and physicians
 5 provided with a one page report containing smoking-related information
 6 and recommendations based on the information provided during the patient
 7 assessment
 8 *Control description:* Physicians in the control condition were not given any training
 9 and were instructed to continue their usual smoking cessation practices; Patients
 10 completed the same assessments but did not receive the report (being the one page
 11 report characterising patients smoking habits)
 12 *Duration of intervention:* One session only
 13 *Intervention delivered by:* Health educator
 14 *Intensity:* One, 40 minute session

10 **Outcomes** *Pre-specified outcome data:* Patients asked - Did your doctor... ask whether you
 11 smoke, ask whether you are ready to quit, advise you to quit smoking, help you to
 12 quit smoking, help you set goals about quitting, give you written materials about
 13 quitting, refer you to a quit smoking program, talk to you about quit-smoking
 14 medications, make a follow-up appointment to discuss smoking
 15 *Primary outcome measure - 7 day point prevalence abstinence; Longest quit
 16 attempt (in days); Total number of 25 hour quit attempts, stage-of-change
 17 progression
 18 Follow-up period:* Six months

16 **Notes** *Process measures:* None reported
 17 *Validation:* For sub-group of participants - Saliva-cotinine test; Fourteen of 16
 18 samples confirmed abstinence (88%)
 19 n-values re-calculated for meta-analysis to permit intention-to-treat analysis for
 20 primary outcome data

20 **Wang 1994**

21 **Methods** *Country:* Taiwan
 22 *Design:* Randomized Controlled Trial
 23 *Objective:* To assess the stages-of-change model in cigarette smoking and practice
 24 guidelines for practicing cigarette smoking cessation counselling in a short training
 25 program, designed to make physicians more willing to help their patients to quit
 26 smoking and increase success rates
 27 *Methods of analysis:* All data were analysed using either the chi-square or Fisher's
 28 exact tests
 29 *Clustering adjustment made:* No
 30 *Significance of cluster adjustment:* Not applicable


28
29
30
31
32
33
34
35
36
37
38
39

1	Participants	<i>Therapist description:</i> Residents and physicians in Family Medicine	
2		<i>Eligible for study; n-value:</i> Not reported	
3		<i>Randomized; n-value:</i> Group one: lessons n= 9, Group two: posters n= 9, Group three: usual care n= 9	
4		<i>Completed; n-value:</i> Group one: lessons n= 9, Group two: posters n= 9, Group three: usual care n= 9	
5		<i>Age:</i> Not reported	
6		<i>Gender:</i> Not reported	
7		<i>Patient description:</i>	
8		<i>Eligible for study; n-value:</i> Not reported	
9		<i>Randomized; n-value:</i> n= 93, Group one: n= 39, Group two: n= 26, Group three: n= 28	
10		<i>Completed; n-value:</i> n= 82, Group one: n= 35, Group two: n= 24, Group three: n= 23	
11		<i>Age:</i> Group one: <40 n= 14, 40-59 n= 17, ≥ 60 n= 8; Group two: <40 n= 14, 40-59 n= 8, ≥ 60 n= 4; Group three: <40 n= 7, 40-59 n= 12, ≥ 60 n= 9	
12		<i>Gender:</i> Group one: male n= 38 female n= 1; Group two: male n= 24 female n= 2; Group three: male n= 27 female n= 1	
13	Interventions	<i>Therapists:</i> 27 physicians	
14		<i>Patients:</i> 93 patients	
15		<i>Setting:</i> Not reported	
16		<i>Training of those delivering the intervention to the health professional:</i> Not reported	
17		<i>Intervention description:</i> Two intervention groups: Training - stages of change model and practice guidelines; Poster - used as a reminder to give advice	
18		<i>Control description:</i> Usual care	
19	Outcomes	<i>Duration of intervention:</i> Group one: two lessons; Group two: provided with poster only; Group three: no intervention	
20		<i>Intervention delivered by:</i> Not reported	
21		<i>Intensity:</i> Group one: two lessons; Group two: provided with poster only; Group three: no intervention	
22		<i>Pre-specified outcome data:</i> Demographic data, cigarette-smoking habits and health beliefs	
23		<i>Follow-up period:</i> 6-months; Point prevalence of abstinence at 12 months	
24	Notes	No process outcomes	
25		<i>Validation:</i> None	
26		<i>Process measures:</i> None reported	
27	Wilson 1988	Manual adjustment for potential clustering effects performed in the meta-analyses for primary outcome data; The two intervention groups were combined for meta-analyses to produce the single 'Intervention' sample; n-values re-calculated for meta-analysis to permit intention-to-treat analysis for primary outcome data	
28		Methods	<i>Country:</i> Canada
29			<i>Design:</i> Randomized controlled trial; Nested; Clustered
30			<i>Objective:</i> To investigate the effects of a smoking cessation workshop on physician practices and on patients' smoking behaviour
31			<i>Methods of analysis:</i> Analysis of covariance – Obtained by averaging patient values within the practice; Analysis of differences between groups – If there was no difference between the usual care and gum only groups (untrained cohorts) these would be combined and compared with the gum plus (trained cohort); Regression analysis performed on practice unit, adjusting for the effects of predictor variables and treatment
32			<i>Clustering adjustment made:</i> No - None reported
33			<i>Significance of cluster adjustment:</i> Not reported
34			
35			
36			
37			
38			
39			


1 2 3 4 5 6 7 8 9 10 11	Participants	<p><i>Therapist description:</i> Physicians <i>Eligible for study:</i> n= 460 Family physicians <i>Randomized:</i> n= 90 Physicians <i>Completed:</i> n= 83 Physicians; Usual care n= 27; Gum only n= 29; Gum plus n= 27 <i>Age:</i> Usual care: Mean = 41.64 years; Gum only: Mean = 41.77 years; Gum plus: Mean = 40.57 years <i>Gender:</i> Usual care: Male 92.6%; Gum only: Male 93.1%; Gum plus: Male 81.5% <i>Patient description:</i> <i>Eligible for study:</i> Not stated as n-value; Participation consent rates were: Usual care 91%; Gum only 83%; Gum plus 76% <i>Randomized:</i> Not reported <i>Completed:</i> Usual care n= 601; Gum only n= 726; Gum plus n= 606 (total n= 1933) <i>Age:</i> <25 years: Usual care 22%; Gum only 19%; Gum plus 17%; 25 to 44 years: Usual care 50%; Gum only 54%; Gum plus 56%; ≥ 45 years: Usual care 27%; Gum only 27%; Gum plus 27% <i>Gender:</i> Male: Usual care 39%; Gum only 42%; Gum plus 33%</p>
12 13 14 15 16 17 18 19	Interventions	<p><i>Setting:</i> Clinical practice setting – Participation during routine physician consultation; Based in Ontario, Hamilton <i>Training of those delivering the intervention to the health professional:</i> Not described; CME Protocol <i>Intervention description:</i> Two intervention groups: Gum only - Physicians instructed to approach patients in their usual manner about quitting smoking and to offer nicotine gum as an aid to quitting; Gum Plus Training - Gum in addition to training <i>Control description:</i> Usual care <i>Duration of intervention:</i> One, 4 hour training workshop to Gum plus physician cohort <i>Intervention delivered by:</i> Not described <i>Intensity:</i> Control - Not explicitly reported; Gum only - Not explicitly reported; Gum plus - One, 4 hour workshop for physicians; For patients - Use of gum, 1 to 6 follow up visits and quit dates</p>
20 21 22 23	Outcomes	<p><i>Pre-specified outcome data:</i> Three month self-reported sustained abstinence prior to bio-chemically validated cessation at 12 months; smoking behaviour, cessation attempts and nicotine gum use measured by telephone interviews; Physicians performance measured by patient flow sheets and patient telephone exit interviews <i>Follow-up period:</i> Point prevalence of abstinence at 12 months</p>
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Notes	<p><i>Process measures:</i> None reported <i>Validation:</i> Salivary cotinine The two intervention groups were combined for meta-analyses to produce the single 'Intervention' sample; Manual adjustment for potential clustering effects performed in the meta-analyses for primary outcome data</p>

Appendix 1. Forest plots of comparisons


Analysis 1.1a. Smoking cessation at longest follow-up (point prevalence)




Analysis 1.1b. Smoking cessation at longest follow-up (continuous abstinence)




Analysis 1.2. Patients asked to set a quit date




Analysis 1.3. Patient asked to make a follow-up appointment




Analysis 1.4. Number of smokers counselled




Analysis 1.5. Number of smokers receiving self-help material



Analysis 1.6. Number of smokers receiving nicotine gum/replacement therapy



Analysis 1.7. Number of smokers prescribed a quit date





3

One-hour training for general practitioners in reducing the implementation gap of smoking cessation care: A cluster-randomized controlled trial

Marjolein E.A. Verbiest¹, Mathilde R. Crone¹,
Margreet Scharloo², Niels H. Chavannes¹,
Victor van der Meer¹, Ad A. Kaptein² &
Willem J.J. Assendelft^{3,1} (2014)

¹Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands

²Department Medical Psychology, Leiden University Medical Centre, Leiden, the Netherlands

³Department Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Nicotine & Tobacco Research, 16(1), 1-10

1 **ABSTRACT**

2 3 **Introduction**

4 This study examined the effectiveness of low-intensity, practice-tailored train-
5 ing for general practitioners (GPs) aimed at personal and organizational barriers
6 that arise when routinely asking patients' smoking status, advising to quit, and
7 arranging follow-up.

8 9 **Methods**

10 A cluster-randomized controlled trial with 49 GPs and 3,401 patients (677 smok-
11 ers). Two patient groups participated: 2,068 patients (433 smokers) at baseline
12 and 1,333 patients (244 smokers) post-intervention. At follow-up, 225 smokers
13 of both groups participated. The primary outcome was GP smoking cessation
14 counseling (asking about smoking status, advising to quit, prescribing pharma-
15 cotherapy, and referring for behavioural support). Secondary outcomes were
16 GPs' attitudes toward smoking cessation care, patients' intention to quit, and
17 long-term quit rates. Outcomes were measured with GP self-report and patient
18 report.

19 20 **Results**

21 Patients of trained GPs reported more often being asked about smoking behaviour
22 compared to patients of untrained GPs (OR = 1.94, 95% CI = 1.45–2.60). According
23 to GP self-report, the training increased the provision of quit-smoking advices
24 (difference 0.56 advice per day; 95% CI = 0.13–0.98) and the ability and intention
25 of providing smoking cessation care. We found no effect on GPs' arrangement of
26 follow-up, smokers' intention to quit, and long-term quit rates.

27 28 **Conclusions**

29 After 1 hour of training, we found significant differences between trained and
30 untrained GPs on the frequency in which they asked about smoking (patient
31 reported) and advised smokers to quit (GP self-reported). The training did not
32 increase prescriptions of pharmacotherapy, referrals to behavioural support, or
33 quit rates. Future training methods should focus on the GPs' ability, tools, and
34 skills to arrange follow-up to ensure intensive smoking cessation support.

35
36
37
38
39

1 INTRODUCTION

2
3 General practitioners (GPs) play a key role in the delivery of smoking cessation
4 interventions to their patients. Even a GPs' minimal intervention of advising
5 smokers to quit has the potential to significantly benefit smokers' motivation to
6 quit and smoking abstinence.^{1,2} Guidelines recommend that GPs put into practice
7 a systematic approach of asking every patient about tobacco use, advising all
8 smokers to quit, assessing smokers' willingness to make a quit attempt, assisting
9 smokers with treatment and referrals, and arranging follow-up contacts.³⁻¹⁰ In
10 spite of the well-documented effectiveness of these guidelines^{1,6,9}, many GPs fail to
11 routinely implement them.¹¹⁻¹³ This results in a substantial evidence-practice gap.

12 Several factors may affect the implementation of smoking cessation care (SCC)
13 in general practice, related to the health professional and the organisation.¹⁴⁻¹⁶
14 Personal barriers of GPs that impede the implementation of tobacco support are
15 doubts and concerns regarding their ability to deliver SCC, and the effectiveness
16 and the appropriateness of SCC.¹⁷⁻²⁰ Also, organisational barriers may hamper
17 guideline implementation, as GPs often report role confusion, time and financial
18 constraints.²⁰ For this reason, interventions aimed at enhancing the implemen-
19 tation of SCC guidelines should be multifaceted and tailored to the needs of the
20 health professional and organisation.^{2,18,21-25}

21 Training health professionals in improving SCC has been shown to benefit
22 the implementation of counseling tasks, such as asking patients to set a quit
23 date and providing self-help materials, as well as patient smoking abstinence.²⁶
24 However, these training programmes often fail to address organisational con-
25 straints that impede full implementation of smoking cessation guidelines.²⁶
26 Since smoking cessation counseling varies widely between general practices²⁷,
27 strategies are needed that address the specific constraints GPs deal with in order
28 to maximize the implementation of smoking cessation support and patients'
29 smoking abstinence rates.

30 Therefore, we developed and examined the effectiveness of a new low-intensity,
31 practice-tailored training method aimed at improving smoking cessation coun-
32 seling activities of GPs. This method is tailored to the personal and organisational
33 barriers that arise during the implementation of SCC in regular daily practice. In
34 the present study we focus on the implementation of routinely asking patients'
35 smoking status, advising smokers to quit, and arranging follow-up. This simpli-
36 fied approach (also called the A-A-A approach) has recently been introduced in
37 healthcare settings where professionals face insurmountable barriers, such as
38 a lack of time to provide assistance to smokers who want to quit.^{28,29} Because
39 preventive tasks, such as intensive lifestyle counseling, are more often delegated

1 to the practice nurse within Dutch general practice, this simplified approach is a
2 promising solution to reduce the implementation gap of smoking cessation care
3 in general practice.

4 We hypothesize that our training method will increase GPs' smoking cessation
5 counseling activities, especially the rate at which smokers are identified, advised,
6 and referred. Since we focus on the implementation of GPs' minimal cessation
7 intervention, we expect a small but significant effect on smoker's intention to
8 quit. If trained GPs succeed to increase the rate at which smokers are referred
9 to intensive cessation support, we expect higher rates of long-term smoking
10 abstinence reported by patients of trained GPs.

11

12

13 **METHODS**

14

15 **Design**

16 We performed a cluster-randomised controlled trial in general practice. In order
17 to account for a lack of independence between the patients of the same GP, the
18 GP was the unit of randomisation. GPs were matched according to gender, age
19 and practice type and randomly assigned to one of two conditions using a simple
20 randomisation procedure (coin tossing) by an independent researcher not in-
21 volved in the recruitment of the GPs. Patients were unaware of the allocation
22 during the entire study period. GPs remained unaware about the allocation until
23 after the baseline measurements; thereafter, the GPs were informed about the
24 allocation. GPs in both conditions were aware of the aim of the intervention
25 during the entire study period. The study was approved by the Medical Ethical
26 Board of the Leiden University Medical Centre (P10.125).

27

28 **Intervention**

29 We earlier conducted a systematic review on the effectiveness of training health-
30 care professionals in SCC.²⁶ The results of this meta-analysis show that a single,
31 short training session is likely to be just as effective as multiple longer sessions.
32 Therefore, we developed a single, one-hour training session in order to anticipate
33 time constraints GPs often face. The GP training was delivered by a certified
34 trainer of the Dutch Expert Centre on Tobacco Control (STIVORO) and was based
35 on the 5-A behaviour change model from which we derived the 6 I-Model^{4,5}; an
36 Inventory was made of GPs' current knowledge and skills as well as organisa-
37 tional and personal barriers regarding SCC and the GP was Informed about the
38 effectiveness of SCC in general practice. GPs' motivation to implement SCC was
39 Identified and less motivated GPs were Inspired using Motivational Interviewing

1 techniques, such as exploring and resolving ambivalence.³⁰ GPs were Instructed
2 on knowledge and skills related to the barriers they indicated. Several themes
3 could be addressed, such as the content of the SCC guideline, behavioural and
4 pharmacological SCC support, skills in motivating smokers to quit, and organi-
5 sational aspects of SCC, such as task allocation, referral and registration. The
6 training concluded with concrete, individual implementation goals which were
7 summarized into an action plan. In addition, all GPs received a toolkit, which
8 contained a SCC flowchart, a summary of pharmacological support, and leaflets
9 for patients. Afterwards, the GP was given the opportunity to receive additional
10 feedback support (Intervision). GPs in the control condition continued their
11 usual SCC. Usual care can be defined as the SCC that is usually provided by the
12 GP when not being trained, which is likely to vary between the GPs.²⁷

13

14 **Participants**

15

16 **General practitioners**

17 We recruited GPs by letter and a follow-up telephone call. Eligibility criteria were
18 the self-reported number of provided stop-smoking advices per week (maximum
19 of five³¹), in order not to select 'best practice' GPs only. In addition, we selected
20 only one GP per practice in order to prevent contamination. Among 228 GPs who
21 returned the screening questionnaire, 64 agreed to participate. Six GPs were
22 excluded because they provided on average more than 5 stop-smoking advices
23 per week, and another 9 GPs already had a participating colleague in the same
24 practice; this resulted in 49 GPs for randomisation. After randomisation, 4 GPs
25 (3 intervention, 1 control) were partly excluded from further analyses because
26 they did not complete their measurements, leaving 45 GPs for full analysis (22
27 intervention, 23 control).

28

29 **Patients**

30 During the study period (January-August 2011), adult patients visiting participat-
31 ing GPs in both conditions were asked to complete a questionnaire after consul-
32 tation. The baseline group consisted of 2068 patients (1002 intervention, 1066
33 control) including 433 smokers (195 intervention (19.5%), 238 (22.3%) control)
34 who completed the questionnaire during the three weeks prior to the GP train-
35 ing. The post-intervention group consisted of 1333 patients (630 intervention,
36 703 control), including 244 smokers (98 intervention (15.6%), 146 (20.8%) control)
37 who completed the questionnaire during the three weeks after the GP training.
38 All smoking patients of both the baseline and post-intervention group were sent
39 a postal questionnaire 9 months after the intervention, which was completed by

1 225 smokers (112 intervention (response rate 38.2%), 113 control (response rate
2 29.4%)) (Figure 1).

4 **Outcomes**

5 The primary outcome was GP smoking cessation counseling. Secondary out-
6 comes were GPs' attitudes, self-efficacy and intentions towards implementing
7 SCC, and patients' intention to quit and long-term smoking abstinence.

9 **GPs' smoking cessation counseling**

10 We measured GPs' smoking cessation counseling by means of GP self-report
11 and patient report. At baseline, GPs in both conditions completed a tracking
12 list at the end of 2 working days per week, during 3 consecutive weeks. Ques-
13 tions were about smoking cessation activities during that day (asking, advising,
14 prescribing pharmacological aids, and referring for behavioural support). In the
15 intervention group, GP training in SCC took place within 2 weeks after this first
16 tracking period. One week after the training a second tracking period started
17 for GPs in both conditions. On those days that GPs completed the tracking lists,
18 all adult patients who visited the participating GPs were asked to complete a
19 questionnaire after consultation. These questionnaires included information on
20 socio-demographics and GP performance with regard to SCC.

22 **GPs' attitudes, self-efficacy and intention towards implementing SCC**

23 Secondary endpoints were GPs' attitudes, perceived self-efficacy and intentions
24 regarding routinely implementing SCC, measured with a pre- and post-question-
25 naire based on previous studies.³²⁻³⁴

27 **Patients' smoking behaviour**

28 Patients' intention to quit smoking was dichotomised (0=no intention to quit
29 within 6 months, and 1=intention to quit within 6 months). Smoking patients
30 were sent a postal questionnaire 9 months after the GP training in order to
31 assess long-term smoking abstinence rates. Because patients visit their GP on
32 average 4 times per year, we assumed that most smokers in the baseline group
33 revisited their GP in this 9-month period and as a consequence were exposed to
34 a trained GP (intervention) or non-trained GP (control).³⁵ Therefore, we included
35 smokers from both the baseline and post-intervention group in the follow-up
36 analyses. We examined self-reported 7-day point prevalence abstinence and
37 continuous abstinence.³⁶ In total, 225 smokers completed the 9-month follow-up
38 questionnaire (33.7%). Of these responders, 112 smokers consulted a GP in the
39 intervention group (70 at baseline (35.9%) and 42 post-intervention (42.9%)), and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39




Figure 1. Flowchart of the intervention study

1 113 smokers consulted a GP in the control group (72 at baseline (30.3%) and 41
2 post-intervention (28.1%)).

3

4 **Sample size**

5 Assuming that 21% of the Dutch adult smokers currently receive a stop-smoking
6 advice from their GP¹², to detect a doubled proportion of smoking patients re-
7 ceiving a stop-smoking advice from their GP, with a power of 80% (assuming an
8 ICC of 0.013 and a design effect of 1.104³⁷ based on 25 clusters), 112 smoking
9 patients per group were required.

10

11 **Statistical analyses**

12 We compared GP characteristics and practice characteristics between the inter-
13 vention and control group using the χ^2 -test and independent samples t-test for
14 dichotomous and continuous data, respectively. In addition, characteristics of
15 patients in the intervention and control group were compared at baseline and
16 post-intervention. The impact of the training on GP-reported outcomes was as-
17 sessed using linear regression analyses, adjusting for values at baseline. Missing
18 data were imputed according to the last-observation-carried-forward method,
19 assuming that the outcome data did not change post-intervention.³⁸ The im-
20 pact of the training on GP smoking cessation activities reported by patients
21 was analysed using generalised estimating equations (GEE) in order to adjust
22 for clustering. In addition, GEE was used to assess smoking abstinence rates of
23 patients at follow-up. Smokers lost to follow-up were treated as not refraining
24 from smoking at follow-up.³⁹

25

26

27 **RESULTS**

28

29 **GP cessation counseling**

30

31 **General practitioners**

32 None of the GP and practice characteristics showed a significant difference
33 between the intervention and control condition (Table 1). With regard to demo-
34 graphics, the sample was similar to the average Dutch GP population.⁴⁰ After
35 adjustment for baseline values, we found a difference for the GP reported mean
36 number of stop-smoking advices provided per day post-intervention (difference
37 0.56 advice per day; 95% CI=0.13-0.98) (Table 2). There was no significant differ-
38 ence in the mean number of times GPs asked smokers about smoking status,
39 referred for behavioural support and prescribed pharmacological aids.

Table 1. Background characteristics of participating GPs and practices

	Intervention (n=25)	Control (n=24)
GP characteristics		
Gender, male	16 (64%)	12 (50%)
Cultural background, Dutch	24 (96%)	22 (92%)
Years of employment, > 10 years	19 (76%)	19 (79.2%)
Smoking status		
Smoker	0 (0%)	2 (8.3%)
Ex-smoker	8 (32%)	7 (29.2%)
Previous training in SCC	11 (44%)	8 (33.3%)
Age in years (M, SD)	49.9 (8.1)	51.3 (8)
Patients seen per week (M, SD)	115.8 (39.8)	109.5 (46.7)
Hours of work per week (M, SD)	38.3 (9.0)	38.1 (10.4)
Practice characteristics		
Type of practice		
Single-handed	12 (48%)	10 (41.7%)
Duo	6 (24%)	9 (37.5%)
Group	5 (20%)	2 (8.3%)
Health care centre	2 (8%)	3 (12.5%)
Number of practice nurses		
None	1 (4%)	3 (12.5%)
1 practice nurse	17 (68%)	16 (66.7%)
2 or more practice nurses	7 (28%)	5 (20.8%)
Previous training in SCC practice nurse	19 (76%)	14 (58.3%)

GP=general practitioner, SCC=smoking cessation care, M=mean, SD=standard deviation. Differences were examined using χ^2 -tests for dichotomous variables and independent samples t-tests for continuous variables

28 Patients

29 Table 3 reports the characteristics of patients at baseline, post-intervention
30 and at follow-up. At baseline, more patients in the control group reported a
31 chronic airway disease compared to the intervention group (15.4% vs. 12.4%;
32 $p=0.03$). Post-intervention, patients in the control group were younger, more
33 often reported a non-Dutch cultural background and being a smoker (Table 3).
34 After adjustment for clustering effects and patient background characteristics,
35 a time-by-condition interaction was found for patients' report of being asked
36 about smoking status (OR=1.94, 95% CI=1.43-2.60) (Table 2); patients in the
37 intervention group who visited their GP post-intervention reported being asked
38 about their smoking status more often than patients who visited their GP prior
39 to the training. We found no effect on patient's report of being advised to quit

Table 2. Effect of GP training in SCC on smoking cessation activities by GPs (GP self-report and patient-report) and on patients' intention to quit smoking

	Baseline			Post-intervention			Time X Group Interaction			
	Intervention (n=22)	Control (n=23)	P	Intervention (n=22)	Control (n=23)	P	Intervention (n=630)	Control (n=703)	P	
GP self-report, SCC^a										
Asked about smoking status	2.94 (1.80)	4.09 (5.19)	-1.15 (-3.51 - 1.21)	0.33	4.98 (0.62)	3.27 (0.60)	1.71 (-0.04 - 3.46)	0.06		
Advised to quit	1.09 (0.75)	1.43 (2.11)	-0.33 (-1.29 - 0.63)	0.50	1.61 (0.15)	1.05 (0.15)	0.56 (0.13 - 0.98)	0.01		
Provided pharmacotherapy	0.10 (0.12)	0.10 (0.18)	-0.002 (-0.09 - 0.09)	0.96	0.10 (0.03)	0.09 (0.03)	0.01 (-0.08 - 0.10)	0.87		
Arranged follow-up or referred	0.49 (1.04)	0.29 (0.38)	0.20 (-0.26 - 0.67)	0.38	0.56 (0.16)	0.26 (0.15)	0.30 (-0.14 - 0.74)	0.18		
Patient report, SCC^b										
Asked about smoking status ^c	32.7%	40.8%	0.79 (0.47-1.33)	0.37	41.5%	37.1%	1.60 (0.83-3.08)	0.16	1.94 (1.45-2.60)	<0.00
Smoker report, SCC										
Asked about smoking status ^c	45.2%	56.0%	0.74 (0.37-1.51)	0.41	53.1%	54.5%	1.27 (0.48-3.19)	0.68	1.79 (0.96-3.32)	0.07
Advised to quit ^c	40.2%	43.8%	0.79 (0.43-1.43)	0.43	43.3%	44.1%	1.37 (0.49-3.84)	0.56	1.70 (0.71-4.06)	0.24
Provided with pharmacotherapy ^c	17.4%	16.4%	1.38 (0.71-2.69)	0.34	13.3%	19.9%	0.76 (0.29-1.96)	0.57	0.54 (0.22-1.36)	0.54
Arranged for follow-up or referred ^c	12.3%	8.8%	1.43 (0.75-2.74)	0.28	16.0%	9.8%	2.38 (0.97-5.86)	0.06	1.40 (0.49-4.14)	0.52
Intention to quit smoking ^d	33.1%	33.3%	1.10 (0.70-1.70)	0.70	34.4%	37.7%	0.98 (0.55-1.73)	0.93	0.95 (0.46-1.98)	0.90
GP self-report, attitudes										
Attitude ^e	2.86 (0.39)	2.72 (0.54)	0.14 (-0.13 - 0.41)	0.30	2.84 (0.08)	2.65 (0.08)	0.19 (-0.05 - 0.43)	0.11		
Perceived self-efficacy ^e	2.56 (0.44)	2.39 (0.45)	0.18 (-0.08 - 0.43)	0.18	2.69 (0.07)	2.43 (0.07)	0.26 (0.05 - 0.46)	0.02		
Intention ^f	1.88 (1.09)	1.46 (0.78)	0.42 (-0.13 - 0.97)	0.13	2.32 (0.22)	1.00 (0.23)	1.32 (0.67 - 1.97)	0.00		

GP=general practitioner, SCC=smoking cessation care, B=unstandardised regression coefficient indicating difference, OR=odds ratio, CI=confidence interval

^a Average number of smoking cessation activities per day measured on a continuous scale

^b Generalised Estimating Equations adjusted for clustering and patient characteristics

^c Control group = reference category

^d No intention to quit within 6 months = reference category

^e 5-point scale: 0=very negative attitude/low perceived self-efficacy; 4=very positive attitude/high perceived self-efficacy

^f 4-point scale: 0=no intention within 6 months; 1=intention within one month; 2=intention within one month; 3=already full implementation

Table 3. Characteristics of participating patients at baseline, post-intervention and 9-month follow-up

	Baseline n=2068		Post-intervention n=1333		9 month follow-up n=225 ^a	
	Intervention n=1002 (48.5%)	Control n=1066 (51.5%)	Intervention n=630 (47.3%)	Control n=703 (52.7%)	Intervention n=112 (49.8%)	Control n=113 (50.2%)
Age in years, M (SD)	52.9 (16.7)	52.2 (17.4)	54.0 (16.2)	52.3 (17.3)	51.7 (14.9)	48.9 (14.3)
Gender, Men	374 (37.3%)	425 (39.9%)	282 (44.8%)	278 (39.5%)	62 (55.9%)	45 (40.2%)
Cultural background, Dutch	918 (91.6%)	933 (87.5%)	586 (93.0%)	626 (89.0%)	111 (99.1%)	106 (94.6%)
Education level						
High	375 (37.4%)	401 (37.6%)	250 (39.7%)	294 (41.8%)	41 (36.6%)	34 (30.4%)
Medium	356 (35.5%)	349 (32.7%)	203 (32.2%)	215 (30.6%)	37 (33.0%)	41 (36.6%)
Low	224 (22.4%)	242 (22.7%)	145 (23.0%)	162 (23.1%)	33 (29.5%)	35 (31.2%)
Physical condition						
Chronic airways disease	124 (12.4%)	164 (15.4%)	73 (11.6%)	78 (11.1%)	20 (17.9%)	22 (19.5%)
Diabetes	73 (7.3%)	90 (8.4%)	42 (6.7%)	60 (8.2%)	11 (9.8%)	8 (7.1%)
Cardiovascular disease	125 (12.5%)	108 (10.1%)	78 (12.4%)	84 (12.0%)	17 (15.2%)	8 (7.1%)
Pregnant	5 (0.5%)	7 (0.7%)	3 (0.5%)	6 (0.9%)	1 (0.9%)	0 (0.0%)
Smoker	195 (19.5%)	238 (22.3%)	98 (15.6%)	146 (20.8%)		

ns=not significant, M=mean, SD=standard deviation

Differences were examined using χ^2 -tests for dichotomous variables and independent samples t-tests for continuous variables^a Smokers at baseline and post-intervention were included into the follow-up measurement

1 smoking, being prescribed pharmacotherapy, or being referred for behavioural
2 support (Table 2).

4 GPs' attitudes, self-efficacy and intention

5 We found an effect of the training on GPs' perceived self-efficacy and intention
6 towards implementing SCC (Table 2).

8 Patient's intention to quit and smoking abstinence

9 After adjustment for clustering effects and patient background characteristics,
10 we found no effects of the GP training on smokers' intention to quit (Table 2).
11 Nine months after the GP training, more patients in the intervention group (base-
12 line and post-intervention) completed the follow-up questionnaire compared to
13 patients in the control group (38.2% vs. 29.4%; $p=0.02$). We compared patients
14 who completed the follow-up questionnaire with patients who did not complete
15 the questionnaire. The patients did not differ on the background characteristics
16 they filled out in the first questionnaire (age, gender, cultural background, and
17 educational level). Also, responders and non-responders did not differ on the
18 number of times they reported being asked about their smoking behaviour, were
19 advised to quit, were prescribed pharmacotherapy or were referred for behav-
20 ioural counseling during the GP visit, as indicated in the first questionnaire.
21 After controlling for clustering effects and patient background characteristics,
22 26.8% of patients in the intervention group reported not having smoked during
23 the past 7 days and 10.8% refrained from smoking since they completed the
24 first questionnaire (Table 4). In the control group 25.0% and 7.1% of the patients
25 reported 7-day point prevalence abstinence and continuous abstinence, respec-
26

27 **Table 4.** Effect of GP training in smoking cessation care on patient smoking behaviour at 9 month
28 follow-up with different assumptions about smoking behaviour of non-responders

29 % non-smokers, 30 not including non-responders	Intervention (n=112)	Control (n=113)	OR (95% CI) ^a	P
31 Point prevalence abstinence	26.8%	25.0%	1.07 (0.57-2.00)	0.89
32 Continuous abstinence	10.8%	7.1%	1.62 (0.60-4.34)	0.34
34 % non-smokers, 35 assuming that all non-responders smoke	Intervention (n=293)	Control (n=384)	OR (95% CI) ^a	P
36 Point prevalence abstinence	10.2%	7.3%	1.33 (0.77-2.31)	0.30
37 Continuous abstinence	4.1%	2.1%	1.93 (0.77-4.89)	0.16

38 GP=general practitioner, OR=odds ratio, CI=confidence interval

39 Generalised Estimating Equations adjusted for clustering effects and patient characteristics

^a Control group = reference category

tively. We did not find an effect on long-term patient smoking behaviour (Table 4). Also, when analysing responders of the baseline and post-intervention group separately, no effect of the GP training on long-term smoking abstinence was found (data not shown). We performed a sensitivity analysis using the conservative assumption that non-responders did not change their behaviour and still smoked at follow-up.³⁹ This analysis did not change the findings on long-term patients smoking abstinence rates (Table 4).

DISCUSSION

Major findings

This study evaluated the effectiveness of a low-intensity, practice-tailored training in smoking cessation care (SCC) for GPs, addressing both personal and organisational barriers that arise during the implementation of these counseling activities. After the training we found significant differences between trained and untrained GPs on the frequency they asked about smoking (according to the patients) and gave advice to quit (according to the GPs themselves).

However, we did not find an effect on the arrangement of follow-up support, neither on provision of pharmacological therapy, nor on referrals for behavioural support. In addition, we found no effects on patients' intention to stop smoking after GP consultation and long-term cessation rates.

Study findings compared to previous research

Our training managed to increase the frequency at which patients reported being asked about smoking, and at which GPs reported the provision of stop-smoking advices. Compared to several other training programmes that did not find an increase in these counseling activities, this is a hopeful outcome.⁴¹⁻⁴³ However, we found relatively small rates of smokers for whom GPs had arranged referral and follow-up; other studies found rates of behavioural follow-up ranging from 25-59% and pharmacological prescriptions from 14-37%.⁴¹⁻⁴⁵

With regard to the long-term effect of the GP training on patients' smoking behaviour, a recent meta-analysis of 14 studies found comparable long-term quit rates as a result of training health professionals in smoking cessation care.²⁶ However, the majority of the individual studies within this meta-analysis did not confirm statistical significance between quit rates in the intervention and control group, which is in line with our finding. Although our data suggest that trained GPs more often advised smokers to quit, they failed to increase referral rates and the intention to quit of smokers. This might explain the lack of long-term

1 results. A study of McRobbie et al. has shown the effectiveness of a brief training
2 session addressing skills for referral of smokers on the number of GP referrals
3 to evidence-based cessation support.⁴⁶ In addition, more and more studies show
4 the increasing role and effectiveness of in-practice cessation support delivered
5 by practice nurses.⁴⁷⁻⁵¹ Moreover, referring and connecting smokers to evidence-
6 based quit lines is likely to increase smoking cessation.^{29;52}

7 8 **Strengths and limitations**

9 Some limitations with regard to the study design should be considered when
10 interpreting the results of our study. First, the exact response rate of patients
11 who completed the questionnaire at baseline and post-intervention is unknown.
12 Reasons for non-response might be attributed to GPs who did not hand over the
13 patient questionnaires, or to patients who forgot or were unwilling to complete
14 the questionnaire.

15 Second, participating GPs relatively often advised their patients to quit at
16 baseline (40.2% and 43.8%, respectively, compared to only 21% found in another
17 Dutch study.¹² An explorative analysis showed that the GPs' awareness of the
18 aim of the intervention and completing tracking lists regarding smoking cessa-
19 tion counseling might make them more prone to ask about smoking, compared
20 to GPs that did not complete tracking lists and were unaware of the study topic
21 (data not shown). Despite this possible priming effect, we found an additional
22 significant effect of the training on the number of times patients who were asked
23 about their smoking status (patient-reported) and advised to quit (GP-reported).

24 A third limitation is the fact that smoking abstinence at follow-up was self-
25 reported and lacked biochemical verification due to financial constraints. In
26 addition, a large number of patients were lost to follow-up (66.4%), especially
27 in the control group (69.9%). Attrition is common in lifestyle intervention trials,
28 which may affect the study power, cause bias and threaten generalisability.⁵³

29 Fourth, the different sources were slightly inconsistent. On the one hand, GPs
30 reported an increase in the number of stop-smoking advices. On the other hand,
31 patients only reported a significant increase in the number of times they were
32 asked about their smoking status. This discrepancy is in line with other stud-
33 ies, reporting a lack of agreement between patient and provider surveys when
34 measuring tobacco counseling actions.⁵⁴⁻⁵⁷ This might be explained by patients'
35 perception of a stop-smoking advice as being embedded in a general discussion
36 about smoking behaviour and therefore have escaped their attention. This could
37 have led to recall bias and may have contributed to the lack of effect on patients'
38 motivation to quit and long-term smoking cessation. Finally, a minority of the
39 participating GPs did not have direct access to smoking cessation programmes of

1 a (trained) practice nurses during the study period, which may have contributed
2 to the lack of effect on GPs' referrals for behavioural cessation support.

3 Nevertheless, the major strengths are the pragmatic nature of this study (a
4 low-intensity and pragmatic training method) in a specific setting (GP practice),
5 tested in a cluster-randomised controlled trial preventing contamination be-
6 tween GPs, with outcome measures being assessed on both short-term GP and
7 long-term patient level.

8

9 **Conclusions**

10 Our low-intensity, practice-tailored training for GPs in the implementation of
11 asking patients' smoking status, advising smokers to quit, and arranging referral
12 and follow-up does not lead to an increased patient access to more intensive
13 smoking cessation support. Future training methods should also include prac-
14 tice nurses and focus on the GPs' role as gatekeeper for referring or connecting
15 smokers to cessation support, such as quit lines and practice nurses. This ap-
16 proach is likely to ensure pharmacological and behavioural cessation support
17 and increase patient abstinence rates.

18

19

20 **ACKNOWLEDGEMENTS**

21

22 This study was performed under MIRO, a national programme for optimising
23 smoking cessation. MIRO is an initiative of Pfizer and Caphri. This project is sup-
24 ported by an unrestricted grant from Pfizer and Caphri.

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

REFERENCES

1. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal contact smoking cessation program for Dutch general practitioners: a randomized controlled trial. *Prev Med* 2001; 32(2):182-190.
2. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane Database Systematic Reviews* 2008; (4).
3. Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al. NHG-Standaard Stoppen met roken [Dutch College of General Practitioners Guideline for Smoking Cessation]. *Huisarts Wet* 2007; 50(7):306-314.
4. Fiore MC, Wetter DW, Bailey WC, Blennett G, Cohen SJ, Dorfman SF et al. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. *JAMA-J Am Med Assoc* 1996; 275(16):1270-1280.
5. Fiore MC, Jaén CR, Baker TB, Bailey WC, Bennett G, Benowitz NL et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. *Am J Prev Med* 2008; 35(2):158-176.
6. Puschel K, Thompson B, Coronado G, Huang Y, Gonzalez L, Rivera S. Effectiveness of a brief intervention based on the '5A' model for smoking cessation at the primary care level in Santiago, Chile. *Health Promot Int* 2008; 23(3):240-250.
7. Segaar D. STIMEDIC Stoppen met roken: Effectieve stapsgewijze stoppen-met-rokenbegeleiding door zorgverleners [STIMEDIC method for smoking cessation: an effective minimal contact program for smoking cessation in Dutch health care]. Utrecht, the Netherlands: Hollandse Meesters BNO; 2009.
8. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Behandeling van Tabaksverslaving [Guideline Treatment of Tobacco Dependence]. Alphen aan den Rijn, the Netherlands: Van Zuiden Communications B.V.; 2009.
9. Takahashi K, Saso H, Saka H, Saso H, Iwata M, Hashimoto I et al. A pilot study on inducement of smoking cessation by a simple 5A (asking, advice, assess, assist, and arrange) approach at outpatient clinics. *Asian Pac J Canc Prev* 2006; 7(1):131-135.
10. The Royal Australian College of General Practitioners. Supporting Smoking Cessation: a Guide for Health Professionals 2011. Available from <http://www.treatobacco.net/en/uploads/documents/Treatment%20Guidelines/Australia%20treatment%20guidelines%20in%20English%202011.pdf>.
11. de Korte D, van Schayck OCP, van Spiegel P, Kaptein AA, Sachs A, Rutten-van Mólken M et al. Supporting smoking cessation in healthcare: obstacles in scientific understanding and tobacco addiction management. *Health* 2010; 2(11):1272-1279.
12. de Korte D, Nagelhout GE, Willemsen MC. Stoppen-met-rokenadvisering door de huisarts [Smoking cessation advisement in Dutch general practice: 2001-2009] 2010. The Hague, the Netherlands, STIVORO - for a smoke-free future.
13. Quinn VP, Stevens VJ, Hollis JF, Rigotti NA, Solberg LI, Gordon N et al. Tobacco-cessation services and patient satisfaction in nine nonprofit HMOs. *Am J Prev Med* 2005; 29(2):77-84.
14. Fleuren M, Wiefferink K, Paulussen T. Determinants of innovation within health care organizations: literature review and Delphi study. *Int J Quality Health C* 2004; 16(2):107-123.

- 1 15. Crone MR, Willemsen MC, van Soelen P, Reijneveld RA, Hira Sing RA, Paulussen
2 TGWM. Sustainability of the prevention of passive infant smoking within well-baby
3 clinics. *Health Educ Behav* 2006; 33:178-196.
- 4 16. Amemori M, Michie S, Korhonen T, Murtomaa H, Kinnunen TH. Assessing implemen-
5 tation difficulties in tobacco use prevention and cessation counseling among dental
6 providers. *Implementat Sci* 2011; 6(50):1-10.
- 7 17. Djalalinia S, Tehrani FR, Malekafzali H, Dovvom MR, Neot R, Peykari N. Training of
8 general practitioners about smoking cessation counseling. *J Pakistan Med Assoc* 2011;
9 61(5):449-452.
- 10 18. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs'
11 engagement in smoking cessation: a multi-country literature review. *Brit J Gen Pract*
12 2009; 59(566):682-690.
- 13 19. Twardella D, Brenner H. Lack of training as a central barrier to the promotion of
14 smoking cessation: a survey among general practitioners in Germany. *Eur J Public*
15 *Health* 2005; 15(2):140-145.
- 16 20. Vogt F, Hall S, Marteau TM. General practitioners' and family physicians' negative
17 beliefs and attitudes towards discussing smoking cessation with patients: a system-
18 atic review. *Addiction* 2005; 100(10):1423-1431.
- 19 21. Baskerville NB, Liddy C, Hogg W. Systematic review and meta-analysis of practice
20 facilitation within primary care settings. *Ann Fam Med* 2012; 10(1):63-74.
- 21 22. Harris M. The role of primary health care in preventing the onset of chronic disease,
22 with a particular focus on the lifestyle risk factors of obesity, tobacco and alcohol
23 2008; 1-21. Centre for Primary Health Care and Equity, UNSW. Available from [http://](http://www.preventativehealth.org.au/internet/preventative_health/publishing.nsf/Content/0FBE203C1C547A82CA257529000231BF/$File/commpaper-primary-hlth-care-harris.pdf)
24 [www.preventativehealth.org.au/internet/preventative](http://www.preventativehealth.org.au/internet/preventative_health/publishing.nsf/Content/0FBE203C1C547A82CA257529000231BF/$File/commpaper-primary-hlth-care-harris.pdf)
25 [health/publishing.nsf/Cont](http://www.preventativehealth.org.au/internet/preventative_health/publishing.nsf/Content/0FBE203C1C547A82CA257529000231BF/$File/commpaper-primary-hlth-care-harris.pdf)
26 [ent/0FBE203C1C547A82CA257529000231BF/\\$File/commpaper-primary-hlth-care-](http://www.preventativehealth.org.au/internet/preventative_health/publishing.nsf/Content/0FBE203C1C547A82CA257529000231BF/$File/commpaper-primary-hlth-care-harris.pdf)
27 [harris.pdf](http://www.preventativehealth.org.au/internet/preventative_health/publishing.nsf/Content/0FBE203C1C547A82CA257529000231BF/$File/commpaper-primary-hlth-care-harris.pdf).
- 28 23. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic
29 review of 102 trials of interventions to improve professional practice. *Can Med Assoc*
30 *J* 1995; 153(10):1423-1431.
- 31 24. Tremblay M, Gervais A, Lacroix C, O'Loughlin J, Makni H, Paradis G. Physicians Taking
32 Action Against Smoking: an intervention program to optimize smoking cessation
33 counseling by Montreal general practitioners. *Can Med Assoc J* 2001; 165(5):601-607.
- 34 25. Zwar NA, Richmond RL. Role of the general practitioner in smoking cessation. *Drug*
35 *Alcohol Rev* 2006; 25(1):21-26.
- 36 26. Carson KV, Verbiest MEA, Crone MR, Brinn MP, Estermann AJ, Assendelft WJJ et al.
37 Training health professionals in smoking cessation. *Cochrane Database Systematic*
38 *Reviews* 2012; (5).
- 39 27. Ellerbeck EF, Ahluwalia JS, Jolicoeur DG, Gladden J, Mosier MC. Direct observation of
smoking cessation activities in primary care practice. *J Fam Pract* 2001; 50(8):688-693.
28. Berndt NC, Bolman C, de Vries H, Segaar D, van Boven I, Lechner L. Smoking cessa-
tion treatment practices: recommendations for improved adoption on cardiology
wards. *J Cardiovasc Nursing* 2013; 28(1):35-47.
29. Vidrine JI, Shete S, Cao Y, Greisinger A, Harmonson P, Sharp B et al. Ask-advise-
connect: a new approach to smoking treatment delivery in health care settings.
JAMA-Int Med 2013; 173(6):458-464.

- 1 30. Rollnick S, Miller WR. What is Motivational Interviewing? *Behav Cogn Psychoth* 1995;
2 23:325-334.
- 3 31. Koolhaas C. Campagne 'Meer huisartsen gaan voor minder' [Campaign 'More general
4 practitioners go for less']. STIVORO - for a smokefree future, 2005. Amsterdam, the
5 Netherlands, TNS NIPO. Available from [http://stivoro.nl/wp-content/uploads/2012/
6 docs/rapporten/TNSNIPO/Campagne%20' Meer%20huisartsen%20gaan%20voor%20
7 minder%20rokers'.pdf](http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/TNSNIPO/Campagne%20' Meer%20huisartsen%20gaan%20voor%20minder%20rokers'.pdf)
- 8 32. Drossaert CHC, Pieterse ME, Seydel ER, Drenthen A. PROMISE: PROgrammistisch
9 toepassing van de Minimale Interventie Strategie stoppen-met-roken in een Experi-
10 mentele setting. Evaluatie onder huisartsen en patiënten [PROMISE: A PROgram-
11 matic application of the Minimal Intervention Strategy (MIS) for smoking cessation
12 in an Experimental setting. Evaluation of general practitioners and patients] 1999.
- 13 33. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal
14 contact smoking cessation program for Dutch general practitioners: a randomized
15 controlled trial. *Prev Med* 2001; 32(2):182-190.
- 16 34. Mudde AN, Willemsen MC, Kremers S, de Vries H. Meetinstrumenten voor onderzoek
17 naar roken en stoppen met roken [Measurement instruments for research related to
18 smoking and smoking cessation] 2000. The Hague, the Netherlands, STIVORO - for a
19 smoke-free future.
- 20 35. Jurling B, Koster L, Batterink M, Vunderink L, Schippers M, Karsson B. Praktijkkosten
21 en opbrengsten van huisartsen [Practice costs and income research in primary
22 care] 2013. Available from: [http://www.nza.nl/
23 104107/138040/Significant_praktijk-
24 kosten_en_inkomensonderzoek_huisartsenzorg.pdf](http://www.nza.nl/104107/138040/Significant_praktijkkosten_en_inkomensonderzoek_huisartsenzorg.pdf)
- 25 36. Smit ES, de VH, Hoving C. Effectiveness of a Web-based multiple tailored smoking
26 cessation program: a randomized controlled trial among Dutch adult smokers. *J Med
27 Internet Res* 2012; 14(3).
- 28 37. Lennox AS, Bain N, Taylor NJ, McKie L, Donnan PT, Groves J. Stages of change training
29 for opportunistic smoking intervention by the primary health care team. *Health Educ
30 J* 1998; 57:140-149.
- 31 38. Streiner D, Geddes J. Intention to treat analysis in clinical trials when there are miss-
32 ing data. *Evidence Based Mental Health* 2001; 4(3):70-71.
- 33 39. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials:
34 proposal for a common standard. *Addiction* 2005; 100(3):299-303.
- 35 40. Hingstman L, Kenens RJ. Cijfers uit registratie huisartsen [Figures of the registration
36 of general practitioners] 2010. Utrecht, Netherlands Institute for Health Services
37 Research. Available from: [http://www.nivel.nl/sites/default/files/bestanden/cijfers-
38 uit-de-registratie-van-huisartsen-peiling-jan-2010.pdf](http://www.nivel.nl/sites/default/files/bestanden/cijfers-uit-de-registratie-van-huisartsen-peiling-jan-2010.pdf).
- 39 41. Cornuz J, Humair JP, Seematter L, Stoianov R, van Melle G, Stalder H et al. Efficacy of
resident training in smoking cessation: a randomized, controlled trial of a program
based on application of behavioural theory and practice with standardized patients.
Ann Int Med 2002; 136(6):429-437.
42. Hymowitz N, Schwab J, Haddock CK, Pyle S, Meshberg S. The Pediatric Resident Train-
ing on Tobacco Project: Interim Findings. *JAMA-J Med Assoc* 2013; 98(2):190-203.
43. Joseph AM, Arikian NJ, An LC, Nugent SM, Sloan RJ, Pieper CF. Results of a random-
ized controlled trial of intervention to implement smoking guidelines in Veterans

- 1 Affairs medical centers: increased use of medications without cessation benefit. *Med*
2 *Care* 2004; 42(11):1100-1110.
- 3 44. Anderson P, Jane-Llopis E. How can we increase the involvement of primary health
4 care in the treatment of tobacco dependence? A meta-analysis. *Addiction* 2004;
5 99(3):299-312.
- 6 45. Hymowitz N, Schwab J, Haddock CK, Pyle S, Meshberg S. The Pediatric Residency
7 Training on Tobacco Project: Baseline Findings from Patient Tobacco Survey. *Prev Med*
8 2005; 41:159-166.
- 9 46. McRobbie H, Hajek P, Feder G, Eldridge S. A cluster-randomised controlled trial of a
10 brief training session to facilitate general practitioner referral to smoking cessation
11 treatment. *Tobac Control* 2008; 17(3):173-176.
- 12 47. Smit ES. Motivating smokers to quit. Effectiveness and feasibility of a web-based
13 multiple tailored smoking cessation programme and tailored counseling by practice
14 nurses 2012. Maastricht University; 2012. Available from http://phdthesis.nl/sites/default/files/Thesis_Smit_1.pdf.
- 15 48. Hoving C, Mudde AN, de VH. Intention to adopt a smoking cessation expert system
16 within a self-selected sample of Dutch general practitioners. *Eur J Canc Prev* 2006;
17 15(1):82-86.
- 18 49. Hall S, Vogt F, Marteau TM. A short report: survey of practice nurses' attitudes to-
19 wards giving smoking cessation advice. *Fam Pract* 2005; 22(6):614-616.
- 20 50. Zwar NA, Richmond RL, Forlonge G, Hasan I. Feasibility and effectiveness of nurse-
21 delivered smoking cessation counseling combined with nicotine replacement in
22 Australian general practice. *Drug Alcohol Rev* 2011; 30(6):583-588.
- 23 51. Sheffer CE, Barone C, Anders ME. Training nurses in the treatment of tobacco use
24 and dependence: pre- and post-training results. *J Advanced Nursing* 2011; 67(1):176-
25 183.
- 26 52. Borland R, Balmford J, Bishop N, Segan C, Piterman L, McKay-Brown L et al. In-
27 practice management versus quitline referral for enhancing smoking cessation in
28 general practice: a cluster randomized trial. *Fam Pract* 2008; 25(5):382-389.
- 29 53. Fewtrell MS, Kennedy K, Singhal A, Martin RM, Ness A, Hadders-Algra M et al. How
30 much loss to follow-up is acceptable in long-term randomised trials and prospective
31 studies? *Arch Dis Child* 2008; 93(6):458-461.
- 32 54. Conroy MB, Majchrzak NE, Silverman CB, Chang Y, Regan S, Schneider LI et al.
33 Measuring provider adherence to tobacco treatment guidelines: a comparison of
34 electronic medical record review, patient survey, and provider survey. *Nicotine &*
35 *Tobacco Research* 2005; 7(1):35-43.
- 36 55. Mant J, Murphy M, Rose P, Vessey M. The accuracy of general practitioner records of
37 smoking and alcohol use: comparison with patient questionnaires. *J Public Health*
38 *Med* 2000; 22(2):198-201.
- 39 56. Szatkowski L, McNeill A, Lewis S, Coleman T. A comparison of patient recall of smok-
ing cessation advice with advice recorded in electronic medical records. *BMC Public*
Health 2011; 11(291):1-4.
57. Ward J, Sanson-Fisher R. Accuracy of patient recall of opportunistic smoking cessa-
tion advice in general practice. *Tobac Control* 1996; 5(2):110-113.



4

Use of action planning to increase provision of smoking cessation care by general practitioners: Role of plan specificity and enactment

Marjolein E.A. Verbiest¹, Justin Presseau²,
Niels H. Chavannes¹, Margreet Scharloo³, Ad A. Kaptein³,
Willem J.J. Assendelft^{4,1} & Mathilde R Crone¹ (2014)

¹Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands

²Institute of Health and Society, Baddiley-Clark Building, Newcastle University, United Kingdom

³Department Medical Psychology, Leiden University Medical Centre, Leiden, the Netherlands

⁴Department Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Submitted

1 **ABSTRACT**

2

3 **Background**

4 Strategies are needed to help general practitioners (GPs) to promote smoking
5 cessation as recommended by guidelines. This study examines whether the
6 quality of action planning among GPs improves their provision of smoking ces-
7 sation care.

8

9 **Methods**

10 The effectiveness of a 1-hour training programme was examined in a cluster
11 randomized controlled trial in which 49 GPs participated. GPs who followed the
12 training (intervention group; n = 25) formulated action plans related to i) enquir-
13 ing about smoking, ii) advising to quit smoking, and iii) arranging follow-up for
14 smokers motivated to quit. GPs also formulated a coping plan for encountering
15 smokers not motivated to quit. The quality of these plans (i.e. plan specificity)
16 was rated and, 6 weeks after the training, GPs reported on the performance of
17 these plans (i.e. plan enactment). Multilevel regression analyses were used to
18 examine the effects of plan specificity and plan enactment on patient-reported
19 smoking cessation activities of the GPs in the intervention group (n=1632 pa-
20 tients) compared with the GPs in the control group (n=1769 patients). In these
21 analyses, the changes in time (baseline versus post-intervention) were examined
22 and compared to the control group.

23

24 **Results**

25 Compared to the control group, GPs who formulated a highly specific action plan
26 during the training asked their patients about smoking more often after the
27 training compared to prior to the training (OR 2.11, 95% CI 1.51-2.95). GPs were
28 most likely to have asked patients about smoking after the training compared to
29 prior to the training when they had enacted a highly specific formulated action
30 plan (OR 3.08, 95% CI 2.04-4.64). The effects of GP plan specificity and plan enact-
31 ment on asking patient about smoking were most prominent among GPs who, at
32 baseline, intended to provide smoking cessation care.

33

34 **Conclusions**

35 A highly specific action plan formulated by a GP on when, how and by whom
36 patients will be asked about smoking had a positive effect on GPs' asking pa-
37 tients about smoking, especially when these professionals also reported to have
38 enacted this plan. This effect was most prominent among GPs who intended to
39 provide smoking cessation care prior to the intervention. Training in devising

1 personalised coping plans is recommended to further increase GPs' provision of
2 advice to quit smoking and arranging follow-up support to quit smoking.

3 4 5 **INTRODUCTION**

6
7 Current guidelines recommend that general practitioners (GPs) routinely ask
8 patients about smoking, advise them to quit, assess their motivation to quit,
9 assist them with quitting, and arrange follow-up quit smoking support (the 5-A
10 Model).^{1,2} However, GPs report difficulties when translating these guidelines into
11 practice³⁻⁷ resulting in a substantial gap between evidence and practice. A study
12 in Dutch general practice showed that 79% of all smokers and 40% of smok-
13 ers who discussed smoking with their GP, did not receive stop-smoking advice.⁸
14 The development of strategies that facilitate the implementation of guideline-
15 recommended smoking cessation care may result in more patients being advised
16 to quit and being provided with evidence-based quit-smoking support and,
17 ultimately, giving up smoking.⁹⁻¹¹

18 Strategies to facilitate the implementation of evidence-based clinical guide-
19 lines often focus on influencing the behaviour of the healthcare profession-
20 als.¹²⁻¹⁵ Efforts to change the clinical behaviour of healthcare professionals often
21 involve didactic modes of delivery aimed at educating these professionals.¹³⁻¹⁵
22 However, this approach implies a lack of knowledge and assumes that additional
23 knowledge will change the behaviour of healthcare providers, neither of which
24 may necessarily be true. In fact, enhancing knowledge alone may not be the best,
25 or even an adequate strategy, to influence the clinical behaviour of healthcare
26 professionals.¹⁶ Similarly, the motivation and/or the beliefs of GPs to routinely
27 adopt evidence-based guidelines are not always a reliable predictor of the rou-
28 tine implementation of these guidelines.¹⁷

29 Psychological theories may provide a basis for identifying the predictors of GP
30 behaviour and of behaviour change.¹⁶ Clinical practice is a form of human be-
31 haviour that is sensitive to theory-based strategies that have proven effective in
32 patient samples.¹⁸⁻²² However, a systematic review showed that only a minority
33 of the 235 interventions that previously aimed to facilitate guideline implemen-
34 tation by healthcare professionals actually used theory-based strategies.¹²

35 One of the well-established theory-based strategies (albeit in other popula-
36 tions) is the self-formation of 'conditional plans', such as action plans and coping
37 plans.^{23,24} Action plans in the form of if-then plans (i.e. 'implementation inten-
38 tions'²⁵) link a situational cue to behaviour in order to promote behaviour change
39 and habit formation, e.g. 'if X occurs (if the patient visits me because of a cough more

1 than 3 times a year), then I will do Y (I will advise the patient to quit smoking)'. Coping
2 plans anticipate potential barriers to behaviour change which impede action plans
3 from working. Such plans aim to bridge the gap between the individual's intention
4 to perform the behaviour and the actual performance of that behaviour.^{26;27}

5 The mechanisms that underlie the effectiveness of action and coping plans
6 involve a heightened accuracy and speed of detecting the contextual cue for per-
7 forming the intended behaviour.²⁸⁻³¹ Plans that are more specific are suggested to
8 result in a greater improvement of the intended behaviour compared to incom-
9 plete or vague plans.^{32;33} In addition, studies have shown that individuals who act
10 according to their formulated action plans (i.e. plan enactment) are more likely
11 to benefit from their plans, e.g. enacting an action plan to remove all tobacco
12 products results in a higher likelihood to actually quit smoking.^{34;35} The effects
13 of plan specificity and enactment on behaviour are strongest among those in-
14 dividuals who are the most motivated to change the intended behaviour.^{32-34;36}

15 It has been shown that planning predicts the clinical behaviour of GPs in vari-
16 ous conditions.³⁷⁻³⁹ Moreover, an intervention study showed that incorporating
17 planning in postgraduate education increased the use of a practitioner-guided
18 procedure among mental health professionals.³⁶ However, to our knowledge, no
19 studies have examined whether planning improves the provision of evidence-
20 based smoking cessation care by GPs.

21 The present study incorporates action planning within a training session for
22 GPs, aimed at increasing their provision of smoking cessation tasks as recom-
23 mended in clinical guidelines, including asking patients about smoking, advis-
24 ing them to quit, and arranging follow-up quit smoking support for smokers.
25 Because GPs often indicate that patients' lack of motivation to quit may act as a
26 barrier to the provision of guideline-recommended smoking cessation care⁴⁰⁻⁴³,
27 GPs also formulated a coping plan to address this potential barrier.

28 Based on the reported positive effects of action planning in patient samples⁴⁴⁻⁴⁶,
29 we hypothesized that GP action planning would improve their performance of
30 these smoking cessation tasks. Secondly, we hypothesized that formulating a
31 coping plan for smokers who are not motivated to quit provided GPs with a
32 solution for this type of barrier, thereby increasing the provision of smoking ces-
33 sation care for this group.^{39;47-51} Since the present GP training includes multiple
34 behaviour change strategies, we also examined the nature of action planning
35 including plan specificity and plan enactment. In line with previous findings
36 on plan specificity and self-reported plan enactment³²⁻³⁶, we hypothesized that
37 GPs who formulated a highly specific plan and reported a high level of plan
38 enactment would be more likely to provide smoking cessation care post-training.
39 Finally, we hypothesized that these effects would be most evident among GPs

1 with high intention to routinely implement smoking cessation care prior to the
2 training.

3 4 5 **METHODS**

6 7 **Design and intervention**

8 The present paper reports the results of a two-group cluster randomized
9 controlled trial in general practice. GPs were randomly assigned to either the
10 intervention or control condition. The intervention entailed a 1-hour individual
11 training session for GPs in the delivery of smoking cessation care. The training
12 was based on behaviour change techniques related to methods that underlie the
13 current Dutch guidelines for treating tobacco addiction (the 5-A Model ^{2,52}): 1)
14 GPs' implementation barriers were identified, 2) GPs were provided with state-
15 of-the-art evidence about the effectiveness of smoking cessation care, 3) GPs'
16 motivation to routinely implement the guideline was identified and improved
17 using motivational interviewing techniques, 4) GP instruction was provided and
18 tailored to the identified implementation barriers, and 5) GPs were given the op-
19 portunity to receive additional feedback support. Action planning was the final
20 component of the GP training programme. Previously, the effects of the multi-
21 component training on GPs' provision of smoking cessation care were tested
22 and reported elsewhere.⁵³ Action planning was one of the components of the GP
23 training and our initial RCT did not provide insight into the effects of this single
24 behaviour change technique. Therefore, the present study focuses on a further
25 examination of the effects and nature of action planning among the trained GPs.

26 27 **Participants**

28 During the study period (January-August 2011) 25 GPs received a 1-hour training
29 programme that incorporated action planning. At baseline (pre-intervention)
30 these 25 GPs saw 1002 patients, of whom 195 (19.5%) were smokers. Post-inter-
31 vention, the same GPs saw a different group of 630 patients, of whom 98 (15.6%)
32 were smokers. In the control condition, 24 GPs and 1769 patients (baseline: 1066,
33 post-intervention: 703) were included, of whom 384 (21.7%) were smoking pa-
34 tients (baseline: 238 (22.3%), post-intervention: 146 (20.8%)).

35
36
37
38
39

1 Measurements

2

3 GP intention

4 Six weeks prior to the training programme, GPs rated their intention to implement
5 guideline-recommended smoking cessation care on a 4-point scale ('no intention
6 to routinely implement smoking cessation treatment within six months' (0), 'intention to
7 routinely implement smoking cessation treatment within six months' (1), 'intention to
8 routinely implement smoking cessation care within one month' (2), and 'already routinely
9 implemented smoking cessation treatment' (3). To facilitate testing of the hypotheses,
10 we used a post-hoc categorisation in line with the principles from the Health
11 Action Process Approach⁵⁴ to classify GPs into three groups depending on their
12 response to the question about their intention: 1) 'GP pre-intenders' (answer cat-
13 egory 0; 4 GPs, 393 patients), 'GP intenders' (answer category 1 and 2 combined;
14 14 GPs, 2211 patients), and 'GP actors' (answer category 3; 7 GPs, 797 patients).

15

16 Patient-reported provision of smoking cessation care

17 During the three weeks prior to and after the GP training programme, all patients
18 completed a questionnaire immediately after their GP consultation in which
19 they rated their GP's smoking cessation activities during that consultation. This
20 questionnaire included the following items: 'Did your GP ask you about smoking
21 during the consultation?', 'Did your GP advise you to quit during the consultation?' and
22 'Did your GP refer you to any kind of follow-up quit smoking support during the consulta-
23 tion'? For each item, patients could answer 'Yes' (1) or 'No' (0).

24

25 Action planning

26 During the GP training programme, action planning was assessed based on the
27 separate plans formulated by the GP for: a) identifying smokers, and b) advising
28 smokers to quit. GPs wrote down *who* was going to perform the activity, *when*
29 the activity was going to be performed, and *how* the activity was going to be
30 registered in the patient's electronic health record. In addition, GPs formulated
31 an action plan for c) arranging follow-up for smokers who are motivated to quit,
32 and a coping plan for d) arranging follow-up for smokers who are not motivated
33 to quit. In these plans, GPs formulated the *what*, *who* and *how* of each plan. This
34 method is comparable to that used in similar studies with patient samples.³²

35

36 Specificity of GP plans

37 The degree of specificity of each of the components of the GPs' plans (*who*, *when*,
38 *what* and *how*) was assessed using a rating method based on previous studies.
39 ^{32;33;35} The *who* component of the plans was rated as *not completed* (0) or *completed*

1 (1). The when, what, and how components of the plans were rated on a 4-point
 2 scale; components were rated as *not completed* (0) if GPs did not write down any
 3 plans, and components were rated as being *low specific* (1) when GPs described
 4 them in rather general terms, e.g. 'I will ask my patients about their smoking during
 5 the consultation'. Components that were specified with moderate precision were
 6 rated as being *moderately specific* (2), e.g. 'I will ask my patients about their smoking,
 7 routinely once a year'. A component was rated as being *highly specific* (3) when GPs
 8 specified their future action with a sufficient amount of precision e.g. 'I will ask
 9 my patients about their smoking when they present with smoking-related complaints
 10 during the consultation'.

11 Analyses of the *when component* showed that GPs specified either a particular
 12 moment (e.g. during the consultation), or a particular type of patient (e.g. pa-
 13 tients with smoking-related complaints), or both; therefore, we decided to rate
 14 both these types of specifications. As a result, the total specificity score for the
 15 first two action plans (asking about smoking and advising to quit) ranged from
 16 0-10, and for the third action plan (dealing with smokers who were motivated to
 17 quit) and the coping plan (dealing with smokers who were not motivated to quit)
 18 scores ranged from 0-7 (Appendix 1).

19 Two researchers independently rated the specificity of all components of the
 20 GPs' plans. Kappa statistics were used to estimate the inter-rater agreement; this
 21 resulted in a high level of agreement between the two researchers for the total
 22 specificity scores of the GPs' plans: i.e. for asking about smoking 0.998 (95% CI
 23 0.995-0.999), for advising to quit 0.940 (95% CI 0.864-0.973), for arranging follow-
 24 up for smokers who are motivated to quit 0.945 (95% CI 0.850-0.978), and for ar-
 25 ranging follow-up for smokers not motivated to quit 0.962 (95% CI 0.907-0.984).
 26 These high kappa coefficients are probably due to the type of rating method
 27 used. Disagreements were discussed until consensus was achieved. For analyses,
 28 the GPs' total plan specificity scores were categorised into low (1) and high (2)
 29 scores, using the mean score as a cut-off.

30

31 **Enactment of GP plans**

32 After the GP training, we were interested in providing the GPs in the intervention
 33 group with their self-formulated if-then plans and ask them if they had the op-
 34 portunity to enact them. Therefore, six weeks after the GP training programme,
 35 via a postal questionnaire, the GPs were asked to report the extent of plan enact-
 36 ment (response rate 76%; n=19). In this questionnaire, each GP was provided
 37 with the four plans that they had previously formulated. GPs were asked to rate
 38 the extent to which they had enacted each plan using a 5-point scale: '*plan not*
 39 *enacted, not intending to enact in the future*' (0), '*plan not enacted, intending to enact*

1 within one month'(1), 'plan not enacted, intending to enact within a week' (2), 'plan
2 partly enacted (3), 'plan fully enacted (4). For missing data, a negative scenario was
3 applied which assumed that GPs who did not complete the questionnaire did
4 not enact their plans (score 0). For the analyses, scores for plan enactment were
5 categorised into low (1) and high (2) scores using the mean score as a cut-off.

6

7 **Statistical analysis**

8 Descriptive statistics were used for the characteristics of the GPs and for scores
9 on specificity of the GP plan and on plan enactment. To test our hypotheses,
10 we linked GP data with patient data and analysed these using two-level logistic
11 regression analyses (generalised estimating equations), including data at the GP
12 and patient level.

13 In our model, data at the GP level included scores on plan specificity and plan
14 enactment as independent variables. To examine the main effects of these vari-
15 ables on GPs' provision of smoking cessation care (patient-reported), all patients
16 were classified into three categories, i.e. patients who had a consultation with
17 a GP who had formulated a highly specific plan/reported a high level of plan
18 enactment (2), patients who had a consultation with a GP who had formulated
19 a low specific plan/reported a low level of plan enactment (1), and patients who
20 had a consultation with a GP within the control condition (0).

21 Data at the patient level included GPs' provision of smoking cessation care,
22 as reported by patients, as dependent variables, including being asked about
23 smoking, being advised to quit, and being provided with quit smoking follow-up.
24 Patient-reported smoking cessation care was included as a dichotomous variable
25 (1=yes, 0=no). The model was adjusted for differences between characteristics
26 of the patients who visited the GPs in the intervention and control condition
27 (gender, cultural background and smoking status).

28 Univariate analysis was used to examine the main effects of GP plan specificity
29 and GP-reported plan enactment on their provision of smoking cessation care
30 (as reported by patients). In addition, interaction analysis was used to examine
31 whether or not the effects of GP plan specificity on the delivery of care, depended
32 on the extent of GP plan enactment. Finally, subgroup analyses were performed
33 to examine whether the effects of GP plan specificity and plan enactment on
34 delivered smoking cessation care, differed between GPs with different baseline
35 intentions to routinely implement smoking cessation care. In all models, we
36 included Time (baseline (0)/post-intervention (1)) by Group (control group (0)/
37 low plan specificity or low plan enactment (1)/high plan specificity or high plan
38 enactment (2)) interaction effects since we included different cohorts of patients
39 at baseline and post-intervention.

1 RESULTS

2 3 Sample characteristics

4 Of the 49 participating GPs, 28 (57.1%) were men and 38 (77.6%) had worked
5 more than 10 years as a GP; in addition, the majority worked on average 38 h/
6 week, had a mean age of 50 years. Most of these GPs worked in collaboration
7 with one (n=33; 67.3%) or two (n=12; 24.5%) practice nurses. None of the GP
8 characteristics were significantly different between the intervention and control
9 condition. A detailed overview of the background characteristics of participating
10 GPs and patients is reported elsewhere.⁵³

11 12 Specificity and enactment of GP plans

13 Descriptive data with regard to the specificity of GPs' plans are presented in
14 Table 1. Most GPs completed all components of their action plans and coping
15 plan. With regard to the 'when' component, most GPs described a *type of moment*
16 for which they planned to ask about smoking or advise to quit, instead of a *type*
17 *of patient* for who they planned to provide this care. Only a minority of the GPs
18 described the *type of moment* or the *type of patient* highly specific, such as 'I'll ask
19 my patient about smoking, when I make a risk profile of the patient' (moment) or 'I'll ask
20 all patients with a chronic illness about smoking' (patient). Only a few GPs described
21 highly specific what the planned to do when they would encounter a smoker
22 who is motivated or unmotivated to quit, such as 'When I encounter a smoker who
23 is motivated to quit, I will discuss the (dis)advantages of quitting, motivation to quit, and
24 I will make a quit plan' or 'When I encounter a smoker who is not motivated to quit, I'll
25 ask the patient's permission to discuss their smoking behaviour again during the next
26 consultation'. Most GPs described highly specific *how* they planned to register the
27 activities in the electronic patient record, for example using the 'International
28 Classification of Primary Care'. Most GPs who formulated an action plan for asking
29 patients about smoking highly specific also reported a high level of plan enact-
30 ment (n=6/9, 66.7%). Similar associations were found between GP plan specificity
31 and plan enactment in the other action and coping plans. However, some GPs
32 who described their plans low specific reported a high level of plan enactment,
33 and vice versa.

34 35 Effect of GP plan specificity and enactment on provision of smoking 36 cessation care

37 Table 2 and 3 show the effects of plan specificity and plan enactment, respec-
38 tively, on GPs' provision of smoking cessation care, contrasting patients seen by
39 GPs in the control group. With regard to GPs task of 'asking about smoking', all

Table 1. Specificity and enactment of GPs' plans to provide guideline-recommended smoking cessation care

	GP action plans		GP coping plan	
	Ask about smoking	Advise to quit	Arrange follow-up motivated to quit*	Arrange follow-up unmotivated to quit*
Plan specificity (score)	(n=25, 100%)	(n=25, 100%)	(n=25, 100%)	(n=25, 100%)
<i>Who, completed (1)</i>	24 (96.0%)	24 (96.0%)	22 (88.0%)	21 (84.0%)
<i>When (moment) / What*</i>				
Not completed (0)	6 (24.0%)	6 (24.0%)	2 (8.0%)	3 (12.0%)
Low specific (1)	13 (52.0%)	14 (56.0%)	6 (24.0%)	8 (32.0%)
Medium specific (2)	3 (12.0%)	4 (16.0%)	13 (52.0%)	5 (20.0%)
Highly specific (3)	3 (12.0%)	1 (4.0%)	4 (16.0%)	9 (36.0%)
Total score, M (SD)	1.12 (0.93)	1.00 (0.76)	1.76 (0.83)	1.80 (1.08)
<i>When (type patient)</i>				
Not completed (0)	20 (80.0%)	20 (80.0%)	n.a.	n.a.
Low specific (1)	0 (0.0%)	1 (4.0%)	n.a.	n.a.
Medium specific (2)	1 (4.0%)	3 (12.0%)	n.a.	n.a.
Highly specific (3)	4 (16.0%)	1 (4.0%)	n.a.	n.a.
Total score, M (SD)	0.56 (1.16)	0.40 (0.87)	n.a.	n.a.
<i>How register</i>				
Not completed (0)	2 (8.0%)	1 (4.0%)	4 (16.0%)	5 (20.0%)
Low specific (1)	4 (16.0%)	5 (20.0%)	7 (28.0%)	6 (24.0%)
Medium specific (2)	2 (8.0%)	6 (24.0%)	8 (32.0%)	10 (40.0%)
Highly specific (3)	17 (68.0%)	13 (52.0%)	6 (24.0%)	4 (16.0%)
Total score, M (SD)	2.36 (1.04)	2.24 (0.93)	1.64 (1.04)	1.52 (1.01)
Total specificity score, M (SD) ^a	5.00 (2.10)	4.60 (1.66)	4.28 (1.79)	4.12 (2.03)
Plan enactment (score)				
Plan not enacted, not intending to in the future (0)	10 (40.0%)	12 (48.0%)	11 (44.0%)	15 (60.0%)
Plan not enacted, intending to within one month (1)	2 (8.0%)	2 (8.0%)	0 (0.0%)	1 (4.0%)
Plan not enacted, intending to within a week (2)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (4.0%)
Plan partly enacted (3)	8 (32.0%)	6 (24%)	3 (12.0%)	3 (12.0%)
Plan fully enacted (4)	5 (20.0%)	5 (20.0%)	11 (44.0%)	5 (20.0%)
Total enactment score, M (SD) ^b	1.84 (1.70)	1.60 (1.73)	2.12 (1.94)	1.28 (1.72)

GPs = general practitioners, IIs = implementation intentions, M = mean, SD = standard deviation

^aTotal specificity scores for action plans 'asking about smoking' and 'advising to quit' could range from 0 to 10 and for the action and coping plans 'arranging follow-up for smokers motivated to quit' and 'arranging follow-up for smokers unmotivated to quit' could range from 0 to 7

^bTotal enactment scores could range from 0 to 4

1 patients (smokers and non-smoking) were included in the analyses but classified
 2 into patients seen by a GP 1) 'in the control condition', 2) 'who formulated a low
 3 specific action plan', and 3) 'who formulated a highly specific action plan'. With
 4 regard to GPs' tasks of 'advising to quit' and 'arranging follow-up', we present the
 5 results for the subsets of patients that reported being a smoker.

6 After adjustment for clustering effects and patient characteristics, we found
 7 a significant time-by-group interaction effect of action planning on GPs' asking
 8 patient about smoking (Table 2); compared to the changes in GPs' asking about
 9 smoking in the control group, patients in the intervention group who visited
 10 their GP post-intervention reported being asked about their smoking status more
 11 often than patients who visited their GP prior to action planning. We only found
 12 a significant effect for highly specific action plans (OR 2.11, 95% CI 1.51-2.95).
 13

14 **Table 2.** Effect of GP plan specificity on the provision of smoking cessation activities (patient-reported)^a

	Baseline		Post-intervention		Time X Group OR (95% CI)
All patients (n=3401)	N Total	% asked	N Total	% asked	
Asked about smoking					
Highly specific GP plan	731	29.9%	437	41.0%	2.11 (1.51-2.95)**
Low specific GP plan	271	40.3%	193	42.8%	1.29 (0.82-2.03)
Control group	1066	40.8%	703	37.1%	1
All smokers (n=665)	N Total	% advised	N Total	% advised	
Advised to quit					
Highly specific GP plan	93	37.1%	49	53.3%	2.28 (0.81-6.40)
Low specific GP plan	102	43.3%	49	33.3%	0.62 (0.21-1.80)
Control group	229	43.8%	143	44.1%	1
Smokers motivated to quit (n=214)	N Total	% arranged	N Total	% arranged	
Arranged for follow-up					
Highly specific GP plan	39	15.4%	20	40.0%	^b
Low specific GP plan	21	28.6%	11	18.2%	^b
Control group	71	18.3%	52	9.6%	1
Smokers not motivated to quit (n=408)	N Total	% arranged	N Total	% arranged	
Arranged for follow-up					
Highly specific GP plan	39	20.5%	21	14.3%	^b
Low specific GP plan	82	4.9%	38	7.9%	^b
Control group	142	4.9%	86	10.5%	1

37 GPs=general practitioners, OR=odds ratio, CI=confidence interval

38 ^a Generalized estimating equations adjusted for clustering and patient characteristics

39 ^b Analyses not possible due to the sparseness of data

*<0.01 **<0.001

1 Similarly, we only found a positive time-by-group interaction effect of high plan
 2 enactment on GPs' asking about smoking (Table 3; OR 3.04, 95% CI 2.10-4.41).
 3 Further analyses showed that the effect of high plan enactment on GP asking
 4 about smoking differed according to the degree of specificity of the action plan
 5 ($p < 0.001$). Compared to the changes in time in the control group, patients who
 6 visited a GP who formulated a highly specific action plan and reported a high
 7 level of plan enactment post-intervention were asked more often about their
 8 smoking behaviour compared to prior to the intervention (OR 3.08, 95% CI 2.04-
 9 4.64) (Table 4).

10 With regard to GPs' plans to routinely advise smokers to quit, and to arrange a
 11 follow-up for smokers who are motivated or not motivated to quit, no significant
 12

13 **Table 3.** Effect of GP plan enactment on the provision of smoking cessation activities (patient-reported)^a

	Baseline		Post-intervention		Time X Group OR (95% CI)
All patients (n=3401)	N Total	% asked	N Total	% asked	
Asked about smoking					
High GP plan enactment	459	34.6%	314	55.7%	3.04 (2.10-4.41)**
Low GP plan enactment	543	31.1%	316	27.3%	1.01 (0.68-1.49)
Control group ^c	1066	40.8%	703	37.1%	1
All smokers (n=665)	N Total	% advised	N Total	% advised	
Advised to quit					
High GP plan enactment	63	57.1%	33	66.7%	0.85 (0.27-2.65)
Low GP plan enactment	132	39.4%	65	46.2%	1.52 (0.58-3.99)
Control group ^c	229	43.8%	143	44.1%	1
Smokers motivated to quit (n=214)	N Total	% arranged	N Total	% arranged	
Arranged for follow-up					
High GP plan enactment	35	17.1%	16	18.1%	^b
Low GP plan enactment	25	24.0%	15	26.7%	^b
Control group ^c	71	18.3%	52	9.6%	1
Smokers not motivated to quit (n=408)	N Total	% arranged	N Total	% arranged	
Arranged for follow-up					
High GP plan enactment	35	17.1%	15	13.3%	^b
Low GP plan enactment	86	7.0%	44	9.1%	^b
Control group ^c	142	4.9%	86	10.5%	1

36 GPs=general practitioners, OR=odds ratio, CI=confidence interval

37 ^a Generalized estimating equations adjusted for clustering and patient characteristics

38 ^b Analyses not possible due to the sparseness of data

39 * < 0.01 ** < 0.001

main or interaction effects of GP plan specificity and plan enactment were found on the delivery of smoking cessation care, as reported by the patients (Table 2 and 3).

Table 4. Interaction effect of GP plan enactment and GP plan specificity on the provision of smoking cessation activities (patient-reported)^{a,b}

	Baseline		Post-intervention		Time X Group OR (95% CI)
	N Total	% asked	N Total	% asked	
Asked about smoking					
High PS * High PE	359	36.5%	221	57.5%	3.08 (2.04-4.64)**
Low PS * High PE	100	24.0%	93	43.0%	3.00 (1.54-5.86)*
High PS * Low PE	372	21.0%	216	20.8%	1.19 (0.74-1.92)
Low PS * Low PE	171	46.8%	100	37.0%	0.71 (0.40-1.26)
Control group	1066	40.8%	703	37.1%	1

GPs=general practitioners, OR=odds ratio, CI=confidence interval, PS=Plan specificity, PE=Plan enactment

^a Includes all patients, both smokers and non-smokers (n=3401)

^b Generalized estimating equations adjusted for clustering and patient characteristics

*<0.01 **<0.001

GP intention

Table 5 presents results of the analyses of three subgroups of patients, namely patients who consulted a GP who reported at baseline to be: 1) a 'pre-intender', 2) an 'intender', or 3) an 'actor' regarding the implementation of smoking cessation care. For each of these subgroups, we explored whether a more specific action plan and a higher plan enactment was associated with a significant increase in the percentage of patients reporting being asked about smoking. Consistent with our hypothesis, we found no positive main effects of GP plan specificity and GP plan enactment among those patients who visited GPs who, at baseline, had already fully implemented smoking cessation care (the 'actors'). Analyses showed a positive significant effect of high plan specificity and high plan enactment among those patients who consulted a 'pre-intender' GP (Table 5). Among patients who consulted an 'intender' GP, both high and low plan specificity, as well as high plan enactment had a positive effect on asking about smoking. In all three patient subgroups we found evidence for the combined effect of high plan specificity and high plan enactment on GP asking about smoking.

Table 5. Effect of specificity and enactment of GPs' plan on asking about smoking (patient-reported) among three subgroups of patients who consulted: 1) a pre-intender GP, 2) an intender GP, and 3) an actor GP^{a,b}

	GP pre-intender (n=393)				GP intender (n=2211)				GP actor (n=797)			
	Pre N total (% asked)	Post N total (% asked)	Time X Group OR (95% CI)		Pre N total (% asked)	Post N total (% asked)	Time X Group OR (95% CI)		Pre N total (% asked)	Post N total (% asked)	Time X Group OR (95% CI)	
Plan specificity												
High	86 (20.9%)	32 (68.8%)	8.26 (2.26-27.39)*	1	416 (31.0%)	274 (44.9%)	1.93 (1.49-2.50)**	1	229 (27.1%)	131 (20.6%)	0.82 (0.48-1.40)	1
Low	9 (33.3%)	0 (00.0%)	^c	1	163 (33.1%)	144 (47.9%)	2.03 (1.38-2.99)**	1	99 (47.5%)	49 (16.3%)	0.19 (0.08-0.46)**	1
Control group	182 (15.4%)	84 (10.7%)		1	719 (40.1%)	495 (40.8%)		1	165 (40.6%)	124 (32.3%)		1
Plan enactment												
High	49 (28.6%)	21 (90.5%)	46.84 (6.8-324.9)**	1	256 (35.9%)	235 (57.0%)	2.80 (2.02-3.89)**	1	154 (64.3%)	58 (72.4%)	0.69 (0.36-1.32)	1
Low	46 (15.2%)	11 (27.3%)	1.49 (0.35-6.38)	1	323 (65.0%)	183 (61.2%)	1.10 (0.77-1.58)	1	174 (59.2%)	122 (80.3%)	0.43 (0.25-0.74)*	1
Control group	182 (10.0%)	84 (10.7%)		1	719 (51.3%)	495 (54.9%)		1	165 (55.5%)	124 (66.9%)		1
PS*PE												
High* High	40 (27.5%)	21 (90.5%)	66.45 (6.65-661.7)**	1	204 (38.2%)	166 (59.0%)	9.78 (3.90-24.53)**	1	115 (36.5%)	34 (29.4%)	37.82 (8.95-159.9)**	1
Low* High	9 (33.3%)	0 (0.00%)	^c	1	52 (26.9%)	69 (52.2%)	4.78 (2.04-11.19)**	1	39 (17.9%)	24 (16.7%)	1.32 (0.31-5.58)	1
High* Low	46 (15.2%)	11 (27.3%)	1.94 (0.32-11.77)	1	212 (24.1%)	108 (23.2%)	1.09 (0.58-2.03)	1	114 (17.5%)	97 (17.5%)	2.04 (0.83-5.02)	1
Low* Low	0 (0.00%)	0 (0.00%)	^c	1	111 (36.0%)	75 (44.0%)	1.60 (0.80-3.20)	1	60 (66.7%)	25 (16.0%)	0.14* (0.04-0.54)	1
Control group	182 (15.4%)	84 (10.7%)		1	719 (44.1%)	495 (41.1%)		1	165 (40.6%)	124 (32.3%)		1

GPs=general practitioners, PS=plan specificity, PE=plan enactment, OR=odds ratio, CI=confidence interval

^a Includes all patients, both smokers and non-smokers (n=3401)

^b Generalized estimating equations adjusted for clustering and patient characteristics

^c Analyses not possible due to the sparseness of data

*<0.01 **<0.001

1 DISCUSSION

3 Main findings

4 This study examined the effects of action planning and coping planning within
5 a training programme for GPs on their provision of guideline-recommended
6 smoking cessation care. In line with our previously reported effects of the GP
7 training⁵³, the 25 GPs in the intervention group more often asked patients about
8 smoking after formulating an action plan during the training compared to prior
9 to the training. In line with our hypothesis, GPs who formulated a highly specific
10 action plan asked their patients more often about smoking than GPs with less
11 specific plans. Moreover, high plan specificity had a positive effect on GPs' asking
12 patients about smoking when they also highly enacted their plan. The effects of
13 plan specificity and plan enactment were particularly present among GPs who
14 initially intended to implement smoking cessation care but who had not yet
15 routinely implemented such care. No effects of action planning, plan specificity
16 and plan enactment were found on GPs' provision of quit smoking advice and
17 arranging follow-up care for smokers who were motivated to quit. In addition,
18 no effects were found of GP coping planning on arranging follow-up for smokers
19 who were not motivated to quit.

21 Interpretation of the findings

22 Our finding that action planning incorporated in a training programme for GPs
23 increased the extent to which these professionals asked their patients about
24 smoking is in line with earlier results on the positive effects of incorporating
25 self-formulated conditional plans in an educational class for healthcare profes-
26 sionals.³⁶ However, no evidence was found for GP action planning on GPs' provi-
27 sion of other tasks, such as advising to quit and arranging follow-up for smokers
28 who were motivated to quit. This latter finding does not correspond with general
29 evidence for action planning on intended behaviours in patient samples.⁴⁴⁻⁴⁶
30 Nevertheless, the percentage of smokers that was advised to quit smoking by
31 GPs who formulated a highly specific related action plan post-intervention was
32 substantial larger compared to baseline (37.1% versus 53.3%). A comparable
33 pattern was observed with regard to the percentage of smokers who were mo-
34 tivated to quit and for who a follow-up was arranged by the GP (15.4% versus
35 40.0%). These substantial positive changes in time were not observed within the
36 control group (advised to quit at baseline: 43.8% versus 44.1% post-intervention;
37 arranged follow-up for smokers motivated to quit at baseline: 18.3% versus 9.6%
38 post-intervention).

1 The small sample sizes may have impeded statistical confirmation of these
2 findings. Another explanation for this may be that GPs might have more dif-
3 ficulty to act upon other action plans compared to merely asking their patients
4 about smoking. The percentage of smokers who report being advised to quit or
5 for who follow-up support was arranged in our study is indeed overall lower
6 than the percentage of patients who were asked about their smoking behaviour.
7 Smokers tend to express more resistance and negative statements about quit-
8 ting when being advised to quit compared to being asked about their smoking
9 behaviour.^{55;56} In addition, GPs indicate that they lack an overview of health
10 promotion programmes in their own neighbourhood to which they can refer
11 their patients.⁴⁰ Therefore, GPs may derive more benefit from training in coping
12 plans on how to deal with these difficulties. A second explanation might relate
13 to the quality of the action plans, which has shown considerable variability in
14 patient samples.¹⁷ In the present study, although we rated the specificity of GPs'
15 action plans, a specific plan does not necessarily mean a 'good' plan. Indeed, for
16 maximal impact of a plan, GPs require the opportunity to enact the plan as often
17 as possible. Other aspects of planning, such as opportunity, could be explored in
18 future studies. A final explanation may be related to the lack of a prior power
19 analysis, which could have described the power required to detect the intended
20 effects.

21 Although coping planning anticipates potential barriers to behaviour (i.e. en-
22 counteracting smokers who are not motivated to quit), no effect of GPs' coping plan
23 was found on their provision of guideline-recommended smoking cessation care
24 to these smokers. The current guideline for smoking cessation care offers GPs
25 a solution for this type of barrier, i.e. asking the smoker's permission to discuss
26 their smoking behaviour during a subsequent consultation.¹ Of our 25 GPs, only
27 six (24%) formulated this guideline-recommended activity highly specific; this
28 might indicate that not all GPs were familiar with this guideline-recommended
29 solution, or that this solution may not be appropriate for all GPs. Additionally,
30 GPs may face more specific obstacles, such as the resistance of smokers or lack
31 of time to provide adequate smoking cessation care. Therefore, we recommend
32 that future studies involve GPs in formulating their own obstacles and solutions
33 to provide smoking cessation care. A volitional help sheet (providing a list of
34 possible obstacles and behavioural responses) is often effective in translating
35 individuals' intention into action and might also be a suitable tool for healthcare
36 professionals.⁴⁸⁻⁵¹

37 We also examined the effects of plan specificity and self-reported plan enact-
38 ment on GPs' provision of smoking cessation care. In line with previous studies
39 within patient samples, we found evidence for the positive effects of formulat-

1 ing a highly specific action plan on GPs' asking about smoking compared to a
2 low specific action plan.^{32,57} We also found evidence for GP-reported high plan
3 enactment on the frequency with which GPs asked their patients about smoking.
4 This latter finding is in line with de Vries et al.³⁴ and Ziegelmann et al.³⁵ who
5 found that a self-reported plan enactment predicted smoking abstinence and
6 an increase in physical activity, respectively. Moreover, our analyses showed that
7 GPs were most likely to ask their patients about smoking when they enacted a
8 highly specific formulated action plan. To our knowledge, this interaction effect
9 has not yet been examined and provides additional insight into the mechanisms
10 underlying action planning.

11 All the described effects were present among GPs who, at baseline, intended
12 to implement smoking cessation care and were lacking among GPs who, at base-
13 line, were already categorised as 'actors'. These findings are in line with theories
14 suggesting that action planning is a post-intentional strategy which aims to
15 bridge the gap between the individual's intention to perform the behaviour and
16 the actual performance of that behaviour.^{25,58} At baseline, GPs who indicated that
17 they had already fully implemented smoking cessation care in their practice may
18 already have a clear idea of when, where and how they will ask their patients
19 about smoking. Indeed, highly conscientious individuals might benefit less from
20 self-formulated conditional plans as they may already use such approaches.¹⁷
21 As reported elsewhere, the GP training programme focused on increasing the
22 GP's intention to implement smoking cessation care, and succeeded therein.⁵³
23 This might explain why 'pre-intender' GPs also benefitted from action planning;
24 however, the small size of this subgroup resulted in ORs with a wide confidence
25 interval, indicating a low level of precision of this finding.

26

27 **Study strengths and weaknesses**

28 A strength of the present study is that it explored whether a training programme
29 with action planning (a strategy proven effective in patient samples) increases
30 the provision of guideline-recommended smoking cessation activities among
31 GPs. In addition, we examined the specificity of the plans GPs made and the ex-
32 tent to which they enacted these plans; these aspects are often neglected within
33 planning interventions.¹⁷ There is increasing interest in the effects of planning
34 interventions on the clinical behaviour of healthcare professionals.⁵⁹ The present
35 study provides further insight into the feasibility of applying this strategy in a GP
36 sample and generates new hypotheses that can be examined in future research.

37 Some limitations should also be mentioned. First, we assessed the effects of
38 the GP training incorporating action planning on patient-reported smoking ces-
39 sation activities of GPs. Patients may have perceived the GP's quit smoking advice

1 or referral for follow-up support as being embedded in a general conversation
2 about smoking behaviour; in that case, the smoking cessation activities of the
3 GP might have escaped their attention. Such recall bias may have led to a lack
4 of effect of action planning on the delivery of these smoking cessation activities.
5 Secondly, the precise response rate of patients who completed the questionnaire
6 (at baseline and post-intervention) is unknown. Reasons for non-response might
7 be attributed to GPs who failed to hand out the patient questionnaires, or to
8 patients who forgot or were unwilling to complete the questionnaire. Thirdly,
9 the relatively small sample of GPs and smoking patients might have reduced
10 the chance of detecting a true effect of action planning, plan specificity and/or
11 plan enactment on GPs' provision of quit smoking advice and referrals. Also, we
12 measured GPs' intention and plan enactment with single item measures. Further
13 research is needed to examine the validity of these measures. Finally, during the
14 study period, some of the GPs did not have direct access to the smoking cessa-
15 tion programmes of (trained) practice nurses, which may have contributed to the
16 lack of effect on GPs' referrals.

17 **Conclusions**

19 Action planning within a training programme for GPs improves the frequency
20 with which the GPs ask patients about their smoking. Action planning was par-
21 ticularly beneficial among those GPs who had a pre-existing intention to imple-
22 ment smoking cessation care. Importantly, a highly specific action plan that was
23 well enacted was most likely to result in patients being asked about smoking by
24 their GP. Since action planning did not improve the provision of other GP tasks
25 regarding smoking cessation care, future studies should further examine the
26 effects of coping plans on the provision of these GP tasks. These plans might help
27 GPs to anticipate possible barriers that impede them from acting on their inten-
28 tions. In addition, we recommend that our findings be replicated in randomised
29 controlled studies with a larger GP sample and a long-term follow-up.⁶⁰

31 **ACKNOWLEDGEMENTS**

34 This study was performed under MIRO, a national programme for optimizing
35 smoking cessation. MIRO is an initiative of Pfizer and Caphri. This project is sup-
36 ported by an unrestricted grant from Pfizer and Caphri.

1 REFERENCES

- 2 1. Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al. Dutch College of General Practitioners Guideline for Smoking Cessation [NHG-
3 Standaard Stoppen met roken]. *Huisarts Wet* 2007; 50(7):306-314.
- 4 2. Fiore MC, Jaén CR, Baker TB, Bailey WC, Bennett G, Benowitz NL et al. A clinical
5 practice guideline for treating tobacco use and dependence: 2008 update. A U.S.
6 Public Health Service report. *Am J Prev Med* 2008; 35(2):158-176.
- 7 3. Coleman T, Murphy E, Cheater F. Factors influencing discussion of smoking between
8 general practitioners and patients who smoke: a qualitative study. *Brit J Gen Pract*
9 2000; 50(452):207-210.
- 10 4. Coleman T, Cheater F, Murphy E. Qualitative study investigating the process of giving
11 anti-smoking advice in general practice. *Patient Educ Couns* 2004; 52(159):163.
- 12 5. Geense WW, van de Glind IM, Visscher TL, van Achterberg T. Barriers, facilitators and
13 attitudes influencing health promotion activities in general practice: an explorative
14 pilot study. *BMC Fam Pract* 2013; 14(20).
- 15 6. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs' engagement
16 in smoking cessation: a multi-country literature review. *Brit J Genl Pract*
17 2009; 59(566):682-690.
- 18 7. Vogt F, Hall S, Marteau TM. General practitioners' and family physicians' negative
19 beliefs and attitudes towards discussing smoking cessation with patients: a systematic
20 review. *Addiction* 2005; 100(10):1423-1431.
- 21 8. de Korte D, Nagelhout GE, Willemsen MC. Stoppen-met-rokenadviesing door huisartsen
22 in Nederland 2001-2009. [Smoking cessation advisement in Dutch general
23 practice: 2001-2009]. 2010. The Hague, the Netherlands, STIVORO - for a smoke-free
24 future.
- 25 9. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal
26 contact smoking cessation program for Dutch general practitioners: a randomized
27 controlled trial. *Prev Med* 2001; 32(2):182-190.
- 28 10. Puschel K, Thompson B, Coronado G, Huang Y, Gonzalez L, Rivera S. Effectiveness of
29 a brief intervention based on the '5A' model for smoking cessation at the primary
30 care level in Santiago, Chile. *Health Promot Int* 2008; 23(3):240-250.
- 31 11. Takahashi K, Saso H, Saka H, Saso H, Iwata M, Hashimoto I et al. A pilot study on
32 inducement of smoking cessation by a simple 5A (asking, advice, assess, assist, and
33 arrange) approach at outpatient clinics. *Asian Pac J Canc Prev* 2006; 7(1):131-135.
- 34 12. Davies P, Walker AE, Grimshaw JM. A systematic review of the use of theory in the
35 design of guideline dissemination and implementation strategies and interpretation
36 of the results of rigorous evaluations. *Implementation Science* 2010; 5(14).
- 37 13. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L et al. Effectiveness
38 and efficiency of guideline dissemination and implementation strategies. *Health Technology Assessment* 2004; 8(6):1-72.
- 39 14. Mazza D, Bairstow P, Buchan H, Chakraborty SP, Van HO, Grech C et al. Refining a
taxonomy for guideline implementation: results of an exercise in abstract classification. *Implementation Science* 2013; 8(32).
15. Medves J, Godfrey C, Turner C, Paterson M, Harrison M, MacKenzie L et al. Systematic review of practice guideline dissemination and implementation strategies for

- 1 healthcare teams and team-based practice. *Int J Evidence-Based Healthcare* 2010;
2 8(2):79-89.
- 3 16. Bonetti D, Johnston M, Pitts NB, Deery C, Ricketts I, Tilley C et al. Knowledge may not
4 be the best target for strategies to influence evidence-based practice: using psycholo-
5 gical models to understand RCT effects. *Int J of Behav Med* 2009; 16(3):287-293.
- 6 17. Sniehotta FF. Towards a theory of intentional behaviour change: Plans, planning, and
7 self-regulation. *Br J Health Psychol* 2009; 14:261-273.
- 8 18. Eccles MP, Grimshaw J, Walker A, Johnston M, Pitts N. Changing the behavior of
9 healthcare professionals: the use of theory in promoting the uptake of research
10 findings. *J Clin Epid* 2005; 58(2):107-112.
- 11 19. Eccles MP, Hrisos S, Francis J, Kaner EF, Dickinson HO, Beyer F et al. Do self- reported
12 intentions predict clinicians' behaviour: a systematic review. *Implementation Science*
13 2006; 1(21).
- 14 20. Godin G, Belanger-Gravel A, Eccles M, Grimshaw J. Healthcare professionals' inten-
15 tions and behaviours: a systematic review of studies based on social cognitive
16 theories. *Implementation Science* 2008; 3(36).
- 17 21. Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A. Making psychologi-
18 cal theory useful for implementing evidence based practice: a consensus approach.
19 *Qual Safety in Health Care* 2005; 14(1):26-33.
- 20 22. Perkins MB, Jensen PS, Jaccard J, Gollwitzer P, Oettingen G, Pappadopulos E et al.
21 Applying theory-driven approaches to understanding and modifying clinicians'
22 behavior: what do we know? *Psych Serv* 2007; 58(3):342-348.
- 23 23. Leventhal H, Watts JC, Pagano F. Effects of fear and instructions on how to cope with
24 danger. *J Pers Soc Psychol* 1967; 6(3):313-321.
- 25 24. Leventhal H, SINGER R, JONES S. Effects of fear and specificity of recommendations
26 upon attitudes and behavior. *J Pers Soc Psychol* 1965; 2:20-29.
- 27 25. Gollwitzer PM. Implementation Intentions: Strong Effects of Simple Plans. *Am Psy-*
28 *chol* 1999; 54(7):493-503.
- 29 26. Orbell S, Sheeran P. "Inclined abstainers": a problem for predicting health-related
30 behaviour. *Brit J Social Psychol* 1998; 37:151-165.
- 31 27. Sheeran P, Milne S, Webb TL, Gollwitzer PM. Implementation intentions and health
32 behaviour. *Predicting Health Behaviour. Research and Practice with Social Cognition*
33 *Models*. 2nd ed. ed. Berkshire, UK: Open University Press; 2005. 276-323.
- 34 28. Parks-Stamm EJ, Gollwitzer PM, Oettingen G. Action control by implementation
35 intentions: Effective cue detection and efficient response initiation. *Social Cognition*
36 2007; 25(2):248-266.
- 37 29. Webb TL, Sheeran P. Identifying good opportunities to act: Implementation inten-
38 tions and cue discrimination. *Eur J Soc Psychol* 2004; 34(4):407-419.
- 39 30. Webb TL, Sheeran P. How do implementation intentions promote goal attainment?
A test of component processes. *J Exp Soc Psychol* 2007; 43(2):295-302.
- 31 31. Webb TL, Sheeran P. Mechanisms of implementation intention effects: the role of
32 goal intentions, self-efficacy, and accessibility of plan components. *Brit J Soc Psychol*
33 2008; 47:373-395.
- 34 32. de Vet E, Oenema A, Brug J. More or better: Do the number and specificity of imple-
35 mentation intentions matter in increasing physical activity? *Psychol Sport and Exercise*
36 2011; 12:471-477.

- 1 33. van Osch L, Lechner L, Reubsaet A, de Vries H. From theory to practice: An explorative study into the instrumentality and specificity of implementation intentions. *Psychology & Health* 2010; 25(3):351-364.
- 2
- 3 34. de Vries H, Eggers SM, Bolman C. The role of action planning and plan enactment for smoking cessation. *BMC Public Health* 2013; 13(393).
- 4
- 5 35. Ziegelmann JP, Lippke S, Schwarzer R. Adoption and maintenance of physical activity: Planning interventions in young, middle-aged, and older adults. *Psychol & Health* 2006; 21(2):145-163.
- 6
- 7 36. Casper ES. Using implementation intentions to teach practitioners: changing practice behaviors via continuing education. *Psychiatr Serv* 2008; 59(7):747-752.
- 8
- 9 37. Eccles MP, Grimshaw JM, Johnston M, Steen N, Pitts NB, Thomas R et al. Applying psychological theories to evidence-based clinical practice: identifying factors predictive of managing upper respiratory tract infections without antibiotics. *Implementation Science* 2007; 2(26).
- 10
- 11 38. Grimshaw JM, Eccles MP, Steen N, Johnston M, Pitts NB, Glidewell L et al. Applying psychological theories to evidence-based clinical practice: identifying factors predictive of lumbar spine x-ray for low back pain in UK primary care practice. *Implementation Science* 2011; 6(55).
- 12
- 13 39. Presseau J, Johnston M, Heponiemi T, Elovainio M, Francis JJ, Eccles MP et al. Reflective and Automatic Processes in Health Care Professional Behaviour: a Dual Process Model Tested Across Multiple Behaviours. *Ann Behav Med* 2014.
- 14
- 15 40. Geense WW, van de Glind IM, Visscher TL, van AT. Barriers, facilitators and attitudes influencing health promotion activities in general practice: an explorative pilot study. *BMC Fam Pract* 2013; 14(20).
- 16
- 17 41. Pipe A, Sorensen M, Reid R. Physician smoking status, attitudes toward smoking, and cessation advice to patients: an international survey. *Pat Educ Couns* 2009; 74(1):118-123.
- 18
- 19 42. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs' engagement in smoking cessation: a multi-country literature review. *Brit J Gen Pract* 2009; 59(566):682-690.
- 20
- 21 43. Young JM, Ward JE. Implementing guidelines for smoking cessation advice in Australian general practice: opinions, current practices, readiness to change and perceived barriers. *Fam Pract* 2001; 18(1):14-20.
- 22
- 23 44. Adriaanse MA, Vinkers CD, De Ridder DT, Hox JJ, De Wit JB. Do implementation intentions help to eat a healthy diet? A systematic review and meta-analysis of the empirical evidence. *Appetite* 2011; 56(1):183-193.
- 24
- 25 45. Bélanger-Gravel A, Godin G, Amireault S. A meta-analytic review of the effect of implementation intentions on physical activity. *Health Psychol Rev* 2013; 7(1):23-54.
- 26
- 27 46. Gollwitzer PM, Sheeran P. Implementation Intentions and Goal Achievement: A Meta-analysis of Effects and Processes. *Adv Exper Soc Psychol* 2006; 38:69-119.
- 28
- 29 47. Sniehotta FF, Scholz U, Schwarzer R. Action plans and coping plans for physical exercise: A longitudinal intervention study in cardiac rehabilitation. *Br J Health Psychol* 2006; 11(Pt 1):23-37.
- 30
- 31 48. Armitage CJ, Arden MA. A volitional help sheet to reduce alcohol consumption in the general population: a field experiment. *Prev Sci* 2012; 13(6):635-643.
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39

- 1 49. Arden MA, Armitage CJ. A volitional help sheet to reduce binge drinking in students:
2 a randomized exploratory trial. *Alcohol Alcoholism* 2012; 47(2):156-159.
- 3 50. Armitage CJ. A volitional help sheet to encourage smoking cessation: a randomized
4 exploratory trial. *Health Psychol* 2008; 27(5):557-566.
- 5 51. Armitage CJ, Arden MA. A volitional help sheet to increase physical activity in people
6 with low socioeconomic status: A randomised exploratory trial. *Psychol Health* 2010;
7 25(10):1129-1145.
- 8 52. Fiore MC, Wetter DW, Bailey WC, Blennett G, Cohen SJ, Dorfman SF et al. The Agency
9 for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline.
10 *J Am Med Assoc* 1996; 275(16):1270-1280.
- 11 53. Verbiest MEA, Crone MR, Scharloo M, Chavannes NH, van der Meer V, Kaptein AA
12 et al. One-Hour Training for General Practitioners in Reducing the Implementation
13 Gap of Smoking Cessation Care: A Cluster-Randomized Controlled Trial. *Nic Tobac Res*
14 2013.
- 15 54. Schwarzer R. Self-efficacy in the adoption and maintenance of health behaviors:
16 theoretical approaches and a new model. *Self-efficacy: Thought Control of Action*.
17 Washington, DC: Hemisphere; 1992. 217-243.
- 18 55. Pilnick A, Coleman T. "I'll give up smoking when you get me better": patients' resis-
19 tance to attempts to problematise smoking in general practice (GP) consultations.
20 *Soc Sci Med* 2003; 57(1):135-145.
- 21 56. Verbiest MEA, Chavannes NH, Passchier E, Noordman J, Scharloo M, Kaptein AA et al.
22 Sequence-analysis of video-recorded practitioner-patient communication about
23 smoking in general practice: Do smokers express negative statements about quit-
24 ting? *Pat Educ Couns* 2014 [ahead of print].
- 25 57. van Osch L., Reubsæet A, Lechner L, de Vries H. The formation of specific action
26 plans can enhance sun protection behavior in motivated parents. *Prev Med* 2008;
27 47(1):127-132.
- 28 58. Sniehotta FF, Scholz U, Schwarzer R. Bridging the intention-behaviour gap: Plan-
29 ning, self-efficacy, and action control in the adoption and maintenance of physical
30 exercise. *Psychology & Health* 2005; 20(2):143-160.
- 31 59. Squires J, Pressau J, Francis J, Bond CM, Fraser C, Patey A et al. Self-formulated
32 conditional plans for changing health behaviour among healthcare consumers and
33 health professionals. *Cochr Datab Syst Rev* 2013;(12).
- 34 60. Presseau J, Francis JJ, Jonhston M, Mackintosh J, Grimshaw JM, Kaner E et al. Improv-
35 ing Diabetes care through Examining, Advising, and prescribing (IDEA): Protocol for
36 a theory-based cluster randomised controlled trial of a multiple behaviour change
37 intervention aimed at primary healthcare professionals. *Implementation Science* 2014.
- 38
- 39

Appendix 1. Rating of the specificity of GPs' plans with regard to smoking cessation activities

GP plans	Who	When - Moment	When - Patient	How to register	Specificity score
Ask about smoking	0 / 1	0 / 1 / 2 / 3	0 / 1 / 2 / 3	0 / 1 / 2 / 3	(0-10)
Advise to quit	0 / 1	0 / 1 / 2 / 3	0 / 1 / 2 / 3	0 / 1 / 2 / 3	(0-10)
	What	Who	How to register		
Arrange follow-up for smokers motivated to quit	0 / 1 / 2 / 3	0 / 1	0 / 1 / 2 / 3		(0-7)
Arrange follow-up for smokers not motivated to quit	0 / 1 / 2 / 3	0 / 1	0 / 1 / 2 / 3		(0-7)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

5

Sequence-analysis of video-recorded practitioner-patient communication about smoking in general practice: Do smokers express negative statements about quitting?

Marjolein E.A. Verbiest¹, Niels H. Chavannes¹,
Esther Passchier¹, Janneke Noordman², Margreet Scharloo³,
Ad A. Kaptein³, Willem J.J. Assendelft^{4,1} &
Mathilde R. Crone¹ (2014)

¹Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands

²Netherlands Institute for Health Services Research, Utrecht, the Netherlands

³Department Medical Psychology, Leiden University Medical Centre, Leiden, the Netherlands

⁴Department Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Patient Education and Counseling [ahead of print]

1 **ABSTRACT**

3 **Objective**

4 To provide insight into the professional-patient interaction during unsolicited
5 dialogues about smoking; to examine the extent to which smokers express nega-
6 tive statements about quitting and the extent to which these statements influ-
7 ence general practitioners' (GPs') and practice nurses' (PNs') (dis)continuation of
8 guideline-recommended smoking cessation care.

10 **Methods**

11 Fifty-two video-consultations were observed (GP-consultations: 2007-2008;
12 PN-consultations: 2010-2011). Dialogues were transcribed verbatim and profes-
13 sionals' and patients' speech units were coded and analysed using sequential
14 analyses (n=1424 speech units).

16 **Results**

17 GPs focused on asking about smoking (GPs: 42.4% versus PNs: 26.2%, p=0.011) and
18 advising to quit (GPs: 15.3% versus PNs: 3.5%, p<0.001) whereas PNs focused on
19 assisting with quitting (GPs: 25.4% versus PNs: 55.2%, p<0.001). Overall, patients
20 expressed more negative statements about quitting than positive statements
21 (negative: 25.3% versus positive: 11.9%, p<0.001), especially when PNs assessed
22 their willingness to quit (OR 3.61, 95% CI 1.44-9.01) or assisted with quitting (OR
23 2.23, 95% CI 1.43-3.48).

25 **Practice implications**

26 An alternative approach to smoking cessation care is proposed in which GPs'
27 tasks are limited to asking, advising, and arranging follow-up, such as referrals
28 to the PN. This approach seems the least likely to evoke negative statements of
29 patients about quitting during dialogues with GPs and is compatible to tasks and
30 skills of PNs who could subsequently assist smokers with quitting.

1 INTRODUCTION

2
3 Evidence-based guidelines for smoking cessation care recommend general prac-
4 titioners (GPs) and practice nurses (PNs) to routinely ask patients about smoking,
5 advise smokers to quit, assess their motivation to quit, assist them with quitting,
6 and arrange follow-up support.^{1,2} A full implementation of these '5 A's' signifi-
7 cantly improves smoking abstinence rates³⁻⁵ and is cost-effective.⁶

8 Nevertheless, GPs and PNs (see Appendix 1 for description of PNs' role in Dutch
9 general practice) report various barriers to the implementation of these guidelines
10 during routine consultation.⁷⁻¹² Although patients state they are willing to discuss
11 their smoking behaviour during a practitioner-initiated dialogue¹³, GPs and PNs re-
12 port that smokers regularly express negative statements regarding quitting during
13 unsolicited dialogues about smoking, such as a lack of motivation or discipline to
14 quit.⁷⁻¹² These negative statements about quitting impede a structural implemen-
15 tation of guideline-recommended smoking cessation care.⁷⁻¹² GPs report a limited
16 range of skills for dealing with these negative statements⁸ and as a consequence,
17 tend to avoid these negative statements in order to preserve a good doctor-patient
18 relationship.^{14,15} This is one of the reported reasons for the evidence-practice gap
19 regarding the provision of guideline-recommended smoking cessation care in
20 Dutch general practice. Results show that, for example, 79% of all smokers and
21 40% of smokers who discuss smoking with their GP do not receive a quit-smoking
22 advice.¹⁶ Therefore, we aim to provide more insight into the interaction between
23 primary care professionals and smokers during unsolicited dialogues about smok-
24 ing. These insights may result in recommendations for primary care professionals
25 in how to deal with smokers' negative statements regarding quitting and help
26 them to fully implement guideline-recommended smoking cessation care.

27 Until now, only a few studies have examined the interaction between primary
28 care professionals and smokers. These studies focused on the way patients react
29 when GPs link their health issues to their smoking¹⁷ or when they are counselled
30 to quit smoking based on their readiness to quit.¹⁸ To our knowledge, no studies
31 have examined the responses of smokers when professionals apply a guideline
32 for smoking cessation care. Moreover, the impact of these responses on profes-
33 sionals' continuation of guideline adherence is unknown. More insight into this
34 interaction may contribute to strategies that can benefit the implementation of
35 smoking cessation counseling in general practice.

36 Therefore, we assess the extent to which: i) professionals use the 5 A's for smok-
37 ing cessation care, ii) smoking patients express negative or positive statements
38 about quitting when professionals use these 5 A's, and iii) professionals continue
39 or discontinue their use of the 5 A's after patients express a positive or negative

1 statement about quitting. Based on literature, we hypothesize that an unsolicited
2 conversation about smoking will elicit patients' negative statements about quit-
3 ting. Furthermore, we hypothesize that patients' negative statements about quit-
4 ting will hamper the continuation of guideline adherence, while patients' positive
5 statements about quitting will facilitate it. Since knowledge and skills regarding
6 lifestyle counseling are highlighted in the 'competence profile' of PNs¹⁹, we hypoth-
7 esize that patients' negative statements about quitting are less likely to hamper
8 guideline adherence in dialogues with PNs compared to dialogues with GPs.

11 **METHODS**

13 **Study setting, participants and design**

14 We conducted a cross-sectional study in which we observed video-recordings
15 of random real-life routine consultations in general practice. Such video-taped
16 consultations are regularly used to observe lifestyle counseling²⁰⁻²⁵, provide a
17 complete record of what actually happens during consultations, and can be
18 viewed repeatedly.²⁶ Videos were collected (nationwide) and archived by the
19 Netherlands Institute for Health Services Research (NIVEL). Consultations with
20 GPs and PNs were recorded during 2007-2008 and during 2010-2011, respectively.
21 A detailed overview of the data collection is reported elsewhere.^{27,28}

22 All video-recordings in which smoking was discussed were selected for the
23 present study (n=211). We excluded video-recordings of consultations with
24 non-smokers (n=63), ex-smokers (n=70), consultations in which the patient spe-
25 cifically requested smoking cessation assistance (n=13) and in which patients
26 addressed smoking on their own initiative (n=13). This resulted in a set of 52
27 videos of 33 primary care professionals (17 GPs and 16 PNs). All PNs were trained
28 in motivational interviewing during the study.²⁸ This was not the case for GPs
29 and it is unclear whether the participating GPs were trained in motivational in-
30 terviewing prior to the study. All GPs, PNs and patients were unaware of the fact
31 that the recordings and analyses would focus on smoking cessation care. This
32 study was conducted according to Dutch privacy legislation in which approval of
33 the medical ethics committee was not required.²⁹

35 **Procedure and measurements**

36 After the patients gave their informed consent consultations were recorded. Two
37 researchers observed the video-recordings. Subsequently, the dialogues between
38 professionals and patients about smoking were transcribed verbatim (MV and
39 EP). A coding scheme was developed for every speech unit of patients and profes-

1 sionals. A speech unit is defined as *'the smallest distinguishable speech segment to*
 2 *which a classification may be assigned'*.³⁰ The length of a speech unit can vary from
 3 a single word to a lengthy sentence.

4 5 **Professionals' speech units**

6 We coded speech units of professionals which were related to the core com-
 7 ponents of the guideline for smoking cessation care ('5 A's'). These included: 1)
 8 Ask (about the patient's smoking status, the number of cigarettes, or smoking
 9 history), 2) Advise (to quit smoking or to smoke less), 3) Assess (the smoker's
 10 motivation to quit), 4) Assist (with quitting, which include discussing advantages
 11 of (quitting) smoking, risks of smoking, barriers to quitting, support options,
 12 pharmacological support, or a quit plan), and 5) Arrange (follow-up quit-smoking
 13 support, including referring the smoker to behavioural quit support, arrange a
 14 telephone follow-up, or ask permission to discuss smoking next time). Appendix
 15 2 provides an overview of the coding scheme illustrated by examples of speech
 16 units of primary care professionals and patients.

17 18 **Patients' speech units**

19 We coded both negative and positive statement about smoking cessation
 20 expressed by patients. A negative statement included: 1) barriers to quit, 2)
 21 disadvantages of quitting, 3) advantages of smoking, and 4) reasons to relapse.
 22 Patients' positive statement included: 1) motivators to quit, 2) advantages of
 23 quitting, 3) disadvantages of smoking, and 4) reasons to smoke less or continue
 24 abstinence (see Appendix 2 for coding scheme).

25 26 **Other speech units**

27 The speech units of professionals which we did not code as related to the 5A's
 28 and speech units of patient which we did not code as a negative or positive
 29 statement about quitting, were coded as follows: 1) other (non-)smoke-related
 30 questions/answers, e.g. "I smoke 10 cigarettes per day", 2) other (non-)smoke-
 31 related information, e.g. "These complaints might results from your smoking",
 32 3) other (non-)smoke-related confirmations, e.g. "Yes, I agree", 3) other (non-)
 33 smoke-related speech units, e.g. "Thank you". In contrast to '5A-related' speech
 34 units, 'other smoke-related' speech units of professionals included general
 35 statements about smoking and its risks and were unrelated to quitting or the
 36 patient's motivation to quit (see Appendix 2 for coding scheme).

37
38
39

1 Inter-rater agreement

2 Two researchers (MV and MC) independently coded five randomly selected dia-
3 logues (in total 153 speech units) which resulted in a moderate inter-rater agree-
4 ment (kappa 0.66). During this pretest of our coding scheme, we encountered two
5 coding difficulties. Firstly, some disagreements occurred regarding differentiating
6 between speech units of professionals related to 'Assisting a quit attempt' and to
7 'providing smoke-related information'. These disagreements were resolved via
8 a third person (NC) and we decided to code a speech unit as 'Assisting a quit
9 attempt' solely when it was related to the patients' motivation to quit, such as
10 an exploration of barriers and motivators to quit, e.g. "*Can you tell me a bit more
11 about the reasons why you want to quit?*". When professionals only made general
12 statements about smoking unrelated to quitting or the patient's motivation to
13 quit, we coded the speech unit as 'other, smoke-related: the provision of smoke-
14 related information', e.g. "*Your smoking has an impact on your vocal cords*".

15 Secondly, the pretest of our coding scheme showed that the number of coding
16 categories for patients' negative and positive statements about smoking cessa-
17 tion was too limited (it originally included only the coding categories 'barriers to
18 quit' and 'motivators to quit'). After consulting a third person (NC), we therefore
19 decided to extend these coding categories, including '(dis)advantages of quit-
20 ting', '(dis)advantages of smoking', 'reasons to relapse', and 'reasons to smoke
21 less or continue abstinence'.

22 The remaining transcripts were coded by one researcher (MV) (see Appendix 2
23 for coding scheme).

24

25 Statistical analyses

26 Firstly, we calculated the total number of speech units of both professionals
27 and patients and the number of speech units per dialogue. Differences between
28 GP- and PN-dialogues were analyzed with a chi-square test.

29 Secondly, we performed a number of sequential analyses which can be defined
30 as '*a set of techniques used to identify temporal patterns embedded within sequences of
31 coded behaviours or stimulus events*'.³¹⁻³³ The main aim of sequential analysis is to
32 determine if a particular sequence of behaviours or events occurs to a greater
33 or lesser extent than can be expected by chance alone.^{31,32} This type of analysis
34 can be regarded as a suitable method for exploring interaction patterns between
35 healthcare professionals and patients.³¹

36 We prepared our data for these analyses by forming a chain of codes repre-
37 senting the speech units of professionals and patients (a total of 1424 speech
38 units). Then, we examined the three speech units (three lags) following each
39 5A-related speech unit for negative and positive statements of smokers about

1 quitting. The existing literature gives only few indications for the optimal num-
2 ber of lags.^{30,31} Yet, because we focused on the immediate responses of patients
3 on the provision of smoking cessation care, we limited our analyses to three
4 lags. Lag 0 represented the 5A-related speech unit of a professional during the
5 dialogue, lag 1 represented the speech unit of the patient immediately following
6 the professional's 5A-related speech unit at lag 0, lag 2 represented the second
7 speech unit of the patient following the professional's 5A-related speech unit
8 at lag 0, and lag 3 represented the third speech unit of the patient following the
9 professional's 5A-related speech unit at lag 0.

10 Next, we calculated transitional probabilities, i.e. the likelihood that a patient
11 expressed one or more negative and positive statements regarding quitting
12 within the three lags following a 5 A-related speech unit of the professional (see
13 Appendix 3). The transitional probabilities were uncorrected for the potential
14 effects of clustering effects of speech units within dialogues. Therefore, we used
15 generalized estimating equations to take into account the multilevel structure
16 of the data. This resulted in corrected odds ratio's (ORs), i.e. the likelihood that
17 a negative or positive statement of the smoker about quitting was preceded by
18 a 5A-related speech unit of the professional compared to any other preceding
19 category of speech units of professionals.

20 The same method was used to compute the likelihood that a negative or positive
21 statement about quitting of the patient was followed within 3 lags by one or more 5 A-
22 related, other-smoke-related or non-smoke-related speech units of the professional.

23 24 25 **RESULTS**

26 27 **Sample characteristics**

28 Table 1 shows the characteristics of the duration of the consultations and dia-
29 logues about smoking, and characteristics of the patients, GPs and PNs who en-
30 rolled in the study. In total, we coded 1424 speech units (mean 27.4 speech units
31 per smoking dialogue, range 4-118) of which 727 were of professionals (51.1%,
32 mean 14.0 speech units per smoking dialogue, range 2-55) and 697 of patients
33 (48.9%, mean 13.4 speech units per smoking dialogue, range 1-63).

34 35 **Speech units**

36 37 **Professionals' smoking cessation care**

38 Overall, half of the speech units of professionals were related to the 5 A's for
39 smoking cessation care (Table 2). Chi-square tests showed that PNs expressed

1 **Table 1.** Characteristics of video-recorded consultations between patients, GPs and PNs

		Dialogues with		
Consultation characteristics		Total (n=52)	GPs (n=20)	PNs (n=32)
4	Total duration (min), M (SD)	22:41 (12:05)	12:29 (4:21)	29:04 (10:56)
5	Duration of smoking dialogue (min), M (SD)	2:57 (2:53)	1:28 (1:04)	3:53 (3:17)
		Dialogues with		
Patient characteristics		Total (n=52)	GPs (n=20)	PNs (n=32)
9	Age in years, M (SD)	53.5 (14.8)	46.1 (15.7)	57.7 (12.6)
10	Gender, female	23 (44.2%)	9 (45.0%)	14 (43.8%)
11	Educational level			
12	Low	11 (21.2%)	3 (15.0%)	8 (25.0%)
13	Middle	29 (55.8%)	8 (40.0%)	21 (65.6%)
14	High	3 (5.8%)	2 (10.0%)	1 (3.1%)
Reason for consultation				
15	Respiratory	16 (30.8%)	8 (40.0%)	8 (25.0%)
16	Cardiovascular	14 (26.9%)	6 (30.0%)	8 (25.0%)
17	Diabetes mellitus	9 (17.3%)	0 (0.0%)	9 (28.1%)
18	Multiple smoke-related	10 (19.2%)	3 (15.0%)	7 (21.9%)
19	Other smoke-related	1 (1.9%)	1 (5.0%)	0 (0.0%)
20	Non-smoke-related	2 (3.8%)	2 (10.0%)	0 (0.0%)
Professional characteristics		Total (n=33)	GPs (n=17)	PNs (n=16)
22	Age in years, M (SD)	46.4 (7.1)	49.9 (6.1)	42.4 (6.2)
23	Gender, female	22 (66.7%)	6 (35.3%)	16 (100.0%)

25 GP=general practitioner, PN=practice nurse, M=mean, SD=standard deviation

27 significantly more speech units related to these 5 A's than GPs (GPs: 37.8% versus
 28 PNs: 55.2%; $p < .001$). Within this category, GPs significantly more often asked
 29 about smoking and advised to quit compared to PNs. PNs significantly more often
 30 assisted with quitting compared to GPs.

31 The remaining speech units of professionals were coded as 'other smoke-
 32 related' speech units (31.4%) and 'other non-smoke-related' speech units
 33 (17.2%). Although no significant differences were found in these coding categories
 34 between GPs and PNs overall, we found a significant difference in one of
 35 the subcategories of 'other smoke-related' speech units: GPs significantly more
 36 often provided general smoke-related information compared to PNs (GPs: 37.0%
 37 versus PNs: 12.6%, $p < 0.001$, data not shown).

1 Patients' statements about smoking cessation

2 Overall, patients expressed significantly more often negative than positive state-
3 ments about quitting during an unsolicited dialogue about smoking (negative:
4 25.3% versus positive: 11.9%; $p < .001$). We found no significant differences be-
5 tween the number of negative statements during dialogues with PNs compared
6 to dialogues with GPs (Table 2).

7 A relative high number of patient's speech units were coded as 'other smoke-
8 related' (49.2%). This category comprised numerous simple answers to and
9 confirmations of the provision of smoke-related questions and information of
10 the professional, e.g. "Yes, I smoke" or "Yes, I agree".

11 Sequential analysis

12 Table 3 shows the transitional probabilities that smokers expressed negative or
13 positive statements about quitting following the 5 A's speech units of professionals.
14 Overall, patients were more likely to express a negative than a positive statement,
15 irrespective of the preceding 5A. The probability that smokers expressed a nega-
16 tive statement about quitting was lowest when professionals *asked* about smoking
17 (11%) or *arranged* a follow-up (15%), and highest when professionals *assessed* the
18 smoker's motivation to quit (55%) or provided *assistance* with quitting (38%).

19 When adjusting for clustering effects, patients were overall significantly more
20 likely to express a negative statement about quitting when professionals pre-
21 ceded with a speech unit related to *assessing* the patient's motivation to quit
22 (OR 3.61, 95% CI 1.44-9.01) or *assisted* with quitting (OR 2.23, 95% CI 1.43-3.48),
23 compared to any other preceding speech unit of professionals. When profes-
24 sionals preceded with a speech unit related to providing *assistance* with quitting,
25 patients were also significantly more likely to express a positive statement about
26 quitting (OR 2.76, 95% CI 1.56-4.89), compared to any other preceding speech
27 unit of professionals. Table 4 shows the results of comparable analyses, sepa-
28 rated for GP and PN dialogues. We found the above-mentioned effects only in PN
29 dialogues. Due to data sparseness, it was not possible to compute all corrected
30 odds ratio's in GP and PN dialogues (Table 4).

31 Figure 1 illustrates the transitional probabilities that GPs and PNs expressed
32 a 5A-related, other smoke-related, or non-smoke-related speech unit following
33 patients' negative and positive statements about quitting. Although we observed
34 that GPs were less likely to continue with using the 5 A's following patients'
35 negative statements compared to preceding positive statements (negative: 19%
36 versus positive: 47%), analyses could not confirm this statistically (OR 0.68, 95%
37 CI 0.17-2.75).

38
39

Table 2. Total number of coded speech units of patients and professionals and the difference between GPs and PNs

Professionals	Total coded speech units (n=1424)				GPs' coded speech units (n=287)				PNs' coded speech units (n=1137)				p ^a
	Number/ Total	Mean	Range	%	Number/ Total	Mean	Range	%	Number/ Total	Mean	Range	%	
Total	727/1424	14.0	2 - 55	51.1%	156/287	14.4	2 - 15	54.4%	571/1137	35.5	2 - 55	50.2%	0.210
Other SR	228/727	4.4	0 - 22	31.4%	54/156	2.7	0 - 9	34.6%	174/571	5.4	0 - 22	30.5%	0.323
Other NSR	125/727	2.4	0 - 16	17.2%	43/156	2.2	0 - 7	27.6%	82/571	2.6	0 - 16	14.4%	<0.001
5A's	374/727	7.2	1 - 33	51.4%	59/156	3.0	1 - 9	37.8%	315/571	9.8	1 - 33	55.2%	<0.001
Ask	107/374	2.1	0 - 6	28.6%	25/59	1.3	0 - 3	42.4%	82/315	2.6	1 - 6	26.0%	0.011
Advise	20/374	0.4	0 - 6	5.4%	9/59	0.5	0 - 3	15.3%	11/315	0.3	0 - 6	3.5%	<0.001
Assess	43/374	0.8	0 - 4	11.5%	8/59	0.4	0 - 2	13.6%	35/315	1.1	0 - 4	11.1%	0.588
Assist	189/374	3.6	0 - 22	50.5%	15/59	0.8	0 - 7	25.4%	174/315	5.4	0 - 22	55.2%	<0.001
Arrange	15/374	0.3	0 - 4	4.0%	2/59	0.1	0 - 1	0.03%	13/315	0.4	0 - 4	4.1%	0.791
Patients									Number/ Total	Mean	Range	%	p
Total	697/1424	13.4	1 - 63	48.9%	131/287	6.6	1 - 16	45.6%	566/1137	17.7	1 - 63	49.8%	0.210
Other SR	343/697	6.6	1 - 32	49.2%	63/131	3.2	1 - 7	48.1%	280/566	8.8	1 - 32	49.5%	0.776
Other NSR	95/697	1.8	0 - 15	13.6%	29/131	1.5	0 - 5	22.1%	66/566	2.1	0 - 15	11.7%	0.002
Negative statements	176/697	3.4	0 - 13	25.3%	25/131	1.3	0 - 7	19.1%	151/566	4.7	0 - 13	26.7%	0.071
Positive statements	83/697	1.6	0 - 8	11.9%	14/131	0.7	0 - 4	10.7%	69/566	2.2	0 - 8	12.2%	0.632

GPs=general practitioner, PNs=practice nurse, SR=smoke-related, NSR=non-smoke-related

^a Differences in the proportion of coded speech units between GP and PN dialogues were calculated with χ^2 tests

Table 3. Transitional probabilities of patients' speech units following speech units of primary care professionals (GPs and PNs combined) related to the five A's for smoking cessation care^{a,b}

Professionals' 5-A speech unit (lag 0)	Patients' speech units (lag 1-3)							
	Negative statement about quitting		Positive statement about quitting		Other smoke-related speech unit		Non-smoke-related speech unit	
	Probability	OR (95% CI)	Probability	OR (95% CI)	Probability	OR (95% CI)	Probability	OR (95% CI)
All 5 A's	0.31 (149/476)	1.88 (1.30-2.72)**	0.09 (41/476)	1.78 (1.07-2.97)*	0.53 (250/476)	3.01 (2.00-4.54)**	0.08 (36/476)	0.42 (0.29-0.59)**
Ask	0.11 (16/142)	1.06 (0.61-1.84)	0.01 (2/142)	0.66 (0.26-1.64)	0.83 (118/142)	11.30 (3.68-34.65)**	0.04 (6/142)	0.24 (1.13-1.45)**
Advise	0.27 (3/11)	0.86 (0.19-3.94)	0.10 (1/11)	-	0.36 (4/11)	1.17 (0.34-3.98)	0.27 (3/11)	0.68 (0.24-2.27)
Assess	0.55 (35/63)	3.61 (1.44-9.01)*	0.13 (8/63)	2.87 (0.89-9.27)	0.27 (17/63)	1.98 (0.58-6.57)	0.05 (3/63)	0.43 (0.13-1.39)
Assist	0.38 (93/247)	2.23 (1.43-3.48)**	0.12 (30/247)	2.76 (1.56-4.89)**	0.41 (102/247)	1.64 (1.00-2.68)*	0.09 (22/247)	0.70 (0.45-1.07)
Arrange	0.15 (2/13)	- ^c	0.00 (0/13)	-	0.69 (9/13)	1.08 (0.26-4.44)	0.15 (2/13)	0.78 (0.20-3.06)
Other SR	0.30 (89/293)	2.44 (1.62-3.66)**	0.12 (35/293)	3.46 (2.01-5.93)**	0.48 (140/293)	1.55 (1.02-2.37)*	0.11 (32/293)	0.81 (0.56-1.17)

^aTransitional probabilities represent the probabilities of speech chains that begin with the event indicated as 'professionals' 5-A speech unit' and end with the specific coded patients' speech unit within the following three speech lags (the ratio of the specific patients' speech unit and the total number of coded speech units of patients in brackets).

^bGeneralised estimating equations (GEE) corrected for the hierarchical structure of the data

^cAnalyses not possible due to data sparseness

*p<0.05, **p<0.001

Table 4. Transitional probabilities of patients' speech units following speech units of GPs and PNs separately related to the five A's for smoking cessation care^{a,b}

GPs' 5-A speech units (lag 0)	Patients' speech units (lag 1-3)					
	Negative statement about quitting		Positive statement about quitting		Other smoke-related speech unit	
	Probability	OR (95% CI)	Probability	OR (95% CI)	Probability	OR (95% CI)
All 5A's	0.23 (17/75)	1.71 (0.71-4.12)	0.12 (9/75)	0.79 (0.18-3.54)	0.56 (42/75)	7.01 (2.50-19.67)**
Ask	0.08 (3/38)	1.65 (0.58-4.75)	0.03 (1/38)	0.84 (0.13-5.32)	0.79 (30/38)	8.79 (1.97-39.34)*
Advise	0.50 (3/6)	2.32 (0.20-26.66)	0.17 (1/6)	-	0.33 (2/6)	-
Assess	0.63 (5/8)	- ^c	0.25 (2/8)	-	0.00 (0/8)	1.88 (0.08-42.27)
Assist	0.27 (6/22)	1.59 (0.33-7.06)	0.23 (5/22)	-	0.41 (9/22)	3.36 (0.61-18.45)
Arrange	0.00 (0/1)	-	0.00 (0/1)	-	10.00 (1/1)	-
Other SR	0.19 (12/59)	1.96 (0.87-4.44)	0.07 (4/59)	2.81 (0.84-9.37)	0.55 (34/59)	1.81 (0.88-3.73)
PNs' 5-A speech units (lag 0)	Probability	OR (95% CI)	Probability	OR (95% CI)	Probability	OR (95% CI)
All 5 A's	0.33 (132/401)	1.91 (1.28-2.85)*	0.08 (32/401)	2.02 (1.16-3.54)*	0.52 (208/401)	2.59 (1.57-4.26)**
Ask	0.13 (13/104)	1.01 (0.54-1.89)	0.01 (1/104)	0.65 (0.23-1.81)	0.85 (88/104)	17.06 (8.29-35.11)**
Advise	0.00 (0/5)	0.51 (0.06-4.00)	0.00 (0/5)	-	0.40 (2/5)	0.69 (0.18-2.60)
Assess	0.55 (30/55)	4.37 (1.69-11.30)*	0.11 (6/55)	2.24 (0.60-8.36)	0.31 (17/55)	2.24 (0.46-10.87)
Assist	0.39 (87/225)	2.20 (1.3803-5.1)**	0.11 (25/225)	3.17 (0.74-5.76)**	0.41 (93/225)	1.50 (0.85-2.66)
Arrange	0.17 (2/12)	-	0.00 (0/12)	-	0.67 (8/12)	0.99 (0.19-5.14)
Other SR	0.33 (77/234)	2.75 (1.75-4.32)**	0.13 (31/234)	3.93 (2.17-7.15)**	0.45 (106/234)	1.57 (0.89-2.76)

GPs = general practitioners, PNs = practice nurses
^aTransitional probabilities represent the probabilities of speech chains that begin with the event indicated as 'professionals' 5-A speech unit' and end with the specific coded patients' speech unit within the following three speech lags (the ratio of the specific patients' speech unit and the total number of coded speech units of patients in brackets)
^bGeneralised estimating equations (GEE) corrected for the hierarchical structure of the data
^cAnalyses not possible due to data sparseness
*^p<0.05, **^p<0.001




Figure 1. Transitional probabilities of GPs' and PNs' 5 A-related speech units (I), other smoke-related speech units (II), and non-smoke-related speech units (III) following patients' positive and negative statements about quitting smoking

DISCUSSION

Main findings

The present study aimed to provide insight into the professional-patient interaction during unsolicited dialogues about smoking. Firstly, we assessed the extent to which primary care professionals use the 5A's for smoking cessation care during unsolicited dialogues about smoking. We found that GPs mainly focused on asking their patients about smoking and PNs on assisting patients with a quit attempt. Overall, little attention was paid to advising smokers to quit, to assessing their motivation to quit, and to arranging follow-up. Secondly, we examined the extent to which smokers expressed positive and negative statements about quitting during these dialogues. Overall, we found that patients more frequently expressed negative statements compared to positive statements about quitting. These negative statements mainly consisted of quit-smoking barriers and were most likely expressed when PNs assessed the patients' willingness to quit or when PNs assisted patients with a quit attempt. Finally, we explored the degree to which primary care professionals (dis)continued the 5 A's following patients' positive or negative statements about quitting. Although we observed that GPs were less likely to continue using the 5 A's following patients' negative statements about quitting, analyses could not statistically confirm this finding.

Interpretation of the findings

In line with previous studies and assumptions underlying current guidelines, we found that GPs and PNs focus on different smoking cessation counseling activities.^{1,20;21;34;35} GPs tend to focus on identifying smokers and informing about risks, whereas stop-smoking support is more often provided by PNs. Although these differences might be explained by the different time-periods in which the consultations were recorded (GPs: 2007-2008, PNs: 2010-2011), it is more likely

1 that these differences can be explained by other factors, such as differences
2 in patient population, characteristics of the professionals (e.g. training, skills,
3 practice protocols), and consultation characteristics (e.g. time available).

4 Both GPs and PNs lacked focus on *arranging* a follow-up for quit-smoking sup-
5 port. This is in line with recent findings showing that GPs in the Netherlands
6 experience a lack of overview of smoking cessation programs in their neighbor-
7 hood.¹² In addition, smokers may lack motivation to quit, which seems a logi-
8 cal reason for not arranging follow-up care. However, even if smokers are not
9 motivated to quit, guidelines recommend primary care professionals to ask the
10 patient's permission to discuss their smoking behaviour in a next consultation.
11 Therefore, when GPs and PNs in our study would have followed these current
12 guidelines, the rate of arranging follow-up should have been much higher than
13 observed.

14 Although not statistically confirmed, we observed that GPs were less likely
15 to proceed with a 5A-related speech unit following a negative statement of pa-
16 tients about quitting. We did not observe this in PN-patient dialogues. A possible
17 explanation for this is that all PNs in the present study were trained in moti-
18 vational interviewing, and that GPs might lack such skills or have insufficient
19 time to apply them.^{36,37} This might also explain why patients were more likely to
20 respond both negatively *and* positively towards quitting during dialogues with
21 PNs: exploring and resolving patients' ambivalence towards behaviour change
22 is an essential part of motivational interviewing.³⁸ Another explanation might
23 be that GPs and PNs encounter different types of patients. For example, patients
24 who visit the GP might be more likely to perceive their complaints as not directly
25 related to their smoking behaviour, resulting in less motivation to quit or discuss
26 smoking. On the other hand, PNs provide care for patients with diabetes mel-
27 litus, asthma, or COPD, including routinely providing information, advice and
28 counseling on lifestyle. These patients might be more inclined to relate their
29 health complaints to their smoking behaviour, which results in a higher motiva-
30 tion to quit or discuss smoking.

31 **Study strengths and limitations**

32 Video-based observations provide an objective method to capture all modalities
33 of the interaction between professionals and patients.²⁶ In addition, sequence
34 analysis exceeds a simple description of frequencies of spoken communication
35 and provides further insight into practitioner-patient interactional processes. To
36 our knowledge, this is the first study using sequence analysis to provide insight
37 into the way smoking cessation care evokes positive and negative responses of
38

1 patients thereby providing further insight into practitioner-patient interactional
2 processes.

3 However, several limitations of our study have to be acknowledged. First, to
4 guarantee the anonymity of the patients, the camera was positioned so that
5 patients were only visible from behind or were not visible at all. Therefore, we
6 were unable to observe non-verbal behaviour, which may also play a role when
7 assessing patients' responses towards smoking cessation. Yet, a recent study
8 showed that communication ratings using only audio or video data are highly
9 correlated.³⁹ Second, due to the small samples it was not always possible to take
10 into account that the possible cluster effects within the data. Third, using video-
11 based observations may limit the external validity of the findings, unless the
12 sample is representative for the overall population.²⁶ Although we were unable
13 to compare our sample of PNs with the average Dutch population of PNs, the GPs
14 in our study were representative for the average Dutch population of GPs with
15 regard to gender and practice type.³⁶ Moreover, none of the GPs and PNs were
16 aware that the observations would focus on dialogues about smoking.

17

18 **Practice implications**

19 Our study findings support alternative approaches to smoking cessation care in
20 healthcare settings where a successful implementation of the 5 A's is lacking.
21 These alternative approaches include the 'Ask-Advise-Arrange' (A-A-R) or 'Ask-
22 Advise-Connect' (A-A-C) approaches.^{40;41} These approaches instruct healthcare
23 professionals to routinely *ask* patient about smoking, *advise* smokers to quit, and
24 to *refer* (A-A-R) or proactively *connect* (A-A-C) smokers to a quit line or face-to-
25 face quit-smoking support. As shown by Vidrine et al., significantly more smok-
26 ers enrolled in quit-smoking treatment following the A-A-C approach (11.4%)
27 compared to the A-A-R approach (0.6%) which is also likely to result in more
28 smokers who successfully quit.⁴¹

29 Since we found that smokers are least likely to express negative statements
30 about quitting when being *asked* about smoking, *advised* to quit and *arranged* with
31 follow-up support, we recommend GPs to focus on implementing these alterna-
32 tive approaches. This might reduce the amount of impeding implementation
33 barriers, such as the amount of time involved in discussing barriers to quitting.
34 These approaches are also compatible with the lifestyle counseling tasks and
35 skills of PNs. PNs could play an important role in motivating smokers to quit and
36 provide behavioural counseling.

37

38

39

REFERENCES

1. Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al. NHG-Standaard Stoppen met roken [Dutch College of General Practitioners Guideline for Smoking Cessation]. *Huisarts Wet* 2007; 50(7):306-314.
2. Fiore MC, Wetter DW, Bailey WC, Blennett G, Cohen SJ, Dorfman SF et al. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. *J Amer Med Assoc* 1996; 275(16):1270-1280.
3. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal contact smoking cessation program for Dutch general practitioners: a randomized controlled trial. *Prev Med* 2001; 32(2):182-190.
4. Puschel K, Thompson B, Coronado G, Huang Y, Gonzalez L, Rivera S. Effectiveness of a brief intervention based on the '5A' model for smoking cessation at the primary care level in Santiago, Chile. *Health Promot Int* 2008; 23(3):240-250.
5. Takahashi K, Saso H, Saka H, Saso H, Iwata M, Hashimoto I et al. A pilot study on inducement of smoking cessation by a simple 5A (asking, advice, assess, assist, and arrange) approach at outpatient clinics. *Asian Pac J Canc Prev* 2006; 7(1):131-135.
6. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mólken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. *Value Health* 2005; 8(3):178-190.
7. Coleman T, Murphy E, Cheater F. Factors influencing discussion of smoking between general practitioners and patients who smoke: a qualitative study. *Brit J Gen Pract* 2000; 50(452):207-210.
8. Coleman T, Cheater F, Murphy E. Qualitative study investigating the process of giving anti-smoking advice in general practice. *Patient Educ Couns* 2004; 52:159-163.
9. Stead M, Angus K, Holme I, Cohen D, Tait G. Factors influencing European GPs' engagement in smoking cessation: a multi-country literature review. *Brit J Gen Pract* 2009; 59(566):682-690.
10. Vogt F, Hall S, Marteau TM. General practitioners' and family physicians' negative beliefs and attitudes towards discussing smoking cessation with patients: a systematic review. *Addiction* 2005; 100(10):1423-1431.
11. Jansink R, Braspenning J, van der Weijden T, Elwyn G, Grol R. Primary care nurses struggle with lifestyle counseling in diabetes care: a qualitative analysis. *BMC Fam Pract* 2010; 11(41).
12. Geense WW, van de Glind IM, Visscher TL, van AT. Barriers, facilitators and attitudes influencing health promotion activities in general practice: an explorative pilot study. *BMC Fam Pract* 2013; 14(20).
13. Ulbricht S, Klein G, Haug S, Gross B, Rumpf HJ, John U et al. Smokers' expectations toward the engagement of their general practitioner in discussing lifestyle behaviours. *J Health Commun* 2011; 16(2):135-147.
14. Francis N, Rollnick S, McCambridge J, Butler C, Lane C, Hood K. When smokers are resistant to change: experimental analysis of the effect of patient resistance on practitioner behaviour. *Addiction* 2005; 100(8):1175-1182.
15. Young JM, Ward JE. Implementing guidelines for smoking cessation advice in Australian general practice: opinions, current practices, readiness to change and perceived barriers. *Fam Pract* 2001; 18(1):14-20.

- 1 16. de Korte D, Nagelhout GE, Willemsen MC. Stoppen-met-rokenadvisering door hui-
2 sartsen in Nederlands 2001-2009 [Smoking cessation advisement in Dutch general
3 practice 2001-2009] 2010. The Hague, the Netherlands, STIVORO - for a smoke-free
4 future. Available from: [http://stivoro.nl/wp-content/uploads/themapublicaties/
5 stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20
6 door%20huisartsen%20in%20Nederland%202001%202009.pdf](http://stivoro.nl/wp-content/uploads/themapublicaties/stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20door%20huisartsen%20in%20Nederland%202001%202009.pdf).
- 7 17. Pilnick A, Coleman T. "I'll give up smoking when you get me better": patients' resis-
8 tance to attempts to problematise smoking in general practice (GP) consultations.
9 Soc Sci Med 2003; 57(1):135-145.
- 10 18. Coleman T, Stevenson K, Wilson A. Using content analysis of video-recorded consul-
11 tations to identify smokers' "readiness" and "resistance" towards stopping smoking.
12 Pat Educ Couns 2000; 41(3):305-311.
- 13 19. LHV [The Dutch National Association of General Practitioners]. Praktijkonder-
14 steuner: Competentieprofiel en eindtermen [Practice nurse: Competence profile and
15 requirements] 2010.
- 16 20. Ellerbeck EF, Ahluwalia JS, Jolicoeur DG, Gladden J, Mosier MC. Direct observation of
17 smoking cessation activities in primary care practice. J Fam Pract 2001; 50(8):688-
18 693.
- 19 21. Humair JP, Ward J. Smoking-cessation strategies observed in videotaped general
20 practice consultations. Am J Prev Med 1998; 14(1):1-8.
- 21 22. Lorencatto F, West R, Christopherson C, Michie S. Assessing fidelity of delivery of
22 smoking cessation behavioural support in practice. Implement Sci 2013; 8(40).
- 23 23. Milder IE, Blokstra A, de Groot J, van Dulmen S, Bemelmans WJ. Lifestyle counseling
24 in hypertension-related visits: Analysis of video-taped general practice visits. BMC
25 Fam Pract 2008; 9(58).
- 26 24. Moran J, Bekker H, Latchford G. Everyday use of patient-centred, motivational tech-
27 niques in routine consultations between doctors and patients with diabetes. Patient
28 Educ Couns 2008; 73(2):224-231.
- 29 25. Noordman J, Verhaak P, van Dulmen S. Discussing patient's lifestyle choices in the
30 consulting room: analysis of GP-patient consultations between 1975 and 2008. BMC
31 Fam Pract 2010; 11(87).
- 32 26. Coleman T. Using video-recorded consultations for research in primary care: advan-
33 tages and limitations. Fam Pract 2000; 17(5):422-427.
- 34 27. Noordman J, Verhaak P, van Beljouw I, van Dulmen S. Consulting room computers
35 and their effect on general practitioner-patient communication. Fam Pract 2010;
36 27(6):644-651.
- 37 28. Noordman J, van der Lee I, Nielen M, Vlek H, van der Weijden T, van Dulmen S. Do
38 trained practice nurses apply motivational interviewing techniques in primary care
39 consultations? J Clin Med Res 2012; 4(6):393-401.
29. CCMO [Central Committee on Research involving Human Subjects.] The review
system in the Netherlands 2012. Available from: [http://www.ccmo-online.nl/main.
asp?pid=1&taal=](http://www.ccmo-online.nl/main.asp?pid=1&taal=).
30. Bensing JM, Verheul W, Jansen J, Langewitz WA. Looking for trouble: the added value
of sequence analysis in finding evidence for the role of physicians in patients' dis-
closure of cues and concerns. Med Care 2010; 48(7):583-588.

- 1 31. Bakeman R, Gottman JM. *Observing interaction: An introduction to sequential*
2 *analysis*. 2nd ed. Cambridge: Cambridge University Press; 1997.
- 3 32. McComas JJ, Moore T, Dahl N, Hartman E, Hoch J, Symons F. Calculating contingencies in natural environments: issues in the application of sequential analysis. *J App*
4 *Behav Anal* 2009; 42(2):413-423.
- 5 33. Quera V, Bakeman R. Quantification strategies in behavioural observation research. In: Brooks, editor. *Behavioural observation: Technology and application in develop-*
6 *mental disabilities*. Baltimore: 2000. 297-315.
- 7 34. Noordman J. *Lifestyle counseling by physicians and practice nurses in primary care. An analysis of daily practice*. Utrecht: Netherlands Institute for Health Services
8 Research; 2013. Available from: [http://www.nivel.nl/sites/default/files/bestanden/](http://www.nivel.nl/sites/default/files/bestanden/Proefschrift-Janneke-Noordman.pdf)
9 [Proefschrift-Janneke-Noordman.pdf](http://www.nivel.nl/sites/default/files/bestanden/Proefschrift-Janneke-Noordman.pdf).
- 10 35. Voogdt-Pruis HR, van Ree JW, Gorgels AP, Beusmans GH. Adherence to a guideline
11 on cardiovascular prevention: A comparison between general practitioners and
12 practice nurses. *Int J of Nurs Stud* 2011; 48(7):798-807.
- 13 36. Noordman J, Koopmans B, Korevaar JC, van der Weijden T, van Dulmen S. Exploring
14 lifestyle counseling in routine primary care consultations: the professionals' role.
15 *Fam Pract* 2012; 30(3):332-340.
- 16 37. Werner JJ, Lawson PJ, Panaite V, Step MM, Flocke SA. Comparing primary care physi-
17 cians' smoking cessation counseling techniques to motivational interviewing. *J*
18 *Addict Med* 2013; 7(2):139-142.
- 19 38. Miller WR, Rollnick S. *Motivational Interviewing: Preparing People to Change Addic-*
20 *tive Behaviour*. New York: Guildford; 1991.
- 21 39. Williams K, Herman R, Bontempo D. Comparing audio and video data for rating
22 communication. *Western J Nurs Res* 2013; 35(8):1060-1073.
- 23 40. Berndt NC, Bolman C, de Vries H., Segaar D, van Boven I, Lechner L. Smoking cessa-
24 tion treatment practices: recommendations for improved adoption on cardiology
25 wards. *J Cardiovasc Nurs* 2013; 28(1):35-47.
- 26 41. Vidrine JI, Shete S, Cao Y, Greisinger A, Harmonson P, Sharp B et al. Ask-advise-
27 connect: a new approach to smoking treatment delivery in health care settings. *J*
28 *Amer Med Assoc Intern Med* 2013; 173(6):458-464.
- 29 42. Deveugele M, Derese A, Brink-Muinen A, Bensing J, De MJ. Consultation length in
30 general practice: cross sectional study in six European countries. *Brit Med J* 2002;
31 325(7362):472.
- 32 43. Heiligers PJM, Noordman J, Korevaar J, Dorsman S, Hingstman L, van Dulmen AM
33 et al. *Praktijkondersteuners in de huisartspraktijk (POH's), klaar voor de toekomst?*
34 *[Practice nurses in general practice (PNs), ready for the future?]* 2012. Utrecht, the
35 Netherlands, NIVEL.
- 36
- 37
- 38
- 39

Appendix 1. Role of practice nurses (PNs) in general practice in the Netherlands

The standard general practice in the Netherlands comprises about 2,350 patients and an average consultation lasts about 10 minutes⁴²; this results in considerable time pressure and workload for general practitioners (GPs). Therefore, in 1999 practice nurses (PN) were introduced in Dutch general practice to reduce the workload of GPs and to improve the quality of care for chronically ill patients.⁴³ Nowadays, PNs are involved in multiple primary prevention activities (e.g. hypertension care) and secondary prevention activities (e.g. routine care for elderly patients and/or patients with diabetes mellitus, asthma, or COPD). PNs work under the supervision of GPs, manage their consultations independently, and base their clinical practice on guidelines developed by the Dutch College of General Practitioners (NHG) and on healthcare standards which specifically focus on the treatment of chronically ill patients. The collaboration between GPs and PNs provides a good basis for identifying smokers, for motivating them to quit, and to deliver effective quit-smoking support.

1 **Appendix 2. Coding scheme for speech units**

2	Theme	Category	Subcategory	Example	
3	Professionals				
4	5 A's	• Ask	Smoking status	"Do you smoke?"	
5			Number of cigarettes	"How many cigarettes do you smoke?"	
6			Smoking history	"At what age did you start smoking?"	
7		• Advise	To quit	"The best prevention for not only your airways but also your coronary problems, is to quit smoking"	
8			To smoke less	[<i>"The best thing to do is quit smoking"</i>]	
9				<i>"but at least cut down on your smoking"</i>	
10			• Assess	Motivation to quit	"Do you still not feel like quitting?"
11			• Assist	Discuss previous quit attempt	"You quit smoking for almost a year, did you think of cigarettes every day in that period?"
12					Discuss quit plan
13		Offer/discuss pharmacotherapy		"Nowadays, we have medication that decreases the craving for cigarettes"	
14		Discuss advantages of smoking		"Well, you get some kind of peace from it.. especially during hard times, then you desire your cigarettes.."	
15		Discuss risks of smoking		"..when you continue your smoking, it's far more likely that you will move from stage 2 to 3, and maybe to stage 4"	
16		Discuss advantages of quitting		"When you say 'I considered quitting', what would be the reasons for this? What would be the positive side of this?"	
17		Discuss barriers to quitting		"Maybe it is more like a habit, is that right?"	
18		Discuss support options		"We talked about it before, I also provide consultations for smoking cessation, so if you think you would like to quit smoking, then we could do that together..."	
19	• Arrange	Ask permission to discuss smoking next time		"Do you mind if we discuss your smoking again next time?"	
20		Plan (telephone) follow-up	"Yes, we'll discuss that next time, do you come back then?"		

34
35
36
37
38
39

Theme	Category	Subcategory	Example
Patients			
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Negative statement about smoking cessation	<ul style="list-style-type: none"> Barriers to quit Reasons for relapse Advantages smoking Disadvantages quitting 	<p>Habit</p> <p>"Meanwhile, it has become a habit after all those years"</p> <p>Lack of motivation/discipline</p> <p>"I quit smoking for a year, but I started again.. I think it depends on your overall lifestyle, maybe a little unhealthy.. I would like to improve that...but that will require some discipline of course..."</p> <p>Denial of consequences</p> <p>"Maybe when you're smoking a package each day, then I should think 'yes, maybe you should cut down a little on your smoking...'"</p> <p>Social environment</p> <p>"Someday I have to quit, but my wife is a smoker as well.."</p> <p>Stress</p> <p>"..but on the other hand, it helps to reduce my stress"</p> <p>(Fear of) weight gain</p> <p>"Yes, I would like to quit smoking, but I'm worried about my weight, to gain weight again..."</p> <p>Previous quit attempt failed</p> <p>" I already tried it 7 or 8 times..."</p> <p>Not the right time</p> <p>"When I quit I'm not very pleasant, and we bought a new house, the transfer will be on the 4th"</p> <p>Addiction</p> <p>"That's the addiction to nicotine of course, it's the same as with alcohol"</p> <p>Smoking is tasteful/enjoyable</p> <p>"It's stupid, but I really like it, especially in the weekends after breakfast..."</p> <p>Satisfied smoker</p> <p>"I'm okay with being a smoker"</p> <p>Lack of distraction/daytime activities</p> <p>"I sit at home for 3 weeks... and then you'll start smoking again"</p> <p>Lack of self-confidence</p> <p>"I want to quit, but I really don't know how"</p> <p>Related to pharmacotherapy (e.g. costs)</p> <p>"I once did a treatment, I had to continue smoking for 10 days and after the pill it would be all over... but it did not work..."</p> <p>No complaints of smoking</p> <p>["What would be reasons for quitting smoking?"] "Well, I feel fine actually"</p> <p>Long-time smoker</p> <p>["Do you think about quitting or not?"] "Well, what do you want? I'm 70.. I only have a few years left so..."</p> <p>Smoking cessation is not profitable</p> <p>"When I don't smoke I still have those complaints"</p> <p>Stigma</p> <p>"Nowadays, if you have a sore knee they will ask you if you're smoking... as if you sprain your ankle because of smoking.. well, that makes me furious"</p>

Theme	Category	Subcategory	Example
		Smoking is the only thing left	"I'll never give up smoking, it's the only thing I still have"
		Withdrawal symptoms	"In the morning I have to smoke a cigarette again, to feel fine again..."
		Psychological complaints	"I quit smoking, but now I go to a psychologist again for depression and I started smoking again.."
		Smoker identity	"I don't see myself refraining from smoking actually...'"
Positive statements about smoking cessation	• Motivators to quit	Health concerns	"The main reason I would say is 'it's not good for your health', that would be the reason to quit"
		Social environment	"I will read that [leaflet], then we can look at it together at home, maybe he'll also say 'when you quit, I will quit'"
		Health of children	"My daughter is pregnant, so nobody smokes anymore. I think I should quit, yes.."
		Fear for disease/illness	"But I'm actually not really afraid of getting lung cancer, but more of getting something here ...[larynx]"
		Quit-smoking advice of health professional	"Yes, you're absolutely right... but, yes well... then I shall do that"
		Smoke-free legislation	"Once I was in prison for 18 months... that was hard, 24 hours inside and not allowed to smoke...I then quitted smoking"
		Costs	"I've already thought about it for a while because, well cigarettes are expensive"
		Smoke smell/taste	"...and they [cigarettes] don't taste very special anymore"
		Sufficient distraction/ daytime activities	"When I'm busy, then it's easy. For example, tomorrow my grandchild will visit me, then it's going perfect"
		Sufficient motivation/ discipline	"I definitely want to quit smoking"
		Positive consequences of quitting	"I often have good results if I refrain from smoking for a while, I feel mentally better than"

32
33
34
35
36
37
38
39

Theme	Category	Subcategory	Example
Professionals and patients			
Other speech units	• Other, smoke-related	Question	“So, coffee and smoking are two risk factors?” [patient]
		Answer	“I smoke one packet a day” [patient]
		Provision information	“People who smoke... this has its effect on the vocal cords” [professional]
		Confirmation	[“You are a smoker, that’s not good” “No, that’s right” [patient]
		Other	[I don’t think you are a good example for your kids this way] “Well, I shall talk about it with my wife” [patient]
	• Other, non-smoke-related	Question	“Do you have a fever?” [professional]
		Answer	“This side is much more painful” [patient; during physical examination]
		Provision information	“With regard to your cholesterol, according to this table, you are still within the normal risk boundaries” [professional]
		Confirmation	[I can give you something to inhale] “Yes” [patient]
		Other	“Thank you, see you next time” [patient]

Appendix 3. Simplified example of transitional probabilities

		Lag 1-3			Total
		A	B	C	
Lag 0	A	0.00 (0/7)	0.43 (3/7)	0.57 (4/7)	1.00 (7/7)
	B	0.40 (2/5)	0.00 (0/5)	0.60 (3/5)	1.00 (5/5)
	C	0.63 (5/8)	0.25 (2/8)	0.12 (1/8)	1.00 (8/8)



6

An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: Population based study

Marjolein E.A. Verbiest¹, Niels H. Chavannes¹,
Mathilde R. Crone¹, Mark N. Nielen², Dewi Segaar³,
Joke Korevaar², & Willem J.J. Assendelft^{1,4} (2013)

¹Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands

²Netherlands Institute for Health Services Research, Utrecht, the Netherlands

³STIVORO, Dutch Expert Centre on Tobacco Control, the Hague, the Netherlands

⁴Department Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Addiction, 108(12), 2183-2192

1 ABSTRACT

2

3 Aims

4 To examine the impact of two national tobacco control interventions in the past
5 decade on (dispensed) prescriptions of stop-smoking medication.

6

7 Design

8 Ecological study with interrupted time-series analyses of quarterly data points
9 of three nationwide representative databases.

10

11 Setting

12 The Netherlands 2001-2012, with the introduction of the guideline for smoking
13 cessation care in general practice (GP) in 2007 and full insurance coverage for
14 smoking cessation treatment in 2011.

15

16 Participants

17 GPs, pharmacists and persons in the general population aged 15 years and older.

18

19 Measurements

20 Time-series plots were visually inspected and segmented regression analyses
21 were performed to estimate the change in level and slope of (dispensed) pre-
22 scriptions of stop-smoking medication and smoking prevalence in the years
23 preceding and after the tobacco control interventions.

24

25 Findings

26 No measurable effects of the GP guideline on (dispensed) prescriptions were
27 observed. Shortly after the start of health insurance coverage, an estimated
28 increase in primary care prescriptions of 6.3 per 1.000 smokers (95% CI 2.9-9.8;
29 $p=0.001$) and 17.3 dispensed items per 1.000 smokers (95% CI 12.5-22.0; $p<0.000$)
30 was accompanied by a sudden drop in smoking prevalence of 2.9% (95% CI
31 4.6-1.1; $p=0.002$) in the first quarter of 2011. Immediately after the coverage
32 abolition, smoking prevalence increased by 1.2% (95% CI 0.5-2.8; $p=0.156$) and
33 dispensed prescription rates decreased with 21.6 per 1.000 smokers (95% CI 26.0-
34 17.2; $p<0.000$).

35

36 Conclusions

37 Full health insurance coverage for smoking cessation treatment in the Nether-
38 lands was accompanied by a significant increase in the number of (dispensed)
39 prescriptions of stop-smoking medication and a decrease in smoking prevalence.

1 INTRODUCTION

2
3 In the past decade, cigarette consumption has declined in various high and
4 middle-income countries.¹ However, about 25% of the Dutch adult population
5 still smokes.² As a result, in the Netherlands, the attributive risk of smoking-
6 related mortality is estimated at 21% which is relatively high compared to 16%
7 in Europe and 12% worldwide.^{3,4} Consequently, 13% of the Dutch disease burden
8 and an annual 2 billion euros in healthcare costs are attributed to the use of
9 tobacco.^{5,6}

10 Therefore, in the last decade multiple national tobacco control interventions
11 were implemented.^{7,8} The Dutch government initiated several policies aimed at
12 reducing exposure to environmental tobacco smoke and discouraging tobacco
13 use. Bans on tobacco advertisement (November 2002) and the sale of tobacco
14 to minors (January 2003) were implemented, and legislation was introduced for
15 smoke-free workplaces (January 2004) and public places (April 2006 and July
16 2008). In addition, national guidelines for smoking cessation support in health
17 care were developed and implemented. Moreover, in the year 2011, full health
18 insurance coverage for evidence-based pharmacotherapy in combination with
19 behavioural counseling was implemented.

20 These tobacco control interventions are likely to reduce smoking initiation,
21 increase the number of quit attempts and/or use of effective treatments and
22 therefore reduce smoking prevalence.⁹⁻¹⁶ For example, in the Netherlands, smok-
23 ing prevalence decreased from 30.1% in 2001 to 25.9% in 2012.² However, the
24 impact of national tobacco control interventions on primary care prescriptions
25 of stop-smoking medication is not yet clear.

26 GPs are more likely to deliver successful smoking cessation treatment when
27 they use a systematic approach and when structural barriers (e.g. lack of fi-
28 nancial reimbursement) are alleviated.^{17,18} Therefore, we examined the impact
29 of two national tobacco control interventions on prescriptions of stop-smoking
30 medication in general practice that were likely to have directly prompted GPs
31 to support smokers to quit. These two interventions are the guideline for smok-
32 ing cessation care introduced in general practice and the full health insurance
33 coverage period of stop-smoking treatment.

34
35
36
37
38
39

1 METHODS

2 3 Design

4 To explore the hypotheses, we used an ecological study design in which the unit
5 of analysis was the population rather than the individual. The main advantage
6 of this type of study is the presence of available data which enabled a relatively
7 fast and inexpensive study. However, the results cannot be extrapolated to the
8 individual level and no confounder data were available. Moreover, inferences
9 regarding causality need to be made with caution, taking into account other
10 explanations for changes in outcomes. Nevertheless, this type of study is useful
11 to generate new hypotheses based on the results.

12 13 National tobacco control interventions

14 We assessed the impact of potentially high-impact national tobacco control
15 interventions on prescriptions of stop-smoking medication in general practice,
16 i.e. i) the introduction of the GP guideline for smoking cessation care, ii) full
17 health insurance coverage of evidence-based pharmaceuticals and behavioural
18 treatment for smoking cessation.

19 Implementation of the first Dutch guideline ‘Treatment of Tobacco Depen-
20 dence’ started in 2004, accompanied by campaigns in which physicians and
21 other healthcare providers were informed about the guideline and were pro-
22 vided with additional insight into the addictive character of smoking.¹⁹ This
23 implementation period resulted in the first version of a guideline for treatment
24 of tobacco use in general practice, developed by the Dutch College of General
25 Practitioners in June 2007.²⁰ This guideline recommends actively enquiring about
26 a patient’s motivation for stopping smoking. When a patient smokes more than
27 10 cigarettes/day and is motivated to quit, the first choice recommendation is to
28 prescribe nicotine replacement therapy (NRT) in combination with behavioural
29 treatment. If specifically requested by the patient, or in case of relapse after NRT,
30 the antidepressant smoking cessation agents bupropion and nortriptyline are
31 recommended. In December 2006 varenicline was introduced in the Netherlands
32 and (after an evaluation period) was incorporated into the GP guideline in March
33 2011.²¹

34 In January 2011, the Dutch government introduced full health insurance cov-
35 erage for evidence-based smoking cessation programs using pharmacotherapy
36 in combination with behavioural counseling. Due to governmental changes, a
37 shift of focus of the Ministry of Health on people’s autonomy regarding lifestyle
38 choices and overall cutting in budget led to the cancellation of full health insur-
39 ance coverage after only one year. As a result, only behavioural support and not

1 pharmacological support for smoking cessation was reimbursed during the year
2 2012.

3 We analysed the effects of both policies within the same regression model
4 which allowed us to quantify the effects of one policy taking into account the
5 effect of the other policy.

6 7 **Data extraction**

8 For a full overview of the number of primary care prescriptions of stop-smoking
9 pharmaceuticals in the past decade we used two nationwide representative
10 databases of i) prescribed medication in general practice and ii) prescriptions
11 dispensed in outpatient pharmacies. The term 'prescription' refers to an order
12 of the GP for the pharmacist to dispense and the patient to take the medication.
13 The act of dispensing is defined as providing a patient with their labelled medi-
14 cation. In the Netherlands all stop-smoking medications are prescription drugs,
15 with the exception of NRT which is also available over-the-counter.

16 At quarterly intervals, we extracted data on prescriptions and dispensed items
17 of stop-smoking medication in general practices and pharmacies. Data on nor-
18 triptyline were excluded because this pharmaceutical is also used for various
19 other indications. Finally, to explore the impact of the tobacco control interven-
20 tions on smoking prevalence a third database was used (see C. below).

21 The privacy regulation of the study was registered at the Dutch Data Protection
22 Authority. According to current Dutch legislation, neither informed consent nor
23 approval is required from a medical ethics committee for observational studies
24 using anonymized data records.²²

25

26 A. The number of quarterly prescribed stop-smoking medication in general prac-
27 tice was derived from the Netherlands Information Network of Primary Care
28 (LINH) in the period 2001-2011. Data were retrieved from electronic medical
29 patient records, kept in a representative sample of 84 general practices with
30 approximately 350,000 listed patients. The characteristics of the study popu-
31 lation (GPs and patients) are comparable with the general Dutch population
32 in terms of age and gender.²³ We selected prescriptions of NRT, varenicline
33 and bupropion in the period 2001-2011 and calculated prescription rates per
34 1,000 smokers. These rates were calculated by dividing the absolute number
35 of primary care prescriptions by the number of smokers, multiplied by 1,000.
36 The number of smokers was based on the total population²⁴ and smoking
37 prevalence.²⁵ In this database it was not possible to differentiate between
38 prescriptions of bupropion as an anti-depressant or for smoking cessation.

39

- 1 B. For prescriptions of stop-smoking medication dispensed in outpatient phar-
 2 macies, we used quarterly data of the Dutch Foundation for Pharmaceutical
 3 Statistics (SFK) in the period 2001-2012. The SFK gathers data from a repre-
 4 sentative panel of 95% of Dutch community pharmacies. Data were extrapo-
 5 lated to nationwide figures. We selected dispensations of NRT, varenicline
 6 and bupropion in the period 2001-2012 and calculated dispensed rates per
 7 1,000 smokers.
 8
- 9 C. We used quarterly data from the Dutch Continuous Survey of Smoking Habits
 10 (DCSSH) from 2001-2012 for smoking prevalence. The DCSSH assesses smok-
 11 ing behaviour of the Dutch adult population (15 years and older). The DCSSH
 12 has been part of the CASI omnibus (Computer-Assisted Self-Interviewing) of
 13 TNS NIPO from 2001-2008. From 2009 onwards, the DCSSH has been perform-
 14 ing an ad-hoc internet survey in which a representative sample of about 350
 15 subjects is selected from a database of 200,000 respondents every week. Up
 16 to 2008, the data of the DCSSH were weighted on the basis of respondents'
 17 gender, age and education level, the province in which they lived, and their
 18 family and community size. Since January 2009, the data are also weighed on
 19 the basis of respondents' social economic status. Smoking prevalence was
 20 assessed by asking participants 'Do you (ever) smoke?'

21 Statistical methods

22 We drew and visually inspected time-series plots to detect marked changes in
 23 the number of (dispensed) prescriptions, and smoking prevalence in the past
 24 decade. Interrupted time-series analyses (SPSS 20.0) were used to evaluate the
 25 impact of the national tobacco control interventions on (dispensed) prescrip-
 26 tions of stop-smoking medications and smoking prevalence.²⁶ The advantages of
 27 these analyses are the fact that they allowed us to assess whether the interven-
 28 tions changed the outcomes immediately as well as over a period of time, taken
 29 into account pre-existing trends in the data.²⁶⁻²⁸ Prior studies have shown that
 30 segmented regression analysis is a suitable method for analysing interrupted
 31 time-series data in order to assess the impact of extraneous events on smoking-
 32 related outcomes.^{26;29-32} We examined the following linear regression equation:

$$33 Y_t = B_0 + B_1 * time_t + B_2 * intervention1_t + B_3 * time\ after\ intervention1_t + B_4 * intervention2_t$$

$$34 + B_5 * intervention3_t + e_t$$

35 *Time* (in quarters) was included as a continuous predictor. *Intervention* indicated
 36 the introduction of the GP guideline, and the introduction and abolition of health
 37

1 insurance coverage of stop-smoking treatment; pre-intervention time points
2 were coded 0 and post-intervention time points were coded 1. *Time after inter-*
3 *vention* was coded 0 up to the last time point before the intervention, and was
4 sequentially coded from 1 thereafter.

5 In the model, Y_t represents the outcome variable at time t (the number of (dis-
6 pensed) prescriptions per 1,000 smokers or smoking prevalence). B_0 estimates
7 the baseline level/intercept of the outcome at time point zero; B_1 estimates
8 the quarterly change in outcome prior to the interventions; B_2 (introduction
9 GP-guideline), B_4 (introduction insurance coverage), and B_5 (abolition insurance
10 coverage) estimates the change in level immediately after the interventions;
11 and B_3 estimates the change in slope after the introduction of the GP-guideline
12 compared with the slope before the intervention. We assessed both full and par-
13 simonious models in which we incorporated all parameters regardless of their
14 significance and only significant covariates, respectively.

15 We did not assess the impact of the GP guideline introduction on the num-
16 ber of (dispensed) prescriptions of varenicline because this pharmaceutical
17 was introduced in the Netherlands around the same time as the GP guideline
18 (December 2006). Furthermore, we only assessed the immediate effect of the
19 introduction and abolition of the insurance coverage in (dispensed) prescriptions
20 and smoking prevalence, since we lacked sufficient time-points to estimate a
21 change in trend.

22 Since time is a predictor in segmented regression analyses, it is likely that
23 consecutive observations are correlated, which is called autocorrelation. Since
24 regression analysis assumes independency between observations and autocor-
25 relation can overestimate or underestimate significance, we examined autocor-
26 relation by visually inspecting residual plots. Autocorrelation was judged to be
27 present if there were statistically significant spikes in the correlogram. In addi-
28 tion, the Durbin-Watson statistic was used to test serial autocorrelation; based
29 on the number of observations and regressors in the model we determined an
30 upper and lower bound and tested the null hypothesis of zero autocorrelation
31 in the data.³³ We found first-order autocorrelation in the time-series of the total
32 prescription rate, prescription rate of NVM, and of the number of (dispensed)
33 prescription of bupropion and varenicline. These time-series were differenced
34 by subtracting the value of an earlier observation from the value of a later ob-
35 servation in order to control for autocorrelation.^{26;28} The regression models were
36 re-checked after time-series were differenced in order to confirm that autocor-
37 relation was accounted for.

38
39

1 RESULTS

2
3 Figure 1 shows the time-series plots of primary care prescriptions of stop-
4 smoking medication and dispensed items in pharmacies in the past decade.
5 It highlights the introduction of the smoking cessation guideline in general
6 practice and the period of the full health insurance coverage of smoking ces-
7 sation treatment. Both time-series were relatively low in the period 2001-2006,
8 but show a small increase after 2007. Next, both time series increased steeply in
9 2011, especially in the first and last quarter. Thereafter, dispensed prescriptions
10 in pharmacies show a decrease in 2012. Overall, the number of stop-smoking
11 medication prescribed in general practices is lower than dispensed in pharma-
12 cies. This can probably be explained by other clinical specialists also prescribing
13 these pharmaceuticals. Further explanations are that GPs sometimes prescribe
14 multiple doses of stop-smoking medications at the same time, and pharmacists
15 sometimes dispense the labelled medication at multiple moments to be able to
16 check for possible side-effects.³⁴

17 Figure 2 shows the number of primary care prescriptions and dispensed items
18 of NRT, varenicline, and bupropion. Visual inspection points out that between
19 2001-2008, the number of primary care prescriptions of NRT increased in the
20 first quarter of every year, which can be defined as seasonality in the time-series.
21 In this period, the prescription rates of NRT show little change, with a single
22 small increase in 2008. Both time-series of NRT show a steep increase in 2011,
23 especially in the first and last quarter.

24 After the introduction of varenicline in December 2006, visual inspection of
25 figure 2 shows that both prescriptions and dispensed items of this pharmaceu-
26 tical rapidly increased, particularly in the first and last quarter of 2011. Next,
27 dispensed items of varenicline show a steep decrease in 2012.

28 With regard to bupropion, we observed a discrepancy between primary care pre-
29 scriptions and dispensed items from 2007 (Figure 2). At that time, bupropion was
30 registered in the Netherlands as an anti-depressant in addition to stop-smoking
31 medication.³⁵ The observed discrepancy can be explained by the fact that the pri-
32 mary care prescriptions in this study represent the total number of prescriptions
33 for both depression and quit smoking and the dispensed items represent only stop-
34 smoking medication. Both prescriptions and dispensed items of bupropion show a
35 single slight increase in 2004. Subsequently, primary care prescriptions of bupropion
36 increase in 2011 and the number of dispensed items show a slight decrease in 2012.

37
38
39




Figure 1. Smoking prevalence and the number of primary care prescriptions and dispensed prescriptions of stop-smoking medication per 1,000 smokers in the period 2001-2012




Figure 2. The number of primary care prescriptions and dispensed prescriptions of nicotine replacement therapy, varenicline, and bupropion per 1,000 smokers in the period 2001-2012

1 GP guideline

2 When accounting for the effect of the introduction of the health insurance
3 coverage, there was no statistically significant immediate (B_2) and long-term (B_3)
4 effect of the introduction of the GP guideline on the number of primary care
5 prescriptions and dispensed items (Table 1).

6 Health insurance coverage

7
8 According to the segmented regression analysis, the total number of stop-
9 smoking medication prescribed in general practices and dispensed in pharma-
10 cies showed a significant increase in 2011, the year in which smoking cessation
11 treatment was reimbursed (Table 1). In the first quarter of 2011, prescriptions
12 and dispensed items increased by 6.3 per 1.000 smokers (95% CI: 2.0-9.8; $p =$
13 0.001) and 17.3 per 1.000 smokers (95% CI:12.5-22.0; $p = <0.000$), respectively
14 (Table 2). This change also occurred in the number of primary care prescriptions
15 and dispensed items of NRT and varenicline (Table 1). Subsequently, a significant
16 decrease in the number of dispensed items of stop-smoking medication was
17 established of 21.6 items per 1.000 smokers (95% CI: -25.9 - -17.2; $p <0.000$) in the
18 first quarter of 2012, immediately after the abolition of the coverage. This effect
19 also occurred in the number of dispensed items of varenicline and NRT.

20 Smoking prevalence

21
22 Visual inspection of figure 1 shows a steady overall decline in smoking prevalence
23 in the period 2001-2012, with a more prominent decrease in 2004, 2007 and 2011.
24 Thereafter, smoking prevalence shows a marked increase in 2012. Segmented
25 regression analyses confirmed a significant decrease in the first quarter of 2011,
26 immediately after the introduction of the health insurance coverage (Table 1).

27 DISCUSSION

28
29
30
31 In the past decade, the number of primary care prescriptions of stop-smoking
32 medication in general practices and dispensed items in pharmacies increased.
33 We found a significant change in (dispensed) prescriptions following full health
34 insurance coverage of stop-smoking support in the year 2011. Moreover, our data
35 suggest a positive impact of this tobacco control policy on smoking prevalence.
36 We did not find measurable effects of the introduction of a guideline for smoking
37 cessation care in general practice on prescription rates.

38
39

Table 1. Results of segmented regression analyses of the number of primary care prescriptions, dispensed prescriptions and smoking prevalence

	Pre GP guideline and insurance coverage period				Post introducing GP guideline for smoking cessation care				Post introduction of insurance coverage				Post abolition of insurance coverage			
	B ₁	95% CI	p		B ₂	95% CI	p	B ₃	(95% CI)	p	B ₄	95% CI	p	B ₅	95% CI	p
Prescriptions																
Total ^a	0.02	-0.09 – 1.14	0.676		0.84	-2.04 – 3.71	0.560	-0.10	-0.40 – 0.20	0.499	6.31	2.86 – 9.76	0.001	-	-	-
Bupropion	0.02	-0.03 – 0.07	0.374		0.12	-1.13 – 1.37	0.845	-0.05	-0.18 – 0.08	0.475	0.91	-0.59 – 2.41	0.227	-	-	-
NRT	-0.00	-0.03 – 0.02	0.832		0.11	-0.52 – 0.73	0.735	-0.00	-0.07 – 0.07	0.986	1.97	1.23 – 2.72	<0.000	-	-	-
Varenicline	0.01	-0.03 – 0.05	0.644		-	-	-	-	-	-	2.97	1.30 – 4.64	0.001	-	-	-
Dispensed items																
Total ^a	-0.01	-0.16 – 0.15	0.924		2.68	-1.23 – 6.59	0.173	0.39	-0.02 – 0.79	0.060	17.26	12.53 – 21.98	<0.000	-21.56	-25.93 – -17.19	<0.000
Bupropion	0.03	-0.03 – 0.08	0.292		-0.31	-1.64 – 1.03	0.645	-0.02	-1.28 – -1.92	0.688	0.32	-1.28 – 1.92	0.688	-0.79	-2.27 – 0.69	0.288
NRT	0.06	0.01 – 0.11	0.026		0.20	-1.15 – 1.55	0.768	0.01	-0.13 – 0.15	0.929	5.45	3.82 – 7.08	<0.000	-5.86	-7.37 – -4.35	<0.000
Varenicline	0.02	-0.07 – 0.12	0.618		-	-	-	-	-	-	4.72	0.65 – 8.79	0.024	-11.30	-16.05 – -6.55	<0.000
Smoking prevalence																
	-0.14	-0.20 – 0.09	<0.000		-0.15	-1.60 – 1.30	0.835	0.17	0.02 – 0.32	0.028	-2.86	-4.61 – -1.11	0.002	1.16	-0.46 – 2.79	0.156

Parameters in the full segmented regression model are reported (parsimonious model showed comparable effects). B₁: quarterly change in the number of (dispensed) prescriptions per 1.000 smoker and smoking prevalence (%) prior to the introduction of the GP guideline and the health insurance period for smoking cessation treatment; B₂: change in the quarterly level of (dispensed) prescriptions per 1.000 smokers and smoking prevalence (%) immediately after the introduction of the GP guideline; B₃: change in trend in quarterly number of (dispensed) prescriptions per 1.000 smoker and smoking prevalence (%) after the introduction of the GP guideline; B₄: change in the quarterly level of (dispensed) prescriptions per 1.000 smoker and smoking prevalence (%) immediately after the introduction of the health insurance coverage for smoking cessation treatment; B₅: change in quarterly level of (dispensed) prescriptions per 1.000 smoker and smoking prevalence (%) immediately after the abolition of the health insurance coverage for smoking cessation treatment

^aTotal number of (dispensed) prescriptions consist of bupropion, NRT, and varenicline

NRT: nicotine replacement therapy; CI: confidence interval

1 **Current results compared to previous research**

2 These results complement other Dutch reports indicating an upward trend in the
3 use of pharmacological aids for smoking cessation in recent years.³⁶ Nevertheless,
4 relatively few stop-smoking prescriptions are actively suggested by GPs and guide-
5 lines for cessation support are often implemented suboptimal in general prac-
6 tice.^{16,37,38} Moreover, these guidelines also comprise behavioural cessation support,
7 which we did not address in our study, which may explain why we did not find
8 effects of the introduction of the GP guideline introduction on prescription rates.

9 Regarding our findings related to the effect of full health insurance coverage on
10 prescription rates and smoking prevalence, latest research also shows a strong
11 association between this policy and a more than ten-fold increase in telephone
12 counseling for smoking cessation.³⁹ Moreover, a recent review of 11 randomized
13 controlled trials of four countries found a positive effect of full health insurance
14 coverage on the use of smoking cessation treatment.¹⁸

15 **Strengths and weaknesses**

16 A strength of our study is that three large nationwide representative databases
17 were used with regard to prescriptions in general practice, dispensed items in
18 pharmacies and smoking prevalence. With regard to the SFK database, in 2011
19 an unknown and possibly substantial part of Dutch health insurance companies
20 covered dispensed prescriptions of stop-smoking medications only of specific
21 (online) pharmacies; therefore, the precise number of dispensed items was un-
22 known in this year. This implies that these data might underestimate the actual
23 situation and that the impact of health insurance coverage might be even larger.
24 Another strength of the study is the fact that in the Dutch healthcare system,
25 almost all non-institutionalized Dutch citizens are registered with a general
26 practice, which resulted in data with strong external validity.

27 Regarding the analyses, we assessed the impact of tobacco control interven-
28 tions with quarterly data points, which enables us to detect subtle temporary
29 effects in the period prior to or immediately after the interventions. Additionally,
30 we included the most recent available data in order to analyse changes in trends
31 following the abolition of the health insurance coverage.

32 However, some limitations of the study have to be mentioned. First, it was not
33 possible to differentiate between bupropion prescriptions for treating depres-
34 sion and those used as a quit-smoking aid in general practice. Furthermore, we
35 did not include data regarding NRT distributed over-the-counter. Because the
36 estimated mean costs of NRT are 2.57 Euro per day⁴⁰, this may have been an
37 incentive for patients to get a prescription of the GP during the period smoking
38 cessation aids were reimbursed. For this reason, it is possible that the reported
39

1 large increase in the number of (dispensed) prescriptions of NRT in the period
2 2011-2012 is partially caused by the fact that over-the-counter distribution of
3 these aids are not included into the analyses in the pre-intervention period.

4 With regard to the segmented regression analyses, when assessing the impact
5 of an intervention on time series, the impact of extraneous events on the observed
6 changes in the series must be taken into account.²⁹ In the past decade, multiple
7 tobacco control policies have been implemented in the Netherlands which might
8 have had an (indirect) effect on the number of prescriptions; for example, tax
9 increases, and smoke-free legislation in the workplace (2004) and other public
10 areas (2008). However, in 2011 no other tobacco control measures were introduced
11 in the Netherlands. Although caution is required in assuming causal relations, it
12 seems likely that the increase in (dispensed) prescriptions and decrease in smok-
13 ing prevalence in 2011 can be attributed to the introduction of the health insur-
14 ance coverage. This assumption is supported by the fact that we visually detected
15 a marked increase in smoking prevalence and statistically confirmed a decrease
16 in dispensed items immediately after the abolition of the coverage.

17 **Conclusion and practical implications**

18 The results of this study suggest that health insurance coverage for smoking ces-
19 sation treatment prompt GPs to prescribe evidence-based pharmaceuticals for
20 smoking cessation and have positive effects on smoking prevalence. Therefore,
21 these results are a relevant addition to the existing evidence demonstrating the
22 importance of tobacco control policies in the effective tackling of the tobacco
23 epidemic.^{10-15;29;41;42}

24 We argue that policy makers and the tobacco-control community consider this
25 evidence in developing future tobacco control policy. Given the limitations of our
26 study, we recommend replication of population based studies to further evaluate
27 the effectiveness of tobacco control interventions.
28
29
30
31
32
33
34
35
36
37
38
39

1 REFERENCES

- 2 1. World Health Organization. Tobacco Fact Sheet. 2011. Available from: http://www.wpro.who.int/mediacentre/factsheets/fs_201203_tobacco/en/index.html.
- 3 2. STIVORO. Dutch key figures of smoking in 2011. An overview of recent Dutch data regarding smoking behaviour 2012. The Hague, the Netherlands, STIVORO.
- 4 3. World Health Organization. WHO global report: Mortality attributable to tobacco 2012. Geneva, Switzerland, World Health Organization. Available from: http://www.who.int/tobacco/publications/surveillance/rep_mortality_attributable/en/.
- 5 4. Nagelhout GE. Summary of the World Health Organization Global Report: Mortality Attributable to Tobacco. 2012. The Hague, the Netherlands, STIVORO. Available from: <http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/gezondheidsschade/Samenvatting%20WHO%20Report%20Mortality%20Attributable%20to%20Tobacco.pdf>.
- 6 5. Statistics Netherlands. Statistics Causes of Death. 2011. Available from: <http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=7233&HD=130716-1139&HDR=T&STB=G1,G2,G3>.
- 7 6. Nagelhout GE. Summary WHO Global Report: Mortality Attributable to Tobacco. 2012. The Hague, the Netherlands, STIVORO. Available at: <http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/gezondheidsschade/Samenvatting%20WHO%20Report%20Mortality%20Attributable%20to%20Tobacco.pdf>.
- 8 7. World Health Organization. WHO Report on the Global Tobacco Epidemic. MPOWER: six policies to reverse the tobacco epidemic. 2008. Geneva, Switzerland, World Health Organization. Available from: http://www.who.int/tobacco/mpower/facts_findings/en/index.html.
- 9 8. World Health Organization. Key facts and findings related to the MPOWER package. 2012. Geneva, Switzerland, WHO Tobacco Free Initiatives. Available from: http://www.who.int/tobacco/mpower/mpower_report_six_policies_2008.pdf.
- 10 9. Boyle RG, Solberg LI, Magnan S, Davidson G, Alesci NL. Does Insurance Coverage for Drug Therapy Affect Smoking Cessation? *Health Affairs* 2002; 21(6):162-168.
- 11 10. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. *Addiction* 2005; 100(7):1012-1020.
- 12 11. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. *Addiction* 2006; 101(11):1656-1661.
- 13 12. Nagelhout GE, Willemsen MC, de VH. The population impact of smoke-free workplace and hospitality industry legislation on smoking behaviour. Findings from a national population survey. *Addiction* 2011; 106(4):816-823.
- 14 13. Nagelhout GE, de VH, Fong GT, Candel MJ, Thrasher JF, van den Putte B et al. Pathways of Change Explaining the Effect of Smoke-Free Legislation on Smoking Cessation in the Netherlands. An Application of the International Tobacco Control Conceptual Model. *Nicotine & Tobacco Research* 2012;1-9.
- 15 14. Nagelhout GE, Levy DT, Blackman K, Currie L, Clancy L, Willemsen MC. The effect of tobacco control policies on smoking prevalence and smoking-attributable deaths. Findings from the Netherlands SimSmoke Tobacco Control Policy Simulation Model. *Addiction* 2012; 107(2):407-416.

- 1 15. Nagelhout GE, de VH, Boudreau C, Allwright S, McNeill A, van den Putte B et al. Com-
2 parative impact of smoke-free legislation on smoking cessation in three European
3 countries. *Eur J Public Health* 2012; 22(1):4-9.
- 4 16. Wilson A, Sinfield P, Rodgers S, Hammersley V, Coleman T. Drugs to support smok-
5 ing cessation in UK general practice: are evidence based guidelines being followed?
6 *Qual Safety Health C* 2006; 15(4):284-288.
- 7 17. Pieterse ME, Seydel ER, de Vries H, Mudde AN, Kok GJ. Effectiveness of a minimal
8 contact smoking cessation program for Dutch general practitioners: a randomized
9 controlled trial. *Prev Med* 2001; 32(2):182-190.
- 10 18. Reda AA, Kotz D, Evers SM, van Schayck CP. Healthcare financing systems for in-
11 creasing the use of tobacco dependence treatment. *Cochrane Database Systematic*
12 *Reviews* 2012; (2).
- 13 19. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Behandeling van Tabaks-
14 verslaving [Guideline Treatment of Tobacco Dependence]. Alphen aan den Rijn, the
15 Netherlands: Van Zuiden Communications B.V.; 2009.
- 16 20. Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al.
17 Dutch College of General Practitioners Guideline for Smoking Cessation. *Huisarts*
18 *Wet* 2007; 50(7):306-314.
- 19 21. Wiersma TJ, Chavannes NH. Addendum NHG-Standaard Stoppen met roken: Varenic-
20 line voortaan ook bruikbaar bij stoppen met roken [Addendum Dutch College of
21 general practitioners guideline for smoking cessation: Varenicline hereafter suitable
22 for smoking cessation treatment]. *Huisarts & Wetenschap* 2011; 54(3):156-157.
- 23 22. CCMO [Central Committee on Research involving Human Subjects]. The Review
24 System in the Netherlands. 2012. Available at: [http://www.ccmo-online.nl/main.
25 asp?pid=1&taal=](http://www.ccmo-online.nl/main.asp?pid=1&taal=).
- 26 23. Stirbu-Wagner I, Dorsman S, Visscher S, Davids R, Gravenstein J, Abrahamse H et
27 al. Netherlands LINH databse. Feiten en cijfers over huisartsenzorg in Nederlands
28 [Information Network of Primary Care. Facts and Figures on Dutch General Practice]
29 2010. Utrecht/Nijmegen: NIVEL/IQ. Available from: <http://www.LINH.nl>.
- 30 24. Centraal Bureau voor de Statistiek [Statistics Netherlands]. Bevolking kern-
31 cijfers [Population core figures]. 2013. Available from: [http://statline.cbs.nl/
32 StatWeb/publication/?DM=SLNL&PA=37296ned&D1=0,3,10-13&D2=50-63&HDR=
33 =G1&STB=T&VW=T](http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=37296ned&D1=0,3,10-13&D2=50-63&HDR=G1&STB=T&VW=T).
- 34 25. STIVORO. Percentage rokers 15 jaar en ouder [Percentage smokers adults 15 years
35 and older, 2001-2012] 2013. Available from: [http://stivoro.nl/wp-content/uploads/
36 persberichten/Bijlage%20bij%20persbericht%20rookcijfer%202012.pdf](http://stivoro.nl/wp-content/uploads/persberichten/Bijlage%20bij%20persbericht%20rookcijfer%202012.pdf).
- 37 26. Szatkowski LC. Can primary care data be used to evaluate the effectiveness of to-
38 bacco control policies? Data quality, method development and assessment of the
39 impact of smokefree legislation using data from The Health Improvement Network.
Nottingham, England: The University of Nottingham; 2011.
27. Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: an
example to evaluate regionalized perinatal care. *Am J Public Health* 1981; 71(1):38-46.
28. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of
interrupted time series studies in medication use research. *J Clin Pharm Ther* 2002;
27(4):299-309.

- 1 29. Szatkowski L, Coleman T, McNeill A, Lewis S. The impact of the introduction of
2 smoke-free legislation on prescribing of stop-smoking medications in England. *Ad-*
3 *dition* 2011; 106(10):1827-1834.
- 4 30. Langley TE, Huang Y, McNeill A, Coleman T, Szatkowski L, Lewis S. Prescribing of
5 smoking cessation medication in England since the introduction of varenicline. *Ad-*
6 *dition* 2011; 106(7):1319-1324.
- 7 31. Federico B, Mackenbach JP, Eikemo TA, Kunst AE. Impact of the 2005 smoke-free
8 policy in Italy on prevalence, cessation and intensity of smoking in the overall popu-
9 lation and by educational group. *Addiction* 2012; 107(9):1677-1686.
- 10 32. Bajoga U, Lewis S, McNeill A, Szatkowski L. Does the introduction of comprehensive
11 smoke-free legislation lead to a decrease in population smoking prevalence? *Addic-*
12 *tion* 2011; 106(7):1346-1354.
- 13 33. Savin NE, White KJ. The Durbin-Watson test for serial correlation with extreme
14 sample sizes or many regressors. *Econometrica* 1977; 45(8):1989-1996.
- 15 34. Stichting Farmaceutische Kengetallen [Dutch Foundation for Pharmaceutical Statis-
16 tics]. Uitgifte van stoppen-met-rokenmedicatie door Nederlandse apotheken in de
17 periode 2011-2012 [Stop smoking medication dispensed in Dutch pharmacies in the
18 period 2011-2012] 2012. Available from:
- 19 35. GlaxoSmithKline Receives First European Approval for Wellbutrin XR®. Medical
20 News Today 2007. Available from: [http://www.gsk.com/media/press-releases/2007/](http://www.gsk.com/media/press-releases/2007/glaxosmithkline-receives-first-european-approval-for-wellbutrin-xr.html)
21 [glaxosmithkline-receives-first-european-approval-for-wellbutrin-xr.html](http://www.gsk.com/media/press-releases/2007/glaxosmithkline-receives-first-european-approval-for-wellbutrin-xr.html).
- 22 36. de Korte D, Nagelhout GE, Feenstra D, Zeegers T, van der Meer R, Willemsen MC.
23 Hulpmiddelen voor stoppen met roken 1992-2008 [Aids for smoking cessation 1992-
24 2008] 2008. The Hague, the Netherlands, STIVORO. Available from: [http://stivoro.nl/](http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/stoppenmetroken/Themapublicatie%20Hulpmiddelen%20voor%20Stoppen%20met%20Roken%201992%202008.pdf)
25 [wp-content/uploads/2012/docs/rapporten/stoppenmetroken/Themapublicatie%20](http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/stoppenmetroken/Themapublicatie%20Hulpmiddelen%20voor%20Stoppen%20met%20Roken%201992%202008.pdf)
26 [Hulpmiddelen%20voor%20Stoppen%20met%20Roken%201992%202008.pdf](http://stivoro.nl/wp-content/uploads/2012/docs/rapporten/stoppenmetroken/Themapublicatie%20Hulpmiddelen%20voor%20Stoppen%20met%20Roken%201992%202008.pdf).
- 27 37. de Korte D, van Schayck OCP, van Spiegel P, Kaptein AA, Sachs A, Rutten-van Mólken
28 M et al. Supporting smoking cessation in healthcare: obstacles in scientific under-
29 standing and tobacco addiction management. *Health* 2010; 2(11):1272-1279.
- 30 38. de Korte D, Nagelhout GE, Willemsen MC. Stoppen-met-rokenadvisering foor Ned-
31 erlandse huisartsen 2001-2009 [Smoking cessation advisement in Dutch general
32 practice: 2001-2009] 2010. The Hague, the Netherlands, STIVORO - for a smoke-free
33 future. Available from: [http://stivoro.nl/wp-content/uploads /themapublicaties/](http://stivoro.nl/wp-content/uploads/themapublicaties/stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20door%20huisartsen%20in%20Nederland%202001%202009.pdf)
34 [stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20](http://stivoro.nl/wp-content/uploads/themapublicaties/stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20door%20huisartsen%20in%20Nederland%202001%202009.pdf)
35 [door%20huisartsen%20in%20Nederland%202001%202009.pdf](http://stivoro.nl/wp-content/uploads/themapublicaties/stoppenmetrokenadviezen/Themapublicatie%20Stoppenmetrokenadvisering%20door%20huisartsen%20in%20Nederland%202001%202009.pdf).
- 36 39. Willemsen MC, Segaar D, van Schayck CP. Population impact of reimbursement for smok-
37 ing cessation: A natural experiment in the Netherlands. *Addiction* 2013; 108: 602-604.
- 38 40. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline
39 compared with bupropion, NRT, and nortriptyline for smoking cessation in the
Netherlands. *Curr Med Res Opin* 2008; 24(1):51-61.
41. Bertram MY, Lim SS, Wallace AL, Vos T. Costs and benefits of smoking cessation
aids: making a case for public reimbursement of nicotine replacement therapy in
Australia. *Tobac Control* 2007; 16(4):255-260.
42. Kaper J, Wagena EJ, van Schayck CP, Severens JL. Encouraging smokers to quit: the
cost effectiveness of reimbursing the costs of smoking cessation treatment. *Pharma-*
coeconomics 2006; 24(5):453-464.

7

General discussion

1 This general discussion provides further explanations for the observed findings
 2 of the presented studies, discusses the practical implications of the study results,
 3 and provides recommendations for future research. Furthermore, the empirical
 4 studies in this dissertation will be put into the context of the socio-ecological
 5 model that was introduced in the first chapter.

6

7

8 **IMPROVING GPs' IMPLEMENTATION OF SMOKING CESSATION CARE**


9

10 Successful implementation of innovations within healthcare, including a guide-
 11 line for smoking cessation care in general practice, is a complex and often long-
 12 lasting process.¹ The factors that influence this implementation process operate
 13 on several levels, including the general practitioner (GP), patient, organization,
 14 community, and public policy level. These levels are summarized in a five-level
 15 socio-ecological model depicted in the introductory chapter of this dissertation.
 16 This model constitutes the conceptual framework that guided this dissertation;
 17 all empirical studies addressed factors related to one or more of these levels.

18

19 **GP level**

20 *Chapter three* of this dissertation
 21 presented the effectiveness of a
 22 pragmatic, practice-tailored train-
 23 ing programme for GPs that aimed
 24 to influence the determining GP-
 25 related factors of implementation.
 26 The trained GPs increased the
 27 number of times they asked their
 28 patients about smoking and ad-



29 advised smokers to quit compared to the untrained GPs. In addition, they reported
 30 a higher perceived self-efficacy and intention towards routinely implementing
 31 smoking cessation care. However, in additional analyses we could not confirm
 32 that an increased self-efficacy or an increased intention to implement smok-
 33 ing cessation care was related to improved delivery of such care. There may
 34 be several explanations for this lack of a relation between GPs' self-efficacy,
 35 intention and behaviour. The first possible explanations entail methodological
 36 considerations. The relatively small GP sample may have resulted in low sta-
 37 tistical power and an inadequate way of operationalizing the self-efficacy and
 38 intention constructs may have violated the construct validity within the study.
 39 Other possible explanations entail theoretical considerations. It can be argued


1 that cognitive determinants of behaviour may be too parsimonious to predict
 2 complex human volitional behaviour, such as GPs' advices to quit, prescriptions
 3 for quit-smoking medication, and referrals to follow-up quit smoking support.²
 4 As a result, GPs' provision of such guideline-recommended smoking cessation
 5 care may be influenced by other behavioural attributes than cognitive determi-
 6 nants alone, such as perceived self-efficacy and intention.

8 GP action planning

9 Because the gap between an individual's intention and actual behaviour can be
 10 closed by formulating action plans³⁻⁵, *chapter four* of this dissertation presented
 11 the effects of this strategy among GPs. Based on these results, no conclusions can
 12 yet be drawn on the effectiveness of action planning on GPs' advices to quit and
 13 follow-up arrangements. This might be due to the previously mentioned small
 14 GP and smoker sample sizes. In addition, coping planning might result in more
 15 positive effects on GPs' provision of quit-smoking advices and arrangements of
 16 follow-up support. This type of planning is known to anticipate behavioural bar-
 17 riers that impede action plans from working.⁶

19 Patient level

20 *Chapter five* reports a study in which
 21 a quantitative approach to video-
 22 recorded communication was
 23 used to examine the interaction
 24 between primary care profession-
 25 als and patients during unsolicited
 26 dialogues about smoking. Overall,
 27 this study showed that the prob-
 28 ability that smokers expressed a
 29 negative statement about quitting



30 was lowest when primary care professionals asked about smoking (11%), advised
 31 to quit (27%), or arranged a follow-up (15%), compared to assessing the smoker's
 32 motivation to quit (55%), or providing assistance with quitting (38%). GPs seemed
 33 less likely to continue their use of these 5 A's following smokers' negative state-
 34 ments about quitting (19%) compared to smokers' positive statements about
 35 quitting (47%), which might relate to GPs' fear of harming the doctor-patient
 36 relationship when discussing smoking unsolicited.⁷ Nevertheless, we could not
 37 confirm this last finding statistically. This could be explained by several method-
 38 ological issues. Within multilevel modelling it is desirable to include a sufficient
 39 sample size on each level to obtain sufficient power for the statistical test to

1 confirm effects when these are present.⁸ Our two-level model (GP and speech
2 unit level) included 17 GP consultations on the highest level. Literature suggests,
3 however, a minimum sample size of and a sample size of 100 as sufficient at the
4 highest level of such models.^{9;10} Including a small sample size might have led to
5 biased estimates of the effects.⁸ Nevertheless, some suggest that the appropriate
6 sample size depends on the area of research; a sample size on the highest level
7 of 30 is, for instance, appropriate in educational research, whereas a sample size
8 of 5 at the highest level is appropriate in family and longitudinal research.⁹ Until
9 now, multilevel techniques to examine physician-patient communication are
10 rarely used in general practice¹¹, which makes an estimation of the appropriate
11 GP sample size difficult.

12 13 **GP-patient communication**

14 Studies have shown that emphasizing a link between the patient's (possible fu-
15 ture) health status and his/her current smoking behaviour, as recommended by
16 the current GP-guideline¹², may evoke resistance in a patient.¹³ Achieving mutual
17 agreement on the importance of smoking cessation might reduce this resis-
18 tance.¹³ Following the basic principles of motivational interviewing, GPs may use
19 this resistance, or 'sustain talk', to evoke 'change-talk' in which the patient is en-
20 couraged to verbalize arguments to quit smoking. As shown by a meta-analysis
21 of 14 studies, such motivational interviewing techniques significantly increase
22 smoking abstinence rates when compared to a brief quit-smoking advice.¹⁴ In
23 addition, this approach might result in a more balanced relationship between the
24 GP and patient.¹⁵ As a result, patients will feel engaged in the decision-making
25 process, which is known to result in more positive patient outcomes.^{16;17}


26 Nevertheless, GPs and practice nurses (PNs) apply motivational interviewing
27 techniques only to a minor extent.¹⁸ In addition, it has been suggested that train-
28 ing during and after medical school may not be sufficient for adequately apply-
29 ing these techniques in practice.¹⁹ Although it is still unknown which training
30 components and frequencies are most profitable for healthcare professionals
31 to improve motivational interviewing techniques^{20;21}, previous studies have sug-
32 gested that the provision of systematic (video-)feedback might be effective.^{18;22}
33 Therefore, it is recommended to examine the effects of (long-term) (video-)
34 feedback on GPs' usage of motivational interviewing techniques in dealing with
35 negative statements of smokers about quitting and reaching mutual agreement
36 on the importance of a smoking cessation advice.

37
38
39

1 Organization and community level

2 Chapter two of this dissertation
3 recommended more focus on or-
4 ganizational factors within train-
5 ing programmes for health profes-
6 sionals in smoking cessation care.
7 It may facilitate implementation
8 of such care when the conditions
9 in which these professionals work
10 are addressed. This was recently


11 confirmed by a study by Geense et al., which reports on the organizational and
12 community barriers primary care professionals perceive as impeding for a
13 full implementation of lifestyle interventions.²³ The GP training programme
14 presented in *chapter three* of this dissertation attempted to target such organi-
15 zational factors, including referral opportunities to quit-smoking programmes
16 in the community, and possibilities to register the smoking status of patients in
17 their electronic medical file. Nevertheless, our trained GPs did not refer smok-
18 ers to follow-up care more often. Since we do not know whether the trained
19 GPs improved the organization of smoking cessation care in their practice, we
20 are unable to draw further conclusions regarding the effectiveness of including
21 organizational barriers of implementation in training programmes for GPs based
22 on these findings. Future process evaluations of such training programmes
23 might improve our knowledge about effective strategies tackling organizational
24 and community implementation barriers.



25

26 Public policy level

27 Chapter six reported the results of
28 a population-based study in which
29 we examined the effects of the in-
30 troduction of full health insurance
31 coverage of quit-smoking support
32 in the Netherlands (2011) on GP
33 prescriptions of stop-smoking
34 medication and on smoking
35 prevalence. As shown in this



36 chapter, this public policy was accompanied by an increase in GP prescriptions
37 of stop-smoking medication. Unfortunately, this registration-based study was
38 unable to examine the influence of this policy on the provision of other smoking
39 cessation activities by GPs, such as advices to quit or referrals for quit-smoking

1 support. Another population-based study in the Netherlands, however, showed
2 that the number of smokers who called the national smoking-cessation quit line
3 increased more than tenfold; from 848 smokers that enrolled in telephone treat-
4 ment in 2010 to 9091 smokers in 2011, the year the coverage was introduced.²⁴
5 We also found a significant decrease in smoking prevalence in 2011, which is in
6 line with recent published findings of a longitudinal four-wave web-based survey
7 among a national representative sample of adult smokers.²⁵ This study found
8 that the self-reported number of quit attempts increased in this year as well as
9 the number of smokers who gave up their smoking successfully. However, this
10 study did not find a significant increase in the self-reported use of stop-smoking
11 medication as a result of the health insurance coverage.²⁵ As argued by the au-
12 thors, this is probably due to a time-lag in reporting.²⁵

13 14 15 **CONCLUSIONS**

16
17 It can be concluded that the implementation of smoking cessation care in gen-
18 eral practice can be improved by targeting factors on multiple levels. Neverthe-
19 less, challenges remain for the future. In particular, there is considerable room
20 for improvement regarding GPs' referrals for follow-up quit-smoking support. In
21 addition, GPs seem to discontinue their use of guideline-recommended smoking
22 cessation care when smokers express negative statements about quitting, which
23 may indicate the importance of improving (the use of) motivational interviewing
24 techniques. These conclusions lead to the following implications.

25 26 27 **PRACTICAL IMPLICATIONS**

28
29 This section discusses the practical implications of the study findings for current
30 Dutch GP training programmes, GP guidelines, and tobacco control policies that
31 have the potential to facilitate a successful implementation of smoking cessa-
32 tion care in future general practice.

33 34 **GP training programmes**

35 In the Netherlands, various GP training programmes for improving smoking ces-
36 sation care are currently available. To our knowledge, no evidence exists on the
37 effectiveness of these training programmes, which makes it difficult to compare
38 them with the GP training programme discussed in *chapter three* of this disserta-
39 tion. In addition, large heterogeneity exists with regard to the mode of delivery,

1 duration, and content of these training programmes. In contrast to our indi-
2 vidual, one-hour GP training programme, these programmes most often have a
3 longer duration, ranging from 1.5 hours to four days, and are delivered to a group
4 of professionals. Whereas our GP training programme focused on tailored guid-
5 ance regarding individual implementation barriers, including organizational and
6 community factors, only a minority of other training programmes thoroughly
7 incorporate such implementation aspects.

8 As elaborated upon in *chapter two*, organizational factors should be consid-
9 ered within GP training programmes in order to facilitate a full implementa-
10 tion of guideline-recommended smoking cessation care. Although the training
11 programme discussed in *chapter three* incorporated such organizational factors,
12 it is not clear whether the organization with regard to smoking cessation care
13 in general practice improved. Nevertheless, a majority of the GPs addressed
14 organizational barriers during our training, underpinning its importance. There-
15 fore, we recommend current Dutch training programmes to focus more on the
16 implementation aspects of smoking cessation care in general practice, including
17 organizational factors, such as a clear task distribution and a supportive work
18 environment. In addition, providing a follow-up meeting for GPs and monitoring
19 their progress after the training may ensure that smoking cessation care is suc-
20 cessfully implemented in the long term.

21 To ensure a routine approach to lifestyle counseling in future general practice,
22 it is recommendable to put more emphasis on this during medical school and GP
23 residency. Currently, GP residents are trained in basic motivational interviewing
24 techniques. We recommend to incorporate ongoing (video-)feedback and moni-
25 toring of these GP skills within consultations in which smoking is unsolicited
26 discussed (this approach may also be applied to other aspects of lifestyle coun-
27 seling). Including this feedback in their portfolios can encourage GP residents to
28 reflect on their progress concerning these skills and develop personal learning
29 goals.²⁶

30 In addition, forming action plans on who, when, where, and how to implement
31 such techniques and other smoking cessation activities, such as advising to quit
32 and referring for follow-up, might link situational cues in consultations and
33 other aspects of daily practice to these activities. This strategy may especially
34 alleviate implementation barriers operating on an organizational level since it
35 specifies a clearer task allocation within the practice. Coping planning might
36 further stimulate GPs to anticipate obstacles to implementation that might
37 impede action plans from working. Taking into consideration the importance
38 of achieving mutual agreement with the patient regarding the importance of
39 smoking cessation, combined with increasing time restrictions within consulta-

1 tions, (future) GPs should be prepared thoroughly in order to provide adequate
2 smoking cessation care.

3

4 **GP guideline**

5 As discussed in the *chapter one* of this dissertation, current guidelines for smok-
6 ing cessation care in general practice are based on the 5A-Model, which entails
7 *Asking* about smoking, *Advising* to quit, *Assessing* motivation to quit, *Assisting*
8 *with quitting*, and *Arranging* follow-up.^{12;27-29} Although these guidelines seem to
9 focus on a full implementation of the 5A-Model by the GP, some recommenda-
10 tions are provided with regard to specifically delegating quit-smoking assistance
11 to trained PNs. In line with these recommendations, *chapter five* showed a clear
12 division of tasks between GPs and PNs with regard to the provision of smoking
13 cessation care; when using the 5 A's, GPs focussed on *Asking* about smoking and
14 *Advising* to quit, while PNs focussed on *Assisting* with quitting. Nevertheless,
15 both GPs and PNs lacked sufficient focus on *Advising* smokers to quit, *Assessing*
16 their motivation to quit, and *Arranging* referrals or follow-up appointments.

17 Recently, the (dis)advantages of the 5A-Model were summarized.³⁰ On the
18 one hand, this model is a rather straightforward approach for busy healthcare
19 settings. Additionally, the 5A-Model matches existing practices and patients' ex-
20 pectations well. On the other hand, the 5A-Model is tied to only one professional,
21 in particular to physicians. Yet, smoking cessation interventions have shown the
22 added value of involvement of multiple members of a practice team.³¹ Moreover,
23 various factors impede GPs' implementation of the full 5A-Model, some of which
24 can be considered as insurmountable, such as a lack of sufficient consultation
25 time. Therefore, it may be argued that alternative approaches to the treatment
26 of tobacco addiction should be developed which do not solely rely on the GP, but
27 rather involve multiple members of the practice team.

28

29 **Alternatives to the 5A-Model**

30 A smoking cessation initiative on cardiology wards recommends a simplified
31 *Ask-Advise-Refer* (A-A-R) approach.³² When applying this approach in general
32 practice, busy GPs solely address the patients' smoking behaviour and refer
33 them to effective smoking cessation treatments provided by PNs. Yet, as shown
34 in a previous study¹⁹ and confirmed in *chapter five* of this dissertation, GPs do not
35 frequently refer patients for quit-smoking support. Moreover, the vast majority
36 of smokers who are passively referred to quit lines fail to call for quit-smoking
37 assistance.^{33;34}

38 Therefore, Vidrine et al. developed an approach to smoking cessation care in
39 general practice known as the *Ask-Advise-Connect* (A-A-C) approach.³⁵ Contrary

1 to the A-A-R approach in which patients are passively *referred* to follow-up sup-
2 port, the A-A-C approach proactively *connects* patients' with follow-up support.
3 Connections were made by clicking on an automated link in the patient's elec-
4 tronic medical file that sent the smoker's name and phone number to a quit line.
5 Within 48 hours, the patient was then proactively called and quit-smoking sup-
6 port was scheduled. A group-randomized controlled study showed a significant
7 larger proportion of identified smokers that enrolled in quit-smoking treatment
8 within the A-A-C approach compared to the A-A-R approach (A-A-C: 100% versus
9 A-A-R: 68.7%).³⁵ Although evidence of the A-A-C on smoking abstinence rates is
10 still lacking, previous studies have suggested that such proactive approaches
11 to smoking cessation are just as or even more effective than reactive strate-
12 gies, such as the A-A-R approach.³⁶ In addition, it might be argued that GPs are
13 more inclined to proactively *connect* smokers with follow-up support, because
14 they perceive this approach as more effective when compared to a passive A-A-R
15 approach.

16 **Tobacco control policy**

17 Based on previous studies, we hypothesized that the implementation of smoking
18 cessation treatment in general practice could be facilitated by full health insur-
19 ance coverage of quit-smoking programmes.^{23;37} Following the findings presented
20 in *chapter six*, it is highly recommended to continue the current full health in-
21 surance coverage for quit-smoking programmes. This public policy is likely to
22 further stimulate GPs to provide smoking cessation care (e.g. prescriptions and
23 referrals for behavioural counseling), thereby decreasing smoking prevalence.
24

25 **IMPLICATIONS FOR FUTURE RESEARCH**

26
27 The empirical studies within this dissertation generate a number of hypotheses
28 for future research. In this section, we will address these theoretical consider-
29 ations and measurement instruments, methodological and statistical consider-
30 ations, and further research ideas for facilitating the implementation of smoking
31 cessation care in general practice.
32
33

34 **Theoretical considerations and measurement instruments**

35 In *chapter three* we used a screening questionnaire to examine the implemen-
36 tation barriers GPs experience. This questionnaire was based on the Theory of
37 Planned Behaviour³⁸ and examined GPs' attitudes, social norms, self-efficacy,
38 and intention to routinely implement smoking cessation care. There may be,
39

1 however, other ways to explore underlying theoretical concepts of professional
2 behaviour. Huijg et al. recently developed a theory-based screening questionnaire
3 to examine factors that influence implementation processes within healthcare,
4 in particular healthcare professionals' clinical behaviours.^{39,40} This question-
5 naire is based on the Theoretical Domain Framework, which was developed by
6 a consensus group of behavioural and implementation research experts and
7 integrates multiple behaviour change theories.⁴¹ This framework has been used
8 to identify factors that influence the implementation of smoking cessation care
9 in dental healthcare.⁴² This study showed that the constructs "memory, attention
10 and decision processes" and "professionals' role and identity" were significantly
11 associated with dentists' adherence to smoking cessation guidelines. Identifying
12 such determining constructs among GPs may further improve our understand-
13 ing of the implementation of guideline-recommended smoking cessation care
14 within general practice. As a result, this knowledge can inform future behaviour
15 change techniques that aim to improve GPs' provision of smoking cessation care.

16 **Methodological and statistical considerations**

18 Experimental studies with larger GP samples are recommended to further exam-
19 ine the effects of incorporating organizational factors, as well as action planning
20 and coping planning in GP training programmes on their provision of smoking
21 cessation care. An example of such a study is a recently published protocol of
22 a cluster randomized controlled trial of Pesseau et al., who will examine the
23 effects of action planning on GPs' provision of guideline-recommended care for
24 patients with diabetes.⁴³ In addition, future quantitative studies on the commu-
25 nication between professionals and patients, using sequence analysis and mul-
26 tilevel modelling, are recommended to ensure sufficient power on both levels of
27 the model. Moreover, adding a third level in the model which incorporates char-
28 acteristics of the healthcare professional may result in more reliable outcomes.
29 Finally, a replication of our population-based study on the effects of full health
30 insurance coverage of stop-smoking programmes (*chapter six*) is recommended
31 in order to examine the long-term effects on GP prescription rates and smoking
32 prevalence. In addition, future studies are needed on the effects of this public
33 policy on GPs' provision of other guideline-recommended smoking cessation
34 care, such as quit-smoking advices, quit-smoking assistance, and referrals for
35 quit-smoking support. Such studies may contribute to our knowledge of the
36 facilitating role of public policies on the implementation of smoking cessation
37 care in general practice.

1 **Implementation**

2 We recommend an alternative approach to smoking cessation care in general
3 practice, i.e. an A-A-C approach. Future (qualitative) studies should explore the
4 overall willingness of patients and GPs towards this approach. It is anticipated
5 that several patient groups are reluctant to such a proactive approach.⁴⁴ Iden-
6 tification of these patients allows primary care professionals to tune in to their
7 reluctance by using motivational interviewing techniques. Additionally, we
8 recommend studies that assess the feasibility and effectiveness of this A-A-C
9 approach in Dutch general practice.

10

11

12 **WHAT THIS DISSERTATION ADDS**

13

14 The empirical studies in this dissertation provide insight in a variety of method-
15 ological approaches that can be used to describe and facilitate the implementa-
16 tion of smoking cessation care in general practice. This resulted in study findings
17 which show that training GPs has the potential to facilitate the implementa-
18 tion of smoking cessation care, in particular the degree to which smokers are
19 identified and advised to quit. In addition, full health insurance coverage of
20 stop-smoking programmes increased GP prescription behaviour. Yet challenges
21 remain to incorporate smoking cessation care as a routine procedure in general
22 practice, with a special focus on arranging follow-up support by GPs. This dis-
23 sertation provided several new ideas for future research in order to overcome
24 these challenges. Multifaceted strategies, based on a socio-ecological approach
25 to guideline implementation and including behavioural change theories, have
26 the potential to facilitate a successful implementation of smoking cessation
27 care in general practice. In the end, the delivery of lifestyle counseling, with a
28 focus on smoking cessation care, should become an ingrained habit for GPs.

29

30

31

32

33

34

35

36

37

38

39

1 REFERENCES

- 2 1. Rogers EM. Diffusion of innovation. 4th ed. New York: Free Press; 1995.
- 3 2. Sniehotta FF, Pressau J, Araújo-Soares V. Time to retire the theory of planned behav-
- 4 3. Gollwitzer PM. Implementation Intentions: Strong Effects of Simple Plans. *Am Psy-*
- 5 4. Sniehotta FF, Scholz U, Schwarzer R. Bridging the intention-behaviour gap: Plan-
- 6 5. Sniehotta FF. Towards a theory of intentional behaviour change: Plans, planning, and
- 7 6. Sniehotta FF, Scholz U, Schwarzer R. Action plans and coping plans for physical exer-
- 8 7. Young JM, Ward JE. Implementing guidelines for smoking cessation advice in Austra-
- 9 8. Maas CJM, Hox J. Sufficient Sample Sizes for Multilevel Modeling. *Methodology* 2005;
- 10 9. Maas CJM, Hox JJ. Robustness issues in multilevel regression analysis. *Stat Neerl*
- 11 10. Maas CJM, Hox JJ. The influence of violations of assumptions on multilevel param-
- 12 11. Connor M, Fletcher I, Salmon P. The analysis of verbal interaction sequences in
- 13 12. Chavannes NH, Kaper J, Frijling BD, Van der Laan JR, Jansen PWM, Guerrouj S et al.
- 14 13. Pilnick A, Coleman T. "I'll give up smoking when you get me better": patients' resis-
- 15 14. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation.
- 16 15. Miller WR, Rose GS. Toward a Theory of Motivational Interviewing. *Am Psychol* 2009;
- 17 16. Stewart MA. Effective physician-patient communication and health outcomes: a
- 18 17. Roter D. The enduring and evolving nature of the patient-physician relationship. *Pat*
- 19 18. Noordman J, Koopmans B, Korevaar JC, van der Weijden T, van Dulmen S. Exploring
- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39

- 1 19. Noordman J, Verhaak P, van Dulmen S. Discussing patient's lifestyle choices in the
2 consulting room: analysis of GP-patient consultations between 1975 and 2008. *BMC*
3 *Fam Pract* 2010; 11(87).
- 4 20. Madson MB, Loignon AC, Lane C. Training in motivational interviewing: a systematic
5 review. *J Subst Abuse Treat* 2009; 36(1):101-109.
- 6 21. Noordman J. Lifestyle counseling by physicians and practice nurses in primary care.
7 An analysis of daily practice. Utrecht: Netherlands Institute for Health Services
8 Research (NIVEL) 2013. Available from: <http://www.nivel.nl/sites/default/files/bes->
9 [tanden/Proefschrift-Janneke-Noordman.pdf](http://www.nivel.nl/sites/default/files/bes-).
- 10 22. Veloski J, Boex JR, Grasberger MJ, Evans A, Wolfson DB. Systematic review of the
11 literature on assessment, feedback and physicians' clinical performance. *Med Teach*
12 2006; 28(2):117-128.
- 13 23. Geense WW, van de Glind IM, Visscher TL, van Achterberg T. Barriers, facilitators and
14 attitudes influencing health promotion activities in general practice: an explorative
15 pilot study. *BMC FamPract* 2013; 14(20).
- 16 24. Willemsen MC, Segaar D, van Schayck OC. Population impact of reimbursement
17 for smoking cessation: a natural experiment in The Netherlands. *Addiction* 2013;
18 108(3):602-604.
- 19 25. Nagelhout GE, Willemsen MC, van den Putte B, de Vries H, Willems RA, Segaar D. Ef-
20 fectiveness of a national reimbursement policy and accompanying media attention
21 on use of cessation treatment and on smoking cessation: a real-world study in the
22 Netherlands. *Tobac Control* 2014; [ahead of print].
- 23 26. Dougherty P, Ross PT, Lypson ML. Monitoring resident progress through mentored
24 portfolios. *J Grad Med Educ* 2013; 5(4):701-702.
- 25 27. Fiore MC, Jaén CR, Baker TB, Bailey WC, Bennett G, Benowitz NL et al. A clinical
26 practice guideline for treating tobacco use and dependence: 2008 update. A U.S.
27 Public Health Service report. *American J Prev Med* 2008; 35(2):158-176.
- 28 28. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Behandeling van Tabaks-
29 verslaving [Guideline Treatment of Tobacco Dependence]. Alphen aan den Rijn, the
30 Netherlands: Van Zuiden Communications B.V.; 2009.
- 31 29. Wiersma TJ, Chavannes NH. Addendum bij de NHG-Standaard Stoppen met roken.
32 Addendum NHG-Standaard Stoppen met roken: Varenicline voortaan ook bruikbaar
33 bij stoppen met roken [Addendum Dutch College of general practitioners guideline
34 for smoking cessation: Varenicline hereafter suitable for smoking cessation treat-
35 ment]. *Huisarts & Wetenschap* 2011; 54(3):156-157.
- 36 30. Lawn S, Schoo A. Supporting self-management of chronic health conditions: com-
37 mon approaches. *Pat Educ Counseling* 2010; 80(2):205-211.
- 38 31. Dosh SA, Holtrop JS, Torres T, Arnold AK, Baumann J, White LL. Changing organiza-
39 tional constructs into functional tools: an assessment of the 5 A's in primary care
practices. *Ann Fam Med* 2005; 3(2):50-52.
- 32 32. Berndt NC, Bolman C, de Vries H, Segaar D, van Boven I, Lechner L. Smoking cessa-
33 tion treatment practices: recommendations for improved adoption on cardiology
34 wards. *J Cardiovasc Nursing* 2013; 28(1):35-47.
- 35 33. Bentz CJ, Bayley KB, Bonin KE, Fleming L, Hollis JF, McAfee T. The feasibility of con-
36 necting physician offices to a state-level tobacco quit line. *Am J Prev Med* 2006;
37 30(1):31-37.

- 1 34. Borland R, Segan CJ. The potential of quitlines to increase smoking cessation. *Drug*
2 *Alcohol Rev* 2006; 25(1):73-78.
- 3 35. Vidrine JI, Shete S, Cao Y, Greisinger A, Harmonson P, Sharp B et al. Ask-advise-
4 connect: a new approach to smoking treatment delivery in health care settings.
5 *JAMA Int Med* 2013; 173(6):458-464.
- 6 36. Tzelepis F, Paul CL, Walsh RA, McElduff P, Knight J. Proactive telephone counseling
7 for smoking cessation: meta-analyses by recruitment channel and methodological
8 quality. *J Nat Cancer I* 2011; 103(12):922-941.
- 9 37. Krist AH, Woolf SH, Johnson RE, Rothenich SF, Cunningham TD, Jones RM et al.
10 Patient costs as a barrier to intensive health behaviour counseling. *Am J Prev Med*
11 2010; 38(3):344-348.
- 12 38. Azjen I. The Theory of Planned Behaviour. *Organ Behav Hum Dec* 1991; 50:179-211.
- 13 39. Huijg JM, Gebhardt WA, Crone MR, Dusseldorp E, Pesseau J. Discriminant content
14 validity of a theoretical domains framework questionnaire for use in implementa-
15 tion research. *Implement Sci* 2014; 9:11.
- 16 40. Huijg JM, Gebhardt WA, Dusseldorp E, Verheijden MW, van der Zouwe N, Middelkoop
17 BJ et al. Measuring determinants of implementation behaviour: psychometric prop-
18 erties of a questionnaire based on the theoretical domains framework. *Implement*
19 *Sci* 2014; 9:33.
- 20 41. Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A. Making psychologi-
21 cal theory useful for implementing evidence based practice: a consensus approach.
22 *Qual Safety Health C* 2005; 14(1):26-33.
- 23 42. Amemori M, Korhonen T, Michie S, Murtomaa H, Kinnunen TH. Implementation
24 of tobacco use cessation counseling among oral health professionals in Finland. *J*
25 *Public Health Den* 2013; 73(3):230-236.
- 26 43. Pesseau J, Francis JJ, Jonhston M, Mackintosh J, Grimshaw JM, Kaner E et al. Improv-
27 ing Diabetes care through Examining, Advising, and prescribing (IDEA): Protocol for
28 a theory-based cluster randomised controlled trial of a multiple behaviour change
29 intervention aimed at primary healthcare professionals. *Implement Sci* 2014; [ahead
30 of print].
- 31 44. Ulbricht S, Klein G, Haug S, Gross B, Rumpf HJ, John U et al. Smokers' expectations to-
32 ward the engagement of their general practitioner in discussing lifestyle behaviours.
33 *J Health Commun* 2011; 16(2):135-147.
- 34
- 35
- 36
- 37
- 38
- 39



8

Summary

1 The WHO acclaimed the tobacco epidemic as one of the biggest public health
2 threats the world has ever faced. Therefore, tobacco control has been identified
3 as the most urgent and immediate priority intervention to reduce the prevalence
4 of non-communicable disease. **Chapter one** elaborates on the current state-of-
5 the-art evidence with regard to pharmacological and behavioural quit-smoking
6 support and stresses the importance of a routine approach to smoking cessa-
7 tion care in general practice. Nevertheless, a substantial gap exists between
8 the evidence-based knowledge on the treatment of tobacco dependence and
9 real-world practices of primary care professionals. Therefore, the aim of this
10 dissertation was to examine the implementation of smoking cessation care in
11 general practice. A five-level socio-ecological model is introduced as the con-
12 ceptual framework that guided this dissertation; all empirical studies in this
13 dissertation addressed one or more factors related to the general practitioner
14 (GP), patient, organization, community, or public policy level which determine
15 the implementation of smoking cessation care in general practice.

16

17 The aim of **chapter two** was to examine the overall effectiveness of training
18 health professionals in the delivery of smoking cessation interventions to their
19 patients. In addition, this chapter aimed to examine which training character-
20 istics are most likely to be effective, such as the content, delivery method and
21 intensity. In a systematic review, 17 randomized controlled trials were included
22 in which the intervention was training of health care professionals in providing
23 smoking cessation care, and in which outcomes for patient smoking behaviour at
24 least six months after the intervention were reported. These studies were found
25 during a systematic search procedure using the Cochrane Tobacco Addiction
26 Group's Specialised Register, electronic databases and the bibliographies of iden-
27 tified studies. Two independent reviewers extracted information relating to the
28 characteristics of each included study for interventions, participants, outcomes
29 and methods. Raw data of studies was requested from the study authors where
30 needed. Studies were combined in a meta-analysis where possible and reported
31 in narrative synthesis in text and table. A meta-analysis of 14 studies for point
32 prevalence of smoking produced a statistically and clinically significant effect
33 in favour of the intervention. A meta-analysis of eight studies that reported
34 continuous abstinence was also statistically significant in favour of the interven-
35 tion. In addition, healthcare professionals who had received training were more
36 likely to perform tasks of smoking cessation than untrained controls, including
37 asking patients to set a quit date, make follow-up appointments, counseling of
38 smokers, providing self-help material, and prescribing a quit date. No evidence
39 of an effect was observed for the provision of nicotine gum/replacement therapy.

1 With regard to the training characteristics, we found that health professionals
2 who were trained using only a single session and in a group setting were just as
3 likely if not more likely to have patients quit smoking as those being trained with
4 multiple delivery sessions and one-on-one training (i.e., face to face with the
5 trainer). Similarly, the duration of training for the health professional of between
6 40 minutes to two hours was just as effective, and in some cases more so, than
7 a duration of greater than two hours. To conclude, this study found evidence
8 for training health professionals to provide smoking cessation interventions on
9 the point prevalence of smoking, continuous abstinence and professional per-
10 formance. The one exception was the provision of nicotine gum or replacement
11 therapy, which did not differ between groups.

12
13 We developed a one-hour, practice-tailored training for GPs which aimed to alle-
14 viate GP-related and organizational barriers that arise when routinely asking pa-
15 tients' smoking status, advising to quit, and arranging follow-up. **Chapter three**
16 reports the effectiveness of this GP training programme which we examined in
17 a cluster-randomized controlled trial including with 49 GPs and 3,401 patients
18 (677 smokers). Two patient groups participated: 2,068 patients (433 smokers) at
19 baseline and 1,333 patients (244 smokers) post-intervention. At follow-up, 225
20 smokers of both groups participated. The primary outcome was GPs' smoking
21 cessation counseling (asking about smoking status, advising to quit, prescribing
22 pharmacotherapy, and referring for behavioural support). Secondary outcomes
23 were GPs' attitudes toward smoking cessation care, patients' intention to quit,
24 and long-term quit rates. Outcomes were measured with GP self-report and pa-
25 tient report. Multilevel regression analyses showed that patients of trained GPs
26 more often reported being asked about smoking behaviour compared to patients
27 of untrained GPs. According to GP self-report, the training also increased the
28 provision of quit-smoking advices and improved GPs' perceived self-efficacy
29 and intention to routinely implement smoking cessation care. No effects of the
30 training were found on GPs' arrangement of follow-up quit-smoking support,
31 smokers' intention to quit, and long-term quit rates.

32
33 One of the training components consisted of action planning among the GPs.
34 **Chapter four** reports the results of a study that examined if this strategy in-
35 creased the provision of smoking cessation care among the GPs, with a special
36 focus on the quality of the action plans. During the training programme, the
37 GPs formulated action plans related to i) enquiring about smoking, ii) advising
38 to quit smoking, and iii) arranging follow-up for smokers motivated to quit. The
39 GPs also formulated a coping plan for encountering smokers not motivated to

1 quit. The quality of these plans (i.e. plan specificity) was rated and, 6 weeks after
2 the training, GPs reported on the performance of these plans (i.e. plan enact-
3 ment). Multilevel regression analysis was used to examine the effects of plan
4 specificity and plan enactment on patient-reported smoking cessation activities
5 of the GPs before the training compared with these activities after the train-
6 ing. These analyses showed that GPs who formulated an action plan of high
7 specificity more often asked their patient about smoking, especially when these
8 professionals also enacted this plan. This effect was most prominent among GPs
9 who intended to provide smoking cessation care prior to the intervention. No
10 effects of (the quality of) action planning were found on GPs' advices to quit
11 and arrangements for follow-up quit-smoking support. Based on these study
12 findings, recommendations are made in additional training in devising coping
13 plans to further increase GPs' provision of advice to quit smoking and arranging
14 follow-up support to quit smoking.

15

16 In order to provide more insight in the interaction between primary care profes-
17 sionals and patients during consultations in which smoking is unsolicited dis-
18 cussed, **chapter five** presents the results of sequential analyses of communication
19 obtained from video-recorded consultations. In this study, 52 video-recordings of
20 consultations in primary care were collected, in which 17 GPs and 16 practice
21 nurses (PNs) initiated a conversation about smoking. Dialogues about smoking
22 were transcribed verbatim. Professionals' speech units were coded according to
23 the core aspects of the GP guideline. Patients' speech units were coded as either
24 positive or negative statements about smoking cessation. All other speech units
25 of professionals and patients were coded as other smoke- or non-smoke-related.
26 Descriptive and sequential analyses (two-level multilevel modeling) were used
27 to determine if particular sequences of speech units occurred to a greater or
28 lesser extent than could be expected by chance alone. These analyses showed
29 that, compared to PNs, GPs focused more on asking about smoking and advising
30 to quit. PNs focused more on assisting patients with quitting. In addition, the
31 analyses showed that smokers responded more often negatively than positively
32 towards quitting, especially when PNs assessed their willingness to quit or as-
33 sisted them with a quit attempt. Moreover, we found that GPs seemed more likely
34 to discontinue their use of guideline-recommended smoking cessation care fol-
35 lowing patients' negative statements about quitting. However, this finding could
36 not be statistically confirmed. Based on these findings, this chapter concludes
37 with the recommendation to limit GPs' tasks for smoking cessation care to iden-
38 tifying smokers, advising them to quit and arranging follow-up support. This

39

1 approach seems the least likely to evoke negative responses of patients and is
2 complimentary to lifestyle counseling tasks and skills of PNs.

3

4 Next to factors on a GP, patient, organization, and community level, we know
5 from previous literature that the implementation of smoking cessation care
6 may also be influenced by factors operating on a public policy level. Therefore,
7 **chapter six** discusses the results of a population-based study on the effects of
8 two national tobacco control interventions (the introduction of the GP guideline
9 for smoking cessation care in 2007 and the introduction of full health insurance
10 coverage for stop-smoking medication in 2011) on the number of (dispensed)
11 prescriptions of stop-smoking medication in general practice. This ecological
12 study analysed quarterly data points of three nation-wide representative data-
13 bases using interrupted time-series analyses. These analyses showed no effects
14 of the introduction of the GP guideline on (dispensed) prescriptions. Shortly after
15 the introduction of the health insurance coverage, an estimated significant in-
16 crease in primary care prescriptions of 6.3 per 1,000 smokers and 17.3 dispensed
17 items per 1,000 was accompanied by a sudden drop in smoking prevalence of
18 2.9% in the first quarter of 2011. Immediately after the coverage abolition, smok-
19 ing prevalence significantly increased by 1.2% and dispensed prescription rates
20 decreased with 21.6 per 1,000 smokers. This chapter concludes with recommen-
21 dations for policy makers and the tobacco control community to consider these
22 findings in developing future tobacco control policy.

23

24 The general discussion in **chapter seven** provides further explanations for the
25 observed findings of the presented studies, discusses the practical implications
26 of the study results, and provides recommendations for future research. Theory-
27 based screening questionnaires are recommended to further explore factors that
28 influence the implementation process of smoking cessation care, in particular
29 GPs' clinical behaviours. This knowledge can inform future behaviour change
30 techniques that aim to improve GPs' provision of smoking cessation care. In ad-
31 dition, experimental studies with larger GP samples are recommended to further
32 examine the effects of incorporating organizational factors, action planning
33 and coping planning in GP training programmes on their provision of smoking
34 cessation care and on patient smoking behaviour. Furthermore, a replication of
35 our population-based study on the effects of full health insurance coverage of
36 stop-smoking programmes is recommended in order to examine the long-term
37 effects on GP prescription rates and smoking prevalence. Finally, we discuss an
38 alternative approach to smoking cessation care in general practice, i.e. an ask-
39 advise-connect (A-A-C) approach. Future (qualitative) studies should explore the

1 overall willingness of patients and GPs towards this approach. Additionally, we
2 recommend studies that assess the feasibility and effectiveness of this A-A-C
3 approach in Dutch general practice.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Nederlandse samenvatting

1 De Wereldgezondheidsorganisatie heeft de tabaksepidemie uitgeroepen tot een
2 van de grootste bedreigingen voor de publieke gezondheid die de wereld ooit
3 heeft gekend. Om die reden wordt het ontmoedigen van tabaksgebruik gezien als
4 de meest urgente interventie om de prevalentie van niet-overdraagbare ziekten
5 terug te dringen. In **hoofdstuk één** van dit proefschrift wordt wetenschappelijk
6 onderzoek besproken dat de positieve effecten van farmacologische en gedrags-
7 matige stoppen-met-rokenbegeleiding heeft aangetoond. Onderzoek laat tevens
8 zien dat zorgprofessionals in de huisartspraktijk een belangrijke rol kunnen
9 spelen bij tabaksontmoediging door deze vormen van begeleiding routinematig
10 aan patiënten aan te bieden. De literatuur laat echter ook zien dat er een kloof
11 bestaat tussen enerzijds de wetenschappelijk aangetoonde positieve effecten van
12 stoppen-met-rokenbegeleiding en anderzijds de implementatie hiervan in de da-
13 gelijkse praktijkvoering van huisartsen; rokers worden niet structureel door hun
14 huisarts geadviseerd en begeleid bij het stoppen met roken. Om die reden is het
15 doel van dit proefschrift de implementatie van stoppen-met-rokenbegeleiding in
16 de huisartspraktijk te onderzoeken. De implementatie van onderzoeksbevindingen
17 in de praktijk wordt door tal van factoren beïnvloed. Deze factoren worden
18 in een sociaalecologisch model in vijf niveaus ingedeeld: het niveau van de
19 zorgprofessional, de patiënt, de organisatie, de community, en het beleid. Op elk
20 niveau zijn er factoren die de implementatie van stoppen-met-rokenbegeleiding
21 in de huisartspraktijk kunnen belemmeren of verbeteren. Dit sociaalecologisch
22 model vormt het raamwerk van dit proefschrift; alle empirische studies in het
23 proefschrift behandelen een of meerdere factoren gerelateerd aan een of meer-
24 dere niveaus van dit model.

25

26 Hoofdstuk twee, drie en vier van dit proefschrift richten zich op het niveau
27 van de huisarts en de huisartspraktijk. In **hoofdstuk twee** wordt nagegaan wat
28 het effect is van een training aan zorgprofessionals in het begeleiden van hun
29 patiënten bij het stoppen met roken. Ook wordt nagegaan welke eigenschappen
30 van dergelijke trainingen het meest effectief zijn, zoals de inhoud van de train-
31 ning, de wijze van trainen en de intensiteit van de training. In totaal werden 17
32 studies samengevoegd waarin het effect van een training aan zorgprofessionals
33 in het begeleiden van patiënten bij het stoppen met roken werd vergeleken met
34 een controlegroep waarin zorgprofessionals niet getraind werden. Alle studies
35 bekeken het effect van de training van zorgprofessionals op het rookgedrag van
36 patiënten minimaal zes maanden na de training. Alle studies zijn gevonden door
37 middel van een systematische zoekprocedure waarbij gebruik werd gemaakt van
38 een gespecialiseerd register van de *Cochrane Tobacco Addiction Group*, elektronische
39 databases en bibliografieën van de geïdentificeerde studies. Twee onderzoekers

1 extraheerden onafhankelijk van elkaar informatie over de studies met betrek-
2 king tot de eigenschappen van de participanten, uitkomstmaten en onderzoeks-
3 methoden. Waar mogelijk werden de bevindingen van de studies samengevoegd
4 in een meta-analyse. Deze analyses toonden een statistisch en klinisch signi-
5 ficant effect aan van de training van zorgprofessionals op het rookgedrag van
6 patiënten. Bovendien bleek dat getrainde zorgprofessionals vaker stoppen-met-
7 rokenactiviteiten ontplooiden dan ongetrainde professionals, zoals samen met
8 de patiënt een stopdatum bespreken en het maken van een vervolgspraak.
9 Geen effect werd gevonden op het voorschrijven van nicotinevervangende mid-
10 delen. Wat betreft de eigenschappen van de training vonden we dat patiënten
11 van zorgprofessionals die een training gevolgd hadden bestaande uit een enkele
12 sessie en in groepsverband even vaak gestopt waren met roken als patiënten van
13 professionals die een training gevolgd hadden van meerdere één-op-één sessies
14 (face-to-face met de trainer). Ook vonden we dat een training van tussen de 40
15 minuten en twee uur even effectief was, en in sommige studies zelfs effectiever,
16 als een training die langer dan twee uur duurde. Op basis van deze bevindingen
17 kan geconcludeerd worden dat het trainen van zorgprofessionals in het bege-
18 leiden van hun patiënten bij het stoppen met roken positieve effecten heeft op
19 de prevalentie van roken en op de prestaties van de zorgprofessionals. De enige
20 uitzondering hierop was het voorschrijven van nicotinevervangende middelen.
21 Dit verschilde niet tussen getrainde en ongetrainde gezondheidsprofessionals.

22

23 Vervolgens ontwikkelden we voor huisartsen een één-uur-durende, op de praktijk
24 afgestemde training in het begeleiden van patiënten bij het stoppen met roken.
25 Deze training had tot doel het verminderen van barrières die huisartsen ervaren
26 bij het structureel vragen naar de rookstatus van patiënten, het adviseren van
27 rokers om te stoppen, en het doorverwijzen van rokers naar stopondersteuning.
28 In **hoofdstuk drie** van dit proefschrift wordt de effectiviteit van deze training
29 besproken. In een cluster gerandomiseerde, gecontroleerde trial werden 49
30 huisartsen en 3.401 patiënten (677 rokers) geïncludeerd. Twee patiëntengroepen
31 namen deel: 2.068 patiënten (433 rokers) voor de interventie en 1.333 patiënten
32 (244 rokers) na de interventie. Aan de vervolgmeting (na 9 maanden) namen nog
33 225 rokers van beide groepen deel. De primaire uitkomstmaat vormde de mate
34 waarin de huisarts tijdens het consult aandacht besteedde aan het rookgedrag
35 van de patiënt (vragen naar de rookstatus, adviseren om te stoppen met roken,
36 het voorschrijven van farmacotherapie en doorverwijzen naar stopondersteu-
37 ning). Secundaire uitkomstmaten waren de attitude, gepercipieerde eigenef-
38 fectiviteit en intentie van de huisarts om patiënten routinematig stoppen-met-
39 rokenbegeleiding aan te bieden, de intentie van de patiënt om te stoppen met

1 roken en het rookgedrag van de patiënt op de lange termijn. Deze uitkomstmaten
2 werden gemeten door middel van zelfrapportage van de huisartsen en patiënten
3 en vervolgens geanalyseerd met behulp van multilevel regressie-analyses. Deze
4 analyses toonden aan dat patiënten van getrainde huisartsen vaker gevraagd
5 werden naar hun rookgedrag dan patiënten van ongetrainde huisartsen. Volgens
6 de zelfrapportage van huisartsen werden rokende patiënten van getrainde
7 huisartsen ook vaker geadviseerd om te stoppen dan patiënten van ongetrainde
8 huisartsen. Ook verbeterde de training de eigeneffectiviteit en intentie van de
9 huisartsen. We vonden geen effect van de training op het voorschrijven van
10 farmacotherapie, doorverwijzen naar stopondersteuning, intentie van de patiënt
11 om te stoppen met roken en het rookgedrag van de patiënt op de lange termijn.

12

13 Een van de onderdelen van de hierboven beschreven training aan huisartsen
14 was het maken van actieplannen. Voor deze actieplannen beschreven de huis-
15 artsen de wijze waarop zij van plan waren enkele zorgtaken op het gebied van
16 stoppen-met-rokenbegeleiding in de toekomst te gaan implementeren. Deze
17 actieplannen waren gerelateerd aan de volgende taken: 1) het vragen naar de
18 rookstatus, 2) het adviseren om te stoppen met roken, en 3) het regelen van
19 stopondersteuning voor rokers die gemotiveerd zijn om te stoppen. De huis-
20 artsen formuleerden ook een copingplan waarin zij weergaven wat ze zouden
21 doen als zij rokers spraken die ongemotiveerd bleken te zijn om te stoppen
22 met roken. De huisartsen beschreven wie deze verschillende taken zou gaan
23 uitvoeren, wanneer deze plannen zouden worden uitgevoerd en hoe deze taken
24 in het huisartsinformatiesysteem geregistreerd zouden gaan worden. Eerdere
25 studies lieten zien dat wanneer het gaat om gezondheidsgedrag (zoals stoppen
26 met roken, meer bewegen, deelname aan kankerscreening) het formuleren van
27 dergelijke plannen een positief effect had op het uitvoeren van het gewenste
28 (gezondheids)gedrag. In **hoofdstuk vier** van dit proefschrift wordt nagegaan of
29 deze gedragsveranderingsstrategie ook een positief effect had op het aanbieden
30 van stoppen-met-rokenbegeleiding door de huisartsen. Hierbij lag de nadruk op
31 de kwaliteit van de plannen die de huisartsen maakten. De kwaliteit van deze
32 plannen, met andere woorden de specificiteit van de plannen, werd bepaald
33 door de onderzoekers. Daarnaast rapporteerden de huisartsen zes weken na de
34 training in hoeverre zij de plannen hadden uitgevoerd zoals beschreven. Multi-
35 level regressie-analyses werden gebruikt om het effect van de specificiteit en de
36 uitvoering van de plannen op de daadwerkelijke stoppen-met-rokenactiviteiten
37 van de huisartsen voor en na de training te bepalen. Deze analyses toonden aan
38 dat patiënten vaker gevraagd werden naar hun rookgedrag indien huisartsen
39 hiertoe een hoog-specifiek plan maakten, vooral wanneer huisartsen daarnaast

1 tevens aangaven dit plan te hebben uitgevoerd. Dit effect was het sterkst onder
2 huisartsen die voorafgaand aan de training al een hoge intentie hadden om rou-
3 tinematig stoppen-met-rokenbegeleiding te bieden. We vonden geen significant
4 effect van de (kwaliteit van de) actieplannen op het aantal rokende patiënten dat
5 geadviseerd werd om te stoppen, of waarvoor stopondersteuning was geregeld
6 door de huisarts. Voor toekomstige trainingen wordt om die reden aanbevolen
7 om voor de implementatie van deze activiteiten op maat gesneden copingplan-
8 nen als onderdeel van een training toe te voegen. Deze plannen kunnen mogelijk
9 leiden tot meer positieve effecten op de stopadvisering en doorverwijzing van
10 rokers naar stopondersteuning door huisartsen.

11

12 **Hoofdstuk vijf** verschaft meer inzicht in de interactie tussen professionals in de
13 huisartsenpraktijk en hun patiënten tijdens consulten waarin het rookgedrag
14 van de patiënt besproken wordt. Oftewel, in hoeverre beïnvloeden factoren op
15 het niveau van de patiënt de implementatie van stoppen-met-rokenbegeleiding
16 in de huisartsenpraktijk? Hiertoe werden 52 video-opnames van consulten in de
17 huisartspraktijk geobserveerd (van 17 huisartsen en 16 praktijkondersteuners
18 (POH's)). In alle consulten initieerden de professionals het gesprek over het rook-
19 gedrag van de patiënt. De dialogen tussen professionals en patiënten werden
20 letterlijk uitgeschreven. Gesprekseenheden van professionals werden vervolgens
21 gecodeerd op basis van de kernaspecten van de NHG-Standaard Stoppen met
22 roken (5 A's; Ask, Advise, Assess, Assist en Arrange). Gesprekseenheden van de
23 patiënten werden gecodeerd als positieve of negatieve uitlatingen over stoppen
24 met roken. Alle andere gesprekseenheden van professionals en patiënten werden
25 gecodeerd als 'anders (niet-)rookgerelateerd'. Met behulp van beschrijvende en
26 sequentieanalyses werd nagegaan of bepaalde volgorden van gesprekseenheden
27 vaker of minder vaak voorkwamen dan verwacht zou kunnen worden op basis
28 van toeval. Deze analyses toonden aan dat huisartsen vaker naar de rookstatus
29 van hun patiënten vroegen en rokers adviseerden om te stoppen dan POH's. POH's
30 assisteerden daarentegen de rokers vaker bij het stoppen. Daarnaast toonden de
31 analyses aan dat rokende patiënten zich tijdens de consulten vaker negatief dan
32 positief uitlatingen over stoppen met roken, met name wanneer POH's vroegen naar
33 de motivatie om te stoppen of hen assisteerden bij het stoppen. Na een negatieve
34 uitlating over het stoppen met roken van de patiënt leken huisartsen minder
35 vaak het gebruik van de richtlijn voort te zetten dan na een positieve uitlating
36 van de patiënt. Deze bevinding kon echter niet statistisch bevestigd worden. Op
37 basis van de bevindingen wordt aanbevolen om de taken van de huisartsen te
38 beperken tot het vaststellen van de rookstatus van de patiënt, het adviseren van
39 de roker om te stoppen en het regelen van stopondersteuning. Deze aanpak lijkt

1 het minst te leiden tot negatieve uitlatingen van de patiënt over het stoppen met
2 roken en sluit goed aan bij de taken en vaardigheden van POH's ten aanzien van
3 leefstijlbegeleiding.

4

5 De voorgaande onderzoeken zijn met name gericht op kenmerken van de
6 patiënt, huisarts en huisartsenpraktijk die de implementatie van stoppen-met-
7 rokenbegeleiding in de huisartspraktijk kunnen beïnvloeden. Maatregelen op be-
8 leidsniveau kunnen hierin echter tevens een rol spelen. In **hoofdstuk zes** wordt
9 daarom een populatieonderzoek beschreven naar de effecten van twee nationale
10 maatregelen om tabaksgebruik te ontmoedigen op het aantal voorschriften van
11 stoppen-met-rokenmiddelen vanuit de huisartspraktijk alsook de prevalentie
12 van roken. Het betreft de invoering van de NHG-Standaard Stoppen met roken in
13 2007 en de invoering van de vergoeding van het stoppen-met-rokenprogramma
14 in 2011. Deze laatste beleidsmaatregel betrof een vergoeding voor een combi-
15 natie van farmacologische en gedragsmatige begeleiding van rokers bij het
16 stoppen met roken vanuit de basiszorgverzekering, waar de roker een keer per
17 kalenderjaar gebruik van kan maken. Deze vergoeding werd een jaar later, in
18 januari 2012, afgeschaft en in 2013 weer ingevoerd. In dit ecologisch onderzoek
19 werden data (kwartaalcijfers) van drie nationaal representatieve databases
20 geanalyseerd door middel van tijdreeksanalyses. Deze analyses toonden geen
21 effect aan van de invoering van de NHG-Standaard Stoppen met roken op het
22 aantal voorschriften en uitgiften van stoppen-met-rokenmiddelen door respec-
23 tievelijk de huisarts en apotheker. Kort na de invoering van de vergoeding van
24 het stoppen-met-rokenprogramma in 2011 steeg echter het aantal voorschriften
25 en uitgiften van stoppen-met-rokenmiddelen significant met respectievelijk 6,3
26 en 17,3 per 1.000 rokers. Deze stijging in het aantal voorschriften en uitgiften van
27 hulpmiddelen in het eerste kwartaal van 2011 ging gepaard met een significante
28 daling van 2,9% van de prevalentie van roken. Onmiddellijk nadat de vergoeding
29 van het stoppen-met-rokenprogramma werd afgeschaft (eerste kwartaal 2012)
30 steeg de prevalentie van roken weer met 1,2% en daalde het aantal uitgiften
31 van stoppen-met-rokenmiddelen door apothekers met 21,6 per 1.000 rokers.
32 Dit hoofdstuk sluit dan ook af met aanbevelingen voor beleidsmakers om deze
33 bevindingen in overweging te nemen bij de ontwikkeling van toekomstig beleid
34 op het gebied van de ontmoediging van tabaksgebruik.

35

36 De algemene discussie in **hoofdstuk zeven** bespreekt de onderzoeksbevindingen
37 beschreven in dit proefschrift. Daarnaast biedt dit hoofdstuk inzicht in
38 hetgeen de onderzoeksbevindingen voor de praktijk en toekomstig onderzoek
39 betekenen. Om verder inzicht te verschaffen in de factoren die de implementatie

1 van stoppen-met-rokenbegeleiding in de huisartspraktijk beïnvloeden worden
2 theoriegestuurde determinantenvragenlijsten aanbevolen. Op basis van deze
3 kennis kunnen in de toekomst strategieën verder ontwikkeld worden die het kli-
4 nisch handelen van huisartsen volgens de richtlijn verder verbeteren. Daarnaast
5 worden experimentele studies met grotere steekproeven aanbevolen om na te
6 gaan wat de effecten zijn van trainingsprogramma's voor huisartsen waarin or-
7 ganisatorische factoren alsook actie- en coping planning geïncorporeerd worden.
8 Tevens wordt in dit hoofdstuk aanbevolen om het populatieonderzoek naar de
9 effecten van de vergoeding van stoppen-met-rokenprogramma's te herhalen. Op
10 die manier kunnen ook de langetermijneffecten van deze beleidsmaatregel op
11 het voorschrijven van stoppen-met-rokenmiddelen en op de prevalentie van ro-
12 ken onderzocht worden. Ten slotte wordt een alternatieve aanpak voor stoppen-
13 met-rokenbegeleiding in de huisartspraktijk besproken, de zogenaamde Ask-
14 Advise-Connect (A-A-C) aanpak. In vergelijking met het huidige 5A-Model worden
15 de taken van de huisarts binnen de A-A-C aanpak beperkt tot het routinematig
16 identificeren en adviseren van rokers. Daarnaast worden rokers op proactieve
17 wijze doorverwezen voor stopondersteuning. Amerikaans onderzoek laat zien
18 dat door middel van deze proactieve aanpak significant meer rokers uiteindelijk
19 gebruikmaken van professionele stopondersteuning. Toekomstig (kwalitatief)
20 onderzoek zou kunnen nagaan hoe patiënten en huisartsen in Nederland tegen
21 deze aanpak aankijken. Tevens worden studies aanbevolen die de haalbaarheid
22 en het effect van de A-A-C aanpak in de Nederlandse huisartspraktijk onderzoe-
23 ken.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39



Curriculum Vitae

1 Marjolein Verbiest is geboren op 18 april 1986 te Bergen op Zoom. Haar basis- en
2 voorbereidend wetenschappelijk onderwijs genoot zij op de openbare basis-
3 school Oost en de Roncalli Scholengemeenschap te Bergen op Zoom. Tussen 2005
4 en 2008 volgde zij de opleiding tot Bachelor of Science in *Social Psychology* aan de
5 Universiteit Utrecht. Vervolgens volgde zij tussen 2009 en 2010 de masteroplei-
6 ding *Health Psychology* aan de Universiteit van Leiden alwaar zij haar Basisaante-
7 kening Psychodiagnostiek behaalde. Gedurende haar opleiding tot Gezondheids-
8 psycholoog ontwikkelde zij haar interesse in gedragsverandering, op het snijvlak
9 van de somatische gezondheidszorg en psychologie. In 2010 startte zij dan ook
10 in de hoedanigheid van Gezondheidspsycholoog/-onderzoeker aan een tweeja-
11 rig onderzoeksproject op de afdeling Public Health en Eerstelijns geneeskunde
12 van het Leids Universitair Medisch Centrum. Zij ontwikkelde en onderzocht de
13 effectiviteit van een training voor huisartsen in het leveren van stoppen-met-
14 rokenbegeleiding. Een succesvol verloop van dit onderzoek, vervolgprojecten op
15 dit onderzoeksgebied en intensieve scholing in het wetenschappelijk onderzoek
16 mondde in 2014 uit in een proefschrift. Tevens werkt zij sinds 2014 als post-
17 doctoraal onderzoeker aan een onderzoek op het gebied van de ontmoediging
18 van tabaksgebruik onder jongeren in de huisartspraktijk. Gedurende haar jaren
19 als onderzoeker is zij betrokken geweest bij het universitair onderwijs aan de
20 faculteit Sociale Wetenschappen en Geneeskunde van de Universiteit Leiden.
21 Tevens nam zij actief deel aan diverse nationale en internationale symposia en
22 congressen op het gebied van de Gezondheids- en Medische Psychologie.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39



Dankwoord

1 Dit proefschrift had niet tot stand kunnen komen zonder de hulp van anderen.

2

3 Als eerste zou ik graag mijn promotores, prof. dr. Pim Assendelft en prof. dr. Ad
4 Kaptein, willen bedanken voor de gelegenheid die zij mij boden dit proefschrift
5 te schrijven. Het promotietraject op het snijvlak van de somatische geneeskunde
6 en psychologie bood mij de uitdaging waar ik naar op zoek was. Jullie vertrouwen
7 in en enthousiasme voor mijn promotietraject heb ik altijd als erg inspirerend en
8 motiverend ervaren.

9

10 Tevens zou ik mijn co-promotores, dr. Matty Crone en dr. Niels Chavannes, wil-
11 len bedanken. Matty, dankzij jouw betrokkenheid en onze fijne samenwerking
12 heb ik mijn promotietraject als zeer leerzaam en plezierig ervaren. Niels, jouw
13 expertise, enthousiasme en uitgebreid netwerk stelde mij daarbij in de gelegen-
14 heid om inspirerend en innovatief onderzoek te verrichten. Jullie boden mij het
15 vertrouwen om dit promotietraject tot een succesvol einde te brengen.

16

17 Deze promotie had niet kunnen plaatsvinden zonder de bereidheid van de leden
18 van de leescommissie om dit proefschrift te beoordelen. Om die reden wil ik
19 dan ook prof. dr. Sandra van Dulmen, prof. dr. Mattijs Numans en prof. dr. Marc
20 Willemsen bedanken.

21

22 Also, I would like to thank all the co-authors of the studies within my dis-
23 sertation, including my colleagues of the University of Adelaide, University of
24 Sydney, Queen Elisabeth Hospital of Adelaide, Newcastle University, Netherlands
25 Institute for Health Services Research (NIVEL), and STIVORO. It was very exciting
26 and intellectually stimulating to work with such a diverse group of excellent
27 researchers who all provided me with the trust and motivation to perform my
28 research.

29

30 Het SCIP-IT onderzoek had niet kunnen plaatsvinden zonder het vertrouwen van
31 MIRO en de medewerking van de huisartsen van het LEON. Hiervoor wil ik hen
32 allen bedanken. Ook wil ik Bertie Happel en Simone Könings bedanken voor het
33 verzorgen van de trainingen aan de huisartsen in het kader van dit onderzoek.

34

35 Tevens zou ik de wetenschappelijk onderzoekers van de afdeling Public Health en
36 Eerstelijns geneeskunde van het LUMC willen bedanken voor de fijne werksfeer
37 die ertoe heeft bijgedragen dat ik elke dag weer met plezier aan mijn onderzoek
38 kon werken. In het bijzonder wil ik mijn paranimfen, Iris Groenberg en Rianne

39

1 van der Kleij, bedanken voor hun ondersteuning tijdens de laatste loodjes van
2 mijn promotietraject.

3

4 Chello en Milou wil ik bedanken voor de nodige ontspanning tijdens de jaren dat
5 ik intensief aan mijn onderzoek werkte.

6

7 Ten slotte wil ik me richten tot mijn lieve man, Remco. Tijdens mijn promotie-
8 traject steunde jij mij voor de volle 100%. Je was betrokken, dacht mee, hoorde
9 me aan, ontzag me en was enthousiast over alles wat ik deed. Hiervoor wil ik je
10 ontzettend bedanken.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39